FINAL PROGRAMME

34th Annual Congress of the European Association of Nuclear Medicine
# TABLE OF CONTENTS

**WELCOME WORDS**
- 4

**GENERAL INFORMATION**
- Board & SP Council 6
- SPC & Session Coordinators 7
- EANM’21 Reviewers 8
- EANM’21 Chairpersons 15
- EANM National Societies: Delegates / Deputies 18
- UEMLS/EBNM National Societies: Delegates / Deputies 20
- UEMLS/EBNM committees 22
- General Information 24
- Committee Interest Group Meetings during EANM’21 26

**SCIENTIFIC & TECHNOLOGISTS’ PROGRAMME**
- Plenary Sessions 28
- Pre-Congress Symposia 30
- Continuing Medical Education/CME Sessions 32
- Technologists’ Track 34
- Joint Symposia 36
- Pitfalls & Artefacts Sessions 38
- Teaching Sessions 39
- Special Track 40
- Cutting Edge Science Track 42
- M2M – The 8th “From Molecule to Man” Track 44
- Clinical Oncology Track 45
- Further Oral Presentations 46
- e-Poster Presentations 47
- e-Poster sessions 48
- Programme Overview 52

**PRE-Congress Symposia** 60

**Oral Presentations** 67

**E-Poster Presentations** 166

**E-Poster Sessions** 193

**Industry Programme**
- Satellite Symposia 215
- Exhibitors & Sponsors 222
- List of Society Booths 223
- Company Profiles 224

**Useful Contacts** 258
WELCOME WORDS

BY THE CONGRESS CHAIR

Dear Colleagues, dear Friends,

On behalf of the European Association of Nuclear Medicine, it is my honour to invite you to the 34th Annual EANM Congress. The event will run virtually from 20 to 23 October 2021.

Despite the difficult time we are experiencing due to the pandemic, nuclear medicine continues to grow both in diagnostic imaging and therapy. New radiopharmaceuticals which facilitate the study and treatment of new targets are being introduced, more and more protocols which cover unmet clinical needs and new applications are running, and the use of nuclear medicine procedures is increasingly being incorporated into clinical practice and guidelines. This success remains related to that very peculiar characteristic of our specialty, namely, its functional approach to medicine. This is mainly true with respect to imaging, but also for therapy.

In recent years we have proudly celebrated the status of the EANM Congress as the world’s leading meeting for nuclear medicine. In 2019, for example, we reached almost 7000 participants, a truly memorable record. As we all know, the pandemic of 2020 forced all events to move to a virtual format and we did our best to prepare a great event. We succeeded in keeping all of our scientific programmes running with 11 parallel channels and received excellent feedback from participants. As mentioned, we are unable to return to the live format we are used to and would have all hoped for in 2021. Therefore, we have planned a great event with a full scientific programme once more, but have arranged some significant improvements after the lessons learnt last year. In 2021, pre-congress symposia will run a couple of weeks before the congress, which, as a result, has been shortened by one day. Furthermore, most of the several parallel tracks will not run according to the traditional time sequence but will always be available on demand to facilitate access and productivity for attendees.

In summary, we are working on providing you a congress with superb and comprehensive scientific content as well as a lot of other features to make your participation enjoyable whatever you are looking to achieve.

Stefano Fanti
EANM Congress Chair 2020–2022
BOARD & SP COUNCIL

EANM BOARD

President 2021 – 2022
Jolanta Kunikowska (Poland)

President Elect 2021 – 2022
Rudi A.J.O. Dierckx (Netherlands)

Congress Chair 2020 – 2022
Stefano Fanti (Italy)

Education Chair 2020 – 2022
Paola A. Erba (Italy)

Secretary/Treasurer 2021 – 2022
Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2021 – 2022
Michael Lassmann (Germany)

SCIENTIFIC PROGRAMME COUNCIL

EANM thanks all Scientific Programme Council Members for their great effort in composing the EANM’21 Virtual Sessions.

Congress Chair
Stefano Fanti (Italy)

Bone & Joint Committee
Salvatore Annunziata (Italy), Tim Van den Wyngaert (Belgium)

Cardiovascular Committee
Fabien Hyafil (France), Hein J. Verberne (Netherlands)

Dosimetry Committee
Uta Eberlein (Germany), Erik Verburg (Netherlands)

Drug Development Committee
Johnny Verroust (Belgium), Graham Smith (United Kingdom)

Inflammation & Infection Committee
Giorgio Treglia (Switzerland), Andor Glaudemans (Netherlands)

Neuroimaging Committee
Henry Barthel (Germany), Stavros Morbelli (Italy)

Oncology & Theranostics Committee
Ken Hermann (Germany), Nicolas Aide (France)

Paediatrics Committee
Pinar Kristal (Turkey), Pietro Zucchetta (Italy)

Radiation Protection Committee
Liqia Cunha (Portugal), François Jamar (Belgium)

Radiotherapy Committee
Peter Laverman (Netherlands), Filippo Lodi (Italy)

Thyroid Committee
Andrea Santos (Portugal), Luca Camoni (Italy)

Translational Molecular Imaging & Therapy Committee
Fijs van Leeuwen (Netherlands), Margit Schottelius (Switzerland)

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

Aerts, A. (Belgium)

Aide, N. (France)

Albert, N. (Germany)

Ali, L. (United Kingdom)

Annunziata, S. (Italy)

Attard, M. (Netherlands)

Bacher, K. (Belgium)

Balogova, S. (Slovakia)

Bar Sevet, Z. (Israel)

Barthelb, H. (Germany)

Beheshli, M. (Austria)

Brendel, M. (Germany)

Burger, J. (Switzerland)

Camoni, L. (Italy)

Campenni, A. (Italy)

Cecchin, D. (Italy)

Cicone, F. (Italy)

Cunha, L. (Portugal)

de Geus-Oei, L. (Netherlands)

Deandreis, D. (Italy)

Deichert, C. (Austria)

Denis-Bacelar, A. (United Kingdom)

Dickson, J. (United Kingdom)

Eberlein, U. (Germany)

Evangelista, L. (Italy)

Fanti, S. (Italy)

Farolfi, A. (Italy)

Gelashvili, T. (Russia)

Glattling, G. (Germany)

Gnanasegaran, G. (United Kingdom)

Goffin, K. (Belgium)

Hatt, M. (France)

Hermann, K. (Germany)

Jarai, F. (Belgium)

Kobe, C. (Germany)

Konynenberg, M. (Netherlands)

Koole, M. (Belgium)

Křížerová, T. (Czech Republic)

Kreissl, M. C. (Germany)

Laeisz, O. (France)

Lauri, C. (Italy)

Leccisotti, L. (Italy)

Lodi, F. (Italy)

Lopri, E. (Italy)

Lubberink, M. (Sweden)

Luporsi, M. (France)

Morbelli, S. (Italy)

Nanni, C. (Italy)

Nappi, C. (Italy)

Noriega-Álvarez, E. (Spain)

Palmesu, H. (Germany)

Pietta, A. (Poland)

Rahba, K. (Germany)

Rahbar, K. (France)

Rischpler, C. (Germany)

Santos, A. (Portugal)

Saraste, A. (Finland)

Schoettle, M. (Switzerland)

Scott, A. (Australia)

Semilie, Y. (Netherlands)

Senah, F. (France)

Shi, K. (Switzerland)

Strand Olsen, R. (Denmark)

Takib, D. (France)

Tervoeghe, C. (Belgium)

Treglia, G. (Switzerland)

van Berckel, B. (Netherlands)

Van den Wyngaert, T. (Belgium)

Verberne, H. (Netherlands)

Visvikis, D. (France)
# EANM’21 Reviewers

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott, B.</td>
<td>United States of America</td>
</tr>
<tr>
<td>Abgral, R.</td>
<td>France</td>
</tr>
<tr>
<td>Acampa, C.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ahmadzadehfar, H.</td>
<td>Germany</td>
</tr>
<tr>
<td>Ak Sivrikoz, I.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Aktolun, C.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Aloj, L.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Altini, C.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ambrosini, V.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ametamey, S.M.</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Anunziata, S.</td>
<td>Italy</td>
</tr>
<tr>
<td>Antunovic, L.</td>
<td>Italy</td>
</tr>
<tr>
<td>Artigas, C.</td>
<td>Belgium</td>
</tr>
<tr>
<td>Asenbaum-Nan, S.</td>
<td>Austria</td>
</tr>
<tr>
<td>Atay Kapucu, L.Ö.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Attard, M.C.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Baldari, S.</td>
<td>Italy</td>
</tr>
<tr>
<td>Balkay, L.</td>
<td>Hungary</td>
</tr>
<tr>
<td>Ballinger, J.</td>
<td>Canada</td>
</tr>
<tr>
<td>Balogova, S.</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Barbet, J.</td>
<td>France</td>
</tr>
<tr>
<td>Bar-Sever, Z.</td>
<td>Israel</td>
</tr>
<tr>
<td>Barthel, H.</td>
<td>Germany</td>
</tr>
<tr>
<td>Beer, A.</td>
<td>Germany</td>
</tr>
<tr>
<td>Behe, M.</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Beheshti, M.</td>
<td>Australia</td>
</tr>
<tr>
<td>Ben-Haim, S.</td>
<td>Israel</td>
</tr>
<tr>
<td>Bergstroem, K.</td>
<td>Finland</td>
</tr>
<tr>
<td>Bernsen, M.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Bianchi, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Biassoni, L.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Bilgin, B.E.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Bogovic-Cinetic, T.</td>
<td>Croatia</td>
</tr>
<tr>
<td>Bolch, W.</td>
<td>United States of America</td>
</tr>
<tr>
<td>Boasj, J.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Borbély, K.</td>
<td>Hungary</td>
</tr>
<tr>
<td>Botelho, M.F. R.R.</td>
<td>Portugal</td>
</tr>
<tr>
<td>Bozkurt, M.</td>
<td>Germany</td>
</tr>
<tr>
<td>Brendel, M.</td>
<td>Germany</td>
</tr>
<tr>
<td>Brenner, W.</td>
<td>Germany</td>
</tr>
<tr>
<td>Brian, D.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Brousers, A.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Bucersius, J.</td>
<td>Germany</td>
</tr>
<tr>
<td>Buchert, R.</td>
<td>Germany</td>
</tr>
<tr>
<td>Buckle, T.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Burak, Z.E.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Buroni, L.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ca, W.</td>
<td>United States of America</td>
</tr>
<tr>
<td>Camoni, L.</td>
<td>Italy</td>
</tr>
<tr>
<td>Campanini, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Cantinho-Lopes, M.G.</td>
<td>Portugal</td>
</tr>
<tr>
<td>Cantilho Vaz, S.</td>
<td>Portugal</td>
</tr>
<tr>
<td>Carp, I.</td>
<td>Spain</td>
</tr>
<tr>
<td>Castell Comesa, J.</td>
<td>Spain</td>
</tr>
<tr>
<td>Castellucci, P.</td>
<td>Italy</td>
</tr>
<tr>
<td>Cawthorne, C.</td>
<td>Belgium</td>
</tr>
<tr>
<td>Cecchin, D.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ceci, F.</td>
<td>Italy</td>
</tr>
<tr>
<td>Cermik, T.F.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Chakravarthy, R.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chiesa, C.</td>
<td>Italy</td>
</tr>
<tr>
<td>Chitt, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ciappuccini, R.</td>
<td>France</td>
</tr>
<tr>
<td>Cicone, F.</td>
<td>Italy</td>
</tr>
<tr>
<td>Cook, G.J.R.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Cornelissen, B.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Costa, G.</td>
<td>Portugal</td>
</tr>
<tr>
<td>Cremoresi, M.</td>
<td>Italy</td>
</tr>
<tr>
<td>Cuocolo, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Curran, D.</td>
<td>Ireland</td>
</tr>
<tr>
<td>Da Pieve, C.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dalm, S.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>De Bondt, P.</td>
<td>Belgium</td>
</tr>
<tr>
<td>De Geus-Oei, L-F.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>de Keizer, B.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>De Palma, D.</td>
<td>Italy</td>
</tr>
<tr>
<td>De Swart, J.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>De Andres, D.</td>
<td>Italy</td>
</tr>
<tr>
<td>Decristoforo, C.</td>
<td>Austria</td>
</tr>
<tr>
<td>Delgado Bolton, R.C.</td>
<td>Spain</td>
</tr>
<tr>
<td>Denis-Boceta, A.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Deflin, T.</td>
<td>Germany</td>
</tr>
<tr>
<td>Deuther-Conrad, W.</td>
<td>Germany</td>
</tr>
<tr>
<td>Dickson, J.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dienicky, L.</td>
<td>France</td>
</tr>
<tr>
<td>Drezeza, A.</td>
<td>Germany</td>
</tr>
<tr>
<td>Duatt, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Dziuk, M.</td>
<td>Poland</td>
</tr>
<tr>
<td>Eberlein, U.</td>
<td>Italy</td>
</tr>
<tr>
<td>Ekmekcioglu, O.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Erényi, T.</td>
<td>Turkey</td>
</tr>
<tr>
<td>Elchebehere, E.</td>
<td>Brazil</td>
</tr>
<tr>
<td>Evangelista, L.</td>
<td>Italy</td>
</tr>
<tr>
<td>Fani, M.</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Farolfi, A.</td>
<td>Italy</td>
</tr>
<tr>
<td>Fins, M.</td>
<td>Italy</td>
</tr>
<tr>
<td>Fiori, W.</td>
<td>Germany</td>
</tr>
<tr>
<td>Garber, C.</td>
<td>Austria</td>
</tr>
<tr>
<td>Gaberscek, S.</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Gabriel, M.</td>
<td>Austria</td>
</tr>
<tr>
<td>Galifa, A.</td>
<td>United States of America</td>
</tr>
<tr>
<td>Gallowitsch, H.-J.</td>
<td>Austria</td>
</tr>
</tbody>
</table>
EANM’ 21 REVIEWERS

Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (Austria)
Gillings, N. (Denmark)
Gimelli, A. (Italy)
Girotto, N. (Croatia)
Glatting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Goffin, K. (Belgium)
Graf, S. (Austria)
Graham, R. (United Kingdom)
Grana, C.M. (Italy)
Gratz, S. (Germany)
Grimm, J. (United States of America)
Grotzinger, C. (Germany)
Guedj, E. (France)
Guillet, B. (France)
Gulliver, N. (United Kingdom)
Haberkorn, U. (Germany)
Handkiewicz-Junak, D. (Poland)
Hatt, M. (France)
Heijmen, L. (Netherlands)
Hendriksen, H. (Netherlands)
Herholz, K. (United Kingdom)
Herrmann, K. (Germany)
Henskamp, S. (Netherlands)
Hesse, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hofman, M. (Australia)
Holm, S. (Denmark)
Howell, R. (United States of America)
Hubalewska-Dytszczyk, A. (Poland)
Hutton, B.F. (United Kingdom)
Hyafil, F. (France)
Iagaru, A. (United States of America)
Iakovou, I. (Greece)
Jamar, F. (Belgium)
Jarzab, B. (Poland)
Jehanno, N. (France)
Kaya, G.C. (Turkey)
Kedves, A. (Hungary)
Kizac, S.F. (Turkey)
Kienenko, M. (Italy)
Kirjavainen, A. (Finland)
Klett, R. (Germany)
Kobe, C. (Germany)
Kolenc, P. (Slovenia)
Konijnem, M. (Netherlands)
Koranda, P. (Czech Republic)
Kostadinova, I.D. (Bulgaria)
Kostkiewicz, M.A. (Poland)
Kotzerke, J. (Germany)
Koutsikos, J. (Greece)
Kraemer-Bordet, F. (France)
Kramer, S. (Switzerland)
Krause, B.J. (Germany)
Kreissl, M.C. (Germany)
Kresnik, E. (Austria)
Kuzuk, N.O. (Turkey)
Kurth, J. (Germany)
Kuwert, T. (Germany)
Lai, Z. (France)
Lammersma, A.A. (Netherlands)
Langbein, T. (Germany)
Langstroth, W. (Austria)
Laxson, C. (France)
Lauri, C. (Italy)
Laverman, P. (Netherlands)
Leccezotti, L. (Italy)
Lemos Pereira, E.A. (Portugal)
Levington, V. (United Kingdom)
Lodi, F. (Italy)
Loupi, E. (Italy)
Lubberink, M. (Sweden)
Luporsi, M. (France)
Lütje, S. (Germany)
Mada, M. (United Kingdom)
Maes, A. (Belgium)
Maino Nock, T. (Greece)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Marsi, L. (Italy)
Marcelli, P. (Italy)
Marcassa, C. (Italy)
Marie, P-Y. (France)
Massalha, S. (Israel)
Mhailovic, J. (Serbia)
Milan, E. (Italy)
Mindl, T.L. (Switzerland)
Min, H. (Netherlands)
Mittavila Casanova, M. (Spain)
Montero, M. (Switzerland)
Morbetti, S. (Italy)
Mottaghy, F.M. (Germany)
Mu, L. (Switzerland)
Nagren, K.A. (Denmark)
Nanni, C. (Italy)
Neels, O. (Germany)
Neglia, D. (Italy)
Nicolau, D. (Romania)
Nobili, F.M. (Italy)
Nock, B.A. (Greece)
Nonnemans, J. (Netherlands)
Noriega-Alvarez, E. (Spain)
Ölmann, C. (Italy)
Olivi, R. (Denmark)
Oprea-Lager, D.E. (Netherlands)
### EANM’21 REVIEWERS

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orlhac, F. (France)</td>
<td></td>
</tr>
<tr>
<td>Orlova, A. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>Örmü, M.T. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Özçan, Z. (Turkey)</td>
<td></td>
</tr>
<tr>
<td>ÖzgenKiratli, P. (Turkey)</td>
<td></td>
</tr>
<tr>
<td>Paganelli, G. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Pagani, M. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Palmedo, H. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Panagiotidaki, E. (Greece)</td>
<td></td>
</tr>
<tr>
<td>Papathanasiou, N. (Greece)</td>
<td></td>
</tr>
<tr>
<td>Pappata, S. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Pasicul, T. (Philippines)</td>
<td></td>
</tr>
<tr>
<td>Patt, M. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Paycha, F. (France)</td>
<td></td>
</tr>
<tr>
<td>Payoux, P. (France)</td>
<td></td>
</tr>
<tr>
<td>Pennelás, I. (Spain)</td>
<td></td>
</tr>
<tr>
<td>Pestean, I.C. (Romania)</td>
<td></td>
</tr>
<tr>
<td>Pethanovic-Ovacicek, P. (Croatia)</td>
<td></td>
</tr>
<tr>
<td>Picu, D. (Romania)</td>
<td></td>
</tr>
<tr>
<td>Pietrzak, A. (Poland)</td>
<td></td>
</tr>
<tr>
<td>Pilkington, P. (Spain)</td>
<td></td>
</tr>
<tr>
<td>Pinch, C. (Austria)</td>
<td></td>
</tr>
<tr>
<td>Poeppe11, T. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Prum, J. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Raevé, R. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Rabiner, I. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Rac, S. (Croatia)</td>
<td></td>
</tr>
<tr>
<td>Rajkovacà, Z. (Bosnia and Herzegovina)</td>
<td></td>
</tr>
<tr>
<td>Rabah-Vidal, L. (France)</td>
<td></td>
</tr>
<tr>
<td>Redondo, F. (Chile)</td>
<td></td>
</tr>
<tr>
<td>ResendeGeao, A.C. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>Rijkema, M. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Rischpler, C. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Rodríguez-Fraile, M. (Spain)</td>
<td></td>
</tr>
<tr>
<td>Raivainen, A.M. (Finland)</td>
<td></td>
</tr>
<tr>
<td>Roland, J. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Röninget, A. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>Rossetti, C.J. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Rubi, S. (Spain)</td>
<td></td>
</tr>
<tr>
<td>Salari, P.-Y. (France)</td>
<td></td>
</tr>
<tr>
<td>Santos, A.I. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>Santos, A. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>Saraste, A. (Finland)</td>
<td></td>
</tr>
<tr>
<td>Sattler, B. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Saxtoft, E.S. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>Schäfers, M.A. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Schibli, R. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>Schödn, A. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Schmidt, E. (Hungary)</td>
<td></td>
</tr>
<tr>
<td>Schmidt, M.C. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Schwarzenbock, S.M. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Sicara, R. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Semblé, Y. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Sera, T. (Hungary)</td>
<td></td>
</tr>
<tr>
<td>Sestris, S. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Shi, X. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>Siclari, G. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Signore, A. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Slatt, R.H.J.A. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Smith, G. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Sobach, C. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Solini, M. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Stefanescu, C. (Romania)</td>
<td></td>
</tr>
<tr>
<td>Stevens, H. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Stolke, C. (Norway)</td>
<td></td>
</tr>
<tr>
<td>Strobel, K. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>Strömwall, A. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>Sunderland, J. (United States of America)</td>
<td></td>
</tr>
<tr>
<td>Talbot, J.-N. (France)</td>
<td></td>
</tr>
<tr>
<td>Teras, M. (Finland)</td>
<td></td>
</tr>
<tr>
<td>Terry, S. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Ternwinge, C. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Testanera, G. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Toddle, S.C. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Tolmachev, V. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>Treglia, G. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>Treses, T. (United States of America)</td>
<td></td>
</tr>
<tr>
<td>Turclement, M. (Turkey)</td>
<td></td>
</tr>
<tr>
<td>Uginis, A. (North Macedonia)</td>
<td></td>
</tr>
<tr>
<td>Vaccaro, I. (Italy)</td>
<td></td>
</tr>
<tr>
<td>Van Dongen, G. A.M.S. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>van Essen, M. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>van Lith, S. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Van Velden, F. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Van Weerhaeghe, D. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Vandenberghue, S. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Volante, L. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>Vlajkovic, M. (Serbia)</td>
<td></td>
</tr>
<tr>
<td>Vlasnikos, A. (Cyprus)</td>
<td></td>
</tr>
<tr>
<td>Vriens, D. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Walz, J. (France)</td>
<td></td>
</tr>
<tr>
<td>Weber, W. (Germany)</td>
<td></td>
</tr>
<tr>
<td>Weler-Sage, M. (Israel)</td>
<td></td>
</tr>
<tr>
<td>Welch, A. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Windhorst, A.D. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Xavier, C. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Zalestek, K. (Slovenia)</td>
<td></td>
</tr>
<tr>
<td>Zambo, K. (Hungary)</td>
<td></td>
</tr>
<tr>
<td>Zerza, I. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Zhang-Yin, J. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Zimmer, L. (France)</td>
<td></td>
</tr>
</tbody>
</table>
Course Programme 2022

In order to make it easier for our community to make the most of their Continuous Medical Education, ESMIT is expanding its educational offers.

Our 2022 programme will include:

4 new Online Courses | 15 new Live Webinars | 7 new Advanced Courses in Vienna

... organised in 5 Thematic Tracks:
Artificial Intelligence and Quantification | Clinical Nuclear Medicine | Scientific Track | Theranostics | Cardiac Amyloidosis. (EURO-LEARN)

Registration for 2022 will open during the EANM 2021 Congress.
Do not forget to visit the ESMIT Booth!

Get your Dose of Education
More information at eanm.org/esmit or contact us at esmit@eanm.org

EANM thanks all reviewers for their invaluable commitment.

Adam, J. (Amsterdam)
Aide, N. (Caen)
Al Ibraheem, A. (Amman)
Albert, N. (Munich)
Alessi, A. (Milan)
Aloj, L. (Cambridge)
Armstrong, I. (Manchester)
Attard, MC. (Zwolle)
Balogová, S. (Bratislava)
Bar-Sever, Z. (Petach Tikva)
Barrington, S. (London)
Barthel, H. (Leipzig)
Bauckneht, M. (Genoa)
Beer, A. (Ulm)
Behe, M. (Villigen)
Benesova, M. (Heidelberg)
Boelkaard, R. (Amsterdam)
Brendel, M. (Munich)
Camoni, L. (Brescia)
Campenni, A. (Messina)
Caobelli, F. (Basel)
Castellucci, P. (Bologna)
Cecchin, D. (Padua)
Ceci, F. (Turin)
Cerci, J. (Cunntiba)
Cheze Le Rest, C. (Poitiers)
Chiesa, C. (Milan)
Ciccone, F. (Catanzaro)
Cleeren, F. (Leuven)
Cunha, L. (Azores)
D’Alessandria, C. (Munich)
De Geus-Oei, L. F. (Leiden)

Deandreis, D. (Turin)
Denis-Bacetar, A. (Teddington)
Deoanse, C. (Leuven)
Deuther-Conrad, W. (Leipzig)
Dickson, J. (London)
Eberlein, U. (Würzburg)
Eder, A.C. (Freiburg)
Eiber, M. (Munich)
Ekmeckizoglou, O. (İstanbul)
Evangelista, L. (Padua)
Farolfi, A. (Bologna)
Fendler, W. (Essen)
Flux, G. (Sutton)
Garrigue, P. (Marseille)
Gear, J. (London)
Gelashvili, T. (Moscow)
Gheyrens, D. (Brussels)
Glattling, G. (Ulm)
Gaudemans, A. W.J.M. (Groningen)
Goffin, K. (Leuven)
Goesevisch, A. (Munich)
Guedj, E. (Marseille)
Guillet, B. (Marseille)
Hartenbach, M. (Vienna)
Hatt, M. (Brest)
Hermann, K. (Essen)
Heskamp, S. (Nijmegen)
Hindie, E. (Pessac)
Holm, S. (Copenhagen)
Hyafil, F. (Paris)
Israel, O. (Haifa)
Jamar, F. (Brussels)
EANM’ 21

CHAIRPERSONS

Jonca, B. (Paris)
Kappadath, S. C. (Houston)
Kedves, A. (Kaposvár)
Koč, C. (Cologne)
Konijnendijk, M. (Rotterdam)
Koole, M. (Leuven)
Kreissl, M. (Magdeburg)
Kunikowska, J. (Warsaw)
Lapa, C. (Augsburg)
Lauri, C. (Rome)
Laverman, P. (Nijmegen)
Lodi, F. (Bologna)
Lopas, E. (Milan)
Lubberink, M. (Uppsala)
Luporsi, E. (Milan)
Luurteme, G. (Groningen)
Lynch, T. (Belfast)
Massalha, S. (Haifa)
Masukawa, M. (Curitiba)
Minguez Gabiña, P. (Barakaldo)
Morbelli, S. (Genoa)
Mottaghy, F. (Aachen)
Nanni, C. (Bologna)
Nappi, C. (Naples)
Neels, O. (Dresden)
Nekolla, S. (Munich)
Niegero-Alvarez, E. (Ciudad Real)
Olanti, C. (Florence)
Öpther-Lager, D. (Amsterdam)
Oyen, W. J. G. (Amsterdam)
Pálmedo, H. (Bonn)
Panagiotidou, E. (Thessaloniki)
Payaux, P. (Toulouse)
Petranović Ovčariček, P. (Zagreb)

Pietrzak, A. (Poznan)
Rbah-Vidal, L. (Nantes)
Repp, S. (Budapest)
Reyes-Torres, E. (London)
Roschpee, C. (Esen)
Santos, A. I. (Almada)
Santos, A. J. (Lisbon)
Saraste, A. (Turku)
Schaarschmidt, R. (Düsseldorf)
Schneider, K. (Munich)
Schottelius, M. (Zurich)
Schwarzenbock, S. (Rostock)
Semmler, Y. (Rotterdam)
Shi, K. (Bern)
Smith, A. L. (London)
Spiliotis, M. (Milan)
Sosabowski, J. (London)
Strand Olsen, R. (Copenhagen)
Strömwall, L. (Umeå)
Terry, S. (London)
Terwenghe, C. (Leuven)
Tran-Gia, J. (Zürich)
Traub-Weding, T. (Vienna)
Treglia, G. (Bologna)
van Beekel, B. (Amsterdam)
Van den Wyngaert, T. (Antwerp)
Vanhove, C. (Ghent)
Verbeken, H. J. (Amsterdam)
Versij, R. (Nijmegen)
Villar del Moral, J. M. (Granada)
Wissink, D. (Brest)
Wachmis, A. (Limassol)
Zachis, H. (Aalborg)

FROM THE INVENTORS OF 360° CZT TECHNOLOGY FOR TOTAL-BODY SCANNING

VERITON-CT
DIGITAL SPECT/CT

We’ve extended the limits of possibility.
Spectrum Dynamics Medical revolutionizes the industry with a multipurpose SPECT/CT system that transforms the way imaging is executed and scheduled.

With its revolutionary 360° ring-shaped gantry digital SPECT/CT, VERITON-CT® establishes 3D imaging as the new standard of care in nuclear imaging.
EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

<table>
<thead>
<tr>
<th>SOCIETY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenian Society of Nuclear Medicine</td>
<td>V. Barsogian</td>
<td>M. Grigoryan</td>
</tr>
<tr>
<td>Austrian Society of Nuclear Medicine</td>
<td>H. J. Gallowitsch</td>
<td>I. Vegolini</td>
</tr>
<tr>
<td>Azerbaijani Society of Nuclear Medicine</td>
<td>F. Novruzov</td>
<td>A. Alleyev</td>
</tr>
<tr>
<td>Belgian Society of Nuclear Medicine</td>
<td>F. Jamar</td>
<td>N. Witschofs</td>
</tr>
<tr>
<td>Bosnian Society of Nuclear Medicine</td>
<td>Z. Rajkovac</td>
<td>D. Racin</td>
</tr>
<tr>
<td>British Nuclear Medicine Society</td>
<td>R. Graham</td>
<td>S. Dzidarevic</td>
</tr>
<tr>
<td>Bulgarian Society of Nuclear Medicine</td>
<td>V. Hadziyska</td>
<td>L. Chavarrova</td>
</tr>
<tr>
<td>Croatian Society of Nuclear Medicine</td>
<td>M. Franceschi</td>
<td>D. Snajder</td>
</tr>
<tr>
<td>Cypriot Society of Nuclear Medicine</td>
<td>D. Kyprianou</td>
<td>R.K. Demetrioudu</td>
</tr>
<tr>
<td>Czech Society of Nuclear Medicine</td>
<td>M. Simonek</td>
<td>P. Koranda</td>
</tr>
<tr>
<td>Danish Society of Clinical Physiology and</td>
<td>L.T. Jensen</td>
<td>P. Hovind</td>
</tr>
<tr>
<td>Nuclear Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutch Society of Nuclear Medicine</td>
<td>A. Glaudemans</td>
<td>R. Kejser</td>
</tr>
<tr>
<td>Estonian Nuclear Medicine Society</td>
<td>S. Nazaranko</td>
<td>K. Ulst</td>
</tr>
<tr>
<td>Finnish Society of Nuclear Medicine</td>
<td>H. Musalo</td>
<td>K. Timonen</td>
</tr>
<tr>
<td>Macedonian Society of Nuclear Medicine</td>
<td>D. Mladnova</td>
<td>A. Ugrinska</td>
</tr>
<tr>
<td>French Society of Nuclear Medicine</td>
<td>F. Cachin</td>
<td>J-P. Vuillez</td>
</tr>
<tr>
<td>German Society of Nuclear Medicine</td>
<td>B. Krause</td>
<td>K. Herrmann</td>
</tr>
<tr>
<td>George de Hevesy Hungarian Society of NM</td>
<td>T. Györke</td>
<td>L. Pavics</td>
</tr>
<tr>
<td>Georgian Nuclear Medicine Specialists</td>
<td>N. Shengelia</td>
<td>K. Shamatava</td>
</tr>
<tr>
<td>Hellenic Society of Nuclear Medicine &amp; Biology</td>
<td>A. Fotopoulos</td>
<td>V.C. Prassopoulos</td>
</tr>
<tr>
<td>Icelandic Society of Nuclear Medicine</td>
<td>to be nominated</td>
<td>to be nominated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SOCIETY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irish Nuclear Medicine Association</td>
<td>M. O’Connell</td>
<td>R. Killeen</td>
</tr>
<tr>
<td>Israeli Society of Nuclear Medicine</td>
<td>Z. Bar-Sever</td>
<td>Z. Keidar</td>
</tr>
<tr>
<td>Italian Society of Nuclear Medicine</td>
<td>R. Giubbini</td>
<td>M.L. DeRimini</td>
</tr>
<tr>
<td>Latvian Society of Nuclear Medicine</td>
<td>M. Kalnina</td>
<td>J. Lekova</td>
</tr>
<tr>
<td>Lithuanian Society of Nuclear Medicine</td>
<td>S. Sedina</td>
<td>D. Vajauskas</td>
</tr>
<tr>
<td>Luxembourg Society of Nuclear Medicine</td>
<td>C. Alis</td>
<td>J. Zhang-Yin</td>
</tr>
<tr>
<td>Maltese Association of Radiologists and</td>
<td>M.A. Aquila</td>
<td>A. Mallika</td>
</tr>
<tr>
<td>Nuclear Medicine Physicians</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norwegian Society of Nuclear Medicine</td>
<td>T.C. Adamsen</td>
<td>R. Sundset</td>
</tr>
<tr>
<td>Polish Society of Nuclear Medicine</td>
<td>A. Sowa-Starczak</td>
<td>A. Pietrzak</td>
</tr>
<tr>
<td>Portuguese Society of Nuclear Medicine</td>
<td>A.P. Moreira</td>
<td>R. Silva</td>
</tr>
<tr>
<td>Romanian Society of Nuclear Medicine</td>
<td>D. Piciu</td>
<td>C.R. Stainviciu</td>
</tr>
<tr>
<td>Russian Society of Nuclear Medicine</td>
<td>P. Runyanchev</td>
<td>V. Sukhov</td>
</tr>
<tr>
<td>Serbian Nuclear Medicine Society</td>
<td>J. Mihalovic</td>
<td>V. Antkovic</td>
</tr>
<tr>
<td>Slovak Society of Nuclear Medicine</td>
<td>L. Kaliska</td>
<td>E. Takaciovna</td>
</tr>
<tr>
<td>Slovenian Society of Nuclear Medicine</td>
<td>I. Zagar</td>
<td>K. Zaitel</td>
</tr>
<tr>
<td>Spanish Society of Nuclear Medicine</td>
<td>L. Garcia</td>
<td>R. Rua-Grizarr</td>
</tr>
<tr>
<td>Swedish Society of Nuclear Medicine</td>
<td>E. Trägårdh</td>
<td>A. Larson-Stromvall</td>
</tr>
<tr>
<td>Swiss Society of Nuclear Medicine</td>
<td>F. Forrer</td>
<td>M. Wisemeyer</td>
</tr>
<tr>
<td>Turkish Society of Nuclear Medicine</td>
<td>Z. Özcan</td>
<td>L.O. Ayto</td>
</tr>
<tr>
<td>Ukrainian Society of Nuclear Medicine</td>
<td>to be nominated</td>
<td>to be nominated</td>
</tr>
</tbody>
</table>
## UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

nominated from full UEMS Member Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRIA</td>
<td>R. Lipp</td>
<td>M. Gabriel</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>K. Spaepen</td>
<td>G. Moulin-Romsee</td>
</tr>
<tr>
<td>BULGARIA</td>
<td>E. Piperkova</td>
<td>A. D. Tzanevska</td>
</tr>
<tr>
<td>CROATIA</td>
<td>D. Huic</td>
<td>S. Kusacic Kuna</td>
</tr>
<tr>
<td>CYPRUS</td>
<td>R. K. Demetriadou</td>
<td></td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>O. Lang</td>
<td>M. Kaminek</td>
</tr>
<tr>
<td>DENMARK</td>
<td>S. Hess</td>
<td>L. T. Jensen</td>
</tr>
<tr>
<td>ESTONIA</td>
<td>E. Kelk</td>
<td>A. Paksi</td>
</tr>
<tr>
<td>FINLAND</td>
<td>K. Timonen</td>
<td>J. Kemppainen</td>
</tr>
<tr>
<td>FRANCE</td>
<td>E. Gremillet</td>
<td>J. L. Peleter</td>
</tr>
<tr>
<td>GERMANY</td>
<td>W. Brenner</td>
<td>M. Gotthardt</td>
</tr>
<tr>
<td>GREECE</td>
<td>S. Koukouraki</td>
<td>I. Iakovou</td>
</tr>
<tr>
<td>HUNGARY</td>
<td>L. Pavics</td>
<td>I. Szilvasi</td>
</tr>
<tr>
<td>IRELAND</td>
<td>S. Skehan</td>
<td>R. Mcdermott</td>
</tr>
<tr>
<td>ITALY</td>
<td>A. Carmelilo</td>
<td>D. Deandres</td>
</tr>
<tr>
<td>LATVIA</td>
<td>I. Veere</td>
<td>A. Berzina</td>
</tr>
<tr>
<td>LITHUANIA</td>
<td>D. Vajauskas</td>
<td>N. Jurkene</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>P. Paulus</td>
<td>C. Picard</td>
</tr>
<tr>
<td>MALTA</td>
<td>M. A. Aquilina</td>
<td>A. Malta</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>D. Wyndaele</td>
<td>L. P. Antas-Bouda</td>
</tr>
<tr>
<td>NORWAY</td>
<td>A. R. Midha</td>
<td>M. Revheim</td>
</tr>
<tr>
<td>POLAND</td>
<td>M. Dzuk</td>
<td>B. Birkenfeld</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>L. Salgado</td>
<td>T. Cruz Ferreira</td>
</tr>
<tr>
<td>ROMANIA</td>
<td>G. Andries</td>
<td>R. Mititelu</td>
</tr>
<tr>
<td>SERBIA</td>
<td>V. Antiko</td>
<td>J. Mihalovic</td>
</tr>
<tr>
<td>SLOVAKIA</td>
<td>A. Vondrak</td>
<td>P. Pavinec</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>S. Gaberscek</td>
<td>D. Hoastnik</td>
</tr>
<tr>
<td>SPAIN</td>
<td>A. Sorriano</td>
<td>F. Pons</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>C. Wassberg</td>
<td>E. Toagardh</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>A. Boubaker</td>
<td>G. Goerres</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>Y. Du</td>
<td>S. Diedarevic</td>
</tr>
</tbody>
</table>

nominated from UEMS Associate Member Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>TURKEY</td>
<td>G. Altun</td>
<td>Z. Ocan</td>
</tr>
</tbody>
</table>

nominated from UEMS Observer Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRAEL</td>
<td>A. Steinmetz</td>
<td>M. Quastel</td>
</tr>
</tbody>
</table>
EXECUTIVE COMMITTEE

President  S. Mirzaei (Austria)
Secretary & Treasurer R. Hustinx (Belgium)
Member  A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION

Chair  Z. Özcan (Turkey)
Members  A. Boubaker (Switzerland)
I. Kulikiene (Lithuania)
S. I. Carrilho Vaz (Portugal)
J. R. Garcia Garalín (Spain)

EDUCATION & SYLLABUS

Chair  R. Hustinx (Belgium)
Members  J. Darcourt (France)
H. B. Sayman (Turkey)
D. Huic (Croatia)
T. V. Bogsrud (Norway)
P. Castellucci (Italy)

CME ACCREDITATION

Chair  M. Fansad (Italy)
Members  E. Lopci (Italy)
A. Haug (Austria)
S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair  J. Prior (Switzerland)
Committee Members  A. García-Burillo (Spain)
N. Mutluoka (Norway)
P. Van Boxem (Belgium)
M. L. Hall (United Kingdom)
M. Bajc (Sweden)
Ex officio:  S. Mirzaei (Austria)
Corresponding Members  F. Gesel (Germany)
A. Jiménez Hefferman (Spain)
I. Sippo-Tuusunen (Finland)
N. G. Hartman (United Kingdom)
S. E. Bouzoucouf (Algeria)
A. Ciarmiello (Italy)
L. Torres (Cuba)

Welcome and Introduction  Joe O’Sullivan (Chair), UK
Revealing Gaps in the Advanced Prostate Cancer Treatment Landscape  Noel Clarke, UK
Elena Castro, Spain
Precision Medicine: A New Era of Imaging-based Patient Selection  Wim Oyen, The Netherlands
Radiopharmaceuticals in Advanced Prostate Cancer: Past and Future  Joe O’Sullivan, UK
Panel discussion: Maximising MDT collaboration in clinical practice  Led by Joe O’Sullivan, all

This symposium may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities
This symposium is not intended for US healthcare professionals
GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE
Certificates of Attendance will be available in your myEANM Area after the congress.

CLOSING SESSION
The Congress Closing will be broadcasted on October 23, 2021. All registered delegates can join.

CME CREDITS
The EANM'21 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The fourteen EANM'21 CME Sessions have been accredited with 21 European CME credits (ECMEC®s), means 1,5 credits per session.

The twelve EANM'21 Pre-Congress Symposia have been accredited with 30 European CME credits (ECMEC®s), means 2,5 credits per session.

The event has been judged according to the European Qualifications Framework (EQF) Level 8.

The twelve EANM'21 Pre-Congress Symposia that will be held on 20-23 of October and 4-6 & 11-13 of October respectively, as well as the entire congress, is accredited with 30 European CME credits (ECMEC®s).

The event has been judged according to the European Qualifications Framework (EQF) Level 8.

For any questions, please have look at the FAQs first (to be found at the virtual information desk in the congress lobby) as most questions will probably be answered there and then contact us via the info desk in the Lobby of the virtual congress.

Contact us via:
- Email: office@eanm.org
- Phone: +43 1 890 44 27

For CME credits, as well as the entire congress, an evaluation form must also be completed for each session attended.

EANM MEMBERS’ ASSEMBLY
The Members’ Assembly will be held virtually: EANM Members’ Assembly Saturday, October 16, 2021 16:00 – 18:00 CEST | online

Further details will be provided in due time via e-mail to all eligible participants.

Please note: Only EANM members in good standing (having paid their membership dues for the year 2021) are eligible to attend the Members’ Assembly.

EBAMP ACCREDITATION
EBAMP accredits the EANM’21 Congress and Pre Congress Symposia that will be held on 20-23 of October and 4-6 & 11-13 of October respectively, as CPD event for Medical Physicists at EQF Level 8.

The event has been judged according to the EBAMP protocol and it has been assigned CPD credit points 55.

INSURANCE & LIABILITY
Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

OPENING CONCERT
At the end of the first congress day, starting at 19:30, there will be the Opening Concert by the party band Bad Powells. During the concert, we invite you to discover the chat function and network with your colleagues!

Join us on Wednesday, October 20, 2021 at 19:30-20:30.

SOCIAL MEDIA AND NEWSLETTER
For up-to-date information follow us on our Social Media Channels and subscribe to the Congress Newsletter!

Facebook @officialEANM
Twitter @officialEANM
LinkedIn @officialEANM
YouTube @officialEANM
Newsletter Click here for Subscription

TICKET AVAILABILITY
Please note that the deadline for purchasing a ticket for the main congress is October 23, 2021. This ticket will grant access to the main congress days (October 20-23, 2021) plus access to all on-demand material (including collection of CME credits) for 2 more months (until December 31, 2021).

The ticket for all Pre-Congress Symposia (PCS) will also be available for purchase until October 23, 2021. Of course, live interaction will be limited to the specific date and time of broadcasting of each PCS. However, the ticket grants access to the on-demand material of all PCS until December 31, 2021 (including collection of CME credits) as well.
COMMITTEE INTEREST GROUP MEETINGS DURING EANM’21

VIRTUAL COMMITTEE INTEREST GROUP MEETINGS

EANM Bone and Joint Committee
T. Van den Wyngaert Tuesday, October 19 14:45-15:30
EANM Dosimetry Committee
J. Gear Monday, October 18 13:45-14:30
EANM Drug Development Committee
J. Vercouillie Tuesday, October 19 10:45-11:30
EANM Infection & Inflammation Committee
O. Gheysens Tuesday, October 19 12:45-13:30
EANM Neuroimaging Committee
S. Morbelli Tuesday, October 19 16:45-17:30
EANM Oncology and Theranostics Committee
K. Herrmann Monday, October 18 15:45-17:30
EANM Paediatrics Committee
P. Zucchetta Tuesday, October 19 15:45-16:30
EANM Physics Committee
D. Visvikis Monday, October 18 11:45-12:30
EANM Radiation Protection Committee
S. Holm Tuesday, October 19 09:45-10:30
EANM Radiopharmacy Committee
M. Part Monday, October 18 12:45-13:30
EANM Technologists Committee
A. Santos Tuesday, October 19 13:45-14:30
EANM Thyroid Committee
L. Giovanella Monday, October 18 09:45-10:30

AGENDA

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15–16:25</td>
<td>Welcome and introduction</td>
<td>Shaunak Navalkissoor</td>
</tr>
<tr>
<td>16:25–16:45</td>
<td>Moving towards precision medicine with RLT: Advances in imaging</td>
<td>Vikas Prasad</td>
</tr>
<tr>
<td>16:45–17:05</td>
<td>Moving towards precision medicine with RLT: Advances in blood biomarkers</td>
<td>Andrea Frilling</td>
</tr>
<tr>
<td>17:05–17:20</td>
<td>Moving towards precision medicine with RLT: Evolving theranostics in and beyond NETs</td>
<td>Shaunak Navalkissoor</td>
</tr>
<tr>
<td>17:20–17:40</td>
<td>How can we make the best use of all tools available for optimal patient outcomes?</td>
<td>Panel discussion</td>
</tr>
<tr>
<td>17:40–17:45</td>
<td>Summary and conclusion</td>
<td>Shaunak Navalkissoor</td>
</tr>
</tbody>
</table>

This symposium is accessible only to healthcare professionals registered to EANM 2021.
PLENARY SESSIONS

1. Wednesday, October 20, 2021 | 09:10 - 10:00
   • Highlights Lecture
     Presenters: Irene Burger (Switzerland), Nathalie Albert (Germany)

2. Wednesday, October 20, 2021 | 14:40 - 16:00
   • Tharonostics Applications and Challenges (incl. Marie Curie Lecture)
     Chairpersons: Jolanta Kunkowska (Poland), Benjamin Guillot (France)
     - We are Tharonostics, Benjamin Guillot (France)
     - PSMA Tharonostics in 2023, Daniela Oprea-Lager (Netherlands)
     - Marie Curie Lecture: Other New Tharonostics, Rodney Hicks (Australia)
     - Handling Challenges, Laura Evangelista (Italy)
     - Risk Analysis in Radionuclide Therapy, Rudi Dierckx (Netherlands)
     - Tech Challenges, Andrea Santos (Portugal)
     - Reimbursement Challenges, Jolanta Kunkowska (Poland)
     - Discussion, All Speakers

PLENARY SESSIONS

3. Thursday, October 21, 2021 | 13:30 - 14:50
   • Conventional Nuclear Medicine - Oldies but Goldies
     Chairpersons: Ora Israel (Israel), Fred Verzijlbergen (Netherlands)
     - Why some Scans are Evergreen, Ora Israel (Israel)
     - Bone Scan, Gopinath Gnanasegaran (United Kingdom)
     - Thyroid Scan, Evanthia Giannoula Karamanou (Greece)
     - Renal Scan, Manka Kainina (Latvia)
     - V/Q Scan, Patrick Pilkington (Spain)
     - Parathyroid Imaging, Petra Petranović Ovčariček (Croatia)
     - Lessons from the Past, Fred Verzijlbergen (Netherlands)
     - Discussion, All Speakers

4. Friday, October 22, 2021 | 13:30 - 14:50
   • Isotopes’ Past and Future
     Chairpersons: Jane Sosabowski (United Kingdom), Peter Laverman (Netherlands)
     - The Importance of the Isotopes, Jane Sosabowski (United Kingdom)
     - Clinical Applications of Alpha vs Beta, Matthias Eiber (Germany)
     - New Isotopes on the Blocks, Ulli Köster (France)
     - Isotopes’ Availability, Verena Pichler (Austria)
     - Zr and Friends, Danielle Vugts (Netherlands)
     - Beta Emitters for Surface Therapy, Paolo Castellucci (Italy)
     - The Best has yet to Come, Peter Laverman (Netherlands)
     - Discussion, All Speakers

The Plenary Sessions are the most prestigious sessions of EANM and organized by the Congress Chair. Each Plenary covers a different topic and will put a spotlight on the different aspects and points of view.

As a novelty for the EANM Congress, the Highlights Session will be the start of the congress – pointing out the most interesting sessions and hot abstracts, thus you do not miss them in the following days.

However, not a novelty is the plan to start all plenaries, once again, with a musical intro.
## PRE-CONGRESS SYMPOSIAS

**DATES: OCT 4-13, 2021**

<table>
<thead>
<tr>
<th><strong>PRE-CONGRESS SYMPOSIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong></td>
</tr>
<tr>
<td><strong>2</strong></td>
</tr>
<tr>
<td><strong>3</strong></td>
</tr>
<tr>
<td><strong>4</strong></td>
</tr>
<tr>
<td><strong>5</strong></td>
</tr>
<tr>
<td><strong>6</strong></td>
</tr>
</tbody>
</table>

## PRE-CONGRESS SYMPOSIAS

<table>
<thead>
<tr>
<th><strong>PRE-CONGRESS SYMPOSIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7</strong></td>
</tr>
<tr>
<td><strong>8</strong></td>
</tr>
<tr>
<td><strong>9</strong></td>
</tr>
<tr>
<td><strong>10</strong></td>
</tr>
<tr>
<td><strong>11</strong></td>
</tr>
<tr>
<td><strong>12</strong></td>
</tr>
</tbody>
</table>
## CONTINUING MEDICAL EDUCATION (CME) SESSIONS

<table>
<thead>
<tr>
<th>CME Session</th>
<th>Date/Time/Location</th>
<th>Title</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Wednesday, October 20, 2021</td>
<td>10:15 - 11:45</td>
<td>Channel 1</td>
</tr>
<tr>
<td>2</td>
<td>Wednesday, October 20, 2021</td>
<td>12:00 - 13:30</td>
<td>Channel 1</td>
</tr>
<tr>
<td>3</td>
<td>Wednesday, October 20, 2021</td>
<td>16:15 - 17:45</td>
<td>Channel 1</td>
</tr>
<tr>
<td>4</td>
<td>Wednesday, October 20, 2021</td>
<td>18:00 - 19:30</td>
<td>Channel 1</td>
</tr>
<tr>
<td>5</td>
<td>Thursday, October 21, 2021</td>
<td>09:00 - 10:30</td>
<td>Channel 1</td>
</tr>
<tr>
<td>6</td>
<td>Thursday, October 21, 2021</td>
<td>10:45 - 12:15</td>
<td>Channel 1</td>
</tr>
<tr>
<td>7</td>
<td>Thursday, October 21, 2021</td>
<td>15:05 - 16:35</td>
<td>Channel 1</td>
</tr>
<tr>
<td>8</td>
<td>Thursday, October 21, 2021</td>
<td>16:50 - 18:20</td>
<td>Channel 1</td>
</tr>
<tr>
<td>9</td>
<td>Friday, October 22, 2021</td>
<td>09:00 - 10:30</td>
<td>Channel 1</td>
</tr>
<tr>
<td>10</td>
<td>Friday, October 22, 2021</td>
<td>10:45 - 12:15</td>
<td>Channel 1</td>
</tr>
<tr>
<td>11</td>
<td>Friday, October 22, 2021</td>
<td>15:05 - 16:35</td>
<td>Channel 1</td>
</tr>
<tr>
<td>12</td>
<td>Friday, October 22, 2021</td>
<td>16:50 - 18:20</td>
<td>Channel 1</td>
</tr>
<tr>
<td>13</td>
<td>Saturday, October 23, 2021</td>
<td>09:00 - 10:30</td>
<td>Channel 1</td>
</tr>
<tr>
<td>14</td>
<td>Saturday, October 23, 2021</td>
<td>10:45 - 12:15</td>
<td>Channel 1</td>
</tr>
</tbody>
</table>

Continuing Medical Education will span over all days of the EANM’21 main congress days. EANM applied for CME accreditation at EACCME®. The exact number of CME credits granted will be announced after confirmation.
TECHNOLOGISTS’ TRACK

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

CONTINUING TECHNOLOGIST EDUCATION (CTE) SESSIONS

1. Tech Guide Launch
   Technologists Committee / SNMMI

2. Managing the Paediatric Patient in Nuclear Medicine Departments
   Technologists + Paediatrics Committee

3. PET/CT for RT Planning
   Technologists Committee / ESTRO

4. Cardiac PET/CT
   Technologists Committee

5. Update in Inflammation Imaging
   Technologists + Inflammation & Infection Committee

6. Radionuclide Therapy Management
   Technologists Committee

7. Research - Technologist’s Involvement
   Technologists Committee

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS’ TRACK INCLUDES 3 MINI COURSES:

1. Safety in PET/MRI
   Technologists Committee

2. Case Studies (PET/CT & PET/MRI)
   Technologists Committee

3. Case Studies (Conventional Nuclear Medicine)
   Technologists Committee

The Technologists Committee places a massive effort into delivering the most up-to-date and highest quality educational initiatives. All sessions of this track are aimed specifically at the technologist audience.
JOINT SYMPOSIA

ON-DEMAND AVAILABLE FROM
OCTOBER 20 - DECEMBER 31, 2021

1. PET/MRI in MSK - Be Hybrid!
   Bone & Joint + Inflammation & Infection + Paediatrics Committee / ESSR

2. PET-MPI vs. SPECT-MPI - Is it Worth the Price?
   Cardiovascular Committee / ASNC

3. MPI after the ISCHEMIA Trial - Still Alive?
   Cardiovascular Committee / EACVI

4. Biokinetics and Dosimetry in Intraarterial Therapy
   Dosimetry Committee / CIRSE

5. Targeting Cancer with Peptides, Fragments or Antibodies
   Drug Development + Radiopharmacy + Oncology & Theranostics Committee / SRS

6. Modifying Radiopharmaceuticals to Alter Pharmacokinetics
   Drug Development + Radiopharmacy + Translational Molecular Imaging & Therapy Committee / SRS

7. My Foot is on Fire - Find the Hot Spot
   Inflammation & Infection Committee / EASD

8. PET/CT and PET/MRI in Patients with Autoimmune Disorders
   Inflammation & Infection + Bone & Joint Committee / EULAR

9. The New ATN Diagnostic Concept in Alzheimer’s Disease
   Neuroimaging Committee / EAN

10. PET/MRI in Epilepsy
    Neuroimaging Committee / ILAE

11. Advancements in Neuro-Oncology
    Neuroimaging + Oncology & Theranostics Committee / EANO

12. Nuclear Medicine in Precision Oncology
    Oncology & Theranostics Committee / EDTC

13. Biomarkers in Lymphoma
    Oncology & Theranostics Committee / EHA

    Oncology & Theranostics Committee / EHA

15. Imaging Challenges in Multiple Myeloma - Quo Vadis 2021?
    Oncology & Theranostics Committee / EHA

16. Combination Treatments - What can Radioligand Therapy be Combined with?
    Oncology & Theranostics Committee / ESMO

17. What to Do and Not Do in Prostate Imaging
    Oncology & Theranostics Committee / EAU

18. Urological Challenges for Imaging Beyond Prostate
    Oncology & Theranostics Committee / EAU

19. Harmonisation and Standardisation
    Physics Committee / AAPM

20. Artificial Intelligence for Image Processing and Quantification
    Physics Committee / AAPM

    Physics Committee / AAPM

22. The MEDITRAD Project - Impact on Nuclear Medicine Practice
    Radiation Protection + Thyroid + Dosimetry Committee / EURAMED

23. Extremity Dosimetry - It’s in Your Hands!
    Radiation Protection + Technologists Committee / EURADOS

24. Theranostics in Thyroid Cancer Beyond Radioactive Iodine
    Thyroid + Oncology & Theranostics Committee / ESMO

25. Global Cost-Effectiveness of Different DTC Management Strategies
    Thyroid Committee / ESE / ESO

26. Imaging Mitochondria and Mitochondrial Dysfunction
    Translational Molecular Imaging & Therapy Committee / ESMI/WMIS

27. Advances in Molecular Imaging of Neurodegenerative Disorders
    Neuroimaging Committee / JSNM

28. Lancet Oncology Commission on Medical Imaging and Nuclear Medicine
    EANM / IAEA
PITFALLS & ARTEFACTS SESSIONS

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

This year there will be six Pitfalls & Artefacts Sessions. Renowned specialists will present interesting cases with challenging findings, either pitfalls and/or artefacts to improve your skills.

PITFALLS & ARTEFACTS SESSIONS

1. Pitfalls in Cardiovascular Imaging
   Cardiovascular + Physics + Technologists Committee

2. Pseudoprogression and Pseudoresponse in Brain Tumours
   Neuroimaging + Oncology Committee

3. Challenging Cases in Nuclear Neurology
   Neuroimaging Committee

4. Sentinel Lymph Node in Head & Neck, Penile and Gynaecological Cancers
   Oncology & Theranostics + Translational Molecular Imaging & Therapy Committee

5. Pitfalls & Pearls in Paediatric Musculoskeletal
   Paediatrics Committee

6. Pitfalls & Artefacts in Endocrine Imaging
   Thyroid Committee

TEACHING SESSIONS

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

This year there are six Teaching Sessions. Specialists will present interesting cases and will guide you from patients’ history through diagnosis to treatment options.

TEACHING SESSIONS

1. Imaging of Prosthetic Knee Joint Loosening - Spotlight on Quantitative and Multidisciplinary Algorithms
   Bone & Joint + Inflammation & Infection Committee / AGA

2. All About Cardiac SPECT
   Cardiovascular Committee

3. Radiobiology as a Missing Link in Improving and Understanding Nuclear Medicine
   Dosimetry + Translational Molecular Imaging & Therapy + Radiation Protection Committee

4. Immunotherapy - Assessing Organs and Events on [18 F]FDG PET/CT
   Oncology & Theranostics Committee

5. Radiation Detection and Measurement
   Radiation Protection + Physics Committee

   Translational Molecular Imaging & Therapy + Drug Development + Radiopharmacy + Technologists Committee
SPECIAL TRACK

The Special Track is a new feature within the scientific congress programme. It consists of Interviews with the Experts, Trials Sessions, Case Reports and a Special Talk. Y

INTERVIEW WITH THE EXPERT

1 Wednesday, October 20, 2021 | 10:15-10:40 | Channel 2
Therapy
Irene Virgolini & Stefano Fantie

2 Wednesday, October 20, 2021 | 11:00-11:20 | Channel 2
Imaging Myeloma
Cristina Nanni & Paolo Castellucci

3 Wednesday, October 20, 2021 | 12:00-12:45 | Channel 2
Nuclear Endocrinology

4 Wednesday, October 20, 2021 | 12:45-13:30 | Channel 2
Neuroimaging

5 Thursday, October 21, 2021 | 09:00-09:35 | Channel 2
Creating Tracers!
Uwe Haberkorn & Stefano Fantie

6 Thursday, October 21, 2021 | 09:45-10:30 | Channel 2
Paediatric NM Today

7 Thursday, October 21, 2021 | 14:00-15:00 | Channel 2
The Theranostic Unit
Physics Committee

8 Friday, October 22, 2021 | 09:00-09:30 | Channel 2
Vision Trial
Bernd Krause & Stefano Fantie

9 Friday, October 22, 2021 | 09:45-10:30 | Channel 2
The Best Young NM
Ken Herrmann & Stefano Fantie

10 Friday, October 22, 2021 | 10:45-11:30 | Channel 2
Running a Preclinical Lab in New York City

11 Friday, October 22, 2021 | 11:30-12:15 | Channel 2
New PET Tracers in Oncology

12 Friday, October 22, 2021 | 16:30-17:25 | Channel 2
Radiopharmacy Running
Clemens Decristoforo & Stefano Fantie

13 Saturday, October 23, 2021 | 09:00-09:45 | Channel 2
A Life in NM

14 Saturday, October 23, 2021 | 09:45-10:30 | Channel 2
Prostate Cancer Imaging

15 Saturday, October 23, 2021 | 11:15-12:15 | Channel 2
Reflections on the Development of PET and Theranostics Downunder – A 25-Year Journey into the Light

THE TOP 3 TRIALS SESSIONS

1 Wednesday, October 20, 2021 | 16:15-17:45 | Channel 2
Prostate

2 Thursday, October 21, 2021 | 15:05-16:35 | Channel 2
Rest of Science

3 Friday, October 22, 2021 | 15:05-16:35 | Channel 2
Nuclear Endocrinology

CASE REPORTS SESSION

1 Wednesday, October 20, 2021 | 18:00-19:30 | Channel 2
What’s the Case? Report it Now!

SPECIAL TALK

1 Saturday, October 23, 2021 | 10:45-11:15 | Channel 2
Prostate Cancer along the Yellow Brick Road
Declan Murphy
CUTTING EDGE SCIENCE TRACK

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

The Cutting Edge Science Track (formerly known as the International Symposium on Dosimetry and Molecular Radiotherapy) will take place during the 34th Annual Congress of the European Association of Nuclear Medicine.

CUTTING EDGE SCIENCE TRACK

209 TROP Session: Radiobiology Meets Dosimetry
309 TROP Session: Dosimetry Methods
509 TROP Session: Lu-177 Dosimetry
609 TROP Session: Clinical Dosimetry and Radioembolisation
809 TROP Session: Diagnostic Dosimetry
909 Featured Session: From Safety Culture to Fieldwork in Radiation Protection
1009 TROP Session: New Imaging Equipment and Techniques
1109 Featured Session: Software Developments in Total Body PET

1209 TROP Session: Imaging of Non-Standard Radionuclides
1309 Featured Session: Harmonisation and Standardisation
1409 TROP Session: Data Analysis
1609 Featured Session: PET Reconstructions and Corrections
1709 TROP Session: Data/Image Processing Based on Deep Learning
1809 TROP Session: Artificial Intelligence – Clinical Applications
1909 TROP Session: Radiomics – Methodology and Clinical Applications
M2M TRACK

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

M2M - The 8th “From Molecule to Man” Track, covering translational developments in Imaging and Therapy will take place during the 34th Annual Congress of the European Association of Nuclear Medicine.

M2M TRACK

208 TROP Session: Prostate Cancer Imaging – The Various Angles of Attack
308 TROP Session: It’s the Alpha, not the Beta
508 TROP Session: Theranostics – Various Targets
608 Featured Session: Mapping Brain Structures
808 Featured Session: Functional Brain Imaging
908 TROP Session: Tumour Microenvironment and Immunotherapy
1108 TROP Session: Peptides Only!
1208 TROP Session: Radiochemistry – Cook it or Leave it
1308 TROP Session: Out of the Box Innovations

CLINICAL ONCOLOGY TRACK

ON-DEMAND AVAILABLE FROM OCTOBER 20 - DECEMBER 31, 2021

The Clinical Oncology Track assembles the accepted abstracts which were submitted to the field of Oncology. Oncological diseases represent in average >80% of the daily clinical workload in Nuclear Medicine. Accordingly it is of utmost importance to stay ahead of the curve and be informed what are the most important scientific developments.

CLINICAL ONCOLOGY TRACK

210 TROP Session: Head and Neck / Colorectal
310 TROP Session: Breast
510 TROP Session: Lung
610 TROP Session: Gastro-Intestinal
810 TROP Session: Neuroendocrine
910 Featured Session: Radioguided Surgery and Sentinel Lymph Nodes
1110 TROP Session: Prostate Staging
1210 TROP Session: Prostate Varia and Others
1310 TROP Session: Prostate BC Recurrence
1410 TROP Session: Local Radionuclide Therapy and Other Oncological Treatments
1610 Featured Session: Prostate Cancer Therapy
1710 Featured Session: Neuroendocrine Therapy
1810 TROP Session: Lymphoma and Other Hematological Tumours
1910 TROP Session: Gynaecological and Melanoma
### FURTHER ORAL PRESENTATIONS

<table>
<thead>
<tr>
<th>211</th>
<th>Featured Session: Quantification in MPI – A Must!</th>
</tr>
</thead>
<tbody>
<tr>
<td>311</td>
<td>Featured Session: Show me your Heart!</td>
</tr>
<tr>
<td>511</td>
<td>Featured Session: New Kids on the Cardiovascular Block!</td>
</tr>
<tr>
<td>611</td>
<td>TROP Session: Top of Cardiovascular and Soft Tissue Infection/Inflammation Imaging</td>
</tr>
<tr>
<td>811</td>
<td>TROP Session: Top of Nuclear Medicine in COVID-19</td>
</tr>
<tr>
<td>911</td>
<td>Featured Session: Molecular Imaging of Alzheimer’s Disease</td>
</tr>
<tr>
<td>1111</td>
<td>Featured Session: Molecular Imaging of Movement Disorders</td>
</tr>
<tr>
<td>1211</td>
<td>Featured Session: Amino Acid Imaging of Gliomas</td>
</tr>
<tr>
<td>1311</td>
<td>Featured Session: Brain Tumor Imaging – More than Amino Acids in Gliomas</td>
</tr>
<tr>
<td>1411</td>
<td>Featured Session: Novel Molecular Brain Imaging Applications</td>
</tr>
<tr>
<td>1611</td>
<td>TROP Session: Paediatric Nuclear Medicine</td>
</tr>
<tr>
<td>1711</td>
<td>TROP Session: General Nuclear Medicine</td>
</tr>
<tr>
<td>1811</td>
<td>TROP Session: Nuclear Thyroidologist and Thyroid Cancer Management – Current Update and Future Perspectives</td>
</tr>
<tr>
<td>1911</td>
<td>TROP Session: Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders</td>
</tr>
</tbody>
</table>

### e-POSTER PRESENTATIONS

<table>
<thead>
<tr>
<th>212</th>
<th>e-Poster Presentation Session 1: The Nuclear Cardiovascular World at its Best</th>
</tr>
</thead>
<tbody>
<tr>
<td>312</td>
<td>e-Poster Presentation Session 2: Dosimetry</td>
</tr>
<tr>
<td>512</td>
<td>e-Poster Presentation Session 3: More on Infection &amp; Inflammation Imaging and NM in COVID-19</td>
</tr>
<tr>
<td>612</td>
<td>e-Poster Presentation Session 4: Radiochemistry</td>
</tr>
<tr>
<td>812</td>
<td>e-Poster Presentation Session 5: Theranostics</td>
</tr>
<tr>
<td>912</td>
<td>e-Poster Presentation Session 6: Molecular Brain Imaging</td>
</tr>
<tr>
<td>1012</td>
<td>e-Poster Presentation Session 7: An Overview on Endocrine Disease</td>
</tr>
<tr>
<td>1112</td>
<td>e-Poster Presentation Session 8: Imaging in Recurrent Prostate Cancer</td>
</tr>
<tr>
<td>1212</td>
<td>e-Poster Presentation Session 9: Imaging in Primary Prostate Cancer</td>
</tr>
<tr>
<td>1312</td>
<td>e-Poster Presentation Session 10: Lymphoma and Other Hematological Diseases</td>
</tr>
<tr>
<td>1412</td>
<td>e-Poster Presentation Session 11: Neuroendocrine and Lymphoma</td>
</tr>
<tr>
<td>1612</td>
<td>e-Poster Presentation Session 12: Head Neck / Breast / Lung</td>
</tr>
<tr>
<td>1712</td>
<td>e-Poster Presentation Session 13: Image Acquisition / Reconstruction / Processing 1</td>
</tr>
<tr>
<td>1812</td>
<td>e-Poster Presentation Session 14: Image Acquisition / Reconstruction / Processing 2</td>
</tr>
<tr>
<td>1912</td>
<td>e-Poster Presentation Session 15: AI and Radiomics</td>
</tr>
</tbody>
</table>
e-POSTER SESSIONS

01 Preclinical Studies -> Medical Preclinical -> Preclinical Oncology
02 Preclinical Studies -> Medical Preclinical -> Preclinical Therapy
03 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Breast
Including Mesothelioma
04 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lung
05 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)
06 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Neuroendocrine (Pancreatic and Others)
07 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Colorectal
08 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Prostate Other
09 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Thyroid
10 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gynaecological
11 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Lymphoma
12 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Melanoma
13 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Any Other Malignant (including Primary of Unknown Origin)
14 Imaging Clinical Studies -> Other Oncological Clinical Study -> Radioguided Surgery and Radiation Therapy Planning
15 Imaging Clinical Studies -> Other Oncological Clinical Study -> Sentinel Node
16 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Perfusion
17 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Heart Failure (including Sarcoidosis and Amyloidosis)
18 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Other Cardiovascular Imaging (including Plaque)
19 Imaging Clinical Studies -> Endocrinological Imaging Clinical Study -> Endocrinology (including Thyroid Benign)
20 Imaging Clinical Studies -> Infection and Inflammation -> Vasculitis and Endocarditis
21 Imaging Clinical Studies -> Infection and Inflammation -> Other Infections and Inflammatory Diseases
22 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Neuroendocrine Therapy
23 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Prostate Cancer Therapy
24 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Thyroid Therapy
25 Therapy Clinical Study -> Oncological Therapy Clinical Study -> Other Oncological Treatments
26 Technical Studies -> Radiation Protection -> Radiation Exposure and Protection
e-POSTER SESSIONS

27 Technical Studies -> Dosimetry and Radiobiology -> Preclinical Dosimetry and Radiobiology
28 Technical Studies -> Dosimetry and Radiobiology -> Clinical Dosimetry
29 Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - SPECT
30 Technical Studies -> Radiopharmacy/Radiochemistry -> New Radiopharmaceuticals - PET
31 Technical Studies -> Radiopharmacy/Radiochemistry -> Radiopharmaceutical Preparation and Quality Control
32 Covid Studies -> Clinical Study
33 Covid Studies -> Other Study (incl. Organisation)
34 Bone & Joint Malignant and Benign Diseases
35 General Isotopic Imaging
36 Technologist Digital ePoster
37 Paediatrics

EARL PET/CT ACCREDITATION NOW OFFERS 

18F STANDARDS 1 & 2, 68GA, 89ZR AND SOON 18F/11C BRAIN PET/CT, HARMONISATION

EARL provides unparalleled support for tomorrow's research needs with today's molecular imaging data.
# PRE-Congress Symposia

## October 4–6, 2021

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Congress Symposium 1</td>
<td>Pre-Congress Symposium 3</td>
<td>Pre-Congress Symposium 5</td>
<td></td>
</tr>
<tr>
<td>09:00 - 12:00</td>
<td>Dosimetry + Translational Molecular Imaging &amp; Therapy Committee</td>
<td>Bone &amp; Joint + Oncology &amp; Theranostics + Paediatrics Committee</td>
<td>Neuroimaging + Radiopharmacy + Drug Development Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pre-Clinical Dosimetry and Extrapolations from Animal Models to Humans</td>
<td>Radiosynoviorthesis - Master Class in Science and Practice</td>
<td>Imaging of Protein Misfolding in Parkinson’s Disease and Related Disorders - Where are we and What do we need?</td>
<td></td>
</tr>
<tr>
<td>14:00 - 17:00</td>
<td>Pre-Congress Symposium 2</td>
<td>Pre-Congress Symposium 4</td>
<td>Pre-Congress Symposium 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular + Physics Committee</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Oncology &amp; Theranostics Committee / ESTRO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Signal Quantification in Cardiac SPECT – Dream or Reality?</td>
<td>Structured Reporting of Oncology PET-CT – Are we Ready for Template-Based Reporting?</td>
<td>Oligocare Concept in Radiation Oncology</td>
<td></td>
</tr>
</tbody>
</table>

## October 11–13, 2021

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Congress Symposium 7</td>
<td>Pre-Congress Symposium 9</td>
<td>Pre-Congress Symposium 11</td>
<td></td>
</tr>
<tr>
<td>09:00 - 12:00</td>
<td>Radiation Protection + Dosimetry Committee</td>
<td>Oncology &amp; Theranostics + Thyroid Committee / ESES</td>
<td>Inflammation &amp; Infection Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biokinetic Modelling in Cancer Therapy and Clinical Impact</td>
<td>Nuclear Endocrinology in the Era of Precision Medicine</td>
<td>Light in the Dark - Hybrid Imaging in Patients with Sepsis/Bacteremia</td>
<td></td>
</tr>
<tr>
<td>14:00 - 17:00</td>
<td>Pre-Congress Symposium 8</td>
<td>Pre-Congress Symposium 10</td>
<td>Pre-Congress Symposium 12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiopharmacy + Oncology &amp; Theranostics + Drug Development Committee</td>
<td>Physics + Dosimetry Committee</td>
<td>Technologists Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Radionuclides for Theranostics on the Horizon</td>
<td>Total Body PET</td>
<td>PET/MR - The Cross Path of Morphology and Functionality</td>
<td></td>
</tr>
</tbody>
</table>
### Final Programme

#### Wednesday, October 20, 2021
- **Opening Ceremony**
- **Plenary 1**
  - Special Track: Interview with the Expert 1 - Therapy
  - CME 1: Oncology & Theranostics: Post-Medical Education
- **CME 2**
  - Special Track: Imaging Myeloma (10:15 - 10:45)
- **CME 3**
  - Special Track: Interview with the Expert 2 - Nuclear Endocrinology (12:00 - 12:30)
- **CME 4**
  - Special Track: The Battle Continues - The Battle Continues - The Battle Continues (14:40 - 15:10)
- **Opening Concert**

#### Thursday, October 21, 2021
- **Opening Ceremony**
- **Plenary 2**
  - Interview with the Expert 3 - German Federal Medium-Sized Businesses (10:15 - 10:45)
- **CME 5**
  - Special Track: Interview with the Expert 4 - Neuroradiology (14:40 - 15:10)
- **CME 6**
  - Special Track: Interview with the Expert 5 - Nuclear Medicine (12:00 - 12:30)
- **CME 7**
  - Special Track: The Top 3 Trials Sessions 2: Best of the Best (13:30 - 14:00)
- **CME 8**
  - Special Track: Interview with the Expert 6 - Nuclear Medicine (15:00 - 15:30)
- **CME 9**
  - Special Track: Interview with the Expert 7 - Radiopharmaceuticals (13:30 - 14:00)
- **CME 10**
  - Special Track: Interview with the Expert 8 - Nuclear Medicine (14:40 - 15:10)
- **CME 11**
  - Special Track: Interview with the Expert 9 - Nuclear Medicine (15:00 - 15:30)
- **CME 12**
  - Special Track: Interview with the Expert 10 - Nuclear Medicine (16:00 - 16:30)
- **CME 13**
  - Special Track: Interview with the Expert 11 - Nuclear Medicine (17:00 - 17:30)
- **CME 14**
  - Special Track: Interview with the Expert 12 - Nuclear Medicine (18:00 - 18:30)
- **CME 15**
  - Special Track: Interview with the Expert 13 - Nuclear Medicine (19:00 - 19:30)

#### Friday, October 22, 2021
- **Opening Ceremony**
- **Plenary 3**
  - Plenary Quiz (08:45 - 09:15)
- **CME 16**
  - Special Track: Interview with the Expert 14 - Nuclear Medicine (09:45 - 10:15)
- **CME 17**
  - Special Track: Interview with the Expert 15 - Nuclear Medicine (10:45 - 11:15)
- **CME 18**
  - Special Track: Interview with the Expert 16 - Nuclear Medicine (11:45 - 12:15)
- **CME 19**
  - Special Track: Interview with the Expert 17 - Nuclear Medicine (12:45 - 13:15)
- **CME 20**
  - Special Track: Interview with the Expert 18 - Nuclear Medicine (13:45 - 14:15)
- **CME 21**
  - Special Track: Interview with the Expert 19 - Nuclear Medicine (14:45 - 15:15)
- **CME 22**
  - Special Track: Interview with the Expert 20 - Nuclear Medicine (15:45 - 16:15)
- **CME 23**
  - Special Track: Interview with the Expert 21 - Nuclear Medicine (16:45 - 17:15)
- **CME 24**
  - Special Track: Interview with the Expert 22 - Nuclear Medicine (17:45 - 18:15)
- **CME 25**
  - Special Track: Interview with the Expert 23 - Nuclear Medicine (18:45 - 19:15)

#### Saturday, October 23, 2021
- **Opening Ceremony**
- **Plenary 4**
  - Plenary Quiz (08:45 - 09:15)
- **CME 26**
  - Special Track: Interview with the Expert 24 - Nuclear Medicine (09:45 - 10:15)
- **CME 27**
  - Special Track: Interview with the Expert 25 - Nuclear Medicine (10:45 - 11:15)
- **CME 28**
  - Special Track: Interview with the Expert 26 - Nuclear Medicine (11:45 - 12:15)
- **CME 29**
  - Special Track: Interview with the Expert 27 - Nuclear Medicine (12:45 - 13:15)
- **CME 30**
  - Special Track: Interview with the Expert 28 - Nuclear Medicine (13:45 - 14:15)
- **CME 31**
  - Special Track: Interview with the Expert 29 - Nuclear Medicine (14:45 - 15:15)
- **CME 32**
  - Special Track: Interview with the Expert 30 - Nuclear Medicine (15:45 - 16:15)
- **CME 33**
  - Special Track: Interview with the Expert 31 - Nuclear Medicine (16:45 - 17:15)
- **CME 34**
  - Special Track: Interview with the Expert 32 - Nuclear Medicine (17:45 - 18:15)
- **CME 35**
  - Special Track: Interview with the Expert 33 - Nuclear Medicine (18:45 - 19:15)
ON-DEMAND CONTENT

AVAILABLE FROM OCTOBER 20, 2021 | 09:00
ON-DEMAND CONTENT

AVAILABLE FROM OCTOBER 20, 2021 09:00
Expedite treatment timelines with SIR-Spheres® during COVID-19

FLEXdose Delivery Programme
Multiple delivery options.
Any day of the week.

Order – Map – Treat
The ability to Map and Treat
Same day – Same stay – Same week

For more information please contact your Sirtex representative

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd
Sirtex Medical Europe GmbH, Joseph-Schumpeter-Allee 33, 50227 Bonn, Germany
www.sirtex.com
APM-EMEA-461 V1.0 0620
<table>
<thead>
<tr>
<th>PCS4</th>
<th>Tuesday, October 5, 2021, 14:00 - 17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Congress-Symposium 4: Structured Reporting of Oncology PET-CT - Are we Ready for Template-Based Reporting?</td>
<td></td>
</tr>
<tr>
<td>PCS-023</td>
<td>Essential Elements of PET-CT Reporting - An Overview</td>
</tr>
<tr>
<td>G. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.</td>
<td></td>
</tr>
<tr>
<td>PCS-024</td>
<td>How to Report PET-CT in Lymphoma</td>
</tr>
<tr>
<td>C. Kobe; University of Cologne, Department of Nuclear Medicine, Cologne, GERMANY.</td>
<td></td>
</tr>
<tr>
<td>PCS-025</td>
<td>How to Report PET-CT in Prostate Cancer</td>
</tr>
<tr>
<td>K. Rahbar; University Hospital Münster, Department of Nuclear Medicine, Münster, GERMANY.</td>
<td></td>
</tr>
<tr>
<td>PCS-026</td>
<td>How to Report PET-CT in Gl and HPB Cancer</td>
</tr>
<tr>
<td>S. Caminha Vaz; Champalimaud Foundation Centre for the Unknown, Nuclear Medicine, Radiopharmacology, Lisbon, PORTUGAL.</td>
<td></td>
</tr>
<tr>
<td>PCS-027</td>
<td>How to Report PET-CT in Melanoma and Myeloma</td>
</tr>
<tr>
<td>C. Nann; Azienda Ospedaliero-Universitaria di Bologna Policlínica S.Orosia, Nuclear Medicine, Bologna, ITALY.</td>
<td></td>
</tr>
<tr>
<td>PCS-028</td>
<td>How to Report PET-CT in Melanoma and Myeloma</td>
</tr>
<tr>
<td>S. Balogová; University Hospitals Leuven, Department of Nuclear Medicine, Leuven, BELGIUM.</td>
<td></td>
</tr>
<tr>
<td>PCS-029</td>
<td>How to Report PET-CT in Neuroendocrine Tumour</td>
</tr>
<tr>
<td>V. Ambrosini; University of Bologna, Policlínica S Orosia Malpighi Bologna, IMM, Nuclear Medicine, Bologna, ITALY.</td>
<td></td>
</tr>
<tr>
<td>PCS-030</td>
<td>How to Report PET-CT in Gynaecological Cancers</td>
</tr>
<tr>
<td>S. Balcázar; Complutense University of Madrid, San Carlos, Nuclear Medicine, Madrid, SPAIN.</td>
<td></td>
</tr>
<tr>
<td>PCS-031</td>
<td>How to Report PET-CT in Neuroendocrine Tumour</td>
</tr>
<tr>
<td>V. Ambrosini; University of Bologna, Policlínica S Orosia Malpighi Bologna, IMM, Nuclear Medicine, Bologna, ITALY.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PCS5</th>
<th>Wednesday, October 6, 2021, 09:00 - 12:10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Congress-Symposium 5: Imaging of Protein Misfolding in Parkinson’s Disease and Related Disorders - Where are we and What do we need?</td>
<td></td>
</tr>
<tr>
<td>PCS-034</td>
<td>Molecular Neuroimaging of PD and Related Disorders - Current State</td>
</tr>
<tr>
<td>S. Morbelli; San Martino Hospital, University of Genoa, Nuclear Medicine, Genoa, ITALY.</td>
<td></td>
</tr>
<tr>
<td>PCS-035</td>
<td>Amyloid and Tau Pathology in PD, DLB, PSP/CBD and MSA</td>
</tr>
<tr>
<td>G. Kovacs; University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, CANADA.</td>
<td></td>
</tr>
<tr>
<td>PCS-036</td>
<td>Relevance of Amyloid Imaging in Parkinson’s Disease and Related Disorders</td>
</tr>
<tr>
<td>N. Bohten; University of Michigan, Department of Radiology, Michigan, UNITED STATES OF AMERICA.</td>
<td></td>
</tr>
<tr>
<td>PCS-037</td>
<td>Tau Imaging in PSP/CBD - Ready for Clinical Trials?</td>
</tr>
<tr>
<td>H. Barthe; University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.</td>
<td></td>
</tr>
<tr>
<td>PCS-038</td>
<td>Alpha-Syn Pathology in PD, DLB, PSP/CBD and MSA</td>
</tr>
<tr>
<td>L. Walker; Newcastle University, Institute of Neuroscience, Newcastle, UNITED KINGDOM.</td>
<td></td>
</tr>
<tr>
<td>PCS-039</td>
<td>Alpha-Syn Imaging in PD, MSA and DLB - Will We Ever Get There?</td>
</tr>
<tr>
<td>J. Seibyl; Institute for Neurodegenerative Disorders, New Haven, UNITED STATES OF AMERICA.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PCS6</th>
<th>Wednesday, October 6, 2021, 14:00 - 17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Congress-Symposium 6 (EANM/ESTRO): Oligocare Concept in Radiation Oncology</td>
<td></td>
</tr>
<tr>
<td>PCS-042</td>
<td>Oligocare for Tailored Medicine</td>
</tr>
<tr>
<td>M. Guckenberger; Department of Radiation Oncology, University Hospital Zurich (USZ), Zurich, SWITZERLAND.</td>
<td></td>
</tr>
<tr>
<td>PCS-043</td>
<td>Radiation Oncologist’s Point of View</td>
</tr>
<tr>
<td>M. Sigaret; Radiotherapy and Radiosurgery Unit, Humanitas University, Pieve Emanuele, ITALY.</td>
<td></td>
</tr>
<tr>
<td>PCS-044</td>
<td>Targeted Imaging and Therapy in Oligometastases</td>
</tr>
<tr>
<td>E. Lopci; Nuclear Medicine Unit, IRCCS – Humanitas Research Hospital, Milan, ITALY.</td>
<td></td>
</tr>
<tr>
<td>PCS-046</td>
<td>The Future of Imaging in Radiotherapy</td>
</tr>
<tr>
<td>P. Oet; Department of Radiation Oncology, Indiana Network, Antwerp, BELGIUM.</td>
<td></td>
</tr>
<tr>
<td>PCS-047</td>
<td>Ongoing Projects and Initiatives</td>
</tr>
<tr>
<td>Y. Lievens; Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, BELGIUM.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PCS7</th>
<th>Monday, October 11, 2021, 09:00 - 12:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Congress-Symposium 7: Biokinetic Modelling in Cancer Therapy and Clinical Impact</td>
<td></td>
</tr>
<tr>
<td>PCS-049</td>
<td>Introduction and Overview</td>
</tr>
<tr>
<td>C. Stokke; Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, NORWAY.</td>
<td></td>
</tr>
<tr>
<td>PCS-050</td>
<td>Biokinetic Modelling and its Clinical Impact for 177Lu-PSMA Therapy of Thyroid Disease</td>
</tr>
<tr>
<td>F. Verburg; Erasmus MC, Nuclear Medicine, Rotterdam, NETHERLANDS.</td>
<td></td>
</tr>
</tbody>
</table>
**EANM’21  WORLD LEADING MEETING**
**OCTOBER 20 - 23, 2021**

**ORAL PRESENTATIONS**

---

**PCS-062**
The Technical Challenges to Provide Novel Radionuclides
R. Mikałajczak; National Centre for Nuclear Research-POLATOM, Otwock, POLAND.

**PCS-064**
Novel Radionuclides - Preclinical Proof of Concept
C. Müller; Paul Scherrer Institute, Center for Radiopharmaceutical Sciences, Zurich, SWITZERLAND.

**PCS-065**
Novel Radionuclides - But in Right Quality and for the Right Target
D. Nicolau; Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering, Bucharest, ROMANIA.

**PCS-066**
Novel Radionuclides - What Do We Already Know in Clinical Applications?
I. Rauscher; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, GERMANY.

**PCS-067**
Novel Radionuclides - Don’t Forget the Regulatory Side
D. Niculae; National Institute of Health and Medical Research (INSERM), Medical Image Processing Lab in Brest, Brest, FRANCE.

**PCS-070**
Precision Medicine in Endocrinology: The Radiopharmacist’s View
M. Fanz; University Hospital Basel, Dept. of Nuclear Medicine, Basel, SWITZERLAND.

**PCS-071**
Functional and Molecular Thyroid Imaging
L. Giovanella; Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine, Bellinzona, SWITZERLAND.

**PCS-072**
Molecular imaging of endocrine neoplasms: a practical approach for well-tailored imaging protocols
D. Taïeb; Centre Hospitalo-Universitaire Timone, Nuclear Medicine, Marseille, FRANCE.

---

**PCS-074**
Impact of Imaging on Personalized Parathyroidectomy in Primary and Renal Hyperparathyroidism
P. Petranovski Ovchar; University Hospital Center Sestre milosrdnice, Oncology and Nuclear medicine, Zagreb, CROATIA.

**PCS-075**
Integration of Molecular Imaging in the Personalized Approach to Patients with Adrenal Masses
M. Raffaelli; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Division of Endocrine and Metabolic Surgery, Department of Medical and Surgical Sciences, Rome, ITALY.

**PCS-076**
Imaging of MEN1, MEN2 and VHL - The Endocrine Surgeon’s View
F. Sebag; Aix-Marseille University, APHM, Department of Endocrine Surgery, Marseille, FRANCE.

**PCS-079**
Translation of the Technical Innovations of Total Body PET in Clinic
L. Nardò; University of California at Davis, Division of Nuclear Medicine, Davis, UNITED STATES OF AMERICA.

**PCS-080**
Clinical Applications of Total Body PET - Bern Experience
A. Rominger; University of Bern, Department of Nuclear Medicine, Bern, SWITZERLAND.

**PCS-081**
Clinical Applications of Total Body PET - Shanghai Experience
H. Shi; Shanghai Hospital of Fudan University, Department of Nuclear Medicine, Shanghai, CHINA.

**PCS-082**
Clinical and Research Benefits of a Long Axial Field-of-View System
M. Daube-Witherspoon; University of Pennsylvania, Department of Radiology, Philadelphia, UNITED STATES OF AMERICA.

**PCS-084**
Development of Detector for Total Body PET
S. Ziegler; University of Munich, Department of Nuclear Medicine, Munich, GERMANY.

**PCS-085**
Instrumentation of Total Body PET
S. Vandenberghe; Ghent University, Department of Electronics and Information Systems, Ghent, BELGIUM.

**PCS-086**
Image Reconstruction for Total Body PET
D. Wovkulic; National Institute of Health and Medical Research (INSERM), Medical Image Processing Lab in Brest, Brest, FRANCE.

**PCS-089**
Level 1 - Diagnostic Yield of FDG PET/CT in Patients with Sepsis/Bacteremia
A. L. Goodman; Centre for Infection and Diagnostics Research, King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

**PCS-090**
Level 2 - Clinical Impact and Outcome Using FDG PET/CT in Patients with Sepsis/Bacteremia
A. W. J. M. Glaudemans; University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS.

**PCS-092**
Level 3 - Cost-Effectiveness and Proposed Optimal Use of FDG PET/CT in Patients with Sepsis/Bacteremia
L. J. Koizumi; Department of Internal Medicine and Radiobud Center for Infectious Diseases, Radiobudvar, Nijmegen, NETHERLANDS.

**PCS-093**
Bonus Level - Other Tracers Beyond FDG
A. Roivainen; Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND.

**PCS-094**
Next Level - Possible Role of FDG PET/MRI
P. Veit-Haibach; University Health Network, Joint Dept. Medical Imaging, Toronto, CANADA.

---

**PCS10**
Tuesday, October 12, 2021, 14:00 - 17:00

**Pre-Congress-Symposium 10: Total Body PET**

**PCS-074**
Impact of Imaging on Personalized Parathyroidectomy in Primary and Renal Hyperparathyroidism
P. Petranovski Ovchar; University Hospital Center Sestre milosrdnice, Oncology and Nuclear medicine, Zagreb, CROATIA.

**PCS-075**
Integration of Molecular Imaging in the Personalized Approach to Patients with Adrenal Masses
M. Raffaelli; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Division of Endocrine and Metabolic Surgery, Department of Medical and Surgical Sciences, Rome, ITALY.

**PCS-076**
Imaging of MEN1, MEN2 and VHL - The Endocrine Surgeon’s View
F. Sebag; Aix-Marseille University, APHM, Department of Endocrine Surgery, Marseille, FRANCE.

**PCS10**
Tuesday, October 12, 2021, 14:00 - 17:00

**Pre-Congress-Symposium 10: Total Body PET**

---

**PCS088**
Game Intro - Sepsis/Bacteremia and the Questions from Clinicians to NM Physicians
A. L. Goodman; Centre for Infection and Diagnostics Research, King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

**PCS089**
Level 1 - Diagnostic Yield of FDG PET/CT in Patients with Sepsis/Bacteremia
A. W. J. M. Glaudemans; University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS.

**PCS090**
Level 2 - Clinical Impact and Outcome Using FDG PET/CT in Patients with Sepsis/Bacteremia
S. Hess; Department of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg, DENMARK.

**PCS092**
Level 3 - Cost-Effectiveness and Proposed Optimal Use of FDG PET/CT in Patients with Sepsis/Bacteremia
L. J. Koizumi; Department of Internal Medicine and Radiobud Center for Infectious Diseases, Radiobudvar, Nijmegen, NETHERLANDS.

---

**PCS-093**
Bonus Level - Other Tracers Beyond FDG
A. Roivainen; Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND.

**PCS-094**
Next Level - Possible Role of FDG PET/MRI
P. Veit-Haibach; University Health Network, Joint Dept. Medical Imaging, Toronto, CANADA.

---

**PCS11**
Wednesday, October 13, 2021, 09:00 - 12:00

**Pre-Congress-Symposium 11: Light in the Dark - Hybrid Imaging in Patients with Sepsis/Bacteremia**

---

**PCS12**
Wednesday, October 13, 2021, 14:00 - 17:15

**Pre-Congress-Symposium 12: PET/MR - The Cross Path of Morphology and Functionality**

---

**PCS096**
Intro
R. Strand Olsen; Bispebjerg and Frederiksberg Hospital, Clinical Physiology; Nuclear Medicine, Copenhagen, DENMARK.

**PCS097**
The PET/MR
T. Lund Andersen; Righospitalet, Dept. of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, DENMARK.

**PCS098**
Performing PET/MR
L. Grannemark; Aarhus University Hospital, Department of Nuclear medicine and PET, Aarhus, DENMARK.

**PCS099**
Onsite Experience with PET/MR
S. Stieners; University hospitals Leuven, Nuclear Medicine department, Leuven, BELGIUM.

**PCS101**
PET/MR Motion Correction
M. Ganz-Benjaminsen; Righospitalet, Copenhagen University Hospital, Neurobiology Research Unit, Copenhagen, DENMARK.

**PCS102**
Interpretation of PET/MR
A. Beer; Ulm University Hospital, Department of Nuclear Medicine, Ulm, GERMANY.
OncoSil™ is a single-use brachytherapy device for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil Medical was granted CE Marking Approval and breakthrough designation for OncoSil™. OncoSil™ comprises of Phosphorous-32 (32P) microparticles suspended in a specially formulated diluent. The microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radioisotope with a physical half-life of 14.27 days in therapeutic use. 98% of the radiation is delivered within 81 days, which gives an absorbed dose equivalent to 100 Gy.

What does the PanCO data 1 could mean in the future for patients with unresectable locally advanced pancreatic cancer? I find it's quite significant, and what's significant is the doubling of downstaging and potential curative surgery to almost 1 in 4 patients from only 12% with standard therapy. How do you think about being able to offer this new treatment to patients? It's very exciting and fills me with optimism – especially as there has not been any significant change before, and that is really driving forward this field of radionuclide therapy. I think this will be big within the next 5-10 years.
OP-0014
New Solutions in Oncology
A. Doma; Institute of Oncology Ljubljana, Nuclear Medicine Dept, Ljubljana, SLOVENIA.

OP-0015
Advancements in Neuroimaging
D. van Weerdhage; Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, BELGIUM.

205

Wednesday, October 20 - Saturday, October 23, 2021
on demand pos, release on Wednesday, October 20 at 09:00

Joint Symposium 1 (EANM/ESSR): PET/MRI in MSK - Be Hybrid!

OP-0017
MR Protocols for Hybrid PET/MRI in MSK
L. Sconfin; IRCSS Istituto Ortopedico Galeazzi, Unit Department of Nuclear Medicine, Central Fondazione Policlinico Gemelli, Rome, ITALY.

OP-0018
PET/MRI in MSK Malignant Diseases
L. Garcia Canamaque; HM Hospitales, Madrid, SPAIN.

OP-0019
PET/MRI in MSK Benign Conditions
S. Wani; University College London, London, UNITED KINGDOM.

OP-0020
PET/MRI in MSK - Be Hybrid!
S. Annunziata; Fondazione Policlinico Gemelli, Rome, ITALY.

206

Wednesday, October 20 - Saturday, October 23, 2021
on demand pos, release on Wednesday, October 20 at 09:00

Joint Symposium 2 (EANM/ASNC): PET-MPI vs. SPECT-MPI - is it Worth the Price?

OP-0022
On Stable Chest Pain
P. Arumugam; Department of Nuclear Medicine, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM.

OP-0023
For Detecting Microvessel Disease
C. Napp; Federico II University of Naples, Department of Advanced Biomedical Sciences, Naples, ITALY.

OP-0024
For Guiding Coronary Revascularisation
R. C. Thompson; University of Missouri - Kansas City, St. Luke’s Mid America Heart Institute, Kansas City, UNITED STATES OF AMERICA.

OP-0025
Inflammatory and Infiltrative Diseases
S. Dorbala; Brigham and Women’s Hospital, Harvard Medical School, Boston, UNITED STATES OF AMERICA.

207

Wednesday, October 20 - Saturday, October 23, 2021
on demand pos, release on Wednesday, October 20 at 09:00

Pitfalls & Artefacts 1: Pitfalls in Cardiovascular Imaging

OP-0026
Clinical Cases
J. Diekmann; Hannover Medical School (HHU), Department of Nuclear Medicine, Hansevet, GERMANY.

OP-0027
Technologist Cases
L. Camoni; University of Brescia, Nuclear Medicine and Molecular Imaging Department, Brescia, ITALY.

OP-0029
Physics Cases
S. G. Nekola; Technical University of Munich, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY.

OP-0030
Impact of the specific activity of 18 F-PSMA-11 on tumor imaging, Ulm University, Ulm, GERMANY, 2Department of Nuclear Medicine, Saarland University, Saarbrücken, GERMANY.

OP-0031
Impact of the specific activity of 18 F-PSMA-11 on tumor uptake in a preclinical prostate cancer model
S. Pirani; J. Verbeek; B. Desalvo; A. Kemeny; C. Vanhove; F. De Vos.

Ghent University, Ghent, BELGIUM, 2Ghent University, Ghent, BELGIUM.

OP-0032
Use of the fibroblast activation protein inhibitor (11Cu) Cu-DOTHA, FAPI-04 to overcome heterogeneity in prostate cancer
O. Belissent; V. Dumoulin-Pereaud; M. Mihal; I. Ben-Salem; E. Croateu; S. Alt-Mohand; E. Turcotte; B. Gutten; J. E. Rousseaux; 1Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 2Centre d’image de médecine nucléaire du CCRUS, Sherbrooke, QC, CANADA, 3Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-0033
Click chemistry-based PSMA ligands for multimodal intraoperative tumor detection of prostate cancer
Y. Derki; M. Rügler; H. Amstaj-Groener; A. Kaj; P. Lawerman; S. Lüge; S. Heskind; D. Lövée; 1Radiobiodiversity medical center, Nijmegen, NETHERLANDS, 2Radiobiodiversity University Hospital, Nijmegen, NETHERLANDS, 3University Hospital Boe, Binn, GERMANY.

OP-0034
Clinical translation of the GRPR antagonist [124Tc]Tc-massS-PEG, RM26 for targeting prostate tumors
A. Abouyazied; S. S. Rinne; N. Lushnikova; A. Rybina; E. Usynin; J. Sörensen; V. Talmachev; V. Chemov; A. Ohlava; 1Uppsala University, Uppsala, SWEDEN, 2Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

OP-0035
P. Fragos Costa; M. Lüthen; J. M. Klue; J. Wang; P. Sandbach; M. Stasiowski; K. Herrmann; J. P. Radlak; S. Tschirnwein; J. Haddad; W. F. Fenster; C. Dai.

Clinic for Nuclear Medicine, Essen, GERMANY, 2German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY, 3Department of Urology, Essen, GERMANY.

OP-0036
Evaluation of the HET-CAM model for biodistribution studies of [18F]PSMA-14
J. Loeffler; C. Heng; A. B. Koch; C. Saßbach; L. Hao; G. Glattings; V. Rasche; J. A. Beer; G. Winter;
1Centre for Translational Imaging, Core Facility Small Animal Imaging, Ulm University, Ulm, GERMANY, 2Department of Nuclear Medicine, Ulm University Medical Faculty, Ulm, GERMANY, 3Department of Nuclear Medicine, Medical Radiation Physics, Ulm University Medical Faculty, Ulm, GERMANY.

OP-0037
Selection of Optimal Radiolabel Position and Composition in DARPin Ec1 for High-Contrast Imaging of EpCam Expression in Prostate Cancer
A. Vorobyeva; T. Xu; A. Schulga; E. Kanovskaya; L. Liu; J. Garusi; S. S. Rinne; M. Larkina; V. Deng; T. Giatsiboul; A. Orlova; S. M. Deyver; V. Talmachev; 1Uppsala University, Uppsala, SWEDEN, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Shermyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN FEDERATION, 4KTH Royal Institute of Technology, Stockholm, SWEDEN.

OP-0040
HER3 targeting 68Ga-labeled affibody provides superior PET imaging contrast compared with 89 Zr-labeled antibody and antibody-fragment based tracers
S. Rinne; A. Abouyazied; C. Dahlström-Leitao; A. Vorobyeva; V. Talmachev; S. Stań; J. Lobnig; A. Orlova; 1Uppsala University, Uppsala, SWEDEN, 2KTH - Royal Institute of Technology, Stockholm, SWEDEN.

OP-0041
Synthesis, radiolabelling and in vitro characterisation of a bimodal BODIPY-labelled PSMA-targeting bioconjugate for dual imaging of prostate cancer
T. Stemmer; H. Harline; S. Maa; J. Rosar; P. Krivtch; S. Ezazdini; E. Klauser; C. Hoffmann; G. Jung; M. Barthold: 1Department of Nuclear Medicine, Saarland University – Medical Center, Homburg/Saar, GERMANY, 2Department of Cellular Neurophysiology, Saarland University, Center for Integrative Physiology and Molecular Medicine, Homburg/ Saar, GERMANY, 3Department of Biophysical Chemistry, Saarland University, Saarbrücken, GERMANY.
ORAL PRESENTATIONS

**OP-0044**
Quantitative Ex Vivo Imaging of $^{131}$Ac with the iQID Alpha Camera

C. Miller,1,2,3, D. Creytens4,5, Y. D'Asseler5,6, K. De Man6, B. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8

1Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 4Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 5Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 6Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, UNITED STATES OF AMERICA, 7Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, 8Department of Radiology, University of British Columbia, Vancouver, BC, CANADA

**OP-0045**
The Impact of Cell Shape on the Doses Delivered to the Nucleus from $^{177}$Lu-labelled Radiotracers

C. Miller1,2,3, D. Creytens4,5, Y. D’Asseler5,6, K. De Man6, B. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8, C. Miller1,2, J. Rousseau3, J. Crawford4, B. Miller5,6, F. Bénard7,3,8, A. Rahmim1,2,8, C. Uribe1,8

1Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 2Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 3Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 4Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, 5Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 6Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, UNITED STATES OF AMERICA, 7Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, 8Department of Radiology, University of British Columbia, Vancouver, BC, CANADA

**OP-0046**
A physiologically-based pharmacokinetic model of $^{90}$Y-labelled pharmaceuticals targeting neuroendocrine tumors in mice

N. Zaid, P. Kletting, G. Winter, A. Beck, G. Glatting; Ulm University, Ulm, GERMANY

**OP-0047**
Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: influence of radiolucide choice

G. Tamborino1,2,3, J. Nonnekens1,2,4, M. De Saint Hubert1, L. Struielen1, L. Struielen1, M. De Jong1, M. Konijnenberg1,2,3; Research in Dosimetric Application, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 4Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS

1Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, 2Oncode Institute, Erasmus MC, Rotterdam, NETHERLANDS
OP-0062 Preliminary evaluation of 18F-ATSM as a tracer of predictive evaluation of neoadjuvant treatment in locally advanced rectal cancer
M. Colonetti1, L. Feron1, M. Lacombe1, V. Furey1, M. Le Thiec1, A. Morel1, B. Mauochnet1, D. Rusu1, N. Varennes1, P. Tremailer1, N. Amari1, J. Rie1, V. Guissart2, J. Massot3, H. Selmeit1, S. Hiert1, P. Sallou3, J. Campon4, A. Vidalt4, F. Haddad4, A. Rauscher5, F. Krauter-Bodneh6, M. Bourgeois7, C. Roussey1
1ICD René Gauducheau, Saint-Herblain, France, 2Université de Nantes, CNRS, INSERM, Nantes, France, 3ICD Paul Papin, Angers, France, 4Amanos, Saint-Herblain, France, 5University Hospital, Brest, France, 6EA GEIT 3878, University Western Brittany, Brest, France, 7SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes, France, 8University Hospital, Nantes, France.

OP-0063 Predictive value of 18F-FDG-PET / CT tumor SUVmax value in terms of overall survival after neoadjuvant therapy in rectal cancer
F. Derin, G. G. Ayo, Takki Gaziomarapusa University, Takii, Turkey.

OP-0064 Postcontraction pelvic fractures on FDG-PET - types, incidence and lack of recognition

OP-0068 Prognostic value of myocardial perfusion imaging using cardio-dedicated CZT-camera
T. Mannarino1, A. D’Antonio1, R. Bologna1, E. Crucisolo1, P. Buongiorno1, E. Casasus1, R. Asanté2, E. Zampella3, V. Gaudien4, R. Green5, V. Cantoni5, M. Petretta6, W. Assapou6, A. Gacoulo6, 1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy, 2IRC S, Diagnostic Imaging, Naples, Italy, 3SDN, Diagnostic Imaging, Naples, Italy.

OP-0069 Dynamic myocardial perfusion imaging in coronary disease; correlation with angiographic findings
J. Pinajcay, E. Rizzi, F. Debordeaux, H. Douard, T. Couffinhal, P. Coste, L. Bardenave, University Hospital of Bordeaux, Bordeaux, France.

OP-0070 Coronary Vascular Function Assessed by Low Dose Dynamic CZT-SPECT MPI in Patients with Diabetes Mellitus
A. D’Antonio1, T. Mannarino1, E. Crucisolo1, R. Bologna1, P. Buongiorno1, R. Asanté2, E. Zampella3, V. Gaudien4, C. Nappi5, R. Green5, V. Cantoni5, M. Petretta6, W. Assapou6, A. Gacoulo6, 1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy, 2IRC S, Diagnostic Imaging, Naples, Italy.

OP-0071 Exercise Ischemia is an Efficient Predictor of Significant Coronary Artery Disease in Routine Reports of a Large-Scale Clinical Cohort using Very Low-Dose Myocardial Perfusion SPECT
M. B. Chawk1, T. Gongaloni2, C. Boursier3, M. Bardonne4, 1A. Verger, L. Imbert1, M. Pennin1, M. Claudin1, V. Roch1, J. Djababulati1, B. Popovci1, E. Camerino1, P. Marie1, 1Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Nancy, France, 2Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Nancy, France, 3SDN, Diagnostic Imaging, Nancy, France.

OP-0072 Prognostic value of heart rate reserve in patients with suspected coronary artery disease undergoing stress myocardial perfusion imaging
F. Reina1, C. Nappi5, M. Petretta6, R. Asanté2, E. Zampella3, V. Gaudien4, V. Cantoni5, M. Green1, L. Popcici2, V. Volpe2, C. Maimoli1, E. Nicolai1, W. Assapou6, A. Gacoulo6, 1Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, 2IRC S, Diagnostic Imaging, Naples, Italy.

OP-0073 Negative Determinant Value of Myocardial Perfusion Scintigraphy on Solid State Gamma Cameras
N. Talay1, E. Sohrt-Kuhl1, T. Bahner1, E. Gudeli1, Ankara City Hospital Nuclear Medicine Department, Ankara, Turkey.

OP-0074 Added value of Myocardial Flow Reserve measurement in cardiac SPECT for coronary artery disease screening
M. Bailly1, P. Thibaut1, G. Alemand1, M. Courtehoux2, D. Aunspach3, M. Ribet4, 1CHR Orleans, Orleans, France, 2CHR Tours, Tours, France.

OP-0075 Prone Myocardial Perfusion SPECT Imaging in attenuation artefacts may obviate the need for a Rest Study: Our Experience

OP-0076 Correlation between myocardial flow, coronary flow and Framingham and ESC-Score cardiovascular risk scores
J. Pinajcay, P. Frenzoi1, F. Debordeaux, H. Douard, Y. Puchla1, T. Couffinhal, L. Bardenave, University Hospital of Bordeaux, Bordeaux, France.

OP-0077 Challenges in Multi-Center Trials Using Radiomics Models - The Role of AI Based Harmonisation
V. Jouen1, Institut Mines Telecom Atlantique, Plouzané, France.

OP-0078 Al and Radiomics for Oncology Applications
M. Sollini1, Humanities University, Nuclear Medicine Division, Milan, Italy.

OP-0079 Potential Role of AI and Radiomics in Cardiac Imaging
C. Rischpler, Hospital Institute, Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

OP-0080 What May Al and Radiomics Bring in Neuroimaging?
R. Buchert1, 1University Medical Center Hamburg-Eppendorf, Department of Nuclear Medicine, Hamburg, Germany.
**OP-0088**

**Paediatric Patient Care - Technologist’s Practice Improvement**
A. Santos; Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

**OP-0092**

**The ISCHEMIA Trial - Clear Answers, Open Questions**
A. Denys; CHUV centre hospitalier universitaire vaudois, Radiodiagnostic et radiologie interventionnelle, Lausanne, SWITZERLAND.

**OP-0097**

**Radio-Embolization and HCC – Where Are We in the Guidelines and Why?**
A. Denys; CHUV centre hospitalier universitaire vaudois, Radiodiagnostic et radiologie interventionnelle, Lausanne, SWITZERLAND.

**OP-0099**

**Dosimetry and Radio-Embolization – Dose Specific Issues and New Solutions**
N. Schaeffers; Centre Hospitalier Universitaire Vaudois (CHUV), Department of Nuclear Medicine and Molecular Imaging, Lausanne, SWITZERLAND.

**OP-1000**

**TBA**

**OP-0102**

**Neurooncologist - The Neurooncologist’s Perspective**
M. Glas; University of Oslo, Oslo, NORWAY, 2Oslo University Hospital, Oslo, NORWAY, 3Oncoinvent AS, Oslo, NORWAY.

**OP-0104**

**Nuclear Medicine Physician – And What About PET?**
J. Law; Copenhagen University Hospital, Dept of Clinical Physiology, Copenhagen, DENMARK.
EANM'21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

ORAL PRESENTATIONS

Lassmann1; 1Department of Radiation Physics, Institute of Clinical Medicine Lund University, Malmo, SWEDEN.

A thyroid iodide uptake and volume determination tool

Martina1,2, S. Mattsson2; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Muenchener, GERMANY, 2Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY.

OP-0158

Evaluation of a new dual-energy quantitative computed tomography (DEQCT) method against 2-point Dixon MRI to quantify the yellow marrow and red marrow volume fraction for bone marrow dosimetry in molecular radiotherapy

M. Salas Ramírez1, J. Tran-Gia1, P. Hartmann2, A. Hedenmalm1, M. Lasmanis1; 1Department of Nuclear Medicine, University of Würzburg, GERMANY, 2Department of Diagnostic and Interventional Radiology, University of Würzburg, GERMANY.

OP-0116

Physiologically-based pharmacokinetic modelling for radiopharmaceuticals using a multilevel object-oriented modelling methodology

R. Bausman1, S. Hermos2, G. de With3; 1Nag, Amhem, NETHERLANDS, 2Emergencias Agapadoas Internacionales, Madrid, SPAIN.

OP-0117

Manual versus artificial intelligence-based segmentations as a pre-processing step in whole-body dosimetry calculations

J. van Sluijs1, W. Noordijk1, E. G. De Vries1, J. C. Kok1, O. A. De Groot1, M. Jalink1, M. N. Lub-de Hooge1, A. H. Bouwman1, R. Boellaard1; 1University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0118

Bone marrow dosimetry for terbium-161 reveals higher dependence on source distribution within the bone marrow cavities compared to lutetium-177

J. Hemmingsson1, J. Svensson1, N. P. van der Meulen2, C. Müller1, P. Bergholm1; 1Department of Medical Radiation Sciences, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Center for Radiopharmaceutical Sciences ETH-PSI-OSZ, Paul Scherrer Institute, Villigen, SWITZERLAND.

OP-0122

The feasibility of dose estimation to thyroid remnants and salivary glands and avid following therapeutic131I administration

M. Abugoobeh1; 1Istanbul University, Istanbul, TURKEY.

OP-0121

Investigation of the effect of small but frequently occurring patient movements onto 3D activity quantification in Siemens 'sPECT Quant reconstruction with integrated motion correction

A. Göswich1, M. Riemann2, K. Khat1, L. Bryer1, G. Patotsch1, P. Bartmester1, A. H. Voig1, G. Gönen1; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Muenchener, GERMANY, 2Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY.

OP-0120

First Oral Presentations and Clinical Oncology Track - TROP Session: Breast Cancer

Clinical Oncology Track - TROP Session: Breast Cancer

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Surgery, Istanbul, TURKEY.

OP-0128

First-in-human study of ‘99mTc-labelled HER2-binding DARPin G3

O. Bragina1, V. Chemov2, A. Schulga2, E. Kononova3, V. Vasilieva4, A. Orlov1, S. Sarensen1, R. Zeichin1, A. Medvedeva1, S. M. Deyev2, V. Tumanov2; 1Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION, 2Research Center for Oncochemotherapy, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION, 4Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, 5Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

OP-0124

First Results of Simultaneous FAPI-PET/MRI Targeting the Fibroblast Activation Protein in Primary Breast Cancer

P. Backhaus1, M. C. Burg1, W. Rolf1, P. Bütcher1, H. Breyholz1, S. B. Wegner4, H. Hendel1, M. Pütz1, P. J. Bank1, J. Tao1, M. Schäfers1; 1Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY, 2European Institute for Molecular Imaging, University of Münster, Münster, GERMANY, 3Clinic for Radiology, University Hospital Münster, Münster, GERMANY, 4Gerhard-Domagk-Institut für Pathologie, University Hospital Münster, Münster, GERMANY, 5Department of Gynecology & Obstetrics, University Hospital Münster, Münster, GERMANY.

OP-0123

Correlation between tumoral infiltrating lymphocytes, **TC HYNIC-IFAP SPECT/CT** and **FDG PET/CT**: a potential imaging biomarker of tumoral microenvironment aggressiveness in breast cancer

O. García-Pérez1, P. Vallega-Armenta1, J. Torres-Agueda1, P. Cassignau, A. Pannas-Reyes1, J. Vargas-Ahumada1, J. Soldevilla-Gallardo1, G. Prieto-Cortés1, E. Monte-Flores1, E. Santos-Cuevas1, B. Ocampo-García1, E. Estrada-Lobato1, P. Cabrera-Gallarán1; 1Instituto Nacional de Cancrologia, Mexico city, MEXICO, 2Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA, 3Instituto Nacional de Investigaciones Nucleares, Mexico city, MEXICO, 4International Atomic Energy Agency, Wien, AUSTRIA, 5Instituto Nacional de Cancrologia, Mexico City, MEXICO.

OP-0125

Comparison of [68Ga]Gafapiti-46 PET/CT and [18F]FDG PET/CT in Breast carcinoma staging: Preliminary results of randomised prospective clinical trial from Azerbaijan

F. Novruzov1, E. Mehdi1, N. Israeu1, Q. Abdulleyev1, N. Taltakov1, M. Moore1, J. Vafii1, S. Rahmazade1, J. Alyev1; 1Azerbaijan National Centre Of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2Azerbaijan National Centre Of Oncology, Department of Woman Health, Baku, AZERBAIJAN, 3Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.

OP-0126

Comparison [68Ga]Gafapiti-46 PET/CT and [18F]FDG PET/CT in Breast carcinoma staging: Preliminary results of randomised prospective clinical trial from Azerbaijan

F. Novruzov1, E. Mehdi1, N. Israeu1, Q. Abdulleyev1, N. Taltakov1, M. Moore1, J. Vafii1, S. Rahmazade1, J. Alyev1; 1Azerbaijan National Centre Of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2Azerbaijan National Centre Of Oncology, Department of Medical Oncology, Baku, AZERBAIJAN, 3SCNIE, TOTIWA, NU, UNITED STATES OF AMERICA, 4Azerbaijan National Centre Of Oncology, Department of Woman Health, Baku, AZERBAIJAN, 5Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.

OP-0127

PET/CT radiomics in breast cancer: promising tool for prediction of the Ki67 expression

C. Shen1, X. Du2, L. Nie1, C. Ding1; 1Wuhan Jiaotong University, Wuhan, CHINA, 2Philips Healthcare, Shanghai, CHINA.

OP-0128

Intramammary metastases are able to serve as a ‘source of second’ breast cancer after axillary lymph node metastasis

M. Almogas1,2, V. Chernov1,2, A. Schulga2,3, E. Konovalova3, A. O. Bragina4,5; 1Department of Radiation Physics, Institute of Clinical Medicine Lund University, Malmo, SWEDEN, 2Medical Radiation Physics, Department of Translational Medicine Lund University, Malmo, SWEDEN.

OP-0129

Impact of hybrid whole-body **FF-FDG PET/MRI for breast cancer patients staging according to accepted guidelines: prospective biomarking markers associated with tumour aggressiveness

E. Valts1, A. Camppte1, J. Garcia1, S. Ortiz1, M. Cozar1, P. Bassa1, C. Galan1, S. Moarret1, M. Sider1, M. Buerba1, A. Blanca1, E. Riera1; 1CTIR-ASIORES, Barcelona, SPAIN.

OP-0130

Impact on the long-term prognostic of FDG PET/CT in luminal breast cancer

M. Caraclo1, L. Liu1, L. Evangelista1, S. Panaro1, N. Quartuccio1, N. Ortolan1, J. Zamberlan1, A. Schirone1, A. Fassaldari1, C. Cittaro1, G. Amone1, M. Bartolomei1; 1National Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Fermo, Fermo, ITALY, 2National Medicine Unit, Department of Nuclear Medicine DIMED, University of Padua, Padova, ITALY, 3National Medicine Unit, ARVAS Caspadi Ci vacia Di Cristina e Bephalais, Palermo, ITALY, 4Clinical Oncology, Oncological Medical and Specialists Department, University Hospital of Fermo, Fermo, ITALY.

OP-0131

The Relationship Between Tumor/ Lymph Node SUV Ratio And Immunohistochemical Features With Distant Metastases In Initial Staging F18-PET/CT In Breast Cancer

H. Tosun1, B. B. Demir2, G. Uzum2; 1Abdulrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY.

OP-0132

Ga-68 PSMA and F-18 FDG PET/CT Imaging in Patients with Tri-gland Negative Breast Cancer and PSMA and Claudin 1, Claudin 4 and Claudin 7 Receptors in Primary Tumor Tissues

E. Arslan1, N. Ergul1, E. Beyhan1, C. Eld1, M. Cor1, S. Battal Havare2, F. D. Can Trabulus1, D. Memur1, S. Akbay2, T. F. Gemlik1, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY, 2Istanbul Training and Research Hospital, Department of Pathology, Istanbul, TURKEY, 3Istanbul Training and Research Hospital, Clinic of Surgery, Istanbul, TURKEY, 4Instituto Nacional de Investigaciones Nucleares, Mexico city, MEXICO, 5Instituto Nacional de Cancerología, Mexico City, MEXICO.

OP-0133
OP-0133
Diagnostic value of bone scintigraphy in cardiac amyloids after domino liver transplantation
E. Prekasakis, I. Lidy\footnote{1}, R. Chequer\footnote{1}, F. Scalbert\footnote{1}, D. Adams\footnote{1}, D. Le Guludec\footnote{2}, M. S. Stama\footnote{3}, D. Samra\footnote{1}, I. Kounou\footnote{1}, F. Rouzet\footnote{1}, V. Albagaren\footnote{1};
Nuclear Medicine Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), DAU APOLLO, Inserm UMR 1148, Université de Paris, Paris, FRANCE, \textit{Cardiology Department, Bichat-Claude Bernard Hospital, AP-HP, Inserm UMR S 1180, Université de Paris, Paris, FRANCE, French Referrant Centre for Rare Diseases for FAP Familial Amyloid Polyneuropathy (CORM-NIER)}, Bicêtre, FRANCE, \textit{Neurology Department, AP-HP Université Paris-Saclay, INSERM U1195, Bicêtre, FRANCE, \textit{Cardiology Department, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, FRANCE, \textit{Centre Hippopo Bâlese, AP-HP Université Paris-Saclay, Hospital Paul Brouse, Villejuif, FRANCE.}}

OP-0134
Evaluation of Cardiac Toxicity in Patients Undergoing Breast Cancer Treatment with HER2-inhibitors
A. Lazar\footnote{1}, M. Mutuleanu\footnote{1}, M. Gheorghe\footnote{2}, I. Irimie\footnote{2};
\textit{Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA, \textit{Oncology Institute Professor Alexander Tandrea\textit{tcea}, Bucharest, ROMANIA.}}

OP-0135
The significance of the intramammary sentinel lymph nodes in the lymphatic mapping
Z. Koc\footnote{1}, P. P. Căzănescu\footnote{2}, D. Daloglu\footnote{1}, M. Berkeşoğlu\footnote{1}, Z. S. Sağlam\footnote{1};
\textit{Mersin University, Mersin, TURKEY, \textit{University Hospital, Department of Radiology, Odense, DENMARK, \textit{Odense University Hospital, Department of Pathology, Odense, DENMARK, \textit{Koelm Academy for Quality and Research in Medicine, Basel, SWITZERLAND, \textit{Centre for Innovative Medical Technology, Odense University Hospital, Odense, DENMARK.}}}}

OP-0136
On-demand pool, release on Wednesday, October 20 at 09:00
Z. Koc\footnote{1}, P. P. Özcan\footnote{1}, F. Daloğlu\footnote{1}, M. Berkeşoğlu\footnote{1}, Z. S. Sağlam\footnote{1};
\textit{Odense University Hospital, Department of Nuclear Medicine, Odense, DENMARK, \textit{Basel Academy for Quality and Research in Medicine, Basel, SWITZERLAND, \textit{Centre for Innovative Medical Technology, Odense University Hospital, Odense, DENMARK.}}

OP-0137
Bone scintigraphy in hereditary ATTR patients: characteristics and prognostic impact of the different clinical phenotypes
F. Mattanza\footnote{1}, M. Squizzato\footnote{2}, P. Massu\footnote{2}, A. Porzio\footnote{2}, A. G. Caporetti\footnote{1}, G. Saturi\footnote{1}, R. Bonfiglioli\footnote{1}, S. Longhin\footnote{1}, C. Gaglardi\footnote{1}, E. Biagini\footnote{1}, P. Cortelli\footnote{1}, N. Galliè\footnote{2}, S. Farini\footnote{2};
\textit{IRCCS Azienda Ospedaliero-Universitaria di Bologna, Metropolitan Nuclear Medicine, Bologna, ITALY, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Cardiology Unit, Bologna, ITALY, IRCCS Institute of Neurological Sciences of Bologna, Bellina Hospital, Bologna, ITALY.}

OP-0140
Bone scintigraphy using the HICL ratio on 3h planar [\textsuperscript{99m}Tc]-TeDTP imaging have additional characteristics and prognostic impact of the different clinical phenotypes
L. Lemos\footnote{1}, P. Soeiro\footnote{1}, R. Ferreira\footnote{1}, M. J. Cunha\footnote{1}, G. Costa\footnote{1}, J. Pedroso de Lima\footnote{1};
\textit{Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, \textit{Instituto de Cânceres Nucleares Aplicadas à Saúde (ICNAS), Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL, \textit{Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.}}

OP-0141
Does semiquantification using the HICL ratio on 3h planar [\textsuperscript{99m}Tc]-TeDTP imaging have additional prognostic value in cardiac amyloids?
L. Lemos\footnote{1}, P. Soeiro\footnote{1}, R. Ferreira\footnote{1}, M. J. Cunha\footnote{1}, G. Costa\footnote{1}, J. Pedroso de Lima\footnote{1};
\textit{Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, \textit{Instituto de Cânceres Nucleares Aplicadas à Saúde (ICNAS), Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL, \textit{Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.}}

OP-0142
Multiparametric assessment of the mechanical function of the left ventricle by Czik MPI: Comparison with cardiac magnetic resonance
E. Cerudelli\footnote{1}, M. Gazzilli\footnote{1}, L. Camoni\footnote{2}, F. Dondi\footnote{2}, A. Mazzoletti\footnote{2}, P. Biagini\footnote{1}, P. Cortelli\footnote{1}, N. Galliè\footnote{2}, S. Fanti\footnote{1};
\textit{Università degli Studi di Bologna, Cardiology Research Institute, Bologna, ITALY, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Cardiology Unit, Bologna, ITALY, IRCCS Institute of Neurological Sciences of Bologna, Bellina Hospital, Bologna, ITALY.}

OP-0143
Qualitative and quantitative cardiac 18F-FDG-PET findings in patients with suspected inflammatory cardiomyopathy: a pilot study
A. Franchini\footnote{1}, A. Scardel\footnote{1}, F. Baldassar\footnote{1}, G. Cabrini\footnote{1}, E. Gay\footnote{1}, M. Millet\footnote{1}, C. Rossetti\footnote{1}, S. Capitanove\footnote{1};
\textit{University of Milano-Bicocca, Milano, ITALY, \textit{ASSG Grande Ospedale Metropolitano Niguarda, Milano, ITALY.}}

OP-0144
Are stress-induced dyssynchrony parameters obtained from different nuclear modalities comparable in terms of identifying high-risk patients after surgical treatment of ischemic cardiomyopathy?
V. Shipulin\footnote{1}, A. Piskay\footnote{1}, S. Andreu\footnote{1}, V. M. Shipulin\footnote{1}, K. Zavadovsky\footnote{1};
\textit{Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.}

OP-0145
Clinical differences between patients with Perugini’s grade 2 and grade 3 cardiac ATTR amyloidosis confirmed by [\textsuperscript{99m}Tc]-DTP scan
F. Sebastian Palacios\footnote{1}, N. Álvarez Mena\footnote{1}, B. Pérez López\footnote{1}, C. Garmazo Laherrán\footnote{1}, P. Turbay Eljach\footnote{1}, M. Alonso Rodríguez\footnote{1}, A. Sáinz Esteban\footnote{1}, C. F. García Garcia\footnote{1}, M. Ruiz Gómez\footnote{1}, M. J. González Soto\footnote{1}, R. Ruano Pérez\footnote{1};
\textit{Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.}

OP-0146
Possibility of scintigraphic indexes of left ventricle mechanical dyssynchrony for predicting benefit from cardiac resynchronization therapy with comparing different response criteria
A. Mishkina\footnote{1}, V. Saushkin\footnote{1}, T. Ataklov\footnote{1}, K. Zavadovsky\footnote{1};
\textit{Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.}

OP-0147
Impact of hybrid 18F-FDG PET/CMR on cardiac sarcoidosis diagnosis and disease stage differentiation
J. García\footnote{1}, R. Oliveres\footnote{1}, P. Bassa\footnote{1}, M. Lopez\footnote{1}, J. Monmeneu\footnote{1}, E. Riera\footnote{1}, L. Evangelista\footnote{1};
\textit{The Sir Peter MacCallum Cancer Center, Melbourne, AUSTRALIA, \textit{The University of Melbourne, University of Melbourne Medical Centers, Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.}}

OP-0148
Marie Curie Lecture: Other New Theranostics
V. Garibott\footnote{1};
\textit{University Hospital of Geneva, Nuclear Medicine and Molecular Imaging Division, Geneva, SWITZERLAND.}

OP-0149
Channel 1
Plenary Quiz (for Plenary 2)

OP-0150
Channel 1
Plenary Quiz
V. Garibotto\footnote{1};
\textit{University Hospital of Geneva, Nuclear Medicine and Molecular Imaging Division, Geneva, SWITZERLAND.}

OP-0151
Plenary 2: Theranostics Applications and Challenges (incl. Marie Curie Lecture)

OP-0152
Channel 1
We are Theranostics
B. Guillot; Radiopharmacy department, University Hospital Marseille, MARSEILLE, FRANCE.

OP-0153
Channel 1
PSMA Theranostics in 2021
D. Oprea-Lager; Amsterdam University Medical Centers, Department of Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0154
Channel 1
Marie Curie Lecture: Other New Theranostics
R. Hick; The Sir Peter MacCallum Cancer Center, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, AUSTRALIA

OP-0155
Handling Challenges
L. Evangelista; University of Padua, Department of Medicine (EAMED), Padua, ITALY.
OP-0156
Risk Analysis in Radiouclide Therapy
R. Dierickx; UMC, University of Medicine, Ghent, Belgium.

OP-0157
Tech Challenges
A. Santos; Hospital CUF Descobertas, Medicina Nuclear Department, Lisbon, Portugal.

OP-0158
Reimbursement Challenges
J. Runinkovska; Medical University of Warsaw, Nuclear Medicine Department, Warsaw, Poland.

OP-0159
Gemelli IRCCS, Nuclear Medicine Unit, Rome, Italy.
L. Leccisotti; FDG-PET for Cardiovascular Infections - Pros and Cons
OP-0160
F. Rouzet; Infections - Pros and Cons

Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and Cons
OP-0161
E. Noriega-Alvarez; Hospital General Universitario de Ciudad Real, Department of Nuclear Medicine, Ciudad Real, Spain.

OP-0162
FDG-PET for Musculoskeletal Infections - Pros and Cons
Z. Reidar; Rambam Health Care Campus, Director, Department of Nuclear Medicine, Haifa, Israel.

OP-0163
Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and Cons
F. Rouzet; CHU Bichat-Claude Bernard, Department of Nuclear Medicine, Paris, France.

OP-0164
FDG-PET for Cardiovascular Infections - Pros and Cons
L. Leccisotti; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, Italy.

OP-0156
Risk Analysis in Radiouclide Therapy
R. Dierickx; UMC, University of Medicine, Ghent, Belgium.

OP-0157
Tech Challenges
A. Santos; Hospital CUF Descobertas, Medicina Nuclear Department, Lisbon, Portugal.

OP-0158
Reimbursement Challenges
J. Runinkovska; Medical University of Warsaw, Nuclear Medicine Department, Warsaw, Poland.

OP-0159
Gemelli IRCCS, Nuclear Medicine Unit, Rome, Italy.
L. Leccisotti; FDG-PET for Cardiovascular Infections - Pros and Cons
OP-0160
F. Rouzet; Infections - Pros and Cons

Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and Cons
OP-0161
E. Noriega-Alvarez; Hospital General Universitario de Ciudad Real, Department of Nuclear Medicine, Ciudad Real, Spain.

OP-0162
FDG-PET for Musculoskeletal Infections - Pros and Cons
Z. Reidar; Rambam Health Care Campus, Director, Department of Nuclear Medicine, Haifa, Israel.

OP-0163
Radiolabelled WBC Scintigraphy for Cardiovascular Infections - Pros and Cons
F. Rouzet; CHU Bichat-Claude Bernard, Department of Nuclear Medicine, Paris, France.

OP-0164
FDG-PET for Cardiovascular Infections - Pros and Cons
L. Leccisotti; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, Italy.
OP-0178
In Peptides, We Trust!
S. Dalm; Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-0179
Antibody Fragments, Fast Kinetics are Essential!
N. Devoogdt; Vrije Universiteit Brussel, Department of Medical Imaging, Brussels, BELGIUM.

OP-0180
Antibodies as Radiopharmaceutical Vectors - Do the Benefits Outweigh the Costs?
B. M. Zeigls; Hunter College, Department of Chemistry, New York, UNITED STATES OF AMERICA.

OP-0182
How to “Fix” Tracer Pharmacokinetics - The Chemist’s Toolbox
M. Schottelius; Department of Nuclear Medicine, Division of Radiopharmaceutical Development, Freiburg, GERMANY.

OP-0183
Linker Modifi cations Strategy to Alter the Pharmacokinetic Profi le of Low Molecular Weight Radiopharmaceuticals
A.-C. Eder; University Clinic (DKFZ), Heidelberg, GERMANY, 2Department of Nuclear Medicine, University Medical Centre Freiburg, Freiburg, GERMANY.

OP-0184
Incorporation of an Albumin Binder to Optimize Tumour Delivery of PSMA-Targeting Radiotherapeutic Agents
K.-S. Lim; University of British Columbia, Department of Radiology, Vancouver, CANADA.

OP-0185
Blood-Brain Barrier Permeation of Brain-Targeted Radioligands
T. Billard; Université Claude Bernard - Lyon, ICBSM - Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Lyon, FRANCE.

OP-0187
Challenging Cases in Neurodegenerative Dementia
A. Charavalloti; University For Verona, Department of Biomedicine and Biotechnology, Rome, ITALY.

OP-0188
Challenging Cases in Movement Disorders
M. Brendel; Department of Nuclear Medicine, University Hospital of Munich, Munich Cluster for Systems Neurology (SyNergize), Munich, GERMANY.

OP-0189
Challenging Cases in Neurooncology
T. Traub-Weidinger; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-0190
Enhanced Therapeutic Effect of the Albumin-Binding [111m]Lu-ibu-DAB-PSMA as Compared to [177]Lu-LuPSMA-617 - A Preclinical Therapy Study
V. Tuchan; F. Bogner, R. Schibli1, C. Müller1; Paul Scherrer Institute, 5232 Villigen PSI, SWITZERLAND, 2ETH Zurich, 8093 Zurich, SWITZERLAND.

OP-0191
Long-term radiotoxicity study with [111m]Lu-LuNeoB
M. Verhoeven; A. E. Rutgers1, M. K. Koenenben1, B. De Gieter2, C. M. de Ridder1, D. C. Steuerman1, M. J. Klop1, L. W. De Kreij-De Bruijn1, L. Bertranone1, K. Rollo1, R. Mann1, M. De Jong1, S. Ud-Dahn2, Ennovus AI, Rotterdam, NETHERLANDS, 2Advanced Accelerator Applications, a Novartis Company, Colleferro Gaetano, ITALY, 3European Research Biology Center, Pomezia, ITALY.

OP-0192
Therapeutic response of CKB8-positive tumours to combinatory treatment with RADI01 and radiolabeled minigastin analogue [177]Lu-Lu-PP-F11N
M. Grzmi1, S. Dobrastle1, A. Blain1, R. Schibli1, M. Rehe1; Paul Scherrer Institute, Villigen PSI, SWITZERLAND, 2Department of Chemistry and Applied Biosciences, ETH Zurich, SWITZERLAND.

OP-0193
A new class of radiopharmaceuticals for CCK8R-expressing malignancies based on the endogenous antagonist EPI-X4
R. Gaonkar1, Y. Schmidt1, R. Mans1, M. Ham1, A. Sedel1, J. Münch1, M. Jan1; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND.

OP-0194
In Vivo Metabolic Activity and Internalisation Investigation of Copper-64 Radiopharmaceuticals As Theranostic Agents for Hypoxic Tumours
T. Liu1, M. Dah1, K. Kersel2, R. Red2; 1Department of Physics, Norwegian University of Science and Technology, Trondheim, NORWAY, 2Department of Radiology and Nuclear Medicine, St. Olav’s Hospital, Trondheim University Hospital, Trondheim, NORWAY.

OP-0195
Alternating PSMA Expression Levels by Ionizing Radiation Exposure as an Additional Feature in PSMA-Targeting Prostate Cancer Treatment: First In Vivo Evaluation
D. Arabuzkov1,2, M. Doll1, A. Grosu1, P. T. Meyer2, M. Edel3, C. Zamboglou4,5, A. Eder1,2,4; 1Department of Nuclear Medicine, University Medical Centre Freiburg, Freiburg, GERMANY, 2Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, GERMANY, 3Department of Radiation Oncology, University Medical Centre Freiburg, Freiburg, GERMANY, 4German Cancer Research Centre (DKFZ), Heidelberg, GERMANY, 5German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, GERMANY.

OP-0197
Imaging-guided co-targeting of HER2 and EpCAM using trastuzumab and DARPin-toxin fusion protein for theranostics of ovarian cancer
H. Ohata1, A. B. Tsuji1, K. Nagatsu1, M. Ogawa2, M. R. Zhang1, H. Obata1, A. B. Tsuji1, K. Nagatsu1, M. Ogawa2, M. R. Zhang1; 1National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, 2Hokkaido University, Hokkaido, JAPAN.

OP-0199
In vivo theranostic evaluation of a Cu-radiolabelled antibody in a murine model of multiple myeloma
C. Métivet1, P. Remaud-Le-Saec1, S. Masionneau-Lambot1, F. Davideau1, C. Chauvet1, C. Sari-Maurel1, R. Schibli2, C. Müller1; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, SLOVENIA, 3Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND.

OP-0200
Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Radiotherapeutic Application
L. Deberle1; 1Department of Radiology and Nuclear Medicine, St. Olav’s Hospital, Trondheim University Hospital, Trondheim, NORWAY.

OP-0201
Production and in vitro evaluation of no-carrier-added radio-cisplatin emitting Auger electrons
H. Obata1; 1National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, 2Hokkaido University, Hokkaido, JAPAN.
**OP-0207**

A simplified method for kidney dosimetry in \(^{177}\)Lu therapies based on single SPECT-CT and multiple external probe measurements.

D. Pistone; T. Lippert; A. Italiani; E. Amati; A. Campanelli; N. Schober; S. Baughdith; S. Baldivieso; S. Grein; MIF, Department of University of Messina, Messina, ITALY; IFN Section of Catania, Catania, ITALY; Institute of Radiation Physics, Lausanne University Hospital and Hospital of University of Lausanne, Switzerland; BIOMORF, Department of University of Messina, Messina, ITALY; Nuclear Medicine Unit, University Hospital; G. Martinet, Messina, ITALY; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Switzerland.

---

**OP-0208**

Evaluation of 2D/3D hybrid dosimetry in PSMA-targeted radioligand therapy.

F. Rosar; H. Schon; A. Bovenhertgen; M. Bartholoma; T. Steimer; S. Maus; T. Riech; S. Ezzadin; A. Schober-Schuerl; Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany.

---

**OP-0209**

Comparison of Voxel S-values and Monte Carlo Simulation in \(^{177}\)Lu-LuDOTATE Quantification for Patient-Specific Dosimetry.

C. Rodrigues; P. Ferreira; P. M. Oliveira; A. Silva; L. Penalta; D. C. Cost; J. Lourenço; M. A. de Almeida; C. Madeira; N. Muchall; F. Braga; J. M. Mendes; J. S. da Silva; P. J. Balboa; G. P. Passos; P. R. Vieira; J. A. Antunes; J. Gomes; H. F. Simões; A. Azevedo; T. Ligonnet; L. Auditore; A. Italiano; E. Amato; A. Konuparambil; A. Kaushik; S. Mitlin; V. Rangarajan.

---

**OP-0210**

Impact of SPECT Segmentation on Accuracy of Lu-177 Activity Quantification for Dosimetry in Radioligand Therapy.

J. Pfeil; J. Zuerbe; I. Apostolov; R. Buchert; S. Kutrman; W. Leitner; Humboldt Universität zu Berlin, Berlin, Germany; University Medical Center, Hamburg, Germany.

---

**OP-0211**

Ga-68-PSMA-11 PET Imaging as a Predictor for Absorbed Doses in Organs at Risk in Small Lesions in Lu-177-PSMA-617 Treatment.

S. Peters; R. Hoffner; B. Privat; M. De Bakker; M. Gathard; F. De Lamper; C. Muelener; A. Wilj; P. Cost; J. Nagasrsah; M. Kynigben; W. Jentzen; Radboudumc, Nijmegen, NETHERLANDS; ESM University Hospital, Essen, GERMANY; University Medical Center, Hamburg, Germany.

---

**OP-0212**

Comparison of Red Marrow Dosimetry Methodologies for Lu-177-PSMA Radionuclide Therapy.

W. Leitner; I. Apostolov; R. Buchert; S. Kutrman; University Medical Center, Hamburg, Germany.

---

**OP-0213**

Simplified dosimetry for peptide-receptor radionuclide therapy using physiologically-based pharmacokinetic and nonlinear mixed effect modelling.

D. Hardiansyah; A. Ronal; F. Kietling; A. I. Beer; G. Glatting; Universitas Indonesia, Depok, INDONESIA; Ulm University, Ulm, GERMANY.

---

**OP-0214**

Optimization of three imaging time points for most reliable renal dosimetry in Peptide Receptor Radioligand Therapy.

A. Konuparambil; A. Naity; A. K. Jha; S. Mitlin; V. Rangarajan.

---

**OP-0215**

Estimation of kidney absorbed doses from \(^{177}\)Lu-DOTATATE using single point SPECT/CT.

S. Balkov; D. Gillett; E. Varcabon; I. Hartp; D. Philid; A. Powell; R. T. Casey; S. Heard; A. Algo; D. Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UNITED KINGDOM; Department of Endocrinology, Cambridge University Hospitals, Cambridge, UNITED KINGDOM; Department of Genetics, Cambridge, Cambridge, UNITED KINGDOM; Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM; Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM.

---

**OP-0216**

Using a semi-supervised clustering method to determine whether a radiopharmaceutical can distinguish primary lung tumors from lung metastases.

V. Cupulo; N. Capite; I. Buhat; F. Orlikac; Laboratory of Translational Imaging in Oncology, U1288 Inserm, Institut Curie, Univ. Paris Saclay, Orsay, FRANCE.

---

**OP-0217**

The immune metabolic prognostic index discloses the presence of radiological progression in patients with non-small cell lung cancer (NSCLC) treated with Nivolumab.

F. Lanfranchi; M. BauschNeth; C. Genova; G. Ross; E. Ripepi; M. G. Dal Bello; G. Ferraccone; M. Tagliamento; C. Delucchi; M. I. Donegov; F. Berli; S. Chas; I. Zul; S. Radio; G. Citron; C. Marin; G. Sammurct; F. Grossi; S. Marb; I.RCCS Ospedale Policlinico San Martino, Largo Rosanna Brasca 10, 16132, Genova, ITALY; Department of Health Sciences (OSSA), University of Genova, Via Antonio Pastore 1, 16132, Genova, ITALY; Department of Internal Medicine (DIME), University of Genova, Viale Benedetto XV 11, 16122, Genova, ITALY; (MC) Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 28, 20122, Milan, ITALY; Department of Translational Medicine, University of Eastern Piedmont, Via Solvay 17, 28100, Novara, ITALY; Humanitas Clinical and Research Center –IRCCS, Via Manzoni 56, Rosazza, 20089, Milan, ITALY; Department of Biomedical Sciences, Humanitas University, Via Rita Lui Montanelli 4, Pieve Emanuele, 20090, Milan, ITALY; Institute of Molecular Biomaging and Physiology (IBM-P), National Research Council (CNR), Via Fratelli Cervi 93, 00900, Segrate, Milan, ITALY; Nuclear Medicine Unit, University of Leopardo, Leopardo, GERMANY; Department of Neurology, University of Leopardo, Leopardo, GERMANY; (Max Plank Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY).

---

**OP-0220**

Machine Learning Radiomics for Prediction of Survival in Non Small Cell Lung Cancer Patients Studied with PET/CT and FDG.

E. Giovannini; L. FiorinaMonte; E. Bonato; C. Baregg; L. Deakdavdav; A. Milan; G. Gianacchini; V. Duce; C. Aschdel; A. Castd; A. Ciascrew.

---

**OP-0221**

Frequency and prognostic value of immune-related adverse effects assessed on 18F-FDGPET/CT in NSCLC treated with immune checkpoint inhibitors.

O. Humber; M. Bauchner; J. God; D. Rever; M. Popat; A. Schiawazz; D. Chezand; C. Genova; R. Schoppa; G. Ross; I. Zul; J. Durcarr; S. Marb; J. Otto; A. Tuacilacasse Cancer Centre; Nice, FRANCE; Nuclear Medicine Unit, RICCS Ospedale Policlinico San Martino, Genova, ITALY; I.RCCS Ospedale Policlinico San Martino, Genova, ITALY; Ospedale Firenze Ande Mercatora, Genova, ITALY.
OP-0221
Therapeutic response assessment using [18F]-FDG-PET/CT in NSCLC patients treated with immune checkpoint inhibitors
I. Duran Derijckere, N. Gohinhami, I. Karfri, G. Cricht, T. Berghman, P. Filamm; 
‘Nuclear medicine department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM; ’Nuclear medicine department, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, BELGIUM; ’Thoracic oncology clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-0222
The role of 18F-FDG PET/CT for evaluating immunotherapy response in patients with NSCLC: a systematic review and meta-analysis
M. Huang; 
The Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, CHINA.

OP-0223
The role of [18F]-FDG-PET/CT in Predicting Response to PD-1 Blocking Immunotherapy and the prognostic significance of immune organs activation
‘Section of Nuclear Medicine, DIM, University ‘Vida More’ Bari, ITALY; ’Interventional Oncology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Istituto Tumori ‘Giovanni Paolo II’, Bari, ITALY.

OP-0224
Digital and respiratory-gated FDG PET/CT for characterization of lung lesions
Kernkliniken Universitätsklinikum Essen, Essen, GERMANY.

OP-0225
Prognostic value of [18F]-FDG PET/CT quantitative metrics in non-small cell lung cancer
Instituto Português de Oncologia do Porto Francisco Gento, EPE, Porto, PORTUGAL.

OP-0226
Tc99m MAA tumor distribution as a predictive risk factor of occult nodal metastasis in clinically N0 non small cell lung cancer patient
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-0227
Discriminative capacity of the [18F]-FDG PET/CT quantitative parameters in the solitary pulmonary nodule
M. Rashi, E. Tintin-Bruhet, D. Rivas-Navas, A. Gonzalez-Amezcua, A. Rodriguez-Fernandez; 
‘Nuclear medicine department, University Virgen de los Neves Hospital, Granada, SPAIN; ’Nuclear Medicine department, Jaen Hospital, Jaen, SPAIN.

OP-0228
Clinical validation of a fully automated lung segmentation method in patients with pulmonary nodules: preliminary results
‘Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY; ’Institute of Informatics, University of Szeged, Szeged, HUNGARY.

Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Featured Session: New Kids on the Cardiovascular Block!

OP-0230
Diamonds in the Rough - New Opportunities in Cardiovascular Imaging
F. Huyse; 
Assistance Publique - Hôpitaux de Paris, European Hospital Georges Pompidou, Nuclear Medicine, Paris, FRANCE.

OP-0231
Glycoprotein Iib/IIa receptor targeted PET/CT imaging for detecting prosthetic valve thrombosis: a proof-of-concept study
‘Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY; ’Department of General and Interventional Cardiology, Heart, and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY; ’Department of Thoracic and Cardiovascular Surgery, Heart, and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY; ’Orth and Hanna Kerniss Institute for Cardiovascular Research & Development (EWH), Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY; ’Ott/Molecular Imaging GmbH, Berlin, GERMANY.

OP-0232
[18F]-FDG in patients with embolic stroke of (ESU): A pilot study to identify and evaluate atherosclerotic plaques
Hospital San Pedro, Logroño (La Rioja), SPAIN.

OP-0233
Detection of acute myocarditis with [18G]DOTATOC digital PET as compared with cardiac MR: preliminary results
C. Boursier, E. Chevaller, J. Variot, L. Filippi, O. Hutton, V. Roch, L. Imbert, E. Albousis, M. Claudin, D. Mandy, F. Rome; 
CHRU Nancy, Vandoeuvre-Ies-Nancy, FRANCE.

OP-0234
Early detection of anthracycline cardiotoxicity by [18F]-PET/MI in oncology patients
T. Yuan, M. Wei, X. Chen, X. Wang; 
Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-0235
Gated tomographic radionuclide angiography using 3D-ring CT Starguide SPECT/CT - head-to-head comparison with a cardiac-dedicated CTZ camera
T. Carusza, F. Thibault, M. Bally; 
CH Orleans, Orleans, FRANCE.

OP-0236
Incremental Value of [18F]FDG Cardiac PET Imaging Over Dobutamine Stress Echocardiography in Predicting Myocardial Ischemia in Patients with Suspected Coronary Artery Disease
E. Zampella, R. Assante, A. D'Antonio, T. Mannarino, E. Zampella; 
1Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Universita Cattolica del Sacro Cuore, Rome, ITALY, 2Faculty of Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 3Unit of Cardiology, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 4Division of Cardiology, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

Wednesday, October 20, 2021, 18:00 - 19:30

OP-0237
Comparison of early imaging of [18F]-BMIPP and myocardial washout rate for diagnosis of triglyceride deposit cardiomyoscalvulopothy
1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, JAPAN, 2Faculty of Medicine, Chiba University Hospital, Chiba, JAPAN, 3Division of Laboratory Medicine, Chiba University Hospital, Chiba, JAPAN, 4Laboratory of Cardiological Disease, Novel, Non-invasive, and Nutritional Therapeutics and Triglyceride Research Center, Graduate School of Medicine, Osaka University, Osaka, JAPAN.

OP-0238
The Impact of lung perfusion scintigraphy in the work-up of Acute Pulmonary Embolism diagnosis: healthcare outcomes and economic aspects
G. Rubini, P. Mammucci, C. Ferrari, G. Leol, P. Mincarone; 
1Section of Nuclear Medicine, DIM, University ‘Vida More’ Bari, ITALY; ’National Research Council, Institute of Clinical Physiology, Branch of Lecce (c/o Campus Ecetekne via Monterone, Lecce, ITALY; ’National Research Council, Institute for Research on Population and Social Policies, Research Unit of Brindisi, Brindisi, ITALY.

OP-0239
Left-ventricular volumes and ejection fraction from cardiac ECG-gated O2-water positron emission tomography compared to cardiac magnetic resonance imaging using simultaneous hybrid PET/MR
PET Center Uppsala Akademiak sjukhuset, Uppsala, SWEDEN.

OP-0240
Incomplete Anatomical Revascularization in Multivessel Coronary Artery Disease: A Quantitative Myocardial Perfusion PET Study
A. Guarnieri, L. Locatelli, G. Grandinetti, L. Locatelli; 
1Nuclear medicine, P. Bruno, T. Cret, M. Mattessy, A. Gandrano; ’Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Universita Cattolica del Sacro Cuore, Rome, ITALY, 2Faculty of Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 3Unit of Cardiology, Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

OP-0241
Everything You Always Wanted to Know, But Were Afraid to Ask
CME 4: Imaging Neuroinflammation – New Approaches
C. Triviño-Ibáñez, D. Rivas-Navas, A. González-nodules circulating elevated tumour marker in cancer, preliminary results
M. Huang.

OP-0242
Comparison of early imaging of [18F]-BMIPP and myocardial washout rate for diagnosis of triglyceride deposit cardiomyoscalvulopothy
1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, JAPAN, 2Faculty of Medicine, Chiba University Hospital, Chiba, JAPAN, 3Division of Laboratory Medicine, Chiba University Hospital, Chiba, JAPAN, 4Laboratory of Cardiological Disease, Novel, Non-invasive, and Nutritional Therapeutics and Triglyceride Research Center, Graduate School of Medicine, Osaka University, Osaka, JAPAN.

OP-0243
Background of TSPO and Non-TSPO Targets and Their Radiotracers
M. Brendel; 
Department of Nuclear Medicine, University Hospital of Munich; Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.
OP-0444
Imaging Neuroinflammation with TSPO Ligands - A Critical Reappraisal
B. van Berckel; VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0445
Imaging Neuroinflammation - Beyond TSPO Receptors
D. van Weeheghes; Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and RUG Leuven, Leuven, BELGIUM.

OP-0400
Whole Body Lymphoscintigraphy and WB DWIBS-MRI in two cases of thoracic lymphangiomatosis
C. Gianati; A. Arenz, A. Perretet, A. Gondo;
University Hospital of Florence, Florence, ITALY, 2Hospital of Prato, Prato, ITALY, 3University Hospital Meyer, Florence, ITALY.

OP-0401
PET/CT as a key role tool in infectious endocarditis (IE) complications: two cases of splenic abscesses, in patients with prosthetic valve endocarditis (PVE)
Z. Dancheva, M. Dyankova, T. Stoeva, S. Chaukheva, T. Yordanova, B. Chaukheva, A. Kizilova;
St Marina University Hospital, Varna, BULGARIA.

OP-0402
Extensive dermatomyositis mimicking insulin-induced skeletal muscle uptake in 18F-FDG PET/CT
1CSL hospital, Vitaliva, Arlon, BELGIUM, 2Oncology, 3CSL hospital, Vitaliva, Arlon, BELGIUM, 4Radiology, 5CSL hospital, Vitaliva, Arlon, BELGIUM.

OP-0403
The usefulness of Gallium-citrate scintigraphy in renal transplant infection
A. Marques, F. Abreu, S. Pintão;
1Institute of Oncology “Prof Dr. Ion Chiricuta”, 2Department of Nuclear Medicine, University Hospitals of Cluj-Napoca, ROMANIA.

OP-0404
The role of 18F FDG PET/CT imaging in the incidental diagnosis of cancer patients with asymptomatic COVID-19 infection
M. Keskin, Merem City Training and Research Hospital, Merem, TURKEY.

OP-0405
Utility of 18F-fluorodeoxyglucose PET-CT in a Rare case of Granulomatosis with Polyangiitis (GPA) with Multi-organ involvement without raised serum Proteinase 3 of Granulomatosis with Polyangiitis (GPA) with Multi-organ involvement without raised serum Proteinase 3
A. Diyar;
MPC cancer hospital, Navi Mumbais, INDIA.

OP-0406
18-FDG-PET/CT in thoracic sarcoïdosis, mimicking a chondrosarcoma progression - a case report
Z. Dancheva, A. Konsouvlova, M. Dyankova, T. Yordanova, B. Chaukheva, A. Kizilova;
1St Marina University Hospital, Varna, BULGARIA, 2Department of Oncology, Complex Oncological Centre, Burgas, BULGARIA.

OP-0407
Molecular Neuroimage and Parkinsonism after SARS-CoV2 Infection
A. Silva Mascarenhas, F. Menezes Marina; Imagens Médicas de Brasilia - IEMB, Brasil, BRAZIL.

OP-0408
Covid Incidental finding in 18 FPSMA1007 PET CT in asymptomatic patient
M. Agolli, L. Solari;
1Center of Nuclear Medicine Clinica Modena, Parana, ARGENTINA.

OP-0409
18F-FDG brain PET in a patient with neurological involvement after severe SARS-CoV-2 infection: a rather fast recovery of brain metabolic function
A. Martini1, G. Carli1, L. Laghia1, L. Kille1, P. Piersare1, D. Penare1, S. Sest01;
1Hospital Santa Stefano Nuclear Medicine Unit, Prato, ITALY, 2University of Florence, AOUC Careggi, Department of Nuclear Medicine, Florence, ITALY, 3University Vita Sallete San Rafaele, Nuclear Medicine Unit Division of Neurosciences, Milan, ITALY, 4Hospital Santa Stefano Nuclear Neurology Unit, Prato, ITALY.

OP-0410
The role of 18F-FDG PET/CT in diagnosis and evaluation of an unsuspected secondary cutaneous lesion in a patient with tumor of unknown origin (TUO) in times of COVID-19 pandemic - a case report
T. Stoeva, T. Yordanova, M. Dyankova, S. Chaukheva, Z. Dancheva, B. Chaukheva, A. Kizilova;
18FIT “Sveti Marina” EAD - Varna, Varna, BULGARIA.

OP-0411
18F-FDG PET/CT diagnostic challenges in differentiating between post-COVID-19 vaccination lymphadenopathy and aortic ligniflamentous melanoma metastasis: A Case Report
Institute of Oncology „Prof Dr. Ion Chiricuta”, Cluj-Napoca, ROMANIA.

OP-0412
Inguinal Bladder Hernia on FDG PET/CT
Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, TURKEY.

OP-0413
Demonstration of Peritoneal-Scrotal Communication by 131I-MAA Scintigraphy
A. Marquez, F. Abreu, S. Pintao;
1St Marina University Hospital of Lisboa Occidental, Lisbon, PORTUGAL.

OP-0414
Pulmonary Embolism on Arzogos Lobe Detected by Ventilation/Perfusion SPECT/CT
Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, TURKEY.

OP-0415
Use of 2- [18F] FDG PET/CT in unusual pediatric tumors
M. Acuña Hernandez, R. Palma Rosillo, R. Moro Ramirez;
1Universidad Autonoma de Bucaramanga, Bucaramanga, COLOMBIA, 2Instituto Nacional de Pediatría, Ciudad de México, MEXICO.

OP-0416
Comparison [68Ga]FAPI-46 PET/CT and [131I] SPECT findings after ablation therapy with high-activity 131I therapy of metastatic papillary thyroid cancer patients: Two case reports
F. Novruzov, A. Alyev, S. Novruzova, N. Durovov, I. Alyev, M. Moor, F. Valta, F. Gammeln, E. Mehti;
1Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2Azerbaijan National Centre of Oncology, Department of Head and Neck Surgery, Baku, AZERBAIJAN, 3Azerbaijan Medical University, Department of Internal Medicine, Baku, AZERBAIJAN.

OP-0417
Peptide Receptor Radionuclide Therapy (PRRT) in Radiodiode-Refractory Thyroid Cancer. A Case Report of Significant Response to 177Lu-Dotatate Treatment
S. Atez, K. Ayaz, T. Mostafali, M. Esmatiroo, H. Mohammad Zadeh Kosari, A. Aghaee;
Mashhad University of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-0418
Subacute Thyroiditis and Cardiovascular Events - a Report of Two Clinical Cases
K. Basak Studen1, K. Zizel1, S. Parnel2, S. Gabarevsk2;
1Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.
OP-0252 Clinical Examples of Rubidium PET/CT
M. Moulden; Isala Hospital, Zwolle, NETHERLANDS.

OP-0253 Research Tracers Used in Cardiac PET/CT
A. Saraste; Turku University Hospital, Heart Center, Turku, FINLAND.

OP-0254 Imaging pituitary microadenoma by using 99mTc-octreotide and 18F-FDOPA, 18F-DOTA-NOC and 18F-FDG PET/CT
S. Li, T. Vallerine, A. Golier, T. Haute-Wingenger, J. Furtner-Sayer, G. Kanaan, A. Haug, M. Hacker; Medical University of Vienna, Vienna, AUSTRIA.

OP-0255 Diabetic Foot Infections - Clinical Challenges for Diabetologists
P. Gane; University Hospitals of Derby and Burton NHS Foundation Trust, Department of Diabetes and Endocrinology, Derby, UNITED KINGDOM.

OP-0256 Diabetic Foot Infections - Clinical Challenges for Radiologists
T. Kwee; University Medical Center Groningen, Department of Radiology, Groningen, NETHERLANDS.

OP-0257 Diabetic Foot Infections - Clinical Challenges for Nuclear Medicine Physicians
C. Lauri; Sant'Andrea Hospital, Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine of ‘Sapienza’ University, Rome, ITALY.

OP-0258 Diabetic Foot Infections - Clinical Challenges for Endocrinologists
F. Mottaghy; University Medical Center of Aachen, Klinik für Nuklearmedizin, Aachen, GERMANY.

OP-0259 Autoimmune Rheumatic Disorders - The Rheumatologist’s Questions
R. Seror; Rheumatology Department, Université Paris Sud; Hôpitaux Universitaires Paris-Sud, Paris, FRANCE.

OP-0260 Autoimmune Paraneoplastic Syndromes - The Clinician’s Point of View
Z. Szekanecz; Department of Rheumatology, University of Debrecen, Debrecen, HUNGARY.

OP-0261 The Current Role of FDG Imaging in Autoimmune Disorders
L. Leccisotti; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.

OP-0262 The Role of Novel Radiotracers - FAPI Imaging in Systemic Sclerosis and IgG4-Related Disease
C. Schmidt; University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY.

OP-0263 Sentinel Lymph Node in Head and Neck Cancers
R. A. Valdés Olmos; University Medical Center of Groningen, Groningen, NETHERLANDS.

OP-0264 Sentinel Lymph Node in Malignant Skin Melanoma
S. Balogová; Comenius University of Bratislava, St. Elisabeth Oncology Institute, Nuclear medicine, Bratislava, SLOVAKIA.

OP-0265 Sentinel Lymph Node in Head and Neck Cancers
S. Vidal Stark; Hospital Clinic Barcelona, Nuclear Medicine Dept., Barcelona, SPAIN.

OP-0266 Sentinel Lymph Node in Penile Carcinoma
O. Brouwer; Netherlands Cancer Institute, Department of Surgical Oncology (Urology), Amsterdam, NETHERLANDS.

OP-0267 Sentinel Lymph Node in Gynaecological Cancers
S. Monasor; Universitätsklinikum Aachen, Klinik für Nuklearmedizin, Aachen, GERMANY.

OP-0268 Evolution of Brain Mapping - From Bedside to Bench...
F. Mattagh; Universitätsklinikum Aachen, Klinik für Nuklearmedizin, Aachen, GERMANY.

OP-0270 Preclinical Evaluation, Kinetic Modelling, and Assessment of Test-Retest Reproducibility of [18F] Synvest-1 For PET Imaging Of Synaptic Vesicle Glycoprotein 2A
D. Bertoglio; J. Verhaeghe1, F. Zajicek1, S. De Lombaerde1, A. Miranda, F. Tamer2, X. Ketelaers1, M. Skuletaj1, C. Dominguez1, Y. Wang1, J. Munne-Sanjuan3, J. Bard1, L. Lui, S. Staehle1; University of Antwerp, Wilrijk, BELGIUM, ‘Antwerp University Hospital, Edegem, BELGIUM, CHIRI Management/CHIRI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-0271 Head-to-Head Comparison of beta-Amyloid-PET Quantification in PET, PET/CT and PET/MRI: Towards Small Animal Multicenter Studies
M. Koehler1, K. Wind1, C. Klaus1, A. Zatezlo1, L. Sebastian Manzou2, J. Grünich1, L. Beyer, F. Eckenwalder, M. Schießle, F. Golkowski, B. van Unger-Sternberg, M. Partl, C. Haas1, P. Bartentien1, J. Herrms1, S. Tashirov1, S. Ziegler, M. Brederle1,2; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY, ‘German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, GERMANY, ‘Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University Munich, Munich, GERMANY, ‘Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, ‘Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, GERMANY, ‘Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ‘Center of Neuropathology and Prion Research, University of Munich, Munich, GERMANY.

OP-0272 Development and Translational Study of Novel Alpha-Synuclein PET Tracers
B. Uzuegbunam, W. Raskowsk1, H. Ågren3, C. Håblad1, D. Librizzi4, B. Weber1, M. Luther1, T. Arzberger1, B. H. Yousef1; Technical University of Munich, Munich, GERMANY, ‘Karolinska Institute, Stockholm, SWEDEN, ‘University of Uppsala, Uppsala, SWEDEN, ‘Philips-University of Marburg, Marburg, GERMANY, ‘Ludwig-Maximilians-University of Munich, Munich, GERMANY.

OP-0273 [18F]MIM-225 PET for the dose-response assessment of tariquidar inhibition of blood-brain barrier P-glycoprotein function in vivo
L. García-Varela1, P. Massé1, P. Aguilar2, A. Daza-Vazquez-Matías1, A. van Waa1, A. T. Willmsen1, A. B. Bartels1, R. A. Dierckx1, P. H. Elings1, G. Luurtsema1; ‘University Medical Center of Groningen, Groningen, NETHERLANDS, ‘Department of Nuclear Medicine and Molecular Imaging Group, Clinical University Hospital, IDS Health Research Institute, Santiago de Compostela, SPAIN, ‘Department of Neurology, University Medical Center Groningen, Groningen, NETHERLANDS.
OP-0274
Longitudinal follow-up of APJ receptor expression by microPET/CT in a rodent model of cerebral ischemia-reperfusion.
O. Nachar, N. Hugue, B. Louiz, L. Balazs, V. Naï, A. Moryan, A. Bouhlet, G. Hache, F. Dignat-George, J. Laurin, P. Gamige, B. Guillet, Ax-Iamsusl Marls, Marseille, FRANCE.

OP-0275
Preclinical evaluation of [(18)F]HS9990 for in vivo visualization of heat shock protein 90 (Hsp90) in brain with positron emission tomography (PET).
R. Cools, K. Vermeulen, C. Cawthorne, G. Bormans, 1UMCG, Groningen, NETHERLANDS, 2Kanazawa University, Advanced Science Research Center, Kanazawa, JAPAN, 3Kanazawa University Hospital, Kanazawa, JAPAN, 4Department of Imaging & Pathology KU Leuven, Leuven, BELGIUM.

OP-0276
Upregulation of Sigma-1 receptor expression depends on the severity of ischemia: Based on the imaging study with the sigma-1 receptor imaging agent, I-125-OI5V.
J. Takl, H. Watabayashi, H. Mier, T. Momatsu, N. Matsuoka, A. Shida, K. Ogawa, S. Kinuya, 1Division of Nuclear Physics, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UNITED KINGDOM, 2Head and Neck Oncology Unit, Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

OP-0277
Pharmacological characterization of [(18)F]-FN1 and evaluation of NMDA receptors activation in rat brain injury model.
M. Beaubier, T. Falzon, D. Perier, S. Boucher, P. Payo, J. Saalabert, 1Toulouse Neuroimaging Center (Tocino), Inserm U1214, Toulouse, FRANCE, 2Institut de Pharmacologie et de Biologie Structurale (IPBS-CNRS), Toulouse, FRANCE, 3CHU de Toulouse, Toulouse, FRANCE.

OP-0278
Measuring histamine H3 receptor occupancy of the experimental anti-Parkinson drug AG0029, using [(11)C]GSK-189254 and PET.

OP-0279
Early detection of Amyloid-b pathology via [(Zr-DFO)-Immuno-PET] with a novel bispecific monoclonal antibody.

OP-0280
Preliminary results of INSPIRE clinical dosimetry study.

OP-0281
Therapy with [(18)F]-DOTATATE: correlation between relative platelets reduction and image based bone marrow low absorbed dose.
S. Mazzaglia, G. Argiroffi, V. Fuoco, M. Mascaciosa, E. Seregni, A. Lorenzani, G. Alberti, M. Kireni, C. Chiesa, 1IRCCS Istituto Nazionale Tumori, Milan, ITALY.

OP-0282
Global Tumour Absorbed Dose Heterogeneity for Patients Treated with [177Lu]Lilotomab Sate traxetan.
J. Blaksiard, A. Landdon, P. J. Doherty, A. Kolitsch, C. Stockle, 1Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORGRA, 2Department of Physics, University of Oslo, Oslo, NORGRA, 3Faculty of Medicine, University of Oslo, Oslo, NORGRA, 4Norwegian Nanotechnology ASa, Oslo, NORGRA, 5Department of Oncology, Oslo University Hospital, Oslo, NORGRA.

OP-0283
M. Uijen, B. Pivit, C. Van Herpen, M. Goethardt, M. Koninjkenberg, S. Peters, J. Nagarajah, Radboudumc, Nijmegen, NETHERLANDS.

OP-0284
G. Della Gala, M. Santoni, G. Pacilani, S. Strini, E. Lodrozzi, A. Capelli, L. Masotti, L. Calderoni, A. Magnani, S. Farati, R. Gofrier, L. Siringo, 1Medical Physics Department IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY, 2Radiation Oncology Center, Department of Experimental, Diagnostic, and Speciality Medicine, IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY, 3Department of Nuclear Medicine, IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, ITALY.

OP-0285
Dosimetric comparison between planning SPECT and monitoring PET for [(90)Y]radioemboliation.
J. Laboaur, T. Baudier, S. Plante-Delorme, F. Khayi, D. Samut, J. Badeil, Centre Léon Bérard, Université de Lyon, CREATIS, CNRS UMS3220, Inserm U1044, INSIA-Lyon, Université Lyon 1, Lyon, FRANCE.

OP-0286
N. McArdle, S. Coumaire, J. McCavana, J. Lucery, J. Ledin Vernet, 1St Vincent’s University Hospital, Dublin, IRELAND, 2University College Dublin, Dublin, IRELAND, 3Faculty of Medicine, Gazi University, Ankara, TURKEY, 4Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, TURKEY, 5Department of Pathology, Faculty of Medicine, Gazi University, Ankara, TURKEY.

OP-0287
Comparison of Two [(90)Y]-charged Glass Microspheres Liver Radioembolisation Dosimetry Methods: Voxel S-values and Monte Carlo – GATE.
M. Ribero, P. Pemesa, P. F. Oliveras, J. Cruz, D. C. Casta, 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2NOVA School of Science and Technology, Amadora, PORTUGAL.

OP-0288
Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC.
E. Veerstra, S. J. Rutters, R. P. Bakken, K. R. de Jong, W. Nasoed, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0289
Head-to-head Comparison of [(18)F]Ga-Fapi-04 and [(18)F]FDG PET/CT in Evaluating the Extent of Disease in Gastric Adenocarcinoma.
J. Kuten, C. Levine, O. Shnami, S. Pelles, J. Wolf, G. Luhtas, E. Mohran, E. Eren-Sapir, 1Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL, 2Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, ISRAEL, 3Cyclotron Radiochemistry Unit, Hadassah Medical Organization and Faculty of Medicine, Jerusalem, ISRAEL, 4Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, ISRAEL, 5Department of Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL.

OP-0290
Respiratory-gated FDG PET/MI in Evaluation of Primary Gastric Lesions and Gastric Lymph Nodes in Patients with Gastric Cancer.
S. Gullbahr Akre, H. A. Ayadil, U. G. Akdemir, O. Yuket, A. Uner, A. Duran, L. O. Aray, 1Department of Nuclear Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY, 2Department of Nuclear Medicine, Faculty of Medicine, Gazi University, Ankara, TURKEY, 3Department of General Surgery, Faculty of Medicine, Gazi University, Ankara, TURKEY, 4Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, TURKEY, 5Department of Pathology, Faculty of Medicine, Gazi University, Ankara, TURKEY.

OP-0291
Static and dynamic FAPI-PET for the differentiation of low grade and high grade intraductal papillary mucinous neoplasms.
A. Spekter, M. Long, E. Gutjahr, U. Heger, C. Tyden, H. Rathke, U. Haberkam, M. Rohrich, 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, 2Department of Surgery, University Hospital Heidelberg, Heidelberg, GERMANY, 3Department of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY.
Moreno Ruiz1, M. Florez Rial1, M. Requena Santos1, A. Gutierrez Cecchin, L. Evangelista; X. Jia1, Y. Wang1, Y. Liu1, Y. Yang1, G. Qiu1, S. Chen2, F. Wang3, J. Malignancies of the Digestive Tract 1, C. Ponce Herrera1, C. Montiel Casado1, F. Moreno Ruiz, M. Requena Santos, M. Florez Rial, V. Martin Parrilla, E. López Rodriguez, M. Nicolás Aguado, L. Lumbrés Vega, D. Ramirez Ortega, M. Puentes Zarzuela; Hospital Regional de Málaga, Málaga, SPAIN.

OP-0302 Se-75-SehCAT in the diagnostic procedure of chronic diarrhoea C. Körber, N. Klieker-Hafner; Nuclear medicine, Fulda, GERMANY.

OP-0303 Accuracy of [(18)F] FDG PET-CT to identify the location and extent of local residual disease in esophageal cancer S. Martin Aguilar, C. Ponce Herrera, C. Montiel Casado, F. Moreno Ruiz, M. Requena Santos, M. Florez Rial, V. Martin Parrilla, E. López Rodriguez, M. Nicolás Aguado, L. Lumbrés Vega, D. Ramirez Ortega, M. Puentes Zarzuela; Hospital Regional de Málaga, Málaga, SPAIN.

Wednesday, October 20 - Saturday, October 23, 2021 on-demand pod; release on Wednesday, October 20 at 09:00 TROP Session: Top of Cardiovascular and Soft Tissue Infection/Inflammation Imaging

OP-0304 Investigation of Pediatric Cardiac-Related Infections with [(18)F] FDG PET/CT: Optimization and Performance G. April, R. Lambert, S. Turpin; CHU Ste-Justine, Montreal, QC, CANADA.

OP-0305 Diagnostic performance of digital PET with a dedicated head and neck protocol for the assessment of inflammation of cranial arteries in giant cell arteritis B. Durand-Bailly1, T. Thibault1, A. Bertaut2, J. Albenque2,1.

1Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, FRANCE; 2Department of Internal Medicine and Clinical Immunology, François-Mitterrand University Hospital Dijon, FRANCE; 3Department of Methodology and Biostatistics, Georges-François Leclerc Research Cancer Center, Dijon, FRANCE; 4INSERM, UMR 1098, University of Bourgogne Franche-Comté, Dijon, FRANCE; 5Department of Nuclear Medicine, Medicare University Center, Jerusalem, SYRIA; 6Department of Nuclear Medicine, Beilinson Medical Center, Petah Tikva, ISRAEL; 7University of Milan, Milan, ITALY; 8Department of Nuclear Medicine, University of Innsbruck, Innsbruck, AUSTRIA; 9University of Erlangen, Erlangen, GERMANY; 10University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY; 11University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY.

OP-0306 New Possible Interpretation Criteria in 18F-FDG PET/CT SCAN For The Diagnosis Of Infective Endocarditis M. Gazzoli1, D. Albano1, S. Lucchini1, A. Pelosi1, E. Cerduelli2, F. Dandri, A. Mazzei1, P. Bellini1, F. Berragga1, R. Ghiabban1,1.

1Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, ITALY; 2University of Milan, Milan, ITALY; 3University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY.

OP-0307 Management in Patients with suspected Myotic Aneurysms: Impact of FDG PET/CT L. Husmann, M. W. Heufler1, H. Grueng1, A. Behrhard1, C. A. Mestres1, Z. Ranieri1, B. Hasse1,1.

1Department of Nuclear Medicine, University of Zurich / University of Zurich, ZURICH, SWITZERLAND; 2Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich / University of Zurich, Zurich, SWITZERLAND.


1Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and COUP, Pisa, ITALY; 2Nuclear Medicine, Humanitas Clinical and Research Center - IRCCS, Rozzano (Milan), ITALY; 3Department of Biomedical Sciences, Humanitas University; Pieve Emanuele (Milan), ITALY; 4Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS; 5Department of Biomedical Photonic Imaging, University of Twente, Enschede, NETHERLANDS.

OP-0309 Blood Ketone Measurements Can Be Used to Predict Myocardial FDG Uptake P. Francis, L. Eldad; Royal Children's Hospital, Melbourne, AUSTRALIA.

OP-0310 The diagnostic value of [(18)F]FDG PET/CT in detecting septic thrombosis in patients with venous catheter-related Staphylococcus aureus bacteremia R. Tünste1, M. Gampelmann1, E. Azrnten1, I. Kouijzer1, E. van Leesten1, M. Breeuwer1, J. ten Oever1, C. Bleeker-Rovers1, G. Wanten1,1.

1Radboud University Medical Center, Nijmegen, NETHERLANDS; 2Elisabeth-TweeSteden Ziekenhuis, Tilburg, NETHERLANDS; 3University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY; 4Clinic for Vascular Surgery, University Hospital of Zurich, Zurich, SWITZERLAND; 5Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, SWITZERLAND.

OP-0311 Inflammatory-Directed Whole-Body PET Can Alter Clinical Management in Patients with suspected Rheumatic Disease R. Werner1, K. G. Guggenberger2, S. Seifling1, T. Hugel1, W. G. Pomper1, S. P. Rowell3, M. Schmolzing1, A. K. Buck1, T. Bley1, M. Hochleitner1,1.

1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY; 2Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, GERMANY; 3Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN; 4The Ruth and Einar S. Madsen Department of Radiology and Radiological Science, Division of Nuclear Medicine, Baltimore, MARYLAND, UNITED STATES OF AMERICA; 5Department of Internal Medicine II, Rheumatology/Experimental Immunology, University Hospital Würzburg, Würzburg, GERMANY.

OP-0312 Evaluation of F-18-FDG-PET/MRI in patients with echinococcosis N. Eberhardt1, J. P. Steiner2, L. Petri1, S. G. Schwede3, R. Kopp1, M. Beer1, C. Salbach1, T. Rull1, B. Grüner1, A. J. Beer1,1.

1Ulm University Medical Center, Department of Nuclear Medicine, Ulm, GERMANY; 2Ulm University Medical Center, Department of Internal Medicine II – Section for Infectious Diseases, Ulm, GERMANY; 3Ulm University Medical Center, Department of Diagnostic and Interventional Radiology, Ulm, GERMANY.

OP-0313 Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging C. Schmidkonz1, S. Rauber1, A. Alzinger1, T. Gatiz1, A. Spoer1, M. Corades1, D. Prante1, P. Rott1, T. Bokan1, M. Náher1, U. Haberkorn1, T. Rüverter1, G. Schett1, A. Ramming1,1.

1University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY; 2University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY; 3University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-0314 [(68)Ga]Ga-Dexforaxime for Imaging of Bacterial Infections - Preliminary Results of a Phase I/II Study B. Nizica1, M. Pein1, C. Rangger1, C. Upprimer1, J. Pflister1, M. Haspach1, G. Weiss1, I. Vargic1; 1Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA; 2Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Innsbruck, CZECH REPUBLIC; 3Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, CZECH REPUBLIC; 4Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, AUSTRIA.
OP-0315
PET-CT Imaging of Pulmonary Inflammation with [68Ga]Ga-DOTATATE E. Pauwels1, F. Legrand1, E. Chiadomina1, J. Verheugen1, J. Sijthooven1, H. Remmelts1, S. Vangast1, O. Kersseboom1, G. Perumaran2, ‘Science for Life Laboratory, Uppsala University, Uppsala, SWEDEN’, 1Department of Medical Chemistry, Uppsala, SWEDEN, 2Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 3Department of KGP, Uppsala University, Uppsala, SWEDEN.

OP-0318
Cardiac Sarcoïdosis O. Gheysens, Cliniques Universitaires Saint-Luc, Leuven, BELGIUM.

OP-0319
Cardiac Amyloidosis T. Kero, University of Helsinki, Department of Nuclear Medicine, Finland.

OP-0320
Endocarditis A. Scholtens, Meander Medical Center, department of nuclear medicine, Amersfoort, NETHERLANDS.

OP-0321
Vasculitis L. Gormsen, Aarhus University Hospital, Department of Nuclear Medicine and PET Center, Aarhus, DENMARK.

OP-0324
Interview - Creating Tracers U. Haberkorn, University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-0325
Interview - Paediatric NM Today L. Bissangi, Great Ormond Street Hospital for Children, Radiology, London, UNITED KINGDOM.

OP-0326
Interview - Paediatric NM Today T. D. Barwick, Imperial College, London, UNITED KINGDOM.

OP-0329
PET/CT for Infectious and Inflammatory Diseases A. W. J. M. Glaudemans, University Medical Center Groningen, Department of Nuclear Medicine, Groningen, NETHERLANDS.

OP-0331
Introduction into the ATN Concept G. Frisoni, Geneva University Hospital, Memory Clinic, Geneva, SWITZERLAND.

OP-0332
PET Tracers to Establish the ATN Profile V. Villermagne, University of Pittsburgh, Department of Psychiatry, Pittsburgh, UNITED STATES OF AMERICA.

OP-0333
A Critical Clinician’s Perspective on the ATN Concept G. Frisoni, Geneva University Hospital, Memory Clinic, Geneva, SWITZERLAND.

OP-0334
PET Data Supporting/Opposing the ATN Concept G. Cheletat, Université de Caen Basse-Normandie, Multimodal Neuroimaging in Brain diseases Lab, Caen, FRANCE.

OP-0336
Introduction P. Federico, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, CANADA.

OP-0337
Epilepsy - The Role of MRI in Epilepsy A. E. Vaudano, OCB Hospital, Neurological Unit, ACU/Madrid, Madrid, SPAIN.

OP-0338
Epilepsy - The Role of FDG-PET and FDG-PET/CT in Epilepsy A. E. Vaudano, OCIB Hospital, Neurological Unit, ACU/Madrid, Madrid, SPAIN.

OP-0339
Is FDG the Only PET Tracer Useful for Patients with Epilepsy? P. Hammers, PET Imaging Centre, King’s College London, London, UNITED KINGDOM.

OP-0341
Physiological, Variants & Benign Tumours D. de Palma, A.O. Ospedale di Circolo e Fondazione Macchi, Department of Nuclear Medicine, Varese, ITALY.

OP-0343
Challenging Cases M. Terrail Cassou, Oncopole, department of Nuclear Medicine, Toulouse, FRANCE.

OP-0345
Introduction Talk P. Payoun, CHU Puissan, Nuclear Medicine Department, Toulouse, FRANCE.

OP-0346
Longitudinal Evaluation Of The First Mutant Huntington PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s Disease D. Bertoglio1, J. Verheugen1, S. De Lambrechts1, F. Zajicek1, T. D. Barwick, Imperial College, London, UNITED KINGDOM, 2Antwerp University Hospital, Edegem, BELGIUM, 3University of Antwerp, Wilrijk, BELGIUM, 4Antwerp University Hospital, Edegem, BELGIUM, 5University of Antwerp, Antwerp, BELGIUM.
OP-0347
Microglia Phenotypes Impact Metabolic Connectivity in Mouse Models of Neurodegenerative Diseases

Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY; German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY; Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, GERMANY; German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY; CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Beijing, CHINA; Center for Neuropharmacology and Pain Research, Ludwig-Maximilians-Universität München, Munich, GERMANY; Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-0348
TREM2 Deficiency Desynchronizes Microglial Activity in the Mouse Brain
A. Zatcepin

Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY; German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY; Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, GERMANY; German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY; CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Beijing, CHINA; Center for Neuropharmacology and Pain Research, Ludwig-Maximilians-Universität München, Munich, GERMANY; Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

OP-0349
Exploring The Neuroprotective Effects Of Montelukast Treatment In A Rat Model Of Quinolinic Acid-Induced Neurotoxicity
S. Shimomi, T. Keller, J. Rajander, E. Löyttyniemi, O. Savin, P. Naulio, S. Kanaya, E. Yatkin, T. J. Grönroos, H. Iida

Turku PET Centre, University of Turku, Turku, FINLAND; National Laboratory of Science and Technology, Anzai City, JARM, Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, FINLAND; Department of Biostatistics, University of Turku, Turku, FINLAND; Central Animal Laboratory, University of Turku, Turku, FINLAND.

OP-0350
Validation of 2-Deoxy-2-[18 F]fluorosorbatol ([18 F]-FDG) repurposed as a PET imaging biomarker of Blood Brain Barrier integrity in vivo
G. Hugon, S. Goulait, A. Daubai, A. Winkele, A. Noveil, N. Tournier, University Fano-Saglia, CEAS, INRIM, BioMaps, Service Hospitalier Fédéral Sjäälland, Oreland, FRANCE.

OP-0351
Dynamic behavior of brain and muscle glucose uptake during insulin challenges
C. H. Malbert, C. Marathe, A. Chauvin, M. Genissel, J. Vercouillie, D. Guilloteau, S. Routier, S. Chalon

University Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Fédéral Sjäälland, Oreland, FRANCE.

OP-0352
Neuroinflammation PET imaging in vivo evaluation of aging process in a Down syndrome animal model
L. Estessi de Souza, M. Pereda da Silva, C. Cristina Renzi, D. De Paula Faria, Universidade de São Paulo, São Paulo, BRAZIL.

OP-0353
Evaluation of ([18F]-DPA PET for detecting microglial activity in the spinal cord of a rat model of neuropathic pain
S. Shimomi
T. Keller, J. Rajander, E. Löyttyniemi, O. Savin, P. Naulio, S. Kanaya, E. Yatkin, T. J. Grönroos, H. Iida

Turku PET Centre, University of Turku, Turku, FINLAND; National Laboratory of Science and Technology, Anzai City, JARM, Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, FINLAND; Department of Biostatistics, University of Turku, Turku, FINLAND; Central Animal Laboratory, University of Turku, Turku, FINLAND.

OP-0354
First Evaluation of PET-Based Human Biodistribution and Radiation Dosimetry of [18F]-PSMA
B. Gänggara Sehrin, B. Rivera-bravo, A. R. Lakkar, M. Auto-Rodriguez

Universidad Nacional Autónoma de México, Ciudad de Mexico, MEXICO; International Atomic Energy Agency, Viena, AUSTRIA.

OP-0355
Cu-ATSM as a therapeutic agent in solid tumor: preliminary results of a whole body human dosimetry study
N. Varinenet, M. Colombié, C. Rousseau, F. Haddad, L. Ferrer

1CIC René Gauducheau, F-44800 Saint-Herblain, FRANCE, 2CICRNA UMR 123 INFRM, F-44000 Nantes, FRANCE, 3GP ARRONAX, F-44800 Saint-Herblain, FRANCE, 4Université de Nantes, F-44000 Nantes, FRANCE, 5SUBATECH, INTL Atlantique, CNRS/INP/INPL, F-44000 Nantes, FRANCE.

OP-0356
Biokinetics and radiation dosimetry of [18F]-PSMA-1007
E. Hvitfeldt, M. Björndal, P. Oldaji, S. Lack Svegrov, G. Beavert, D. Minnik, I. Tragardh

Clinical Physiology and Nuclear Medicine, Skåne University Hospital and Lund University, Malmö, SWEDEN; Radiation Physics, Skåne University Hospital and Lund University, Lund, SWEDEN; Radiation Physics, Skåne University Hospital and Lund University, Malmö, SWEDEN; Wallenberg Center for Molecular Medicine, Lund, SWEDEN.

OP-0362
A revised compartmental model for biokinetics and dosimetry of [18F-FDG
M. Andersson, A. Kamp, D. Nagle, S. Mattsson, A. Guzzani

Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN; Medical Radiation Physics, Department of Translational Medicine Lund University, Malmö, SWEDEN; Department of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection (BSI), Neuberger, GERMANY; Department of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection (BSI), (retired), Neuberger, GERMANY.

OP-0363
Radiation dosimetry of [18F]-CETO, a PET tracer for adrenocortical imaging
M. Lubbeink, I. Silini, A. Morena, F. Argibay, M. Gunettel, M. Brown, S. Rosier, G. Antoni, P. Hellman, A. Sundin

Uppsala University, Uppsala, SWEDEN; University of Cambridge, Cambridge, UNITED KINGDOM; Queen Mary University of London, London, UNITED KINGDOM.

OP-0357
Studying biodistribution and radiation dosimetry in patients with Adrenal Tumors

1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY; Division of Endocrinology and Diabetes, Department of Medicine, University of Würzburg, Würzburg, GERMANY.

OP-0358
Pre therapy [18F]-Nal dosimetry for predicting salivary gland absorbed doses from [18F]-Nal therapy
L. Vávrová, J. Gear, J. Tarpøe, Y. Mummy, S. Brown, J. Swain

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UNITED KINGDOM; ICTR, University of Leeds, Leeds, UNITED KINGDOM; Weston Park Hospital, Sheffield, UNITED KINGDOM; Cardiology Beyond Perfusion Imaging.

Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00
Clinical Oncology Track - TROP Session: Neuroendocrine

**OP-0365**

"[18F]F-18-FDG-PET PET/CT in the diagnosis and management of NETs: a case report and literature review"

N. Fatima1, S. Zaman2, A. Zaman3, U. U. Zaman4; 1AKUH, Karachi, PAKISTAN, 2Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, 3Dr Ruth Pfau (CHK), Karachi, PAKISTAN, 4Sunny Downstate Medical Center, NY, New York, USA.

**OP-0366**

"Prediction of transient bone marrow suppression after [111In]DTPA-DTPA-TATE treatment using [18F]FDG-PET/CT in patients with neuroendocrine tumors"

H. Pyo, S. Cho, J. Paeng, K. Kang, G. Cheon; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

**OP-0367**

"[18F]-Fluoro-Dopa positron emission tomography computer tomography and whole body magnetic resonance imaging are efficient and complementary imaging modalities for evaluation of extension in well-differentiated neuroendocrine tumor of small intestine patients"


**OP-0370**

"Two Birds with One Stone: Can [68Ga]DOTA-NOCANOT PET/CT Image Quality Be Improved through BMI-Adjusted Injected Activity in Neuroendocrine Tumour Patients?"

E. Fortunati, G. Argalia, L. Zanorini, D. Caldarola, C. Malavasi, V. Allegrì, S. Cisovelli, S. Fantini, V. Ambrosioni, F. G. Gelardi; Nuclear Medicine, University of Turin, Turin, ITALY.

**OP-0371**

"[68Ga]Ga-DOTANOC PET/CT Derived Radiomic Features Can Discriminate Pancreatic Neuroendocrine Tumours from Accessory Spleens: Preliminary Results"

G. Argalia, S. Maddavanì, E. Fortunati, D. Caldaroli, D. Campandì, A. Bevilacqua, S. Fantini, V. Ambrosioni, F. G. Gelardi; Nuclear Medicine, University of Turin, Turin, ITALY.

**OP-0372**

"Pancreatic uptake of radiolabeled exendin as a measure of beta cell mass in remission of type 2 diabetes in patients having metabolic surgery"


**OP-0373**

"Ga-68 DOTATE PET / Lut-177 DOTATATE SPECT Theranostics: Discordance in Neuroendocrine Tumor and Organ Distributions"

K. Wong, K. A. Frej, J. Niederbiller, R. K. Karaz, F. P. Warden, Y. K. Chawla; Michigan Medicine, Ann Arbor, MI, UNITED STATES OF AMERICA.

**OP-0374**

"[68Ga]Ga-DOTA-TOC PET/MRI validation compared to PET/CT, in patients with paraganglioma and pheochromocytoma. Initial results"

S. Prado Wohlwend, M. Ballestra Massa, P. B. Arques, M. del Olmo García, J. Torres-Espallardo, J. Merino Torres; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

**OP-0375**

"Prevalence and Significance of 68Ga-DOTA-conjugated Somatostatin Receptor-Targeting Peptide PET/CT Incidental Findings - A Systematic Review"

M. Bentestuen, F. Gavioli, E. E. Almario, H. D. Schaefer; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

**OP-0376**

"Higher diagnostic accuracy of FDG PET/CT than contrast enhance CT in initial staging of pancreatic cancers; Hybrid is better than Solo"

M. Zaman1, N. Fatima1, S. Zaman2, A. Zaman3, U. U. Zaman4; 1AKUH, Karachi, PAKISTAN, 2Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, 3Dr Ruth Pfau (CHK), Karachi, PAKISTAN, 4Sunny Downstate Medical Center, NY, New York, USA, 5UNITED STATES OF AMERICA, 6HONG KONG, CHINA.

**OP-0378**

"Long Covid hallmarks on [18F]FDG-PET/CT: a case-control study"

E. Galardi1, M. Solini1, S. Morboli2, M. Ceccon1, M. Ceccon1, A. Agnese1, P. Morelli1, S. Chio1, A. Chi1; 1Humanitas University, Pieve Emanuele, ITALY, 2University of Genova, Genova, ITALY, 3Humanitas Research Hospital, Rozzano, ITALY.

**OP-0379**

"[18F]FDG-PET/CT imaging of endothelial activation in COVID-19 patients"

E. Arvat1, S. Panareo1, A. Nieri1, C. Cittanti1, L. Uccelli1, L. Lodi1, S. Santinì2, S. Romani1, S. Zaccaria1, A. Turra2, M. Bartolomei1; 1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY, 2Department of Endocrinology, University of Turin, Turin, ITALY.
OP-0382 
Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter observational study

CHU Brest, Brest, FRANCE, 4CH Alpes Léman, Contamine-sur-Arve, FRANCE, 1Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, FRANCE, 2Hopsciences Civils de Lyon, Lyon, FRANCE, 3Hôpital Foch, Suresnes, FRANCE, 1CHU Nancy, Nancy, France, 5JCM, Lyon, FRANCE.

Final Programme | Oral Presentations

OP-0386 
Prior COVID-19 History Increases The Risk of Ischemia in Myocardial Perfusion CZT Detectors Scintigraphy
E. Sahin Kutuk, N. B. Talay, T. Bahceci, E. Ozdemir;
 Ankara City Hospital, Ankara, TURKEY.
OP-0439
Fluorescent FAPI, does it stain FAP or something else?
T. Buckle, R. van Leeuwen, D. van Willigen, F. van Leeuwen; JUMC; Leiden, NETHERLANDS.

OP-0440
Optimization of immune cell labeling efficiency using [111In]In-PLGA-NH\textsubscript{2} nanoparticles modified with TAT cell penetrating peptides
R. Raavé\textsuperscript{1}, B. Mannaerts\textsuperscript{1}, M. Krekorian\textsuperscript{2,3}, M. Srinivas\textsuperscript{1}, J. de Vries\textsuperscript{1}, S. Heckamp\textsuperscript{1}, E. Aarntzen\textsuperscript{1};
\textsuperscript{1}Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud University medical center, Nijmegen, NETHERLANDS, \textsuperscript{2}Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS.

OP-0441
Evaluation of novel anti-CAIX antibodies by PET imaging and biodistribution studies in a colorectal adenocarcinoma model
H. Law\textsuperscript{1}, J. Russaerts\textsuperscript{2}, P.C. McDonald\textsuperscript{2}, E. Lenferink\textsuperscript{3}, N. Colpo\textsuperscript{1}, J. Shepherd\textsuperscript{1}, R. Vosshenrich\textsuperscript{1}, S. Blachier\textsuperscript{1}, E. Aarntzen\textsuperscript{1}, S. Heckamp\textsuperscript{1}.
\textsuperscript{1}Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, \textsuperscript{2}Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud University medical center, Nijmegen, NETHERLANDS, \textsuperscript{3}National Research Council, BC, CANADA.

OP-0442
Development of \textsuperscript{18}F and \textsuperscript{68}Ga-anti-CD103 Fab fragment-based PET imaging for non-invasive assessment of cancer reactive T cell infiltration
M. Wazynska, X. Fan, A. Kol, M. de Bruyn, P.H. Elsinga, H.W. Nijman; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0443
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human lymphocytes
J. Marotte\textsuperscript{1}, M. Capato\textsuperscript{2}, C. Delene\textsuperscript{1}, T. Beauxas\textsuperscript{2}, G. Cadiou\textsuperscript{1}, J. Penn\textsuperscript{1}, M. Chele\textsuperscript{2}, Y. Guillieux\textsuperscript{1}, E. Scottet\textsuperscript{1}, F. Bruchet-Teisseire\textsuperscript{1}, A. Morgenstern\textsuperscript{1}, A. Jarry\textsuperscript{1}, N. Labarrière\textsuperscript{*1,2,3}, J. Gaschet\textsuperscript{*1,2,3}.
\textsuperscript{1}University of Nantes, CNRS, INSERM, CRQNA, Nantes, FRANCE; \textsuperscript{2}LabEx IG20 Immunotherapy, Graft, Oncology; \textsuperscript{3}Nantes, FRANCE; \textsuperscript{4}University of Nantes, CNRS, INSERM, CRQNA, CHU of Nantes, Nantes, FRANCE; \textsuperscript{5}University of Nantes, CNRS, INSERM, CRQNA, ICG Gauducheau, Nantes, FRANCE; \textsuperscript{6}LabEx IG20 Innovative Radiopharmaceuticals in Oncology and Neurology; \textsuperscript{7}Nantes, FRANCE, \textsuperscript{8}GIP Amosais, Saint-Herblain, FRANCE, \textsuperscript{9}European Commission, Joint Research Centre, Karlsruhe, GERMANY.
(\textsuperscript{*}shared last authors)

OP-0444
Development of \textsuperscript{89}Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration
X. Fan, A. Kol, M. Wazynska, M. de Bruyn, P.H. Elsinga, H.W. Nijman; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-0445
Preclinical pharmacokinetic and dosimetry of a 89 Zr labelled anti-PDL1 in an orthotopic lung cancer model
A. Krache\textsuperscript{1,2,3}, C. Fontan\textsuperscript{1}, C. Restouri\textsuperscript{1}, M. Bardet\textsuperscript{1}, P. Payoure\textsuperscript{1,2}, E. Chatelut\textsuperscript{1}, M. White-koning\textsuperscript{1}, A. Salabert\textsuperscript{1,2,3}.
\textsuperscript{1}INSERM UMR1037 - CRCT (centre de recherche en cancérologie de toulouse), team 14 DIAJ, Toulouse, FRANCE, \textsuperscript{2}INSERM UMR1214 - TONIC (Toulouse neurocaging center), team LEYN, Toulouse, FRANCE, \textsuperscript{3}INSERM UMR1214 - TONIC (Toulouse neurocaging center), Toulouse, FRANCE, \textsuperscript{4}INSERM UMR 194 - IRCM (Institut de recherche en cancérologie de Montpellier), Toulouse, FRANCE, \textsuperscript{5}IRCM (Institut de recherche en cancérologie de Montpellier), Toulouse, FRANCE, \textsuperscript{6}INSERM UMR 194 - IRCM (Institut de recherche en cancérologie de Montpellier), Toulouse, FRANCE.

OP-0446
68Ga DOTA FAPI 46 and 18F FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
P. UN, A. R. Bhati\textsuperscript{1}, S. M. Desai\textsuperscript{1}, B. Srinath\textsuperscript{1}, H. Mohan\textsuperscript{2}, S. Shankara cancer hospital and Research center, Bangalore, INDIA.

OP-0447
Synthesis and preclinical evaluation of [18F]JAF-NODA-C6-CTHRSSVVC as a PET tracer for tumor-associated CD163\textsuperscript{*} macrophages
B. Fernandes\textsuperscript{1}, I. F. Antunes\textsuperscript{1}, D. A. Vasquez-Mattas\textsuperscript{1}, K. Prasad\textsuperscript{1}, E. De Mattias\textsuperscript{1}, W. Szymanski\textsuperscript{1}, C. M. Jekel\textsuperscript{2}, E. de Vries\textsuperscript{1}, P. H. Elsinga\textsuperscript{1};
\textsuperscript{1}Dept. of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, \textsuperscript{2}Graduate Program in Biomedical Gerontology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, BRAZIL, \textsuperscript{3}Dept. of Biomedical Sciences of Cells & Systems, Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, \textsuperscript{4}Dept. of of Radiology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.

OP-0448
Preclinical evaluation of [18F]JAF-NODA-C6-CTHRSSVVC as a PET tracer for tumor-associated CD163\textsuperscript{*} macrophages
B. Fernandes\textsuperscript{1}, I. F. Antunes\textsuperscript{1}, D. A. Vasquez-Mattas\textsuperscript{1}, K. Prasad\textsuperscript{1}, E. De Mattias\textsuperscript{1}, W. Szymanski\textsuperscript{1}, C. M. Jekel\textsuperscript{2}, E. de Vries\textsuperscript{1}, P. H. Elsinga\textsuperscript{1};
\textsuperscript{1}Dept. of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, \textsuperscript{2}Graduate Program in Biomedical Gerontology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, BRAZIL, \textsuperscript{3}Dept. of Biomedical Sciences of Cells & Systems, Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, \textsuperscript{4}Dept. of of Radiology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.
OP-0448
Expression of fibroblast activation protein by three prostate cancer cell lines
O. Belissard1, S. Ghorai1, M. I. Messad2, A. Roux-Chavelier1, J. V. Leyton3, E. Rieuvaux1,
1Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 2Département de Pathologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, 3Université de Sherbrooke, Sherbrooke, QC, CANADA

OP-0449
Combined treatment of mice bearing HER2-expressing xenografts by trastuzumab and Affibody-mediated PNA-based pre-targeting improves their survival
M. Orojani1, A. Tard1, A. Vastavaya1, F. Lu2, O. Voronovska1, K. Xu1, K. Westerlund1, A. Olov2, I. V. Talmachenko3, A. Eriksson Karlstrom1,
1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN, 3Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION

OP-0450
"Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
C. Schmidkonig1, J. Distler1, A. Ziringer1, O. Prante1, C. Treutlein2, A. Atzinger1, O. Prante1, C. Schmidkonig2
1Mount Royal University NHI Foundation Trust, Sutton, UNITED KINGDOM, 2Royal Marsden NHI Foundation Trust, Sutton, UNITED KINGDOM

OP-0453
A novel method to determine radiation protection advice following radioisotope therapy by modellling public exposure

OP-0454
Communicating Radiation Issues with Patients: Can We Do Better?
1Istituto Italiano di Fisica Sperimentale, Firenze, ITALY, 2Radiopharmacy unit, Pharmacy, Valence Hospital Center, Valence, FRANCE, 3Istituto Italiano di Fisica Sperimentale, Firenze, ITALY, 4MFT Department, University of Messina & INFN, Messina, ITALY, 5Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morpho-Funional Imaging, University of Messina & INFN, Messina, ITALY, 6Department of Industrial Engineering, University of Bologna, Bologna, ITALY, 7Department of Radiation Oncology, University of Bologna, Bologna, ITALY, 8Istituto Italiano di Fisica Sperimentale, Firenze, ITALY

OP-0455
A Systematic National Review: Safety Assessment as a Tool for Development of Safety Culture in Nuclear Medicine Facilities in Finland
J. Liukkonen1, S. Kaajalisto2, J. Potüntö3, J. Liukkonen3, Radiation and Nuclear Safety Authority (STUK), Helsinki, FINLAND

OP-0457
Adaptation of ICRP 128 Iodine Population Bio-kinetic Model to Thyroid Cancer Patients After Thyroidectomy
L. Peake1, J. Iagossi2, J. Murray2, J. Geer2, G. Flux2
1Centre for Medical Radiation Physics, JCU, Townsville, AUSTRALIA, 2Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 3Department of Radiation Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL

OP-0458
Models of Internal Liver Vasculature within the Mesh-Top Model ICRP Adult Reference Phantom to Support Internal Dosimetry in Radiotherapeutic Medicine
C. Correa Allons1, S. Domati1, J. Withrow1, M. Abdulla1, C. Graubinger1, S. Xing1, S. Shiv1, H. Paggetti1, W. Bolch1, J. A. Roche1
1University of Florida, Gainesville, FL, UNITED STATES OF AMERICA, 2Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA, 3Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA

OP-0459
Relevance of Internal Bremsstrahlung for estimating the exposure to pure beta emitters
L. Audicore1, F. Agu1, A. Italiano2, D. Patone2, Y. Nefzad3, S. Gervais4, E. Amato5
1Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morpho-Funional Imaging, University of Messina, Messina, ITALY, 2Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, 3INFN, National Institute for Nuclear Physics, Section of Catania & MFT Department, University of Messina, Messina, ITALY, 4INFN, National Institute for Nuclear Physics, Section of Catania, Messina, ITALY, 5Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morpho-Funional Imaging, University of Messina & INFN, National Institute for Nuclear Physics, Section of Catania, Messina, ITALY

OP-0460
How To Assess the Real Extremities Dosimetry Based On the Results of a Dosimeter Ring ?
M. Armando1, A. Huett1, F. Vial1, M. Ramonu2, R. Valet2, H. Hida2
1Radiopharmacy unit, Pharmacy, Valence Hospital Center, Valence, FRANCE, 2Radiation Protection, Valence Hospital Center, Valence, FRANCE

OP-0461
Calibration for "Ar of radiation detectors for air exhaust systems
T. Zagni1, S. Vichi1, G. Pantalone2, V. Cabitza3, N. Sabba5, E. Moretti5, F. Zagni5, G. Pantalone3, V. Cabitza4, N. Sabba5, E. Moretti5
1Radiopharmacy unit, Pharmacy, Valence Hospital Center, Valence, FRANCE, 2Radiopharmacy unit, Pharmacy, Valence Hospital Center, Valence, FRANCE, 3Department of Industrial Engineering, University of Bologna, Bologna, ITALY, 4MFT Department, University of Messina & INFN, Messina, ITALY, 5Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morpho-Funional Imaging, University of Messina, Messina, ITALY, 6Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 7Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 8Istituto Italiano di Fisica Sperimentale, Firenze, ITALY, 9Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 10Institutional and Diagnostic Radiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 11Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 12Department of Nuclear Medicine, Kantonsspital Basden, Baden, SWITZERLAND

OP-0466
The value of SSTR2 receptor-targeted PET/CT in proton irradiation of grade I meningioma
M. Pelak1, B. Flech1, R. Galaska1, S. Tubin2, M. Mumot3, E. Hug1, C. Lütgenfeud-Caougy1, MediLatron Ion Therapy Center, Wiener Neustadt, AUSTRIA

OP-0467
Preliminary evaluation of the hybrid tracer Indocyanine Green (ICG) "NaF-nanocolloid for sentinel lymph node biopsy in bladder cancer
D. Rietbergen1, E. van Gennepen1, G. Kleinjan1, M. Donsjou1, B. van Rijen1, R. Velders1, M. van der Poel1, F. van Leeuwen2
1Leiden Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS

OP-0464
Radioguided Surgery in Prostate Cancer - Facilitating Cure?
T. Maurer1, University of Hamburg-Eppendorf (UKE), Hamburg, GERMANY

OP-0465
Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET guided biopsy in patients with suspected prostate cancer
R. Laudicella1, D. A. Ferraro2, K. G. Stempels1, J. Mebert1, J. Müller1, O. Donati1, M. T. Sapenz5, J. H. Rüschä7, N. Rappe1, D. Ebelö1, I. A. Burger1
1Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 2Department of Biomedical and Dental Sciences and Morpho-Funional Imaging, University of Messina, Messina, ITALY, 3Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, BRAZIL, 4Department of Urology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 5Institutional and Diagnostic Radiology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, 6Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND

OP-0462
Ambient Dose Measured at a Nuclear Medicine Department
V. de Sousa1, G. Cardosa1, A. J. Santos3, Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL

107
OP-0468 How signal intensity influences utility of a robotic DROP-IN gamma probe during surgery - a clinical comparison between sentinel lymph node and PSMA-receptor targeted tracers

1Leiden University Medical Center, Leiden, NETHERLANDS, 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 3Martins-Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, 4St. Vincent's Prostate Cancer Centre, Darlinghurst, AUSTRALIA.

OP-0469 Promising results of 1125 Radiougiled seed localization (RSL) surgery of papillary thyroid cancer recurrence


University Clinic of Navarra, Pamplona, SPAIN.

OP-0470 Long Term Results of Sentinel Lymph Node Biopsy Using Combined Method: A Single Institution Experience

B. Zenger; U. Yasarofar, I. C. Tencani, R. L. Dutuosity;
1University of Health Sciences Turkey, Izmir Bayzaky Health Practice and Research Center, Department of General Surgery, Izmir, TURKEY; Ege University Medical Faculty, Department of Nuclear Medicine, Izmir, TURKEY; 2University of Health Sciences Turkey, Izmir Bayzaky Health Practice and Research Center, Department of General Surgery, Izmir, TURKEY; Ege University, Ege University Faculty of Medicine, Department of Public Health, Izmir, TURKEY.

OP-0471 Sentinel lymph node biopsy in muscle-invasive bladder cancer: single-center experience

R. Sadeghi, L. Zamithoumoudi, H. Ghobehati, K. Sadin; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-0472 The impact of the COVID-19 outbreak on breast cancer with indication of surgical treatment and SLNB


911

Wednesday, October 20 - Saturday, October 23, 2021

on-demand pool, release on Wednesday, October 20 at 09:00

Featured Session: Molecular Imaging of Alzheimer’s Disease

OP-0473 Is the hottest sentinel lymph node (SLN) the true SLN in breast cancer or do we need to resect more to find it correctly?


OP-0474 Visual assessment and Centiloid quantification across diagnostic groups: the AMYPAD project


OP-0475 Calibration and Evaluation of the Centiloid Scale for Amyloid Quantitation with Multiple Fluorine-18 Radiotracers

W. Ballhorn, K. Kraemer, N. Cole, A. S. Nelson; MIM Software, Beachwood, OH, UNITED STATES OF AMERICA.

OP-0476 Concordance between molecular imaging, CSF and plasma biomarkers of Alzheimer’s disease: evidence from the memory clinic

S. Stampacchia1, D. Altomare, B. Melvi, F. Ribald1, S. E. Tomczyk1, M. Martini1, M. Manzor2, N. Ashlor2, H. Zetterberg2, K. Blennow1, J. Mer2, G. F. Frosini3, V. Gabinotto3; 1University of Geneva, Geneva, SWITZERLAND, 2University of Gothenburg, Gothenburg, SWEDEN, 3University Hospital Geneva, Geneva, SWITZERLAND, 4University of Geneva and University Hospital Geneva, Geneva, SWITZERLAND.

OP-0477 Association between tau and synaptic density in Alzheimer’s disease: A multicenter [18F]PI-2620 PET study

In vivo Braak staging of tau pathology in Alzheimer’s disease: evidence from the memory clinic

A. Drzezga1, M. Brendel2, M. L. Schroeter3, D. Saur4, J. Levin5, R. Fahmi6, M. Schelte1, R. Perneczky6, S. Tiepoli1, M. Patt1, A. Mueller7, V. Villemagne8, J. Melasch9, R. F. Boada11, A. Drzezga12, P. Scheltens1, Z. Walker13, J. Démonet14, A. Knopman6, J. C. Blennow2, I. Kern3, G. B. Frisoni4, V. Garibotto4; 1University of Geneva, Geneva, SWITZERLAND, 2University College Cologne, Cologne, GERMANY, 3Clinic for Cognitive Neurology, University Hospitals UZ Leuven, Leuven, BELGIUM, 4Department of Nuclear Medicine, University Hospital Geneva, Geneva, SWITZERLAND, 5Life Molecular Imaging, Berlin, GERMANY, 6Department of Psychiatry and Psychotherapy, University Hospital, Leipzig, GERMANY, 7Department of Neurology, University Hospital, Leipzig, GERMANY, 8Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, BELGIUM, 9VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, BELGIUM, 10Private Practice Neurology, Leuven, BELGIUM, 11Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, BELGIUM, 12Department of Old-Age Psychiatry, University Hospitals UZ Leuven, Leuven, BELGIUM.

OP-0478 A PET only 18F-flortaucipir quantification: comparison with an MRI-based method

R. Fahmi, V. Malatoua, V. Van Pech, A. Ivanou, B. Hansenius, R. Lhommel; Université Catholique de Louvain, Brussels, BELGIUM.

OP-0479 Brain imaging for a Biological Definition of Alzheimer’s Disease

A. Drzezga; Cologne University, Nuclear Medicine, Cologne, GERMANY.

OP-0480 In vivo Braak staging of tau pathology in Alzheimer’s disease: a multicenter [18F]FDG-2620 PET study

M. Ruffmann, M. Brendel, M. L. Schroeter, D. Saur, J. Levin, R. Pempezyk, S. Trotta, M. Patti, A. Muhlner, V. Villemagne, J. Classen, A. W. Stephens, G. Sabri, H. Barthel; 1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, GERMANY, 3Clinic for Cognitive Neurology, University of Leipzig, Leipzig, GERMANY, 4Department of Neurology, University of Leipzig, Leipzig, GERMANY, 5Department of Neurology, University Hospital of Munich, LMU Munich, GERMANY, 6Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, GERMANY, 7Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, AUSTRALIA.

OP-0481 Multi-parametric [18F]FDG-2620 tau PET/MRI in Alzheimer’s disease variants: A proof-of-concept study

J. Melasch, M. Ruffmann, C. Schelte, D. Saur, M. L. Schroeter, S. Tiepoli, A. Stephens, N. Kagli1, J. S. Hast1, M. Stauss1, M. Brendel2, G. Aghakhanyan3, A. Schlöder3, D. Saur2, J. Claassen1, K. Hallmåv1, O. Salter, H. Barthel3; 1Department of Nuclear Medicine, University Hospital, Leipzig, GERMANY, 2Department of Neurology, University Hospital, Leipzig, GERMANY, 3Clinic for Cognitive Neurology, University Hospital, Leipzig, GERMANY, 4Life Molecular Imaging, Berlin, GERMANY, 5Department of Psychiatry and Psychotherapy, University Hospital, Leipzig, GERMANY, 6Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, BELGIUM, 7Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, ITALY.

OP-0482 Total P-Tau Brain Load (TTLB) quantification using F18-MK6240 PET: new approach and correlations with CSF-phospho-tau and visual Braak staging

T. Gérard, V. Malatoua, V. Van Pech, A. Ivanou, B. Hansenius, R. Lhommel, Université Catholique de Louvain, Brussels, BELGIUM.

OP-0483 Association between tau and synaptic density in amnestic mild cognitive impairment: a longitudinal follow-up study

G. Vanderlinden1, T. Vande Casteele1, J. Ceccarini1, L. Michiels4,5, T. Gérard, V. Malatoua, V. Van Pech, A. Ivanou, B. Hansenius, R. Lhommel; Université Catholique de Louvain, Brussels, BELGIUM.
OP-0487  In-vivo MRI imaging of locus coeruleus degeneration is coupled to brain glucose metabolism in Alzheimer’s disease pathologies
G. Aghakhanyan1, A. Galagni1, F. Lombardo1, N. Martini1, H. Hlavata2, A. Leo1, J. Gavociova1, G. Tognoni2, P. A. Irba1, N. Navtev1, F. S. Gaggi3, D. Vollerani1; 1Nuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 2Neurology Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 3Cardiovascular and Neurorehabilitation Multimodal Imaging Unit, Fondazione "G. Monasterio" - National Research Council/Tuscany Region, Pisa, ITALY, 4"Deep-Health Unit, Fondazione "G. Monasterio" - National Research Council/Tuscany Region, Pisa, ITALY, 5Clinical Agony Research Unit, Newcastle University, Newcastle upon Tyne NE4 5LP, UNITED KINGDOM.

OP-0488  Accuracy of FDG-PET at the individual level in MCI-LB versus MCI-AD: a stepwise approach from visual to semi-quantitative analysis
S. Raffa1, F. Massar1, A. Chinann1, M. Bauckheh1, E. Penas1, D. Arndt1, M. Palet1, M. Pagan2, B. Nosr1, M. Donegan1, A. Brugnolo2,4, E. Biassoni2, P. Mattioli2, N. Girtler2,4, U. Guerra7, S. T. Van den Wyngaert; 1Department of Health Science (DISSAL), University of Genoa, Genoa, ITALY, 2Neurology Unit, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 3National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY, 4Department of Health Science (DISSAL), University of Genoa, Genoa, ITALY, 5Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne NE4 5LP, UNITED KINGDOM, 6Department of Radiology, University Hospital Aachen, Aachen, GERMANY, 7Philips Research, Zurich, Zurich, SWITZERLAND, 8Delft University of Technology, Delft, NETHERLANDS, 9Forschungszentrum Juelich, Juelich, GERMANY, 10Department of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, GERMANY.

OP-0491  Plenary Quiz (for Plenary 3)

OP-0497  Parathyroid Imaging
P. Petranović Ovčariček; University Hospital Center Sestre Milosrdnice, Oncology and nuclear medicine, Zagreb, CROATIA.

OP-0504  Digital SPECT: Improved Imaging using the Continuous Scan Mode on a General Purpose Whole-body Solid-State CzT Camera
J. Kennedy, Z. Koelemann; Rambam - Health Care Campus, Haifa, ISRAEL, 1009

OP-0505  New multi-focal collimator designed for quantitative SPECT imaging in nuclear neurology applications
F. Massanes1, A. H. Vija2, X. Ding1, D. Spence1, G. Platsch2, A. Yahil1, G. Le Rouzic, J. Kennedy, Z. Koelemann; 1Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, USA, 2Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA, 3Inor, Havana, CUBA, 4Centis, Havana, CUBA, 5Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne NE4 5LP, UNITED KINGDOM, 6Department of Neurology, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, ITALY, 7Philips Research, Zurich, Zurich, SWITZERLAND, 8Delft University of Technology, Delft, NETHERLANDS, 9Forschungszentrum Juelich, Juelich, GERMANY, 10Department of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, GERMANY.

OP-0508  The First Clinical Trial of the Ultra-Compact Fully Integrated Brain PET System BPET
E. Mikhailova, A. Bush1, Y. Davi1, M. Hofbauer1, M. Hülsern1, P. Kauflmann, X. Thelemans1, C. Toumpsi3, V. Treyer1, M. Ahrens1, J. Fischer2,1; 1Positiva AG, Zurich, SWITZERLAND, 2University of Leeds, West Yorkshire, UNITED KINGDOM, 3University Hospital Zurich, Zurich, SWITZERLAND, 4Algorithms and Software Consulting Ltd, London, UNITED KINGDOM.

OP-0509  Monte Carlo simulation of a last generation PET scanner: preliminary results according to the NEMA NU2-2018 standard
A. Merlet1, B. Presles1, A. Cochet1,2, J. M. Vrigneaud1,2; 1Physics of Molecular Imaging Systems / University RWTH Aachen, Aachen, GERMANY, 2Centre Hospitalier Régional d’Orléans, Orleans, FRANCE.

OP-0507  The First Clinical Trial of the Ultra-Compact Fully Integrated Brain PET System BPET
E. Mikhailova, A. Bush1, Y. Davi1, M. Hofbauer1, M. Hülsern1, P. Kauflmann, X. Thelemans1, C. Toumpsi3, V. Treyer1, M. Ahrens1, J. Fischer2,1; 1Positiva AG, Zurich, SWITZERLAND, 2University of Leeds, West Yorkshire, UNITED KINGDOM, 3University Hospital Zurich, Zurich, SWITZERLAND, 4Algorithms and Software Consulting Ltd, London, UNITED KINGDOM.

OP-0508  Dedicated PET/MRI insert for Breast Cancer
V. Schulz1,2, B. Wesseler1, V. Nadig1, S. Schug1; 1F. Mueller, R. Rodemacher1, N. Gross-Withey2, N. Nobl1, M. D. Care1, M. Matthiener1, J. Roehmann1, S. Aschenbrenner, T. O. Wall2, A. Salomon2, D. Schaart2, D. Kuznetsov2, P. Bakker2, K. Langen2, C. Kuhl3; 1Physics of Molecular Imaging Systems / University RWTH Aachen, Aachen, GERMANY, 2Hyppen Hybrid Imaging Systems GmbH, Aachen, GERMANY, 3Physics Institute III, RWTH Aachen University, Aachen, GERMANY, 4Sfutura Composites bv., Heerhugowaard, NETHERLANDS, 5Futurea Composites bv., Heerhugowaard, NETHERLANDS, 6NOMAS MRI Products GmbH, Hachberg, GERMANY, 7Philips Research, Eindhoven, NETHERLANDS, 8Delft University of Technology, Delft, NETHERLANDS, 9Forschungszentrum Juelich, Juelich, GERMANY, 10Department of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, GERMANY.

OP-0509  Colombian 3D Imaging with Sparse Number of Views: Progress on Image Quality @ 511 keV
M. Himmels, G. Lebonvallet1, A. Iltis1, B. Mehadji2, C. Morel2; 1, G. Lebonvallet1, A. Iltis1, B. Mehadji2, C. Morel2; 1Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, USA, 2Department of Radiology, University Hospital Center Sestre Milosrdnice, Oncology and nuclear medicine, Zagreb, CROATIA, 3Inor, Havana, CUBA, 4Centis, Havana, CUBA.

OP-0507  Cutting Edge Science Track - TROP Session: New Imaging Equipment and Techniques
S. Cade, P. Leigh, M. Evans; Royal United Hospitals Bath NHS Foundation Trust, Bath, UNITED KINGDOM.

Plenary Quiz (for Plenary 3)

OP-0491  Plenary Quiz
T. Van den Wyngaert; Antwerp University Hospital, Nuclear Medicine, Antwerp, BELGIUM.

Lessons from the Past
F. Verzijlbergen; University Hospital 12 de Octubre, Madrid, SPAIN.
OP-0512 The addition of PET-CT in CT-guided bone biopsies
D. Rietbergen, M. Droste, J. Bloemendal, M. Oosterom, M. Burgmans, F. van Velden, F. van Leeuwen, D. Rietbergen; Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

OP-0515 Where Are We with Theranostic Imaging Today?
L.-F. de Geus-Oei; Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

OP-0521 Added Value of F18-FDG PET/MR Imaging for Detecting Liver Metastases in Patients with Colorectal Cancer
P. Gündüz; 1, E. Özdalci; 1, D. Kulla Ozturk; 1, M. Arsalç̣; 1, Ç. Sağdη; 2, Ö. Kıcak; 2, G. Ender; 1, K. Kır; 2, Ankara University Faculty of Medicine-Nuclear Medicine Department, Ankara, TÜRKÝE, Ankara University Faculty of Medicine Radiotherapy Department, Ankara, TÜRKÝE.

OP-0532 Global Experience in the Use of Novel Radiotracers for Directed Needle Localization
Paul Scherrer Institute, Center for Radiologie & Nucleaire Geneeskunde, Klinische Fysica, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-0516 Terbium Radioisotopes for Theranostics, What to Expect?
C. Müllner; Paul Scherrer Institute, Center for Radiopharmaceutical Sciences, Villingen, SWITZERLAND.

OP-0517 Quantitative Theranostic Imaging - Challenges and Opportunities
M. Konijn enberg; Radiologie & Nucleaire Geneeskunde, Klinische Fysica, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-0510 The Phases of a Phase I Trial
P. Kunz; 1, M. E. Caplin; 1, E. Thevenot; 1, M. Almog; 1, C. Radenza; 1, J. C. Yao; 1, M. J. Goethe; 1, M. Solé; 1, “Innovative Radiopharmaceutical Science: From Discovery to Application,” Mainz, GERMANY, 1Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, SWEĐEN, 2Movement Disorders Group, Institute of Biomedicine of Seville-BIS, Seville, SPAIN.

OP-0524 The surgical benefits of using bimodal tracers for imaging-guided surgery; multicenter experience in >1900 patients
T. Buckle; 1, P. Dell’Oglio; 1, E. Mazzone; 1, D. Rietbergen; 1, H. de Vries; 1, S. Vidal-Siscart; 1, B. Kanakikutula; 2, M. Klop; 1, O. Brouwer; 1, E. Wit; 1, P. van Leeuwen; 1, H. van der Poel; 3, P. van Leeuwen; 1, IJUMC, Leiden, NETHERLANDS, 6University Hospital Clinic Barcelona, Barcelona, SPAIN, 7Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 8Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Leiden, NETHERLANDS.
1106
Wednesday, October 20 - Saturday, October 23, 2021
on-demand post, release on Wednesday, October 20 at 09:00


OP-0537
From Checkpoint Inhibitors to Cell Therapy - New Standards in Malignant Lymphoma
P. Brückelmann; Faculty of Medicine and University Hospital of Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne (Societé, University of Cologne, Cologne, GERMANY)

OP-0538
Evolution of Response Criteria in Lymphoma
J. J. Eertink; Center for Integrated Oncology Aachen Bonn Cologne (Societé, University of Cologne, Cologne, GERMANY)

OP-0539
Is Deauville Still Score the Solution?
L. Dercle; University of Toulouse, Physics and signal processing, Toulouse, FRANCE

OP-0540
OP-0541
Quantitative and Multidisciplinary Algorithms

OP-0542
Teaching Session 1 (EANM/AGA): Imaging of Prosthetic Knee Joint Loosening - Spotlight on Quantitative and Multidisciplinary Algorithms

OP-0543
Clinical Point of View for Selecting Imaging Modalities for the Assessment of Knee Endoprosthesis
D. Mathis; Kantonsspital Baselland Bruderholz, Department of Orthopedics, Basel, SWITZERLAND

OP-0544
Anatomical Imaging in the Management of Prosthetic Loosening
L. M. Sconfienza; I.R.C.C.S. Istituto Ortopedico Galeazzi, Unit of Diagnostic and Interventional Radiology, Milan, ITALY

OP-0545
Synthesis and biological evaluation of the first "Ga"-in-radio labelled peptide targeting the neuropeptide-Y receptor 5 (Y5) in cancers
S. Bodin1;2, D. J. Worrall1, E. Jestin1, D. Vinoret1, J. I. Arends1, E. Hindle1,2, A. G. Beeck-Sickinger1, C. Morgan1,2;1Univ. Bordeaux, CNRS, INCA, UMR587, F-33000 Bordeaux, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 4University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 5University Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR5247, F-34000 Montpellier, FRANCE, 6Centro Reunion Oceán Indien CYROI, 7 rue Maxime Rivière, F-97490 Sainte-Claude, FRANCE.

OP-0546
Proof-of-concept of a pretargeting strategy mediated by sstr2 antagonist for the therapy of neuroendocrine tumours
S. Koussoudiou1, M. Handula, J. Nonnekens, M. Hendriks-de Jong, S. Koustoulidou1,2, A. G. Beck-Sickinger3, C. Morgat1,2;1Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, URUGUAY, 2Univ. Bordeaux, CNRS, INCA, UMR587, F-33000 Bordeaux, FRANCE, 3Institute of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 4UZ Leuven, Leuven, BELGIUM.

OP-0547
Double targeting of NTS and GRPR receptors using "Ga"-labelled heterodimers
S. Bodin1;2, S. Privat1, E. Jestin1, D. Vinoret1, F. Lamare1,2, J. I. Arends1, E. Hindle1,2, F. Covelle1, C. Morgan1,2;1Univ. Bordeaux, CNRS, INCA, UMR587, F-33000 Bordeaux, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 4University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 5University Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR5247, F-34000 Montpellier, FRANCE, 6Centro Reunion Oceán Indien CYROI, 7 rue Maxime Rivière, F-97490 Sainte-Claude, FRANCE.

OP-0548
New Oral Presentations

1107
Wednesday, October 20 - Saturday, October 23, 2021
on-demand post, release on Wednesday, October 20 at 09:00

M2M Track - TROP Session: Peptides Only!

OP-0549
ORAL PRESENTATIONS

OP-0550
Biodistribution and pharmacokinetics of Zr 89-antiVEGF mAbs using PET in glioblastoma rat models
D. Rey Bretal1, E. García Varela1, X. García Otero2,3, N. Gómez Lade1, A. Moscoso, M. Péreza Fre1, C. Miranda García1, A. Castoya Sánchez, A. Fernández Ferrero1, J. Silva Rodríguez1, A. Ruibal1, P. Aguirre2;1Laboratory of Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 2Laboratory of Virology and Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BELGIUM, 3Univ. Montpellier, CNRS, Université de la Méditerranée, IRBM, UMR5082, 38041 Grenoble, FRANCE, 4Department of Pharmacology, Princess Máxima Center for Oncology, Utrecht, NETHERLANDS, 5Department of Pharmacy & Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 6Department of Clinical Pharmacy, University Hospital Rotterdam, Rotterdam, NETHERLANDS.

OP-0551
Development and Pre-clinical evaluation of a novel hybrid peptide analogue based on Mucin 1Ga-NODAGA-MUC1 and Ga-NODAGA-MUC1-FA hybrid peptide conjugates and Folic acid: Potential breast/ovarian cancers PET imaging agent
I. Aljammaz1, S. Alhabardi2, B. Alotaibi1, S. Okarvi1, L. García Varela1, X. García Otero2,3, N. Gómez Lade1, A. Moscoso, M. Péreza Fre1, C. Miranda García1, A. Castoya Sánchez, A. Fernández Ferrero1, J. Silva Rodríguez1, A. Ruibal1, P. Aguirre2;1Laboratory of Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 2Laboratory of Virology and Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BELGIUM, 3Univ. Montpellier, CNRS, Université de la Méditerranée, IRBM, UMR5082, 38041 Grenoble, FRANCE, 4Department of Pharmacology, Princess Máxima Center for Oncology, Utrecht, NETHERLANDS, 5Department of Pharmacy & Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 6Department of Clinical Pharmacy, University Hospital Rotterdam, Rotterdam, NETHERLANDS.

OP-0552
Summary Suggestion - A Consensus Document in the Approaches in the Management of Knee Prosthetic Loosening
F. Paycha; Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Centre Hospitalier Universitaire Paris Sud, Paris, FRANCE.

OP-0553
Physiologically Based Pharmacokinetic Models to Predict Organ and Tumor Distribution and Assess the Tumor Sink Effect of Ga-DOTA and Ga-HA-DOTATATE in Patients with Gastroenteropancreatic Neuroendocrine Tumors
H. Siebenga1, B. de Wit-van de Ven1, T. P. Doló1, A. D. Huisman1, J. J. Hendriks1;1Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 2Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 3Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, NETHERLANDS, 4Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

OP-0554
Automated preparation and preclivalcal evaluation of "Ga"-labelled DOTA-MGSS for PET/CT imaging of CCK2 expressing tumours
A. Härmmann, M. Ringert, C. Ramges, C. Maas, C. Decristofaro, C. Uppmán, I. von Guggenthals, M. Windrath, Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-0555
Preclinical and Developmental evaluation of a novel hybrid peptide analogue based on Mucin 1Ga-NODAGA-MUC1 and Ga-NODAGA-MUC1-FA hybrid peptide conjugates and Folic acid: Potential breast/ovarian cancers PET imaging agent
I. Aljammaz; S. Alhabardi, B. Alotaibi, S. Okarvi; L. García Varela, X. García Otero, N. Gómez Lade, A. Moscoso, M. Péreza Fre, C. Miranda García, A. Castoya Sánchez, A. Fernández Ferrero, J. Silva Rodríguez, A. Ruibal, P. Aguirre; Laboratory of Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, Laboratory of Virology and Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BELGIUM.

OP-0556
All’EPE 3p-C-NETA-TATE: Combining a versatile and highly effective chelator with an established somatostatin analogue
S. Alhajjam; E. Muren, Y. Semblé, T. Cardinaerts, C. M. Demouze, G. Barmier, M. Omari, F. Greiner, K. Luyten, T. Van Loy, C. Cavithome, C. Denoët, D. Schols; 1Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BELGIUM, 2Laboratory of Virology and Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BELGIUM, 3Univ. Montpellier, CNRS, Université de la Méditerranée, IRBM, UMR5082, 38041 Grenoble, FRANCE, 4Department of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND.

OP-0557
99mTc-HYNIC-LHHR analog as novel breast cancer imaging agent
L. Aliyev, K. Camacho, F. García, M. Cabernos, M. Tassinari, M. Fernández, T. Fréne, E. Cuenaga, J. Gamboa, P. Cabral; 1Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, URUGUAY, 2Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY, 3Instituto Pasteur de Montevideo, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY, 4Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.
**OP-0564**
Clinical validation of a population-based input function for dynamic whole-body 18F-FDG multimodal PET imaging using a standard injector
A. H. Dias; D. Pigg; A. M. Smith; V. Shah; L. C. Gammel; O. L. Munk
Aarhus University Hospital, Aarhus, DENMARK, Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

**OP-0565**
Normative tissue FDG uptake values from 112 patients undergoing whole-body dynamic 18F-FDG PET/CT - Validation of automated software tools and a normal value database
A. H. Dias; G. L. Munk; L. C. Gammel
Aarhus University Hospital, Aarhus, DENMARK.

**OP-0566**
Non-invasive method for quantitative measurement of the cerebral glucose metabolic rate
A. Cuculica Henriksen; M. Lonsdale; V. Nemesjan; D. Kondzewski; L. Mamer
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Bispebjerg, Copenhagen, DENMARK; Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK.

**OP-0567**
Population-based input function and image-derived input function for whole-body dynamic 68Ga-DOTATOC-PET/CT acquisition: methodology and clinical validation
P. Thuillier; D. Bauroux; J. Metges; R. Le Pennec; U. Schick; A. N. Vis; H. Hendrikse
Aarhus University Hospital, Aarhus, DENMARK.

**OP-0569**
ENHANCE-PET: Exploring the Human Functional Connectome Using Total-Body [18F]FDG-PET
L. Shiym Sundaar; R. D. Badawi; R. A. Spencer; E. Li; S. R. Cherry; Y. G. Abdelhakim; K. Shafer; T. Jones; T. Beyer
Medical university of Vienna, Vienna, AUSTRIA; University of California, Davis, CA, UNITED STATES OF AMERICA.

**OP-0571**
Predicting Early Biochemical Progression in Prostate Cancer Patients staged with PSMA PET and multimodar Magnetic Resonance Imaging
D. Mejer; P. J. van Leeuwen; M. L. Donoussis; T. N. Boelmark; J. G. Schoors; H. G. van de Poel; N. H. Hendrikse; D. E. Oprea-Lager; A. N. Vis
Amsterdam UMC, Amsterdam, NETHERLANDS; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

**OP-0572**
Multimodal MRI and [18F]PSMA-1007 PET to detect local prostate cancer: a prospective comparative study with correlation to histopathology
B. Privat; I. Burri; J. Matsen; M. M. van der Leest; C. H. Masseer; G. M. Schilham; P. Zamecnik; J. O. Stanis; G. De Lauw; J. G. Bomers; G. De Lauw; A. J. Smits
Amsterdam UMC, Amsterdam, NETHERLANDS; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

**OP-0573**
The Prognostic Value of Histopathological Nodal Features and PSMA-PET findings in Patients with Pelvic Lymph Node Metastases of Prostate Cancer after Extended Pelvic Lymph Node Dissection
D. Mejer; R. H. Ettema; P. J. van Leeuwen; H. G. van de Poel; N. H. Hendrikse; D. E. Oprea-Lager; E. M. Bekers; A. N. Vis
Amsterdam UMC, Amsterdam, NETHERLANDS; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

**OP-0574**
Standardized Uptake Values as Determined on Prostate-specific Membrane Antigen Positron Emission Tomography/Computer Tomography are associated with Gleason Grade and Biochemical Recurrence of Disease in Patients with Prostate Cancer
Y. Bodar; L. Koistinen; K. De Laer; D. Mejer; N. H. Hendrikse; K. van Leeuwen; B. A. Windhorst; M. Donoussis; R. Boellaard; A. N. Vis; D. E. Oprea-Lager
Amsterdam UMC, Location VUMC, Amsterdam, NETHERLANDS; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

**OP-0579**
A Pilot Study of [68Ga]PSMA11 and [68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
H. Duan; Y. Ferri; P. Ghahrouni; B. Daniel; N. Hatami; G. A. Davidson; C. M. Aparici; A. Thong; G. A. Sorn; A. Jagan
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

**OP-0577**
Prospective Pilot Trial On [68Ga-PSMA AND [68Ga-DOTA-RM2 PET/MRI In High-Risk Prostate Cancer Staging
S. Ghezzo; P. Mappeti; E. Perez; G. Brembilla; V. Coccia; A. Samanes Gajate; C. Barra; L. Presotto; V. Bettonard; S. Savo; P. Magani; R. Menchini; A. Collavino; I. Herr; E. De Gaetano; L. Giani; A. Briganti; F. De Cobelli; P. Scozy; M. Pecheur; V. Vita Salute San Raffaele University, Milan, ITALY; Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY; Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY; Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

**OP-0578**
Prospective analysis of Prostate Cancer Local Staging With [124I-MMPI PET/MRI combined with multimodal PET - a comparison to histopathology in the radical prostatectomy specimen
Amsterdam UMC, Location VUMC, Amsterdam, NETHERLANDS.

**OP-0579**
A Pilot Study of [68Ga]PSMA11 and [68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
H. Duan; P. Ghahrouni; N. Hatami; G. A. Davidson; C. M. Aparici; A. Thong; A. G. Sorn; A. Jagan
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.
ORAL PRESENTATION | FINAL PROGRAMME

Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Featured Session: Molecular Imaging of Movement Disorders

OP-0584 What Lies Behind Cognitive Deficits in Parkinsonian? F. Nobili; University of Genoa and Policlinico San Martino Hospital, Department of Neuroscience (DINOOG), Genoa, ITALY

OP-0585 Prospective paired comparison of [18F]FDG-PET/SPECT images obtained with a 360°-CZT and a conventional camera. V. Pietikova, P. Papyaz, C. Bournier, M. Bardonne, V. Roclt, P. Y. Marchetti, J. L. Imbert, A. Vergel; Université de Lorraine, Department of Nuclear Medicine and Nuclear-striatopallidal Imaging Platform, CHU Nancy, Nancy, FRANCE, Université de Lorraine, Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, FRANCE, Toulouse Neuroimaging Center, University of Toulouse, INSERM, UPS, Toulouse, FRANCE, Université de Lorraine, INSERM, DCAC, Nancy, FRANCE, Université de Lorraine, ADO, INSERM U1254, Nancy, FRANCE

OP-0586 Imaging With [18F]FPE21 Suggests a Non-Linear Relationship Between Dopamine Transporter Availability and Motor Symptom Severity in Patients With Non-Advanced Parkinson’s Disease V. Kornics, P. Porina, A. Sungran, C. Halden, P. Stenningsson, A. Varrone; Karolinska Institute, Stockholm, SWEDEN

OP-0587 18F-FDOPA PET for the diagnosis of cortico-basal syndromes S. Darcourt; A. Schiavo, D. Chardain, A. El Ouazarati, N. Sapin, P. Fouilloy, O. Humbert, C. Gardanne; Centre Antoine Lacassagne - UCA, Nice, FRANCE, CHU - UCA, Nice, FRANCE

OP-0588 Dopaminergic Activity and Functional Connectivity After Intranasal Insulin. A [18]Crapicide PET/MRI Study D. Bocian; 1, M. Kullmayer, B. A. Ingham, A. H. Bender, H. Hanning, G. Resch, H. Pless, C. La Faugere, A. Fitchett, M. Rommel, M. Herl; Nuclear Medicine and Molecular Imaging, Tübingen, GERMANY, Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, GERMANY, Department of Internal Medicine, Division of Hematology, Oncology and Rheumatology, Tübingen, GERMANY, Gesellschaft für Integrierte und Interventionelle Neuroradiologie, Tübingen, GERMANY, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Tübingen, GERMANY

OP-0589 18F-PET/2620 binding in dopaminergic pathways is associated with decreased dopamine transporter availability in four-repeat tauopathies C. Ferschmann, M. Schenfel, H. Baneth; 1, M. Marek, C. Pailler; 2, K. Jaksch, S. Kastakow; 2, U. Fetzek, A. Finer, G. Biechler, J. Beyer, F. Eckenweber, S. Wolff, D. Soul, M. Schreiber, J. Rumpf, M. Rulfmann, A. Schild, M. Patt, A. Steffen; 2, J. Classen; 2, P. Bartenstein; 2, J. Seiber; 2, G. Häglund, O. Sabri; M. Bredel; 3,4, 5Department of Nuclear Medicine, University Hospital Munich, LMU Munich, MUNICH, GERMANY, Department of Nuclear Medicine, University Hospital Leibzig, Leipzig, GERMANY, InnOC, LLC, Boston, MA, UNITED STATES OF AMERICA, Molecular Neuroimaging, Division of mriCRG, New Haven, CT, UNITED STATES OF AMERICA, Department of Neurology, University Hospital of Munich, LMU Munich, Munich, GERMANY, German Center for Neurodegenerative Diseases (DZNE), Bonn, GERMANY, Department of Neurology, University Hospital Leipzig, Leipzig, GERMANY, Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, GERMANY, LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, LIFE Molecular Imaging Center, Berlin, GERMANY, Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, Department of Neurology, Medizinisch Hochschule Hannover, Hannover, GERMANY.
OP-0597
Status of Guidelines on Breastfeeding
S. Leide-Sveegbor;
Radiation Physics, Skåne University Hospital Malmö and Medical Radiation Physics Malmö, Lund University, Malmö, SWEDEN.

OP-0598
The Pregnant Patient - Risks for the Foetus
F. Jamar;
Cliniques universitaires St-Luc, Nuclear Medicine, Brussels, BELGIUM.

OP-0599
How to Estimate the Radiation Doses?
M. Cremonesi;
European Institute of Oncology, Radiation Research Unit, Milan, ITALY.

OP-0600
Feasibility of dose reduction in (18F)-FE-PE2I PET in DAT imaging
T. Lehnshkov, D. Risberg, L. Maner, M. Lornisdale;
Bispertjeg/Fredenberghospital, Copenhagen, DENMARK.

OP-0601
Feasibility of dose reduction in (18F)-FE-PE2I PET in DAT imaging
T. Lehnshkov, D. Risberg, L. Maner, M. Lornisdale;
Bispertjeg/Fredenberghospital, Copenhagen, DENMARK.

OP-0602
Development of a brain perfusion SPECT attenuation correction method using synthetic CT images generated by MRI images with a deep convolutional neural network
Y. Morisawa1, Y. Ochiai2, A. Takaki3, S. Ita1;
Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 1Department of Radiological Technology, Faculty of Fukushima Medical Technology, Tokyo University, Fukushima, JAPAN.

OP-0603
Development of a brain perfusion SPECT attenuation correction method using synthetic CT images generated by MRI images with a deep convolutional neural network
Y. Morisawa1, Y. Ochiai2, A. Takaki3, S. Ita1;
Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 1Department of Radiological Technology, Faculty of Fukushima Medical Technology, Tokyo University, Fukushima, JAPAN.

OP-0604
Development of a brain perfusion SPECT attenuation correction method using synthetic CT images generated by MRI images with a deep convolutional neural network
Y. Morisawa1, Y. Ochiai2, A. Takaki3, S. Ita1;
Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 1Department of Radiological Technology, Faculty of Fukushima Medical Technology, Tokyo University, Fukushima, JAPAN.

OP-0605
Comparative study of Dopamine transporter imaging between a conventional camera and an innovative 3D-ring hybrid gamma-camera: technologist's point of view
J. Dessoubrais, P. Oudot, F. Clouse, M. Bally;
Regional Hospital Center of Orleans, Orleans, FRANCE.

OP-0606
Bayesian penalized likelihood reconstruction algorithm in the advanced digital PET/CT system for 18F DOPA PET/CT in patients with Parkinson’s disease and Glioblastoma Multiforme
R. Alhamdani1, M. Al-Doss2, A. Esmael3, E. Marnagh;
Jaber Alahmad Center for Molecular Imaging, Kuwait, KUWAIT.

OP-0607
Development of the ascending aorta region of interest setting program using deep neural networks for 18F-FDG PET/CT regional cerebral blood flow quantification
T. Sakata1, Y. Uchiyama1, A. Takaki1, S. Ita1;
Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 1Department of Radiological Technology, Faculty of Fukushima Medical Technology, Tokyo University, Fukushima, JAPAN.

OP-0608
Eating should be avoided during the administration and early biodistribution of PSMA-directed radioligand therapy
N. Bruin, V. Mohan, J. van de Kamer, J. Sonke, W. Vogel;
The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0609
Validation process of a new radiolabeled tracers preparation: "11Lu-PSMA-1" and "177Lu-PSMA-1"
F. Orholt, M. Piqumard, P. Bedouch, J. Vuille1, L. Djaleb2, M. Desruet1, J. Lenehard1;
1Radiopharmacy, Grenoble Alpes University Hospital, Grenoble, FRANCE, 2Radiopharmacy department, Grenoble Alpes University Hospital, Grenoble, FRANCE, 3Nuclear Medicine, Grenoble Alpes University Hospital, Grenoble, FRANCE.

OP-0610
Image quality assessment in two different SPECT scanners: study with a phantom
L. Vieira1, E. Perere1, A. Garsi, L. Frere;
1Health & Technology Research Center, ESTeSL - Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL, 2Centro de Investigação em Modelação e Otimização de Sistemas Multifuncionais, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3Centro de Investigação em Modelação e Otimização de Sistemas Multifuncionais, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

OP-0611
Basic study on imaging acquisition conditions for somatostatin receptor scintigraphy with phantom
M. Nishio1, H. Fujita1, H. Ikada2, Y. Oohira3, S. Abe4, A. Kato1;
1Nagoya University, Nagoya, JAPAN, 2Nagoya University Hospital, Nagoya, JAPAN, 3Nagoya University, Nagoya, JAPAN, 4Pharmacy department, Nagoya University Hospital, Nagoya, JAPAN.

OP-0612
Gallium-68 cyclotron production from liquid target: Validation process of a new radiolabeled tracers preparation: "11Lu-PSMA-1" and "177Lu-PSMA-1"
F. Orholt, M. Piqumard, P. Bedouch, J. Vuille1, L. Djaleb2, M. Desruet1, J. Lenehard1;
1Radiopharmacy, Grenoble Alpes University Hospital, Grenoble, FRANCE, 2Radiopharmacy department, Grenoble Alpes University Hospital, Grenoble, FRANCE, 3Nuclear Medicine, Grenoble Alpes University Hospital, Grenoble, FRANCE.

OP-0613
Update in Non FDG WB-MRI - My Favourite!
F. Kraeber-Bodéré;
1Nuclear Medicine Department, Nantes, FRANCE, 2Pharmacy department, Grenoble Alpes University Hospital, Grenoble, FRANCE, 3Nuclear Medicine, Grenoble Alpes University Hospital, Grenoble, FRANCE.

OP-0614
Eating should be avoided during the administration and early biodistribution of PSMA-directed radioligand therapy
N. Bruin, V. Mohan, J. van de Kamer, J. Sonke, W. Vogel;
The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0615
Therapy Assessment with FDG
F. Kroeber-Borinde;
University Hospital of Nantes, Nuclear Medicine Department, Nantes, FRANCE.

OP-0616
Update in Non FDG
C. Lapa;
University Hospital Augsburg Department of Nuclear Medicine, Augsburg, GERMANY.

OP-0617
Eating should be avoided during the administration and early biodistribution of PSMA-directed radioligand therapy
N. Bruin, V. Mohan, J. van de Kamer, J. Sonke, W. Vogel;
The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-0618
Combination Treatment in Prostate Cancer
U. Vogl;
Oncology Institute of Southern Switzerland, Ospedale Regionale de Bellinzona e Valli, Bellinzona, SWITZERLAND.

OP-0619
Combination Treatment in NETs
M. Pavel;
Universityklinikin Brams, Department of Internal Medicine 1, Kirken, GERMANY.

OP-0620
Preclinical Considerations for Combination Treatment
T. Czermin;
University of California Los Angeles, Molecular and Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA.
**ORAL PRESENTATIONS**

**S. Schmitt**

**C. Wichmann**

Durvalumab for Clinical PET Imaging of PD-L1

**OP-0630**

An efficient route to obtain (radio)fluorinated or (radio)iodinated 1,2,3,4-tetrahydro-7-hydroxysoquinoline-3-carboxylic acid (THC(OH)) analogues as potential radiotracers for imaging of solid tumours  


‘UMR 2498 Inserm Clermont-Auvergne University, Clermont-Ferrand, FRANCE, 2Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY. Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Leipzig, GERMANY.  

**OP-0631**

Synthesis and characterisation of the corresponding Cu, In and Lu complexes of a cyclen based chelator with four methylimidazole arms  

I. Hierminger, P. Pfeiffer, T. Stremet, S. Maus, S. Ezardh, M. Bartholomäus,  

Sonstfund University Medical Centre, Homburg, GERMANY.  

**OP-0632**

Preclinical proof of concept study towards modifiable 40Ac-chelators for mild condition labeling and PSMA-targeting  

F. Reissig, D. Bauer, K. Zancher, Z. Novy, A. Bendova, M. Lukáč, K. Kapka, H. Přežíč, M. Petrik, C. Mamat,  

Wzorczyński Institute of Radiopharmaceutical Cancer Research, Graz, AUSTRIA. Department of Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.  

**OP-0633**

Patient Dose Formulation of 177Lu-CH-X-A-OTAPITuximab Using Indigenous sourced 177Lu-Acetate sourced from Nuclear Reprocessing Waste  


MDCR, BARC, Pune, INDIA, 2RMIC, BARC, Pune,  

Mumbai, INDIA, 3HBNI, Mumbai, INDIA, 4PEI, BARC, Trombay, Mumbai, INDIA, 5ACTREC, TMC, Navi Mumbai, INDIA.  

**OP-0636**

Crow, a macrocyclic chelator for Lu-177, Bi-213, and Ac-225  

H. Yang, L. Wharton, C. Zhang, F. Bénard, V. Radchenko, P. Schaffer.  

TRUMED, Vancouver, BC, CANADA.  

**OP-0637**

Impact of DOTA position on biodistribution of 111 Lu-labelled ABD-fusibody molecules  


National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 5AABBody-AB, Sohna, SWEDEN.  

**OP-0634**

Development of In-House Synthesis and Quality Control of [111mTc(Tc)PSMA-11 &5]E  


‘Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Graz, AUSTRIA.  

**OP-0640**

The Impact of Different 177Lu Activities on Dual Isotope Imaging for 177Lu-Holmium Scout Radioembolization Procedure  


University Medical Center, Utrecht, NETHERLANDS.  

**OP-0641**

Dietetic trial with iodine-124 PET dosimetry to optimize therapy of metastatic thyroid cancer: PET scanner’s SUV verification used to check accuracy of activimeters  


1 Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, 2Medical Physics, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY, 3Nuclear Medicine, University Hospital Essen, GERMANY, 4Radiochemistry & Cyclotron, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY, 5Nuclear Medicine, Hospital IRCCS Sacro Cuore Don Calabria, Negrar, ITALY.  

**OP-0642**

Imaging Properties and Quantification Accuracy of 89Ga and 111In in a New Generation Preclinical PET/CT System: A Phantom Study  


1Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, 2Molecules NL, Ghent, BELGIUM.  

**OP-0643**

Y quantification using PET/CT- and SPECT-based PET systems: a phantom study  


1Clinic for Nuclear Medicine, Essen, GERMANY, 2Sarems Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA.  

**OP-0644**

Phantom study of the effect of varying acquisition duration on optimisation of Bayesian penalised likelihood reconstruction for Zirconium-89 PET/CT  

L. Bonney, M. D. Walker, D. R. McGowan.  

1Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM, 2Oxford University, Oxford, UNITED KINGDOM.  

---
**Clinical Oral Presentations**

**OP-0655**

PSMA PET and radiomics for the evaluation of liver metastases in castration-resistant prostate cancer patients: a multicenter retrospective study


D’Institute of Nuclear Medicine, RCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; “Fondazione Centro Diagnostico Nuclear (FCDN), Buenos Aires, ARGENTINA; Flago Medical Institute of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; Department of Radiology, RCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY; Department of Medical Physics, RCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

**OP-0656**

Sarcopenia represents an independent adverse event in metastatic castration-resistant prostate cancer (mCRPC) patients: candidates to Radium-223 therapy

F. D’Amico, R. Lai, M. Donegani, A. Micali, S. Rafii, C. Campi, C. Delucchi, D. Schenone, S. Rebuli, G. Fornarini, M. Parea, G. Mancini, S. Rebuli, G. Sambuceti, M. Baubinetti, IRCSS Ospedale Policlinico San Martino, Genova, ITALY; Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genova, ITALY; Department of Mathematics and Medical Specialities (Di.M.), University of Genova, Genova, ITALY; CNR Institute of Molecular Biomaging and Physiology (BFM), Segrate, ITALY.

**OP-0657**

Clinical utility of molecular imaging in neuroendocrine prostate cancer: Comparison of 18 F-FDG, DOTATOC and PSMA PET/CT


**OP-0658**

The impact of PSMA peptide amount and tumor volume on tumor uptake on “Ga-PSMA PET/CT in primary prostate cancer patients


Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, SPAIN; Faculty of Engineering, Department of Applied Physics, UPV/EHU, Bilbao, SPAIN.

**OP-0659**

Contribution of Ga-68 DOTA-FAPi-4 PET / CT to tumor Imaging: First results in 20 different types of Cancer

N. Ergul, B. Virmam, O. Olguuner-McDonald, T. T.Cermik, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY; University of Health Sciences, Faculty of Pharmacy, Istanbul, TURKEY.

**OP-0661**

Usefulness of "If-FDG PET / CT in the Stage And Restaging Of Thyroid Epithelial Tumors


**OP-0662**

Prognostic Value of Volumetric-Metabolic Parameters Obtained in F18-FDG PET/CT Imaging for the Short-term Follow-up of Patients with Advanced Bladder Cancer

T. Bahceli, E. Sahin Kurak, N. Taloay, E. Cebir, Ankara City Hospital, Ankara, TURKEY.

**OP-0663**

Comparison 2 - (18F)FDG and (68Ga)Ga-DOTATOC and DOTATATE PET/CT in re-staging of patients with Esthesioneuroblastoma

L. Torres, F. O. García Perez, E. Ignacio Álvarez, A. F. Sistierna Salto, D. A. Arquette Pérez

1Autonomous University of Bucaramanga, Bucaramanga, Santander, COLOMBIA; 2The National Cancer Institute (INCan), Mexico City, MEXICO.
ORAL PRESENTATIONS

OP-0665
Impact of Point-Spread Function Reconstruction on Dynamic and Static FDOPA PET/CT Quantitative Parameters in Glioma

OP-0666
Dynamic “FF-Fdopa PET imaging for gliomas: is a semi-quantitative model sufficient?
T. Zaragoti, M. Dagen, F. Rech, M. Blanski, L. Talaudier, L. Imbert, A. Verger; ‘Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE, ‘CHRU-Nancy, Université de Lorraine, Department of Nuclear Medicine & Nancyclope Imaging platform, Nancy, FRANCE, ‘CHRU-Nancy, Université de Lorraine, Department of Nuclear Medicine, Vandoeuvre-lès-Nancy, FRANCE, ‘Université de Lorraine, Centre de Recherche en Automatique de Nancy CRAN, CNRS UMR 7091, Nancy, FRANCE, ‘CHRU-Nancy, Université de Lorraine, Department of Neuro- oncology, Nancy, FRANCE.

OP-0667
1C-methionine PET for the preoperative assessment of molecular subtype and prognosis in patients with grade II/III gliomas: a retrospective study
G. Ninatti, M. Solini, B. Bondi, N. Gazz0, D. Fedorav, L. Antunesco, F. Geraci, F. Pessina, A. Chiari; ‘Istituto Humanitas University, Pieve Emilia (MI), ITALY, ‘Istituto Humanitas Research Hospital, Rozzano (MI), ITALY.

OP-0668
“FF-FET PET diagnostic and prognostic value in pre-treated glioma patients presenting with equivocal MRI findings for glioma recurrence
M. Celi, P. Caroli, L. Fantini, V. Rossetti, I. Manni, G. Paganelli, F. Mattiucci; Istituto Rambamagnela per lo Studio de Tumori “Dina Adamo” - ISTR WCCS, Meldola, ITALY.

OP-0669
Voxel-wise Correlation of Amino Acid and TSPO PET with Relative Contrast Enhancement in T1-Weighted MRI in Gliomas
L. Kaiser, A. Halderwey, M. Untermeier, F. Viettmer, J. Brosh-Leun, A. Goesevich, G. Böning, R. Ruprecht, J. C. Toni, P. Bartensdotter, S. Zeiger; ‘Klinikum rechts der Isar, Department of Nuclear Medicine, University Hospital, LMU Munich, GERMANY, ‘Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY, ‘Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY, ‘Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY.

OP-0670
Prognostic parameters of post-therapeutic position emission tomography using amino acids (AA PET) in malignant brain tumours
M. Schürer, J. Spreker, K. Jaehne, S. Klages, C. Schelbach, P. Kuzman, M. Patt, C. Sedel, G. Sabar, S. Hesse; ‘Department of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, GERMANY, ‘Department of Radiotherapy and Radiocngiology, University of Leipzig Medical Centre, Leipzig, GERMANY, ‘Department of Neurosurgery, University of Leipzig Medical Centre, Leipzig, GERMANY, ‘Clinical Cancer Registry, University of Leipzig Medical Centre, Leipzig, GERMANY, ‘Department of Neurosurgery, University of Leipzig Medical Centre, Leipzig, GERMANY, ‘Department of Neuropathology, University of Leipzig Medical Centre, Leipzig, GERMANY.

OP-0671
Sensitivity of 18F-fluoroethyltyrosine PET in the diagnosis of recurrent high grade glioma
T. Schürmann, S. Kleiner, W. Weber, J. Yakushev, V. Kuzman, M. Patt, R. Laudicella, A. Vento, D. Romeo, S. Russo; ‘Institut für Radiologie, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY, ‘University Hospital, LMU Munich, Munich, GERMANY, ‘University Hospital, LMU Munich, Munich, GERMANY.

OP-0672
The Utility of Dual Time-Point FET-PET/CT in Recurrence Assessment of Glioma Patients
A. Spatara, R. Laudonello, A. Vento, D. Romeo, C. Carletti, G. Giacoppi, F. La Tore, B. Pagano, S. Broglio, F. Minutoli, S. Balda; ‘Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho- Functional Imaging, University of Messina, Messina, ITALY, ‘Department of Radiology, University College London Hospitals NHS Trust, London, UNITED KINGDOM, ‘Department of Brain Repair and Rehabilitation, University College London, London, UNITED KINGDOM.

OP-0673
Diagnostic utility of amino acid PET in the differential diagnosis of recurrent brain metastases and pseudoprogression: a meta-analysis
T. Schlümann, B. Walschukit, W. Weber, J. Yakushev, V. Kuzman, M. Patt, R. Laudicella, A. Vento, D. Romeo, S. Russo; ‘Technische Universität München, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY, ‘Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY, ‘Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY.

OP-0674
A prospective, multi-centre trial of PET Fingloblastoma patients - the TROG 18.06 FIG Study

OP-0675
CME 9: Back to the Future - New Kit-Based Approaches for Labelling Radiopharmaceuticals ("Ga", "Al"("F")...)

OP-0676
Labelling Cold Kit With 68 Ga - The Future is Bright
C. Morgat; ‘Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Nucléaire, Groupe Hospitalier Pellegrin, Bordeaux, FRANCE.

OP-0677
All("F") - From Modules Toward a Kit-Based Radiofluorination?
C. Da Pieve; ‘Institute of Cancer Research, Division of Radiotargeting and Imaging, London, UNITED KINGDOM.

OP-0678
Regulatory Aspects of Cold Kit-Based Radiopharmaceuticals in the EU
O. Neels; ‘Institute of Radiopharmaceutical Cancer Research Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, GERMANY.

1302-1
Interview with the Expert 8 - Vision Trial
S. Fanti; ‘University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

1302-2
Interview with the Expert 9 - The Best Young NM
K. Herrmann; ‘Universitätsklinikum Essen, Nuclear Medicine, Essen, GERMANY.

OP-0680
Interview - The Best Young NM
K. Herrmann; ‘Universitätsklinikum Essen, Nuclear Medicine, Essen, GERMANY.

OP-0681
Interview - Vision Trial
B. Krause; ‘University Medical Center Rostock, Rostock, GERMANY.

1302-3
Interview with the Expert 7 - The Best Young NM
S. Fanti; ‘University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0682
Interview - The Best Young NM
S. Fanti; ‘University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0683
Interview - The Best Young NM
S. Fanti; ‘University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-0684
Interview - The Best Young NM
K. Herrmann; ‘Universitätsklinikum Essen, Nuclear Medicine, Essen, GERMANY.
1304
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Technologists - TROP Session: Sharing Technologist's Experience 2

OP-0685
Reduction of effective dose using single-CT for attenuation correction in myocardial perfusion imaging
C. Brunety1, C. Hasselbring1, M. Simonsen2, M. Toth Cervin1, R. Maduz1.
1Central-Jyllsk Ulker Kistianstaden, Kistianstaden, SWEDEN, 2Department of Nuclear Medicine, Odense, DENMARK.

OP-0686
Cardiac scintigraphy examination for high BMI patients using 3D-ring CZT SPECT/CT
P. Dudat1, J. Desuprava2, F. Claude1, M. Bally1, Centre Hospitalier Regional d’Orleans, Orleans, FRANCE.

OP-0687
Intra- and interobserver variability in LVEF measurements by Multi-Gated Nuclear Ventriculography using semi-automated and manual postprocessing
L. Piet1, T. G. Christensen1, S. Hess1,3, M. W. Kusk1,2, J. Dessoubrais, F. Clouse, M. Bailly, P. Oudot, Centre Hospitalier Regional d’Orleans, Orleans, FRANCE.

1305
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Joint Symposium 17 (EANM/EAU): Urological Challenges for Imaging Beyond Prostate

OP-0690
Comparison of low pulmonary perfusion index using 99mTc-MAA SPECT images and hemodynamic indices in chronic thromboembolic pulmonary hypertension
Y. Ochi, Y. Tsutsumi, N. Fujita, H. Ieda, M. Nishiy, Y. Asano, S. Abe, R. Katoh, A. Nagaya, JAPAN.

OP-0691
Between Different Acquisition Times And Different Reference Tissues In The Interpretation Of The Scintigraphy With 99mTc-HMPAO-Leucocytes In Muscle-Skeleton Infections
R. Rinaldi, D. Alban, E. Donz, Nuclear Medicine dep - ASST Spedali Civili, Brescia, ITALY.

OP-0692
A Phantom Study on Compton Scatter Correction Methods in 99mTc Imaging
M. Can1, O. Karadeniz1, T. Ertay1,2, G. Çapa Kaya1,3; 1Department of Medical Physics, Institute of Health Sciences, Dokuz Eylul University, Izmir, TURKEY, 2Department of Physics, Faculty of Sciences, Dokuz Eylul University, Izmir, TURKEY, 3Department of Nuclear Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, TURKEY.

OP-0693
First clinical experiences with a new long axial field-of-view PET/CT: the technologist’s point-of-view
R. Schepers1, J. Albritt, A. Afsahr-Oromieh, M. Viscone, A. Rominger, Inghespital, Bern, SWITZERLAND.

OP-0694
Learning from our mistakes: a teaching tool to improve the quality of Nuclear Medicine Technologist’s practices
E. Lemos Pereira1, A. Garcia, A. Malaia, M. Fateixa, 1Instituto de Física, Faculdade de Ciências, Universidade do Porto, Porto, PORTUGAL.

1306
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Joint Symposium 18 (EANM/EAU): Urological Disease Beyond Prostate Cancer

OP-0701
The Needs of Urologists and Oncologists in Urological Disease Beyond Prostate Cancer
J. Walz, Department of Urology, Institut Paul-Licetieres Cancer Centre, Marseille, FRANCE.

OP-0702
The Role of PET Imaging in Bladder Cancer
A. Capozza, ASSST San Paolo in Carro, Department of Nuclear Medicine, Milan, ITALY.

OP-0703
PET Imaging with Diverse Radiopharmaceuticals in Renal Cancer
L. Evangelista, University of Padova, Department of Medicine (EMME), Padua, ITALY.

OP-0704
The Role of PET Imaging in the Management of Testicular Cancer
Y. Loriot, Gustave Roussy Institute, Oncology Department, Villejuif, FRANCE.

1307
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool, release on Wednesday, October 20 at 09:00

Teaching Session 3: Radiobiology as a Missing Link in improving and Understanding Nuclear Medicine

OP-0706
Radiobiology in Nuclear Medicine
S. Terry, Kings College London, School of Biomedical Engineering & Imaging Sciences, London, UNITED KINGDOM.

OP-0707
Why We Cannot Rely on EBRT Radiobiology
M. Koninjeben; Radogologie & Nueleaire Geneveundke, Klnische Fysia, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-0708
Need for Radiobiology in Preclinical Research
K. Luckerath, University Hospital Essen, Clinic for Nuclear Medicine, Essen, GERMANY.

OP-0709
Need for Radiobiology in the Clinic
R. Huustia, Centre hospitalier Universitaire de Liege, Liege, BELGIUM.

M2M Track - TROP Session: Out of the Box Innovations

OP-0711
The Imageable Genome
P. Janö, V. Taetman1, E. Janö1, O. Bejöy1, M. Gómez Martínez, R. A. Dumont1, M. A. Walter1.
1Hôpitaux Universitaires de Genève, Geneva, SWITZERLAND, 2Centre d’imagerie biomédicale (CIBM), Geneva, SWITZERLAND, 3Universidad Politécnica de Madrid, Madrid, SPAIN, 4Hospital Universitario Ramón y Cajal, Madrid, SPAIN, 5Université de Geneve, Geneva, SWITZERLAND.

OP-0712
Optimizing a PET nanoradiotracer to overcome tumor heterogeneity
OP-0713 Pharmacokinetic studies and modeling to efficiently predict nanoradiotracet PET biodistribution
Axel-Marseille University, Marseille, FRANCE.

OP-0714 The evaluation of [18F]FDG and [18F]FDT radiotracers as potential biomarkers of early treatment outcome in triple negative breast cancer (TNBC)
P. Rainone1, S. Valtorta1, S. Todde1, D. Salvatore1, R. Moresco1,2,3
1Department of Medicine and Surgery and Tecnomed Foundation, University of Milano – Bicocca, Monza, ITALY, 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Institute of Molecular Imaging and Physiology, National Research Council (IBFM-CNR), Segrate, ITALY.

OP-0715 Copper-64 as a translational tool for evaluating pharmacodynamics and efficacy of a new gene therapy treatment in a preclinical mouse model of Wilson's disease
M. Collantes1,2, M. Eey1, G. Quinones1,2,3, D. Moreno1,2,4, O. Murillo5, V. Moyon, T. Roussel, F. Dignat-George, L. Peng, B. Guillet, P. Garrigue, F. Moisan, H. R. Nemer1,5,6,7,3,8, S. Remacle1, A. Mular1, E. Gumienna-Kontecka1, M. Misslinger4, J. J. S. Terry1, P. J. Blower1, R. T. M. de Rosales1; 1University of Manchester, Manchester, UNITED KINGDOM, 2University of Texas Southwestern Medical Center, Dallas, UNITED STATES, 3University of Bordeaux, Bordeaux, FRANCE, 4University of Bordeaux, Bordeaux, FRANCE, 5University Hospital of Bordeaux, Nuclear Medicine Department, 6Sorbonne University, Paris, FRANCE, 7Institut Curie, Paris, FRANCE, 8CNRS, Gif sur Yvette, FRANCE.

OP-0718 [18Ga]Ga-THP-Pam: A PET Radiotracer for Imaging Ga-PSMA-11 in 60 Minutes Including Beam Time
C. Cancer Institute, Amsterdam, NETHERLANDS, 2GEMS PET Systems, Uppsala, SWEDEN.

OP-0719 Preclinical evaluation of [18F]-labelled artificial siderophores of the Ferrioxamine type
J. N. Hübner1, A. Mulat1, E. Gumenno-Konteksta2, M. Misüssinger3, J. Pfitzer1, H. Haas1, P. Petri1, C. Decastello1, 1Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, 2Faculty of Chemistry, University of Wroclaw, Wroclaw, POLAND, 3Faculty of Pharmacy, University of Wroclaw, Wroclaw, POLAND, 4Division of Molecular Biology, Medical University Innsbruck, Innsbruck, AUSTRIA, 5Division of Molecular Biology, Medizinische Universität Innsbruck, Innsbruck, AUSTRIA, 6VIIMTA, Faculty of Medicine and Dentistry, Palacky University, Innsbruck, AUSTRIA.

OP-0720 New opportunity for imaging in oncology: targeting the neurotransmitter receptor-2 with JMV7488, a new peptide analogue radiolabelled with gallium-68
S. Bodin1, S. Plevé1, E. Jézin1, D. Virenia1, F. Lamare1,2, I. Art-Ara1, S. S. Bertrand1, E. Hindié1,2, F. Cavelier3, C. Morgat1,2; 1Marseille 33 University, F-13000 Marseille, FRANCE, 2University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 3Univ. Montpellier, CNRS, FRANCE, 4University Hospital of Bordeaux, Nuclear Medicine Department, F-33000 Bordeaux, FRANCE, 5Univ. Montpellier, CNRS, 6Univ. Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, F-34000 Montpellier, FRANCE, 7Centre d’Imagerie Clinique Montpellier (CYCOS), 8Centre de Référence et de Pilotage des Traitements par Les Radioéléments (C3PO) – A Multimodality Imaging Phantom for F18 PSMA imaging
R. Oliveira1, F. Oliveira1, C. Carmona1, L. Viera1, M. Casta1, D. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3Mammary Health, Oeiras, PORTUGAL, 4Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

OP-0725 Comparison of quantitative measures between EARL1 and EARL2 specifications in PET/CT studies using Gallium-68
R. Oliveira1, F. Oliveira1, C. Carmona1, L. Viera1, M. Casta1, D. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, 3Mammary Health, Oeiras, PORTUGAL, 4Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

OP-0727 The Effect of Residual Counts from Medical Materials Used for [18F]FDG Injection on Quantitative Parameters of PET/CT Imaging in Pediatric Oncology Patients
N. Galárd1, B. Cogoss1, Department of Nuclear Medicine, Ministry of Health, Ankara City Hospital, Ankara, TURKEY, 2The National Physical Laboratory, Teddington, UNITED KINGDOM, 3Theragnostics Ltd, Bracknell, UNITED KINGDOM, 4Health and Technology Research Centre, Southampton, UNITED KINGDOM.

OP-0728 Development of a patient-specific kidney phantom with inhomogeneous activity distribution using only a single fillable compartment
A. Theisen1, M. Lassmann1, A. K. Buck1, J. Tran-Gia1; 1Department of Nuclear Medicine, University of Würzburg, GERMANY.

OP-0729 Accuracy of thyroid uptake calibration method: a multi-centric study with realistic phantoms
T. Beaumont1, A. Forbes1, F. Fenwick2, E. G. Probert1, B. D. Brigg1, 1IRSN/SDOS/LEDI, Fontenay-aux-Roses, FRANCE, 2Centre Hospitalier Pitié-Salpêtrière, Paris, FRANCE, 3Centre Hospitalier d’Apollon, Avignon, FRANCE, 4CHU Jean Minjoz, Besancon, FRANCE, 5CHU Nîmes, Nîmes, FRANCE, 6CHUV La Timone, Marseille, FRANCE, 7AP-HP hôpital Bécon, Le Kremlin-Bicêtre, FRANCE, 8AP-Hôpital Antoine Béclere, Clamart, FRANCE, 9Centre Hospitalier Régional d’Orléans, Orléans, FRANCE, 10Groupe Hospitalier Pitié-Salpêtrière, Paris, FRANCE, 11CHU de Nice, Nice, FRANCE, 12Centre hospital des hôpitaux d’Avignon, Avignon, FRANCE, 13CHU Jean Minjoz, Besancon, FRANCE, 14CHUV La Timone, Marseille, FRANCE, 15CM Val d’Aurelle, Montpellier, FRANCE, 16Centre Hospitalier Pitié-Salpêtrière, Paris, FRANCE, 17Fondation Charles de Ly, Lyon, FRANCE, 18Institut de cancérologie du Ouest, R. Gauducheau, Saint-Herblain, FRANCE, 19CHU Fréjus Saint-Raphaël, Fréjus, FRANCE.

OP-0730 Radiodiode uptake measurement on planar scintigraphic images: an automatic process reducing thyroid volume effect
T. Beaumont1, A. Forbes1, E. Durand1, A. Castilla-Lleve1, D. Boggi1; 1IRSN/SDOS/LEDI, Fontenay-aux-Roses, FRANCE, 2Centre Hospitalier Béclère, Le Kremlin-Bicêtre, FRANCE, 3AP-Hôpital Antoine Béclere, Clamart, FRANCE.

OP-0731 Myocardial Perfusion Imaging and Extra-Myocardial Uptake: The Effect of Post-Processing Decisions on Left Ventricular Contraction Quantitative Parameters for a Dedicated Cardiac SPECT Camera
J. Kennedy1, T. Haliday2, Z. Keidar3, 1Rambam - Health Care Campus, Haifa, ISRAEL, 2R and D Rapport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.

OP-0732 Towards a comprehensive validation for Monte Carlo SPECT simulations
S. Pells1, D. M. Cullen1, A. P. Robinson1,2, B. Petras1, D. Daedas1, F. ten Haken1, K. Fenner1, A. Fuji1, D. Hamilton1, W. Brett1, P. Julian1, G. Needham1, F. Page1, F. Priot1, J. Tipping1, 1The University of Manchester, Manchester, UNITED KINGDOM, 2The National Physical Laboratory, Teddington, UNITED KINGDOM, 3The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 4Cardiff University, Cardiff, UNITED KINGDOM.
Clinical Oncology Track - TROP Session: Prostate BC Recurrence

**OP-0734**

Therapy impact of "68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer patients with PSA< 1 ng/ml postprostatactomy and "68-Choline PET/CT negative M. Cozar Santiago, J. Garcia Garabito, J. Pastor Perez, P. Bassa Massana, A. Canoves Llobert, J. Aguilà Barrios, R. Sanz Llorens, V. Faus Rodrigo, M. Soler Lopez, J. Ferez Rebolledo, ASCORS-Nuclear Medicine Department. General Hospital University University, Valencia, SPAIN, ASCORS-Radiotherapy Department. General Hospital University University, Valencia, SPAIN.

**OP-0744**

Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer P. Arriola, J. Zatorre, M. Barre, A. Chavarriaval, D. Donner, S. Panarese, I. Evangelista; "University of Padova, Padova, ITALY, "University of Udine, Udine, ITALY, "ICM, Padova, ITALY, "University of Rome, Rome, ITALY, "Hospital de Trento, Trento, ITALY, "University of Ferrara, Ferrara, ITALY.

**OP-0745**

The detection rate of PSMA-PET is still preserved in a low probability setting of a positive scan in patients with biochemical recurrence: a dual phase protocol with diuretic enhancement A. Miceli, V. Feudo, C. Bassocc, C. Genovese, P. Scalari, A. Travissina, G. Sambuceti, C. Pali, "DISGSL, Genoa, ITALY, "Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Universita Cattolica del Sacro Cuore, Rome, ITALY, "Unit of Nuclear Medicine, Aosta Regional Hospital, Aosta, ITALY.

**OP-0746**

Potential value of "68Ga-PSMA-11 PET to predict biochemical recurrence in primary prostate cancer after radical prostatectomy H. Wang, T. Amel, T. Langbein, J. Rauscher, T. Harri, M. Hedt, T. Mauer, W. Weber, M. Eiber; "Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY, "Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, "Department of Radiology, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY, "Theranostics, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.

**OP-0748**

Quantitative Parameters from 18FDG PET/MRI Reveal Intratumoral Heterogeneity in Primer Brain Tumors Confirmed by Pathology K. Seker, E. Celik, O. Aydor, S. Gabilhan Atay, M. A. Inat, U. O. Akdemir, L. O. Atay; "Gazi University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TURKEY, "Gazi University Faculty of Medicine, Department of Neurosurgery, Ankara, TURKEY, "Abdurrahman Vurdatun Oncology Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY, "Gazi University Faculty of Medicine, Department of Medical Pathology, Ankara, TURKEY.

**ORAL PRESENTATIONS**
OP-0572 The rise of metabolism: Expression of pentose phosphate pathway enzymes in treatment-naïve gliomas
E. Kieblermaier1, A. Woehrter1, G. Rickert2, N. Poetsch1, S. Buccon1, A. Miller1, A. Haschen1, T. Balder3, M. Haaker1, H. Viermeister1, M. Mitterhauser1, T. Traub-Wedinger1, 1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Vienna, AUSTRIA, 3Institute of Neurology, Medical University of Vienna, Vienna, AUSTRIA, 4Department of Laboratory Medicine, Medical University of Vienna, Vienna, AUSTRIA.

OP-0573 Role of 64CuO2 in the diagnosis and in the dosimetry assessment in paediatric high-grade gliomas
F. Fiz1, M. Ugalina1, F. Ferran2, A. Cistaro3, G. Bottova4, S. Rice5, M. Mazzola1, A. Cinner6, F. Piccardo7, 1Humanitas Clinical and Research Center - IRCCS, Milan, ITALY, 2E-O “Ospedali Galliera”, Genoa, ITALY, 3A.S.I., J. Genova, ITALY.

OP-0574 Meningiomas as Incidentalomas Visualized on 18Ga-DOTATOC-PET/CT
E. Alevroudis, 1,2 K. Koczyk3, L. Królicki1, J. Kunikowska1; K. Pelka

PET/CT - preliminary experience
E. Alevroudis
DOTATOC-PET/CT
G. Kaltsas3, S. N. Chatziioannou1,2; Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA.

OP-0575 Imaging of primary glial tumor using [18Ga]Ga-PSMA-11 PET/CT - preliminary experience
K. Peika1, K. KocyziL, K. KoczykL, J. Kunikowska, 1Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, 2Department of Methodology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, POLAND, 3Department of Neurosurgery, Medical University of Warsaw, Warsaw, POLAND.

OP-0576 Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours: radionuclide therapy using 177Lu and 68Ga PSMA Therapy for Prostate Cancer
G. Gnansengaram, Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-0577 Multiple-Time-Point 2-[18F]FDG PET/CT: Adrenal Glands Normal Metabolic Pattern Characterization
I. Rodrigues1, A. Martini1, S. Carmona2, J. Veloso2, H. Novais3, A. Domenech4, 1Grupo Joaquim Chaves Saúde - Lisbon, Portugal/ Portuguese Red Cross Health School - Lisbon, Portugal, 2University Hospital Marburg, Department of Nuclear Medicine and Endocrinology, University of Marburg, Germany, 3Department of Nuclear Medicine, Rostock, GERMANY.

OP-0578 Feasibility of 3D TOF PET/CT scanning with reduced [18F]FDG activity obtaining equivalent clinical and semi-quantitative parameters
J. Pilz1, L. Hefenhauer2, G. Schweighofer-Zwink1, G. Rendl2, M. Behrens1, C. Picci1, 1Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,

OP-0579 The effect of patient's body mass indices on PET/CT images with 68Ga PSMA
Y. Parik1, D. Gokhay1, G. Gumusser1, E. Sayit1, Celal Bayar University, Manisa, TURKEY.

OP-0580 Interview with the Expert 10 - Running a Preclinical Lab in New York City
J. Lewis, Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-0581 Interview - Running a Preclinical Lab in New York City
J. Lewis, Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-0582 Interview - Running a Preclinical Lab in New York City
S. Lyashchenko, Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-0583 Interview - Running a Preclinical Lab in New York City
S. Lyashchenko; Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-0584 Image quality of [18F]FDG for patients with different body mass index
B. Olson1, E. Taggarchi1, J. Oddi2, S. Lease-Sveborg3, 1Clinical Physiology and Nuclear Medicine, Lund, SWEDEN, 2Wallenberg Center for Molecular Medicine, Lund, SWEDEN, 3Radiation Physics, Lund, SWEDEN.

OP-0585 Feasibility of Fast NaF PET/CT Study in Assessing the Effect of TOF on Image Quality and its Correlation with patient BMI using [18F]NaF PET/CT
Y. Parlak1, D. Goksoy2, G. Gumuser2, E. Sayit1, 1Department of Nuclear Medicine, London, UNITED KINGDOM, 2Department of Nuclear Medicine and Endocrinology, University of Marburg, Germany.

OP-0586 The effect of TOF on image quality and its correlation with patient BMI using 18F NaF PET/CT
Y. Parlak1, D. Goksoy2, G. Gumuser2, E. Sayit1, 1Department of Nuclear Medicine, London, UNITED KINGDOM, 2Department of Nuclear Medicine and Endocrinology, University of Marburg, Germany.

OP-0587 Feasibility of Side Effects and Complications
J. Pilz1, L. Hefenhauer2, G. Schweighofer-Zwink1, G. Rendl2, M. Behrens1, C. Picci1, 1Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,

OP-0588 Feasibility of 3D TOF PET/CT scanning with reduced [18F]FDG activity obtaining equivalent clinical and semi-quantitative parameters
J. Pilz1, L. Hefenhauer2, G. Schweighofer-Zwink1, G. Rendl2, M. Behrens1, C. Picci1, 1Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,

OP-0589 OP-0772 Mouse Handling for [18F]FDG PET Imaging: Preparing the Way for a Future Guideline
F. Ribeiro1, A. Santos2, J. Veloso2, 1Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), Department of Physics, University of Aveiro (Ex-In, UA), Aveiro, PORTUGAL, 2Institute for Clinical and Biomedical Research (ICB), Faculty of Medicine of the University of Coimbra (FMCUC), Area of Environment Genetics and Oncology (CIMAGO), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL.
Final Programme | Oral Presentations

OP-0778
The Need for Harmonisation and Standardisation in Nuclear Medicine
S. Barrington; King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

OP-0779
PET Harmonisation Beyond EARL
R. Boellaard; VU University Medical Centre, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0780
Towards Harmonisation of SPECT/CT
S. Peters; Radboud University Medical Centre, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-0781
Reproducible Radiomics Through Image Biomarker Standardisation
A. Zwanenburg; National Center for Tumor Diseases, Partner site Dresden, Dresden, GERMANY.

OP-0782
Introduction
M. Hatt; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE.

OP-0783
Modern A.I. Methods for Image Reconstruction
I. Häggström; MSKCC, Physics department, New York, UNITED STATES OF AMERICA.

OP-0784
A.I. Algorithms in Detection and Segmentation Tasks
P.-H. Conze; IMT-Atlantique, Brest, FRANCE.

OP-0786
A.I. Applied to Image Triaging and Predictive Modelling
A. Gafta; UCLA, Department of Molecular and Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA.

OP-0788
Immune Activation on PET - Beneficial or Detrimental?
C. Lasnon; François Baclesse Cancer Centre, Nuclear Medicine, Caen, FRANCE.

OP-0789
Hunting Down Immune Activation and irAEs
N. Aide; CHU de Caen, Service de Médecine Nucléaire, Caen, FRANCE.

OP-0790
Tricky Cases from Daily Routine Activity
R. J. Hicks; The Sir Peter MacCallum Cancer Center, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, AUSTRALIA.

OP-0792
Visual reading and centiloid scaling for the evaluation of brain amyloid PET imaging
E. Prieto, V. Puente, J. J. Rosales, L. Iranzo, B. Echeveste, M. Riverol, J. Arbizu; Clínica Universidad de Navarra, Pamplona, SPAIN.
OP-0797
Evaluation of partial volume correction and comparison of PET normalization methods in PET/MR myocardial viability assessment for recovery prediction of left ventricular contractility after percutaneous revascularisation of coronary chronic total occlusions
A. Villagran Asaies1, T. Vidales2, L. E. Solari1, T. Rehme1, S. G. Nikolski1
1Nuclear medicine and PET, IRCCS Fondazione Policlinico Universitario "A. Gemelli", Rome, ITALY, 2Department of Cardiology, IRCCS Policlinico San Matteo, Pavia, ITALY, 3Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY

OP-0798
Textural Analysis of 18F-FDG PET Images to Evaluate Treatment Response
X. Hu, S. Han, L. Wang1, Q. Zhu, N. Dhiences2, Q. Nie1
1Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, CHINA, 2Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA

OP-0799
Image quality assessment of low dose 68Ga DOTA-TOC PET using traditional semi-quantitative metrics, clinical assessment and radiometric feature extraction
A. McCann, C. Courmane1, E. Loughran1, A. Stone1, R. Kileten1, L. Lein Venticelli1, J. Luxey1
1St Vincent’s University Hospital, Dublin, IRELAND, 2University College Dublin, Dublin, IRELAND

OP-0800
A 3-minute semi-automated PSMA PET organ segmentation method to use in the clinic and train neural networks
G. Chaussé, J. Bailer1, N. Celpe1, L. Pshchiof1, F. Hausel1, J. Bress-Lehn1, S. Preud’homme, A. Rahmy1, C. Urb1, F. Bénard1, BC Cancer / Research Institute, Vancouver, BC, CANADA

Clinical Oncology Track - TROP Session: Local Radiooncide Therapy and Other Oncological Treatments

OP-0805
Holmium-166 radioembolization as adjuvant treatment after radiofrequency ablation of early-stage hepatocellular carcinoma up to 5 cm: a dose escalation study (HORA EST HCC trial)
P. Hendriks1, D. D. Rietbergen1, A. R. van Erkel1, M. J. Coenraad1, M. W. Wiegers1, H. C. de Vet1, J. M. Zijlstra1
1Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, 2Flemish Institute for Oncology, Radboud University Medical Centre, Nijmegen, NETHERLANDS

OP-0807
Dose-response for yttrium-90 resin microsphere radioembolization in Hepatocellular carcinoma
M. Rodríguez-Fraile1, A. Cattaneo1, J. Rosales1, J. Barceló1, F. Gravina1, M. Sanchez2, A. Martínez de la Cuesta1, M. Harmandargui, J. Bibbo1, B. Sangare1
1Clinica Universidad de Navarra, Pamplona, SPAIN, 2Universitat de València, Valencia, SPAIN

OP-0808
Suggested protocol for Y-90 PET/CT dosimetry in liver therapy with Y-90 microspheres
K. Nkwaerek
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA

OP-0809
Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor (FAPI) for Patients With Relapsed or Refractory of Various Cancers: A preliminary study
M. Assadi1, S. Rekaïpouir2, G. Dividanz1, B. Nikkhah1, H. Hmoudaeddine1, S. Jafari1, N. Shoobazad1, N. Jokari1, N. Napour1
1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Khatam PET-CT center, Khatam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Department of Nuclear Medicine, Klinikum Westend, Dortmund, GERMANY

OP-0810
Radioimmunotherapy for relapsed or refractory B cell non-Hodgkin lymphoma: 3-year follow-up of 66 patients
K. Maruyama, K. Ushumoiya1, Y. Kono1, Y. Ueno1, N. Tanigawa1, Kamak Medical University, Osaka, JAPAN

Clinical Oncology Track - TROP Session: Local Radiooncide Therapy and Other Oncological Treatments

OP-0802
A simulation study to compare cross-validation versus holdout or external testing to assess the performance of machine learning based clinical prediction rules
R. Boelaard1, J. J. Eertink1, P. J. L. Lutgenburg1, G. J. Zwanenburg1, S. E. Wiegen1, H. C. de Vet1, J. M. Zijlstra1
1Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, 2Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS

OP-0803
A novel methodology for assessing reproducibility of heterogeneity metrics in PET radiomics using noise-equivalent count rate, Monte Carlo simulation and 3D-printed patient-specific tumour phantoms
G. Needham1, P. Juyal1, D. M. Collin1, J. Tipping1, D. Hamilton1, S. Potts1, A. Fish1
1University of Manchester, Manchester, UNITED KINGDOM, 2The Christie NIHR Foundation Trust, Manchester, UNITED KINGDOM, 3National Physical Laboratory, Teddington, UNITED KINGDOM

Wednesday, October 20 - Saturday, October 23, 2021 on demand post, release on Wednesday, October 20 at 09:00

OP-0806
Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor (FAPI) for Patients With Relapsed or Refractory of Various Cancers: A preliminary study
M. Assadi1, S. Rekaïpouir2, G. Dividanz1, B. Nikkhah1, H. Hmoudaeddine1, S. Jafari1, N. Shoobazad1, N. Jokari1, N. Napour1
1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Khatam PET-CT center, Khatam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Department of Nuclear Medicine, Klinikum Westend, Dortmund, GERMANY

OP-0811
Cosmetic Outcome after Brachytherapy with Not-sealed 188Rh-n resin in Patients with Non-Melanoma Skin Cancers
L. Vetrome1, P. Castlecliff1, F. Savoia1, A. Fanna1, S. Vichi1, F. Zagni1, A. Pantelzi1, L. Stangri1, A. G. Morgante1, S. Fanti1
1Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY, 2Clinical Engineering Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 3Department of Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 4Radiation Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY

OP-0804
The first steps to fully personalized selective internal radiation therapy: intraprocedural MRI-based dosimetry of holmium-166 microspheres
J. Roosen1, M. A. Amet1, M. Janssen1, C. G. Overduin1, M. W. Konijn2, J. J. Futterer1, J. F. Nijman1
1Radboud University Medical Centre, Nijmegen, NETHERLANDS, 2Erasmus Medical Centre, Rotterdam, NETHERLANDS

OP-0803
A novel methodology for assessing reproducibility of heterogeneity metrics in PET radiomics using noise-equivalent count rate, Monte Carlo simulation and 3D-printed patient-specific tumour phantoms
G. Needham1, P. Juyal1, D. M. Collin1, J. Tipping1, D. Hamilton1, S. Potts1, A. Fish1
1University of Manchester, Manchester, UNITED KINGDOM, 2The Christie NIHR Foundation Trust, Manchester, UNITED KINGDOM, 3National Physical Laboratory, Teddington, UNITED KINGDOM

1410

Monday, October 20, 2021 - Saturday, October 23, 2021
ORAL PRESENTATIONS

OP-0822 Learning results in metabolically driven adaptations of brain connectivity
S. Klag, J. Richert, G. M. Godbersen, W. Wadauki, V. Pichler, M. Hasker, R. Langerbanger, A. Hathor; Department of Psychiatry and Psychotherapy, Medical University of Vienna, AUSTRIA, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, AUSTRIA, "Center for Biomarker Research in Medicine (CBmed), Graz, AUSTRIA, "Department of Pharmacology, University of Vienna, Vienna, AUSTRIA.

OP-0823 Relationships between different measures of brain connectivity
I. Yakushin, A. Lazanov, I. Ripp, A. Sala, W. Weber; Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY.

OP-0824 Longitudinal metabolic brain connectivity analysis after acute unilateral vestibulopathy
M. Grosch, S. Becker-Berme, M. Pietschnig, S. Ziegler, A. Zveryseg; German Center for Vertigo and Balance Disorders, LMU Hospital, Munich, GERMANY, "Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY, "Department of Neurology, LMU Hospital, Munich, GERMANY.

OP-0825 Quantification of P-glycoprotein function at the human blood-brain barrier using MRI
P. Mossel, A. T. Willemsen, L. Garcia Varela, W. Arif, R. Boellaard, P. de Deyn, A. L. Bartels, A. L. Lammertsma, A. C. Buchigop, D. de Paula Faria; "Department of Nuclear Medicine, Universidade de Sao Paulo, Sao Paulo, BRAZIL, "Department of Nuclear Medicine, University Hospital Essen and KU Leuven, Leuven, BELGIUM, "Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, "Department of Radiological Sciences, King Saud University, Riyadh, SAUDI ARABIA, "3Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS, "Department of Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS, "Department of Psychiatry, Faculty of Medicine, Medical University of Vienna, Vienna, AUSTRIA, "Centre for Biomarker Research in Medicine (CBmed), Graz, AUSTRIA, "Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Bamburgo (IBB), University of Antwerp, Antwerp, BELGIUM, "Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Bamburgo (IBB), University of Antwerp, Antwerp, BELGIUM, "Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Bamburgo (IBB), University of Antwerp, Antwerp, BELGIUM, "Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Bamburgo (IBB), University of Antwerp, Antwerp, BELGIUM.

OP-0826 First-in-human mapping of the GluN2B subunits of the N-methyl-D-aspartate receptor using (R)-[11C]ME1-N1 and PET
L. Rischka, C. Vlaar, V. Pichler, S. Ruzas, L. Niczi, G. Gryglewski, P. Handachshu, M. Murgits, G. M. Godbersen, R. J. Silverbauer, J. Unterholzer, C. Wastaw, A. Hasker, A. Hathor, N. Schilling, T. Mroczynski, M. Mitterhauser, W. Wadauki, A. Hathor, R. Langerbanger, M. Hasker, S. M. Atemetamy; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, AUSTRIA, "Department of Pharmacology, University of Vienna, Vienna, AUSTRIA, "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, AUSTRIA, "Department of Pharmacology, University of Vienna, Vienna, AUSTRIA, "Centre for Radiopharmaceutical Sciences ETH, Zurich, SWITZERLAND, "Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, "Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, "Center for Biomarker Research in Medicine (CBmed), Graz, AUSTRIA.


1413

Friday, October 22, 2021, 13:10 - 13:30

Plenary Quiz (for Plenary 4)

OP-0831 Plenary Quiz
M. Benesova; DIFK Heidelberg, Molecular Biology of Systemic Radiotherapy, Heidelberg, GERMANY, & G. Bakos; German Cancer Research Center (DKFZ), Molecular Biology of Systemic Radiotherapy (LZB), Heidelberg, GERMANY.
OP-0833
The Importance of the Isotope
J. Sosabowski
Queen Mary University of London, Barts Cancer Institute, Centre for Molecular Oncology, London, UNITED KINGDOM.

OP-0834
Clinical Applications of Alpha vs Beta
M. Ebers
Technical University Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-0835
New Isotopes on the Blocks
U. Köster
Institut Laue-Langevin (ILL), Grenoble, FRANCE.

OP-0836
Isotopes’ Availability
V. Pichler
Department of Pharmacuetical Sciences, Vienna, AUSTRIA.

OP-0837
Zr and Friends
D. Vugts
Umc Imaging Center Amsterdam Radiology & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0838
Beta Emitters for Surface Therapy
P. Castellucci
IRCSS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine Unit, Bologna, ITALY.

OP-0839
The Best has yet to Come
P. Laverme
Radboud University Nijmegen Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-0849
Nuclear Imaging of Bone Metastases
M. Zacha
University Hospital, Department of Nuclear Medicine, Aschaffenburg, GERMANY.

OP-0850
Radiocarbon Therapy of Bone Metastases
A. Alshar-Onnemann
University Hospital Innsbruck-Sappada, Department of Nuclear Medicine, Brenn, SWITZERLAND.

OP-0851
Radiation Therapy of Bone Metastases
P. Dirix
University of Antwerp, Radiation Oncology,iumd network, Antwerp, BELGIUM.

OP-0853
Multi-trials in bone metastases
S. Krebs
University Hospital Insel-Spital, Department of Nuclear Medicine, Bern, SWITZERLAND.

OP-0854
Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
A. Scott
Olivia Newton John Cancer Research Institute, Melbourne, AUSTRALIA.

OP-0855
Use of SPECT with "99mTc-1-thio-D-glucose" for the Diagnosis of Brain Tumors
R. Zelchan
A. Medvedev, O. Brigadn, A. Rubina, E. Stasyuk, V. Chemov, E. Mishina.

OP-0856
*Ga-ABY-025 PET Predicts the Metabolic Response in Breast Cancer Patients: Preliminary Results From a Phase II Study
A. Alhusen-idealhus
H. Lindman
M. Lubben
V. Iyer
P. Livi
T. Sunada
F. V. Fred;
J. Hartmatt
J. Velken.

OP-0857
Preliminary results of a pilot study with [*F]-DPA-714 PET-CT to explore Tumor-Associated-Macrophages in patients with gliobastoma
A. Scott

OP-0860
Pilot phase study of [18 F]-FP-R1-MG-F2 PET in pancreatic cancer patients
N. Nakamoto
F. Verri
D. N. Hovan
M. Giel
J. Rosenberg.

OP-0861
First results of biodistribution and tumour targeting of [89 Zr]Zr-B-Im111 in HNSCC and NSCLC patients progressing on previous anti-PD-1 treatment
I. C. Miedema
M. C. Nisson
G. J. Zwiezen
A. Theile
R. Gremplier
A. P. Patrice
D. J. Vugt;
T. D. de Graaf
C. W. Menke-van der Heuven van Oord.

1. Amsterdam UMC, location VUMc, Amsterdam, NETHERLANDS.
2. Boehringer Ingelheim, Ingelheim am Rhein, GERMANY.

OP-0862
PSMA-PET/CT and additional PET/CT using [F-18]sIPSM-A14: Improvement in local tumour detection in prostate cancer patients with biochemical recurrence after radical prostatectomy and prior to salvage therapy
J. Miksch
F. Funke
W. P. Thoss
J. P. Stensaker
M. Grunert
D. Di Carlo
F. Zengeling
C. Sillaich
M. Beir
T. Wiegel
V. Pazad
H. J. Wester
J. A. Beck.

OP-0863
Pilot phase of the anti-LAG-3 tracer [89 Zr]Zr-B-Im111 in HNSCC and NSCLC patients progressing on previous anti-PD-1 treatment
I. C. Miedema
M. C. Nisson
G. J. Zwiezen
A. Theile
R. Gremplier
A. P. Patrice
D. J. Vugt;
T. D. de Graaf
C. W. Menke-van der Heuven van Oord.

1. Amsterdam UMC, location VUMc, Amsterdam, NETHERLANDS.
2. Boehringer Ingelheim, Ingelheim am Rhein, GERMANY.
OP-0862
First clinical experience with 2-18F-DF-IB22M2C PET/MRI in patients with metastatic cancer
1Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tübingen, GERMANY, 2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, GERMANY, 3Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Radiopharmacy, Eberhard Karls University, Tübingen, GERMANY, 4Department of Nuclear Medicine, University Hospital Zürich, Zürich, SWITZERLAND, 5ImaginAb, Inc, Inglewood, CA, UNITED STATES OF AMERICA.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0876
Hybrid Imaging in Nuclear Medicine - Results from the MEDIRAD Project
K. Bachner; Ghent University, Division of Medical Physics, Ghent, BELGIUM.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0886
Optimization of reconstruction parameters of a block sequential regularized expectation maximization algorithm for 18F-DG-CT/CT (PET/CT) studies
T. Christensen; A. L. Nielsen1, M. H. Vilstrup1, P. Braad3.
1Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0868
Digital Human Phantoms for Dosimetry in Nuclear Medicine Imaging and Therapy - Historical Development and Recent Advances
W. Böck; University of Florida, Advanced Laboratory for Radiation Dosimetry Studies, Gainesville, UNITED STATES OF AMERICA.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0845
Radiation Detectors - Which is the Right One for the Task?
A. Mackenzie; University College London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0869
The Use of Computer Phantoms in Nuclear Medicine Imaging
K. Görgen Gleisner; Lund University, Department of Medical Radiation Physics, Lund, SWEDEN.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0870
Computing Models for Dosimetry, and Beyond
M. Barid; U1194 INSERM/ICM/Montpellier University, Cancer Research Institute of Montpellier, Montpellier, FRANCE.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0847
What and When to Measure? Establishing Standard Operating Procedures
T. Kramarova; University Hospital Motol, Nuclear medicine, Prague, CZECH REPUBLIC

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0885
BSREM for Brain Metastases Detection with [18F]FDG PET/CT in Lung Cancer Patients
1Aarhus University Hospital, Aarhus, DENMARK, 2Siemens Medical Solutions USA, Hoffman Estate, IL, UNITED STATES OF AMERICA, 3University College London Hospitals, Institute of Cancer Research, Sutton, UNITED KINGDOM, 4Department of Nuclear Medicine, University Hospital Zürich, Zürich, SWITZERLAND, 5Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, SWITZERLAND, 6Department of Thoracic Surgery, University Hospital Zürich, Zurich, SWITZERLAND, 7University Hospital Zurich, University Hospital Zürich, Zurich, SWITZERLAND.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0873
Introduction - The MEDIRAD Project
G. Flax; Royal Marsden Hospital and Institute of Cancer Research, Radioisotope Physics, Sutton, UNITED KINGDOM.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0874
Multi-Centre Clinical Trials Involving Dosimetry of Radioidine Treatment for Thyroid Cancer
J. Taprogge; Royal Marsden Hospital and Institute of Cancer Research, Radioisotope Physics, Sutton, UNITED KINGDOM.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0882
Developments in PET Reconstructions and Corrections
B. Hutton; University College London (UCL), Institute of Nuclear Medicine, London, UNITED KINGDOM.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0887
Improvement of myocardial perfusion images with data-driven correction of motion and respiration: Comparison between retrospective and prospective gating methods
K. Nakajima1, T. Shibata1, F. Matsuura1, H. A. Vija1, T. Shima2, S. Yoshida1, H. Yoneyama1, M. Onoguchi1, S. Kinuya1.
1Kanazawa University, Kanazawa, JAPAN, 2Siemens Medical Solutions USA, Hoffman Estate, IL, UNITED STATES OF AMERICA.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0883
Optimization of reconstruction parameters of a block sequential regularized expectation maximization algorithm for 18F-DG-CT/CT (PET/CT) studies
T. Christensen; A. L. Nielsen1, M. H. Vilstrup1, P. Braad3.
1Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0884
Optimization of Q.Clear β Penalization Factor for Dynamic PET Imaging
E. Lyovik; L. G. Mikkelsen1,2, T. Hjemdahl2.
1Oslo University Hospital, Oslo, NORWAY, 2Oslo Metropolitan University, Oslo, NORWAY.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0888
Optimization of reconstruction parameters of a block sequential regularized expectation maximization algorithm for 18F-DG-CT/CT (PET/CT) studies
T. Christensen; A. L. Nielsen1, M. H. Vilstrup1, P. Braad3.
1Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0846
The Importance of Quality Control and Instrumentation Performance
R. Freudenberg; Universitätsklinikum Dresden, Klinik und Poliklinik für Nuklearmedizin, Dresden, GERMANY.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0855
DNA Damage and Repair during Radioiodine Therapy within the MEDIRAD Project
U. Eberlein; University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0843
Safety in the Hybrid PET/MRI System
M. Federri2; Copenhagen University Hospital, Rigshospitalet, Dept. of Nuclear Medicine & PET, Copenhagen, DENMARK.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0842
Safety in Magnetic Resonance Imaging
V. Silva; Centro Hospitalar Universitário São João, Magnetic Resonance Department, Porto, PORTUGAL.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

Mini Course 1: Safety in PET/MRI

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

OP-0841
Magnetic Resonance Department, Porto, PORTUGAL.

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

Joint Symposium 22 (EANM/EURAMED): The MEDIRAD Project - Impact on Nuclear Medicine Practice

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

Joint Symposium 21 (EANM/AAPM): Numerical and Computer Phantoms

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

Teaching Session 5: Radiation Detection and Measurement

Wednesday, October 20 - Saturday, October 23, 2021
on demand pool, release on Wednesday, October 20 at 09:00

Final Programme | Oral Presentations | Final Programme

Wednesday, October 20 - Saturday, October 23, 2021
OP-0888
Regularized Reconstruction in Combination with Quiescent Phase Respiration Gating on a Time-of-Flight PET/MRI Scanner for "FE-FDG Examinations in Patients with Esophageal Cancer"
N. Kasavandou Hult, S. Kremy, J. Hedberg, G. Linde, H. Ahlström, T. Bjerner, M. Lubbern; Upsalla University, Upsalla, SWEDEN.

OP-0889
Prostate cancer imaging with PSMA PET/MRI: The effects of data-driven bulk patient motion and its compensation

OP-0890
Zero-TE vs 2-point Dixon MRI-based Attenuation Correction for Chest FDG PET/MRI with Deep Learning: Comparison of Quantitative Values on Pseudo CT and Reconstructed PET data
M. Nogami, H. Matsuo, M. Nishio, M. Tachibana, J. Inukai, F. Nogami; Kobe University Hospital, Kobe, Hyogo, JAPAN.

OP-0891
Influence of Spatial Resolution and SNR of Attenuation Correction Maps on Breast PET images in a Fully Hybrid PET/MRI system
I. Neri, M. Emerici, C. Canavan, A. Savin, V. Bettinardi, C. Losio, S. Savi, V. Bettinardi, C. Losio; Fondazione IRCCS Ca’ Granda-Ospedale Sacco, University of Milan, Milan, ITALY.

OP-0892
A concept for quality assurance of PET/MRI attenuation correction with B-maps
E. Wallstén, J. A. Lundman, M. Bylund, M. Alpeshwad, A. Larsson, T. Nyholm; Umeå University, Umeå, Sweden.

OP-0893
Minimally Invasive Robot-Assisted PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer Using DROP-IN Radioguidance - A Prospective Feasibility Study
H. de Barros, M. N. van Oosterom, I. Neri, M. Emendi, C. Canevari, A. Savi, V. Bettinardi, C. Losio; Fondazione IRCCS Ca’ Granda-Ospedale Sacco, University of Milan, Milan, ITALY.

OP-0894
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIPE: an international multicenter study

OP-0895
Clinical Oncology Track - Featured Session: Prostate Cancer Therapy

OP-0896
A concept for quality assurance of PET/MRI attenuation correction with B-maps
E. Wallstén, J. A. Lundman, M. Bylund, M. Alpeshwad, A. Larsson, T. Nyholm; Umeå University, Umeå, Sweden.

OP-0897
The prognostic role of inflammatory indices from peripheral blood and clinical factors in metastatic castration resistant prostate cancer (mCRPC) patients treated with Radium-223 (Bio-Ra-223 study)
M. Donegani, S. E. Rebuzzi, M. Porazzano, M. Bauckneht, V. Franzelli, L. Raduzzi, M. Mosconi, L. Rezelli, A. Gaudano, M. L. Stozar, M. Luciani, V. Mora, A. Signori, L. Cavallone, V. Laughi, L. Cindolo, R. P. Costa, A. Spanu, G. Rubini, F. Monari, G. De Vincentiis, G. Ferrani; Department of Health Sciences (DISCSAL), University of Genoa, Genoa, ITALY, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, ITALY, Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapireza University of Rome, Rome, ITALY, Radiation Oncology, IRCCS Ospedale Aristoteliano-Umberto I, Bologna, Bologna, ITALY, Unit of Nuclear Medicine, Spinto Santo Hospital, Pescara, ITALY, Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, ITALY, Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, ITALY, Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, ITALY, Department of Experimental Diagnostic and Specialty Medicine-Alma Mater Studiorum Bologna University, Bologna, ITALY, Department of Surgery, Villa Stuart Private Hospital, Rome, ITALY.

OP-0898
Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer

OP-0899
Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 radioligand therapy
F. Khreish, M. Wiesner, F. Rosar, Z. Ghassas, A. Sabet, S. Mau, J. R. Frentzel, M. Bartholomä, S. Emminen; University Hospital Bonn, Bonn, GERMANY.

OP-0900
Tumor-to-liver ratio (TLR) by 18F-PSMA-11 PET/CT for response assessment and prediction of progression-free survival in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy
F. Khreish, M. Wiesner, F. Rosar, Z. Ghassas, A. Sabet, S. Mau, J. R. Frentzel, M. Bartholomä, S. Emminen; University Hospital Bonn, Bonn, GERMANY.

OP-0901
F. Rosar, J. Krause, M. Bartholomä, S. Mau, T. Stemler, I. Herrmann, J. Lüderswerth, S. Emminen, F. Khreish; Department of Nuclear Medicine, Saarland University, Hospital, Homburg, GERMANY, 11Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, 11Bayer AG, Berlin, GERMANY.

OP-0902
PSMA-targeted photodynamic therapy in surgical prostate tumor samples
Y. Derks, M. Schils, S. van Lith, M. Seelaar, D. Somford, M. Gootard; Martini-Klinik Prostate Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.

OP-0903
The prognostic role of inflammatory indices from peripheral blood and clinical factors in metastatic castration resistant prostate cancer (mCRPC) patients treated with Radium-223 (Bio-Ra-223 study)
M. Donegani, S. E. Rebuzzi, M. Porazzano, M. Bauckneht, V. Franzelli, L. Raduzzi, M. Mosconi, L. Rezelli, A. Gaudano, M. L. Stozar, M. Luciani, V. Mora, A. Signori, L. Cavallone, V. Laughi, L. Cindolo, R. P. Costa, A. Spanu, G. Rubini, F. Monari, G. De Vincentiis, G. Ferrani; Department of Health Sciences (DISCSAL), University of Genoa, Genoa, ITALY, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, ITALY, Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapireza University of Rome, Rome, ITALY, Radiation Oncology, IRCCS Ospedale Aristoteliano-Umberto I, Bologna, Bologna, ITALY, Unit of Nuclear Medicine, Spinto Santo Hospital, Pescara, ITALY, Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, ITALY, Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, ITALY, Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, ITALY, Department of Experimental Diagnostic and Specialty Medicine-Alma Mater Studiorum Bologna University, Bologna, ITALY, Department of Surgery, Villa Stuart Private Hospital, Rome, ITALY.

OP-0908
Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer

OP-0909
Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 radioligand therapy
F. Khreish, M. Wiesner, F. Rosar, Z. Ghassas, A. Sabet, S. Mau, J. R. Frentzel, M. Bartholomä, S. Emminen; University Hospital Bonn, Bonn, GERMANY.

OP-0910
Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 radioligand therapy
F. Khreish, M. Wiesner, F. Rosar, Z. Ghassas, A. Sabet, S. Mau, J. R. Frentzel, M. Bartholomä, S. Emminen; University Hospital Bonn, Bonn, GERMANY.

OP-0911
F. Rosar, J. Krause, M. Bartholomä, S. Mau, T. Stemler, I. Herrmann, J. Lüderswerth, S. Emminen, F. Khreish; Department of Nuclear Medicine, Saarland University, Hospital, Homburg, GERMANY, 11Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, 11Bayer AG, Berlin, GERMANY.

OP-0902
PSMA-targeted photodynamic therapy in surgical prostate tumor samples
Y. Derks, M. Schils, S. van Lith, M. Seelaar, D. Somford, M. Gootard; Martini-Klinik Prostate Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.
**OP-0903**
Factors that could predict tumour sink effect: Experience with Lu177 Prostaspecimen specific membrane antigen therapy
M. Tunçel1, T. Tavl1, M. Tunçalı1, E. Karabulut1; 1Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY; 2Hacettepe University, Department of Biostatistics, Ankara, TURKEY.

**OP-0904**
Tumor regression and response of local tumor in mCRPC patients after two cycles of [177 Lu]Lu-PSMA-617
F. Khreish, F. Flach, M. Bartholomä, S. Maus, S. Ezziddin, F. Rosar; 1University Hospital Münster, Münster, GERMANY.

**OP-0905**
18 F-DOPA PET imaging in pediatric brain tumors: OP-0908
W. ROLL, P. SCHINDLER, M. MASTHOFF, R. SEIFERT, M. BÖGEMANN, M. FOSBØL, L. L. HJALGRIM, A. K. BERTELSEN, L. BORGWART; 1University Hospital Münster, Münster, GERMANY.

**OP-0906**
Pretreated Population with mCRPC; Experience from Efficacy and Safety of Lu-177 PSMA in Heavily Pretreated Population with mCRPC: Experience from 18 F-FDG PET/CT within the paediatric population for stratification and prognostication of brain gliomas
F. Khreish, F. Flach, M. Bartholomä, S. Maus, S. Ezziddin, M. Fosbøl, L. L. Hjalgrim, A. K. Berthelsen, L. Borgwardt; 1University Hospital Münster, Münster, GERMANY.

**OP-0912**
Role of 18F FDG PET/CT in Pediatric Malign Melanoma
E. İsk, S. Kuyumcu, D. Has Şimşec, S. Büyükakapı Bay, R. Kebrudi, S. N. Ünald; 1Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TURKEY; 2Istanbul University Oncology Institute, Department of Pediatric Hematology-Oncology, Istanbul, TURKEY.

**OP-0913**
Evaluating the Diagnostic Utility of 68Ga-DOTA-TOC-PET/CT and 18F-FDG PET/CT in High-Risk Neuroblastoma Patients Compared to the standard Modalities (123I-MIBG, Bone Scans and CT)

**OP-0914**
Evaluation of Physiological Thymic, Splenic and Hepatic Activity with 18F-FDG PET/CT: Evaluation of Normal Range among Pediatric Patients
G. April, K. Lambert, S. Tjurin; CHU Ste-Justine, Montreal, QC, CANADA.

**OP-0915**
Weight based optimization of administered activity for [18 F]FDG PET/CT in paediatric patients
C. C. Cox, D. M. van Aswegen, F. A. Wiltshire, F. Brabant, M. Konijnenberg, M. Seygers; Erasmus MC, Rotterdam, NETHERLANDS.

**OP-0916**
Evaluation of semi-quantitative scoring systems for metaiodobenzylguanidine (mIBG) scans in patients with stage 4 neuroblastoma: A single-center experience
M. Tunçel, M. E. Max, P. O. Kreutz; Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY.

**OP-0917**
[18 F]metafluorobenzylguanidine (MFBG) PET-CT vs. [18 F]metaiodobenzylguanidine (MIBG) imaging in neuroblastoma patients
A. Samim1, G. A. Tytgat1, T. Blom1, A. J. Roat1, N. Talaboon1, A. J. Roost1, M. M. van Noesel1, G. A. Tytgat1, B. de Keizer1; 1Erasmus MC, Rotterdam, NETHERLANDS; 2University Medical Centre Utrecht, Utrecht, NETHERLANDS.

**OP-0918**
Evaluation of semi-quantitative scoring systems for [18 F]FDG PET/CT in paediatric patients
C. Decristoforo, G. A. Tytgat, T. Blom, A. J. Roost, M. M. van Noesel, G. A. Tytgat, B. de Keizer; 1Erasmus MC, Rotterdam, NETHERLANDS; 2University Medical Centre Utrecht, Utrecht, NETHERLANDS.

**OP-0919**
[18 F]FDG PET/CT in pediatric brain tumors: clinical applications and radiation safety profile
M. Pizzoferrro1, C. Poltar1, M. Gai1, S. Soltani1, C. Alirei1, M. F. Villari1, E. Cavascani1, A. Napoli1, G. Curti1, F. Martire1, S. Donatiello1, S. Colalatti1, V. Caninnati1, A. Cacchione1, M. A. de Lena1, A. Mastronuzzi1, M. C. Garagna1; 1IRCCS Bambino Gesù Children’s Hospital, Nuclear Medicine Unit/Imaging Department, Rome, ITALY; 2IRCCS Bambino Gesù Children’s Hospital, Physics Unit, Rome, ITALY; 3IRCCS Bambino Gesù Children’s Hospital, Department of Oncohematology, Rome, ITALY; 4Private Hospital Po Xi, Nuclear Medicine Unit/Imaging Department, Rome, ITALY; 5IRCCS Bambino Gesù Children’s Hospital, Neuroradiology Unit/Imaging Department, Rome, ITALY.
ORAL PRESENTATIONS

ORAL PRESENTATIONS

EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

OP-0933 Skin Contamination Dose on the Fingers
P. Covenys; Vrije Universiteit Brussels, Department of Radiation Protection, Brussels, BELGIUM

OP-0934 Technologist’s Experience
A. Geão; Hospital C.F. Ordescentias, Nuclear Medicine Department, Lisbon, PORTUGAL

OP-0879 Animal models for the evaluation of radiopharmaceuticals
M. Toussaint; Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical-Cancer Research in the Helmholtz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.

OP-0880 How to avoid errors in translation?
T. Balber; Ludwig Boltzmann Institute Applied Diagnostics, Applied Translational Research, Vienna, AUSTRIA.

1706
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool; release on Wednesday, October 20 at 09:00

Joint Symposium 24 (EANM/ESMO): Neuroradiology in Thyroid Cancer Beyond Radioactive Iodine

OP-0936 Molecular Basis of Differentiated Thyroid Cancer
S. Leboulleux; Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, FRANCE.
C. Baun; OP-0878

OP-0937 New Targets for Thyroid Cancer in Pre-Clinical Research
C. D’Alessandria; Head of Radiopharmacy, Nuclear Medicine Department, Klinikum rechts der Isar of Technical University of Munich, Munich, GERMANY.

OP-0938 PSMA in Thyroid Cancer
M. Solimini; Humanitas University, Nuclear Medicine Division, Milan, ITALY

OP-0939 PRRT and Alpha Emitters in Thyroid Cancer
D. Deandreas; Director of Nuclear Medicine Division, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza, Turin, ITALY

1707
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool; release on Wednesday, October 20 at 09:00

Teaching Session 6: Animal Models - Technical Considerations and Recommendations

OP-0878 Animal models: general aspects
C. Baum; Department of Nuclear Medicine, The Preclinical Imaging Facility, Odense University Hospital, Odense, DENMARK

OP-0941 Deep learning for predicting Gamma-Ray Interaction Positions in LSYS Detector

1OP-0942 Monte Carlo-based assessment of a deep learning-based method for acceleration of SPECT imaging by generating synthetic projections
J. Leube, M. Salas-Ramirez, M. Lassmann, J. Gustafsson, J. Tran-Gia.

1OP-0943 Deep learning-based time-of-flight (TOF) PET image enhancement of non-TOF PET/CT scans

1OP-0944 Whole body non-rigid PET/CT alignment using synthetic CT generation from non-attenuation corrected 18F-FDG PET images with a 3D CycleGAN
S. Khouchi, C. A. von Goetz, M. Reyman1,3, L. Sobierl, B. Spatteswode2, P. Ritt, T. Kuevet1, V. Shah1,1,2, A. Erfanbeg, Erlangen, GERMANY; Siemens Medical Solutions USA, Inc, Knoxville, TN; UNITED STATES OF AMERICA; 1Siemens Healthcare GmbH, Erlangen, GERMANY; Siemens, GERMANY; 3Clinical of Nuclear Medicine University Hospital Erlangen, Erlangen, GERMANY.

1OP-0945 The clinical performance of artificial intelligence based PET denoising on a digital PET/CT
K. Wegs1, C. Leson, B. Crippacce, J. Lecureux, E. Ouar2, A. Comoy, D. Deandreas, B. Classen, L. Roussel, S. Bardet, C. Jauffret; Centre Francs Baclesse, Caen, FRANCE.

1OP-0946 Sparse deep-learning: Multi-organ objective segmentation (MOOSE) for 18F-FDG PET/CT total body datasets
L. Shiyam Sundar, G. Kulture, B. Fueger, T. Nakuzi, D. Kishik, M. Hacker, T. Beyer, Medical University of Vienna, Vienna, AUSTRIA.

1OP-0947 Evaluation of a Deep Learning Skeleton Segmentation Method to Aid in the Identification of PSA-positive Bone Lesions
V. Gopakalrishman, P. Saracou, K. Dang, C. Halliy, M. Bending, A. Kizner, A. S. Nelson, MIM Software, Beachwood, OH, UNITED STATES OF AMERICA.

1OP-0948 Automated analysis of total tumour burden on Ga-68 PSMA PET/CT using convolutional neural network and novel watershed filtering
L. McIntosh1,2, J. P. Rau1,2,3, U. B. Shekhar1,2,3, Y. Jaja1,2, A. Nastius1,3, A. F. Anduran1,2,3, V. Rangaswany1,2,3, A. Dekker1,2,3, J. Weer1, Department of Radiation Oncology (Maizstra), GRW School for Oncology, Maastricht University Medical Centre, Maastricht, NETHERLANDS, Tata Memorial Hospital, Mumbai, INDIA; 4Helmholtz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.

1OP-0949 Comparison of Deep Learning-Based Glioma Segmentation Using 18F-FET PET Data With Clinically Established Threshold Methods
B. Kotsulski, A. Holagreve, J. Brosch-Lenz, A. Goewerch, G. Binner, B. Hartenstein, N. L. Albert, S. Ziegler, L. Kaiser, Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

1OP-0950 Automatic lesion detection and segmentation in PSMA PET/CT images using deep neural networks
Y. Xu1,2,3, S. Harasz1,2, A. Orlic, A. Rahmim1,2, J. Lavista1,2,3; Microsoft AI for Good Research Lab, Redmond, WA, UNITED STATES OF AMERICA; 2BC Cancer Research Institute, Vancouver, BC, CANADA; 3University of British Columbia, Vancouver, BC, CANADA.

1OP-0951 Development of a Deep Learning Natural Language Processing Model for Classification of Lung Cancer Radiology Reports
S. Mithun1,2,3, A. K. Jha1,2,3, U. B. Shekhar1,2,3, Y. Jaja1,2, A. Nastius1,3, A. F. Anduran1,2,3, V. Rangaswany1,2,3, A. Dekker1,2,3, J. Weer1, Department of Radiation Oncology (Maizstra), GRW School for Oncology, Maastricht University Medical Centre, Maastricht, NETHERLANDS, Tata Memorial Hospital, Mumbai, INDIA; 4Helmholtz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.

1OP-0952 18F-FDG dynamic brain PET study estimating the arterial plasma radioactivity curve using a convolutional neural network (CNN)
K. Kawachi, C. Karth, Hokkaido University, Sapporo, JAPAN.

1710
Wednesday, October 20 - Saturday, October 23, 2021
on-demand pool; release on Wednesday, October 20 at 09:00

Clinical Oncology Track - Featured Session: Neuroendocrine Therapy

OP-0954 What is coming after NETTER-1
V. Prasad; Department of Nuclear Medicine, Urmankiv Ulm, Ulm, GERMANY.
OP-0955 Comparison Between Standard and Intensive Radiolucide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumors: Preliminary Results from a Randomized Phase II Study

I. Grassi1, M. Monti2, S. Nicolini1, M. Sansavini1, F. Foa1, M. Caraciolo1, A. Conada1, L. Fabbi1, V. Vaiani1, S. Severi1, G. Pagnanelli1
1. Nuclear medicine department IRST “Dino Amadori” IRCCS Meldola, Meldola Fc, ITALY; 2. Unit of Biostatistics and Clinical Trials IRST “Dino Amadori” IRCCS Meldola, Meldola Fc, ITALY; 3. Nuclear medicine unit, University of Ferrara, Ferrara, ITALY; 4. Unit of Biostatistics and Clinical Trials IRST “Dino Amadori” IRCCS Meldola, Meldola Fc, ITALY; 5. Osteoncology and Rare Tumors Center IRST “Dino Amadori” (IRST), IRCCS Meldola, Meldola Fc, ITALY.

OP-0956 A Phase II/II Clinical Trial for High-dose 111In-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Single Myeloablative Chemotherapy and Hemopoietic Stem Cell Transplantation

H. Wakabayashi1, R. Kazuda1, R. Aoki1, I. Miura1, R. Ishimura2, Y. Kawar1, K. Yoshimura1, T. Murayama1, Y. Imai1, T. Funasaka1, T. Wada1, S. Kinuya1
1. Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN; 2. Department of Pediatrics, Kanazawa University Hospital, Kanazawa, JAPAN; 3. Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, JAPAN; 4. Department of Clinical Development, Kanazawa University Hospital, Kanazawa, JAPAN; 5. Innovative Clinical Research Center, Kanazawa University, Kanazawa, JAPAN.

OP-0957 Health-related quality of life during and the years after peptide receptor radiolucide therapy in patients with neuroendocrine tumors

C. Andersson1, P. Heilman1, D. Grothberg1, P. Lagergren1, E. This-Evenmann1, A. Ekedahl1
1. Dept of Surgical Sciences, Uppsala University, Uppsala, SWEDEN; 2. Dept of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, SWEDEN; 3. Dept of Gastronomyt, Oslo University Hospital, Oslo, NORWAY.

OP-0958 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN): PRRT in the Treatment of Neuroendocrine Tumor (NET) Patients

S. Dureja1, T. Kolarova2, M. McDonnell3, D. Van Genechten4, C. S. Dureja
1. University of Toronto, Toronto, ON, CANADA; 2. Department of Life Sciences and Research Center, University of Florence, Florence, ITALY; 3. Medical Physics, Uppsala University, Uppsala, SWEDEN; 4. Medical Physics, Uppsala, SWEDEN.

OP-0959 Lutetium 177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registry

M. Nitajvila Casanovas2, P. Bilinski1, V. Palkul1, A. Garcia1, J. Arbuau1, T. Navarro1, D. Marr1, C. Duran1, C. Field1, B. Llorens1, B. Miguel1, M. Esterch1, J. Hernandez1, A. Custodio1, A. Repetto1, J. Venero-Carone1, A. Munoz1, J. Cano1, E. Caballero1, P. Garcia1, C. Blanca1, J. Aller1, A. Carmona1, P. Jimenez-Fonseca1

OP-0960 Peptide Receptor Radionuclide Therapy (PRRT) as neoadjuvant therapy in neuroendocrine tumors - one center experience

M. Opalinski1, A. Sowa-Statczak1, A. Gromackiewicz1, H. Zwinziewicz1, A. Hubalewska-Dydejczyk1
1. Nuclear Medicine Unit, Endocrinology Department, University Hospital Krakow, Krakow, POLAND; 2. Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

OP-0961 Effects of simplifications of absorbed dose calculation to the kidneys in later therapy sessions in patients with neuroendocrine tumours receiving 177Lu-Octreotide therapy

M. Sandstrom1, M. Lubeck2, K. Foss-Baron1, A. Garske-Roman1, A. Sundin1
1. Nuclear medicine & PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN; 2. Medical Physics, Uppsala, SWEDEN.

OP-0962 Treatment of metastatic paragangliomas with 177Lu-DOTATATE: outcomes from a single centre experience

I. Trivella1, S. F. Costa1, C. Costa1, J. Oliveira, H. Duarte1, I. L. Sampayo1, G. Ferreira1
1. Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-0963 Prospective evaluation of glucose metabolism variations assessed with FDG PET/CT in a cohort of NET patients treated with PRRT

L. Urban1, S. Panareo1, A. Castello1, M. Caracciolo1, J. Zambelich1, N. Ortolan1, A. Niem1, T. Connelly1, A. Carmona1, P. Garcia1, C. Blanco1, J. Aller1, A. Carmona1, P. Jimenez-Fonseca1

OP-0964 Predictive factors of adverse events onset in GEPNET patients treated with PRRT

F. Scalabrini1, S. Argonelli1, A. Loarenci1, M. Boricci1, S. Gandin1, V. Fusco1, N. Pira1, E. Piccaldu1, G. Calareso1, E. M. Garanzini1, S. Mazzaglia1, M. Milone1, C. Chiesa1, E. Seregni1, M. Maccauro1, F. Scalabrini1
OP-0971 Dose Reduced [18F]PSMA-1007 PET is Feasible for Functional Imaging of the Renal Cortex
K. Valderrama1, E. Bosim1, I. Jogy2, D. Minami1, E. Trigárdh1;
1Wallenberg Centre for Molecular Medicine, Lund University, Lund, SWEDEN; 2Clinical Physiology and Nuclear Medicine, Södertörn University Hospital, Lund and Malmo, SWEDEN; *Radiation Physics, Södertörn University Hospital, Lund and Malmo, SWEDEN.

OP-0972 Evaluation of Dynamic Renal ⁶⁸Ga-DOTA-PE2CIT to Monitor the Urinary Efflux and to Estimate the Glomerular Filtration Rate Using a Compartmental Kinetic Modelling Approach
K. Kersing1, M. Sraieb1, R. Seifert1, P. Fragoso Costa1, S. Kazek1, D. Kersting1;
1Department of Nuclear Medicine, University Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

OP-0973 Pulmonary embolism - a diagnostic dilemma with perfusion only SPECT/CT during the COVID-19 pandemic
T. Bessoin1, V. Habouzit1, M. Castan2, A. Viallon2, L. Bertoletti3, N. Prévôt-Bitot1, P. Bonnefoy1;
1Department of Nuclear Medicine, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 2Emergency department, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 3Radiation Oncology, Lausanne University Hospital, Lausanne, SWITZERLAND.

OP-0974 Contribution of Ventilation/Perfusion SPECT/CT in alternative diagnosis for pulmonary embolism suspicion
L. Bessoin1, V. Habouzit1, M. Castan2, A. Viallon2, L. Bertoletti3, N. Prévôt-Bitot1, P. Bonnefoy1;
1Department of Nuclear Medicine, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 2Emergency department, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, FRANCE, 3Radiation Oncology, Lausanne University Hospital, Lausanne, SWITZERLAND.

OP-0975 Diagnosis of pulmonary embolism during COVID-19 pandemic: comparison of perfusion SPECT/CT to CTPA
J. C. Ferro1, S. Carmana2, R. T. Ferrero2, A. I. Santos;
1Hospital Génica de Ota, E.P.E., Almada, PORTUGAL.

OP-0976 Pre-surgical Prognostic Assessment by Methrofenin ⁹⁹mTc Scintigraphy in Patients Undergoing Resective Liver Surgery
J. Uha1, J. Valderrey-Pulido2, A. Allenre Rivero3, C. Cárdenas Negro3; Servicio Canario Salud, Santa Cruz de Tenerife, SPAIN.

OP-0977 Quantitative approaches to selective spleen detection in Technetium-99m-labelled denatured red blood cells scintigraphy - a quantitative single centre analysis
A. Holzgreve1, F. Voiter1, A. Gerschwen1, M. P. Fabritius1, M. Brendel1, N. L. Albert1, J. Jögi1,2; 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 2Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY.

OP-0978 Colorectal scintigraphy and abdominal ultrasound to assess bowel peristalsis during transanal irrigation in spinal cord injury patients: preliminary results
G. Rubin1, A. Bisnar1, G. Frass1, R. Gnoj1; 1Department of Nuclear Medicine and Organ Transplantation, University of Baden, Baden, GERMANY.

OP-0979 Clinical usefulness of ⁹⁹mTc-labelled heat-denatured red blood cell SPECT/CT in the investigation of suspected ectopic splenic tissue
S. Georga1, K. Gkatsikas1, G. Kalogias1, D. Katsampoukas1, G. Arsos1, S. Georga1, K. Gkatsikas1, G. Kalogias1, D. Katsampoukas1, G. Arsos1; 1Section of Nuclear Medicine, DMM, University “Aldo Moro”, Bari, ITALY; 2Physical and Medical Rehabilitation Department of Basic Science, Neuroscience and Sense Organs, University “Aldo Moro”, Bari, ITALY, 3Department of Emergency and Vascular Medicine, University of Bari, Bari, ITALY.

OP-0980 Immunotherapy and Nuclear Medicine diagnostics - Where do we Stand?
E. G. E. de Vries1,2; 1University Medical Center Groningen (UMCG), Department of Medical Oncology, Groningen, NETHERLANDS; 2Radiation Oncology, Amsterdam University Medical Centers, Department of Radiotherapy & Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0981 Interview with the Expert 13 - The Patient views the Doctor – A Roman Conversation
Saturday, October 23, 2021, 09:00 - 10:30
Channel 2

OP-0982 Immunotherapy and Nuclear Medicine diagnostics - Synergisms and Antagonisms
N. Schaefer1,2; 1Centre Hospitalier Universitaire Vaudois (CHUV), Department of Nuclear Medicine and Molecular Imaging, Lausanne, SWITZERLAND, 2Department of Nuclear Medicine, Amsterdam University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0983 Combining Immunootherapy and Radiation - Is the Whole more than the Sum of its Parts?
F. Herrera1; 1Centre Hospitalier Universitaire Vaudois (CHUV), Department of Oncology, Division of Radiation Oncology, Lausanne, SWITZERLAND.

OP-0984 Nuclear Medicine Immunotheranostics - Synergisms and Antagonisms
N. Schaefer1,2; 1Centre Hospitalier Universitaire Vaudois (CHUV), Department of Nuclear Medicine and Molecular Imaging, Lausanne, SWITZERLAND, 2Department of Nuclear Medicine, Amsterdam University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-0985 Interview - The Patient interviews the Doctor – A Roman Conversation
Saturday, October 23, 2021, 09:00 - 09:45
Channel 2

OP-0986 Interview - The Patient interviews the Doctor – A Roman Conversation
Saturday, October 23, 2021, 09:45 - 10:30
Channel 2

OP-0987 Interview - The Patient interviews the Doctor – A Roman Conversation
Patient, Rome, ITALY.

OP-0988 Interview - Prostate Cancer Imaging – Girls Just Want to Have Fun(cional) E-PSMA Guidelines
Saturday, October 23, 2021, 09:00 - 10:30
Channel 1

OP-0989 Interview - Prostate Cancer Imaging – Girls Just Want to Have Fun(cional) E-PSMA Guidelines
Saturday, October 23, 2021, 09:45 - 10:30
Channel 2

OP-0990 Costs of Over - Diagnosis, Treatment and Follow-up of DTC Patients. How to Get Out of a “Vicious Circle”?
T. Gellashvili1, N.N. Blinok National Medical Research Center of Oncology (N.N. Blinok NMRRC), Department of radionuclide therapy department, Moscow, RUSSIA.

OP-0991 Is Active Surveillance of Micro-Differentiated Thyroid Carcinoma Really Cheaper than Surgical Approach? M. Raffaelli1, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Division of Endocrine and Metabolic Surgery, Department of Medical and Surgical Sciences, Rome, ITALY.

OP-0992 Cost-Effectiveness of Different Surgical Approaches in Differentiated Thyroid Cancer Patients
J. Gómez-Ramírez1, Hospital Ramón y Cajal, Madrid, SPAIN.

OP-0993 Cost-Effectiveness of Postsurgical Pretreatment Radiodiagnostic Imaging
J. Mihalovic2, Oncology Institute in Vojvodina, Department of Nuclear Medicine, Sremska Kamena, SERBIA.
OP-0995 Imaging Mitochondrial Dysfunction in the Context of Neuroinflammation
C. Barca; Westfälische Wilhelms-Universität Münster, Münster, GERMANY.

OP-0996 Value of TSP0 Imaging in Cardiac Disease
J. Thackeray; Hannover Medical School, Department of Nuclear Medicine, Translational Cardiovascular Imaging Research Center, Hannover, GERMANY.

OP-0997 Imaging Oxidative Stress in Neurodegenerative Diseases
H. Okazawa; University of Fukui, Biomedical Imaging Research Center, Fukui, JAPAN.

OP-0998 In Vivo Imaging of Mitochondrial Membrane Potential in Cancer
M. Han; UCLA, David Geffen School of Medicine, Division of Pulmonary and Critical Care Medicine, Los Angeles, UNITED STATES OF AMERICA.

OP-1003 A convolutional neural network-based program to predict nodal metastasis of non-small cell lung cancer in 18F-FDG PET
E. Kidera; S. Aoyama, T. Ishihara, Y. Nakamoto, Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN.

OP-1004 Artificial Intelligence based outcome classification from baseline 18F-FDG PET/CT in de novo diffuse Large B-cell lymphoma patients
R. Boelhaar; D. Westerling, C. Centline, B. de Veen, E. Luginbuhl, B. Zwierzynski, S. Wiegens, R. Velt, S. Goës, J. Jylhä; Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS.

OP-1005 Bone scintigraphy classification: a comparison between machine learning and deep learning classifiers using imaging data only
M. Silva1, F. Oliveira, J. Castanheda, A. Silva, L. Vieira, D. Costa;
1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL, 2Instituto Superior Técnico, Lisbon, PORTUGAL, 3Mecenosis, Health Centre, PORTUGAL, 4Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL.

OP-1006 Estimation of FFAA-uptake regions in high-grade glioma from MR images: a preliminary transfer learning artificial intelligence study
L. Presotto; C. Bearz, V. Bettinardi, S. Ghezzi, P. Mapelli1, F. Falaschi, B. Casalambro, A. Castellan1, G. Conte, J. Menni, C. Monterisi1, A. Panzarochi, P. Scolari, L. Gianolli, N. Anastalone1, P. Mancia1;
1Neuroradiology Unit, IRCCS Cappello San Raffaele, Milan, ITALY, 2University of Messina, Messina, ITALY, 3Department of neuroradiology, IRCCS Cappello San Raffaele, Milan, ITALY, 4Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

OP-1007 An exploratory study of the application of convolutional neural networks to 18F-OPD scans for amyloidosis classification
E. Sousa1, A. Tweddle, G. Avery1, A. Turner1, S. J. Archibald1, 2;
1Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, Hull, UNITED KINGDOM, 2School of Physics and Technology, University of Hull, Cottingham Road, Hull, HU6 7RX, Hull, UNITED KINGDOM.

OP-1008 Fully Automated Detection and Segmentation of Hypermetabolic Lesions in Periarticular (‘F’) FDG PET / CT Images of Lymphoma and Sarcoïdosis Patients
A. Iarsan1, P. Lourdas1, M. Frelat1, A. Jadot1, N. Watanabe, C. Derenne1, B. Frai1, J. Gautier, D. Viollier1, M. Hart1, R. Hustinx1, 2;
1LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE, 2Division of Nuclear Medicine and Oncological Imaging, University Hospital of Lège, Lège, BELGIUM, 3OGA-CRC in vivo Imaging, University Hospital of Lège, Lège, BELGIUM, 4Pneumology Department, University Hospital of Lège, Lège, BELGIUM.
OP-1016
Lesion dissemination feature (Dmax) calculated at baseline PET/CT improves risk stratification of ABVD treated Hodgkin Lymphoma patients
R. Durma, A. Cottetouma, L. Rebutch, C. Noachet, A. Ruffet, F. Fiorani, S. Luminita, F. Meri, M. Meignan, J. Buvat, A. Versan; AUSE-MMICS of Reggio Emilia, Reggio Emilia, ITALY, PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY, Department of Nuclear Medicine, Cogeno Hospital, AP-HD, University of Paris, Paris, FRANCE, LITU Laboratory, LW 2188, University Paris South/Inserm/Institute Curie, Orsay, FRANCE, GRADO Onlus, Reggio Emilia, ITALY, Lyon Imaging, Henri Mondor University Hospital, AP-H, University Paris East, Creteil, FRANCE.

OP-1017
The role of "FF-FDG PET/CT parameters in predicting outcome of patients with aggressive B cell lymphoma treated with anti-CD19 CAR-T cell
A. Lorenzoni, A. Guadagni, S. Agnolfi, A. Dadeo, M. Kienola, S. Pazzaglia, M. Pastori, B. Pفادano, A. Chiappella, E. Seregzi, P. Verdina, P. Camadoti, A. Alessi; Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY.

OP-1018
Prognostic role of baseline "FF-FDG PET/CT metabolic parameters in primary gastric DBCL
D. Albano, F. Dondi, A. Maszoleti, P. Bellini, M. Gregoroli, A. Calsola, L. Camoni, F. Bertagna, R. Gubbini; University of Brescia and Special Civil of Brescia, Brescia, ITALY.

OP-1019
Interim FDG PET/CT Predicts Response to Treatment and Outcome in Hodgkin's Lymphoma Patients: Experience from RHCC Tertiary Cancer Center in Jordan
A. Al-Ibraheem, F. M. Anwer, Q. Shagera, M. Juweid, A. N. Al-Ibrheem; King Hussein Cancer Center, Amman, JORDAN, Institute Aures Bandt, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, Jordan University, Amman, JORDAN.

OP-1020
Automatic liver lesion quantification by artificial intelligence in lymphoma patients examined with "FF-FDG PET/CT
M. Sadik, J. López-Urdaneta, J. Utter, G. Enqvist, P. Anderson, E. Trägårdh, L. Edemblandt; Nuclear Medicine, Gothenburg, SWEDEN, "Elgenvision AB, Malmo, SWEDEN, "Egendvision AB and Electrical Engineering, Malmo and Gothenburg, SWEDEN, "Haematology and Medicine, Borås and Gothenburg, SWEDEN, "Clinical Physiology and Nuclear Medicine, Malmo, SWEDEN.

OP-1021
The prognostic significance of "FF-FDG PET/CT in multiple myeloma according to novel interpretation criteria (iMPETUs)
C. Sachpekidis, M. Merz; Y. Wern, A. Kopp-Schneider, A. Jauch, H. Goldschmidt, A. Dimitrakopoulou-Straus; "Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, GERMANY, Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, Institute for Human Genetics, University of Heidelberg, Heidelberg, GERMANY.

OP-1022
The Relationship Between Bone Marrow Involvement on "FF-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Bone Marrow Involvement in Patients with Multiple Myeloma
K. Gebeshhi, F. Bassou, J. Winick, Z. Kampilda; Stellenbosch University, Tygerberg Hospital, Nuclear Medicine Division, Cape Town, SOUTH AFRICA, "Stellenbosch University, Tygerberg Hospital, Haematology Division, Cape Town, SOUTH AFRICA, "Stellenbosch University, Tygerberg Hospital, Hematopathology Division, Cape Town, SOUTH AFRICA.

OP-1023
Semi-automated extraction and histogram analysis of physiological uptake in bone marrow with 18F-FDG PET/CT
Y. Satoh, S. Funayama, M. Imai, H. Onishi; Yamagata PET Imaging Clinic, Chuo, JAPAN, "Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, "Haematology and Pathology Division, Cape Town, SOUTH AFRICA, "Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, "Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, "Department of Oncology, Odense University Hospital, Odense, DENMARK.

OP-1024
Correlation between Baseline PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients
A. Arçay, J. Ayder, C. N. Durand-Gaillaguy, E. Van der, U. Ittar, M. N. Englin, Z. G. Kapsok, A. Bar; "Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY, "Akdeniz University Hospital, Department of Internal Medicine, Antalya, TURKEY.

OP-1025
"Ga-FAP PET/CT Accuracy in Patients With Recurrent Papillary Thyroid Carcinoma
U. Eliboga, Z. Sayiner, E. Sahin, S. Çakur, C. Yaginli, Celen, A. Akarsu; Gaziantep University, Gaziantep, TURKEY.

OP-1026
Diagnostic Radioiodine Scintigraphy After the First Radioiodine Treatment in High-risk Thyroid Cancer: Is it Necessary?
A. Bay, E. Vose Jepsen, N. Meldrup Jakobsen, O. Gerke, L. Basholt, M. Gudbe Hildebrandt, P. Grue; "Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, "Department of Oncology, Odense University Hospital, Odense, DENMARK.

OP-1028
Targeting the Amyloid with "FF-FAV4 for Metull Thyroid Carcinoma PET/CT Imaging
C. Li, P. Zhang, R. Xie, Z. Liang, J. Xie, Z. Yu, R. Yang, Z. Lu; "Department of Nuclear Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, CHINA, "Department of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian, CHINA, "King's College London, School of Biomedical Engineering and Imaging Sciences, St Thomas' Hospital, SE 1 7EH, London, UNITED KINGDOM.

OP-1029
"3C-Hyic-TOC Scan in Differentiated Thyroid Cancer Patients with Negative 18F-FDG Whole-Body Scan: low cost but relatively effective method
A. Aghaali, K. Aranyi, E. Askari, P. Jahan Panah, N. Ayati, S. Shafiee, S. Zakavi; Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-1030
Multivariate analysis of initial prognostic factors in pediatric differentiated thyroid carcinoma after RAI: a multicentric Italian experience
OP-1035 Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis.
Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, IRCCS SDN, Naples, Italy.

OP-1036 Recurrence-free survival and prognostic factors after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma.
Shizuoka City-Shizuoka Hospital, Shizuoka, Japan, Kyoto University, Kyoto, Japan.

OP-1037 Anxiety And Depression In Patients With Differentiated Thyroid Carcinoma (DTC) Treated With Radioiodine in The Pandemic Year.
Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

OP-1038 Prospective, observational study on radioiodine treatment in DTC patients with intermediate risk or micro lymph node metastases.
A. Ledvon, A. Bloeszka, E. Pilatczyk-Cieścień, T. Olczyk, A. Sygula, A. Krapinski, E. Lewandowska-Istłonska, D. Handkiewicz-Junak, Maria Składowska-Curie National Research Institute of Oncology, Gliwice branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland.

OP-1039 Imaging Tumour Metabolism and its Heterogeneity with MRI.
F. Gallagher; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.

OP-1040 Imaging Nucleoside Transport for Monitoring Targeted Therapy in Cancer.
F. Iommelli; National Research Council, Institute of Biostructures and Bioimages, Naples, Italy.

OP-1041 Illuminating Metabolic Heterogeneity and Vulnerabilities in Lung Cancer.
D. Lewis; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

OP-1042 Imaging Tumour Metabolism and its Heterogeneity with MRI.
F. Gallagher; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.

Saturda, October 23, 2021, 10:45 - 11:15
Channel 2

Special Talk by Declan Murphy

OP-1043 Channel 2

Saturday, October 23, 2021, 10:45 - 12:15


R. Hicks; The Sir Peter MacCallum Cancer Centre, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, Australia.

OP-1045 Prostate Cancer along the Yellow Brick Road.
D. Murphy; Consultant Urologist & Director of Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

R. Hicks; The Sir Peter MacCallum Cancer Centre, Department of Oncology, Molecular Imaging and Therapeutic Nuclear Medicine, Melbourne, Australia.

Wednesday, October 20 - Saturday, October 23, 2021

J. Morigi; Royal Darwin Hospital, PET/CT centre, Darwin, Australia.

Joint Symposium 27 (EANM/JSNM): Advances in Molecular Imaging of Neurodegenerative Disorders

Wednesday, October 20 - Saturday, October 23, 2021

Joint Symposium 28 (EANM/IAEA): Lancet Oncology Commission on Medical Imaging and Nuclear Medicine

Wednesday, October 20 - Saturday, October 23, 2021

Joint Symposium 29 (EANM/IAEA): Lancet Oncology Commissions

Wednesday, October 20 - Saturday, October 23, 2021

Joint Symposium 30 (EANM/IAEA): Lancet Oncology Commissions

Wednesday, October 20 - Saturday, October 23, 2021
OP-1054
How to improve the transportability of radiomic models?
F. Orlhac1, C. Nioche1, M. Soussan1,2, I. Buvat1, F. Orlhac1;1Department of Radiology, McGill University Health Centre, Montreal, QC, CANADA, & Precision Health Laboratory of the Research Institute of the McGill University Health Centre, Montreal, QC, CANADA.

OP-1057
A predictive signature based on features extracted from baseline 18F-FDG PET/CT predicts 2-year PFS in Hodgkin Lymphoma patients
R. Duran1, Y. Trapani1, M. Casal1, F. Fournier1, A. Ruffin1, S. Luminari1, F. Men1, M. Ion1, A. Vener1, M. Bertol1;1Istituto IRCCS di Reggiana Emilia, Reggio Emilia, ITALY, & PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY. GRADE Oncus, Reggio Emilia, ITALY.

OP-1058
From multidimensional (PET radiomics, clinical and semantic) to patient-based “short-format” fingerprint for Hodgkin Lymphoma outcome prediction
F. Gelardi1, M. Gazz1, C. Cavallini1, M. Salini1, M. Ajram1, M. Bruni1, F. Rocc1, F. Leva1, A. Santon1, C. Carlo-Stella1, A. Chiti1;1Humàristas University, Pieve Emanuele, ITALY, & IRCCS Humanitas Research Hospital, Rozzano, ITALY. IMX-Modeling and Scientific Computing Lab, Department of Mathematics, Politecnico di Milano, Milan, ITALY. Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY. CADC-Center for Analysis, Decision, and Society, Human Technopole, Milan, ITALY.

OP-1060
Context-aware saliency guided PET/CT radiomics: joint prediction of phenotype and outcome in multi-center head and neck cancer
W. Lu1, J. Ma1, L. Lu2;1Southern Medical University, Guangzhou, CHINA

OP-1062
A radiomic signature based on features extracted from 18F-FDG PET/CT imaging in Diffuse Large B-Cell Lymphoma (DLBCL) patients
L. Travani1, G. Lo Presti1, S. Botta1, S. Raimondi1, M. Zanella1, M. Ferrani1, D. Reaven1, S. Pileri1, M. Cremonese1, F. Ceci1,2, 3European Institute of Oncology, Milan, ITALY.

OP-1066
The performance of 18F-PSMA/PTM radiomics
Z. Wang1, A. Zheng1, W. Dong1, Y. Li1, J. Gao1, Q. Nie2, C. Ding2, X. Duan1;1The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, CHINA, & Philips Healthcare, Shanghai, CHINA.

OP-1064
Postsurgical Gleason score prediction enhanced by PSMA PET/MR radiomics
E. Solari1, A. Gaffar1, S. Schachoff1, B. Bogdanovic1, A. Villaggin1, J. Raucher1, D. Visvikis1, W. Weber1, N. Navai1, M. Steiner1, B. Arendt2, S. G. Nekolla1;1Technical University of Munich, Department of Nuclear Medicine, Klinikum rechts der Isar, MUNICH, GERMANY, & Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA, & INSERM, IUMR 1101, Univ Brest, Brest, FRANCE, & Technical University of Munich, Computer Aided Medical Procedures & Augmented Reality, School of Informatics, München, GERMANY.

OP-1068
Relation Between SUVmax and ADC Values of Primary Cervical Tumor And Their Correlation With Lymph Node Metastasis Detected By PET/MRI
F. Aghazadeh1, R. U. Uba1, B. M. S. Sager1, K. Sannesagha, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TURKEY.

OP-1070
Can 2-18F-FDG PET/CT predict cervical cancer response to chemoradiotherapy?
M. Monti1;1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, & Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, & Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.
OP-1071 Predictive Role of 18F-FDG PET/CT in Gestational Trophoblastic Neoplasia
1Vita-Salute San Raffaele University, Milan, Italy; 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY; 3University of Milano-Bicocca, Milan, Italy

OP-1072 Comparison of FGD-PET/CT findings and quantitative parameters and tumor markers in Ovarian Ca patients with peritoneal metastasis
C. Dünder Çağlayan, F. Aydın, M. Engin, A. Arşen Kuturk, Z. G. Kırkaç, S. Savaş Gökşen, A. Baş, 1Adana University Hospital Nuclear Medicine Department, Antalya, TURKEY; 2Hekim University Hospital Medical Oncology Department, Antalya, TURKEY

OP-1073 Prognostic significance of follow-up 18F-FDG PET/CT in uterine sarcoma
A. R. Majer, K. Kumar, A. Sharma, S. T. Arunraj, C. Bal, A. K. Majeed

OP-1074 An externally validated nomogram to predict 1-year PFS of patients with metastatic melanoma before anti-PD-1 therapy, based on clinical, biological and [18] F-FDG PET-derived features
A. Girard, C. Pontouzeau - Guery, M. Piquet, X. Roland-Navaré, A. Devillers, D. Humbert
1Centre Eugène Marquis, Rennes, FRANCE; 2Department of Nuclear Medicine, Centre Antoine Lacassagne, Université Côte d’Azur (UCA), Nice, FRANCE, 3TROU-UME 4420, UCA/CERA, Nice, FRANCE.

OP-1077 Predictive value of baseline [18F]FDG PET/CT for response to systemic therapy in patients with advanced melanoma
1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY; 2UNEDO - University of Turin, Turin, ITALY; 3Dermatology Clinic, University of Turin, Turin, ITALY; 4PET Center, Affidea IRMET, Turin, ITALY

OP-1078 [18F]FDG-PET/CT in the Staging, Follow-up and Treatment Tailoring of Malignant Melanoma - First “Full-Digital” Experience in a Single Institution
L. Chavdarova, Ç. Göktan, E. Piterkova
1University Specialized Hospital for Active Treatment in Oncology, Clinic of Nuclear Medicine, Sofia, BULGARIA; 2University Specialized Hospital for Active Treatment in Oncology, Clinic of Dermatonecology, Sofia, BULGARIA

OP-1079 TROP Session: Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders

OP-1080 Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules
1University Hospital Maastricht, Maastricht, NETHERLANDS, 2University of Technology, Delft, NETHERLANDS, 3Radboud University Medical Centre, Nijmegen, NETHERLANDS, 4University of Twente, Enschede, NETHERLANDS, 5Rijnstate Hospital, Arnhem, NETHERLANDS, 6University Hospitals, Oudenaarde, BELGIUM

OP-1081 Do ultrasound elastography and thyroid imaging reporting and data systems correctly classify hyperfunctioning nodules on thyroid scintigraphy?
M. Tuncel, B. S. Tunur, Z. Ýlk
Hacettepe University, Department of Nuclear Medicine, Ankara, TURKEY.

OP-1082 Evaluation of treatment efficiency in 301 patients with thyroid cancer treated with a single dose of I-131 as outpatient
1Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TURKEY

OP-1083 Does functional heterogeneity play a role in Graves’ Disease response to RAI treatment? A retrospective decade-long radiologic analysis
M. Montero, A. P. Moreira, G. Costa, J. Idoaro, P. Gil
1Department of Internal Medicine, Hospital Universitario de Coimbra, Coimbra, PORTUGAL; 2Department of Nuclear Medicine, Hospital Universitario de Coimbra, Coimbra, PORTUGAL

OP-1084 The Incidence of Radioiodine-Induced Graves’ Disease Following Treatment of Thyroid Autonomous Tissue
2. Rot, J. Zalewski, D. Krkošek, S. Gobertel, K. Zalewski
1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM; 2Department of Nuclear Medicine, University Medical Centre Maribor, Maribor, SLOVENIA, Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA

OP-1085 Effectiveness of Radioactive Iodine Therapy of Immune Reconstitution Inflammatory Syndrome Associated-Associated Graves Disease in People Living with HIV infection
1University of Pretoria, Pretoria, SOUTH AFRICA, 2University of Ibadan, Ibadan, NIGERIA

OP-1086 Parathyroid scintigraphy in hyperparathyroidism: the added value for radioguided parathyroidectomy

OP-1087 Parathyroid Histopathology and [18F]-Choline Uptake in PET/MR in Primary Hyperparathyroidism
V. Libereš, G. B. Morandi, N. Rupprecht, E. Cinti, D. Deandrea, M. Borgié Diaperin, M. Hothazer, A. Maurer, L. Husmann, C. E. Mader, H. Grünig, A. A. Alharbi, M. Meseri, M. W. Hublauer
1UNIDO - University of Turin, Turin, ITALY; 2Department of Nuclear Medicine, University Hospital Zurich, University of Zürich, Zürich, SWITZERLAND; 3Department of Head & Neck Surgery, University Hospital Zurich, University of Zürich, Zürich, SWITZERLAND

OP-1088 Role of [18F]-Fluoromethylcholine PET/CT in addition to conventional imaging techniques in patients with primary hyperparathyroidism candidate to radioguided surgery
S. Casanueva Elczer, N. Sánchez Izquierdo, M. Manolych Blas, P. Domínguez Ganao, A. Físich Medina, M. Moa Porta, F. Hanza, M. Rodrigo-Cavahn, S. Vidal-Sevall, G. Vidal-Herrero, D. Fuster Pefort, Hospital Clinic Barcelona, Barcelona, SPAIN.

OP-1089 Interobserver agreement and utility of [18F] fluorocholinePET/CT for the assessment of parathyroid adenomas (preliminary results)
1PET-Unit. Department of Nuclear Medicine, L’Hospitalet De Llobregat, Barcelona, SPAIN, 2Endocrine Surgery Unit, Department of Surgery, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.
**Final Programme**

**Scientific e-Posters**

**EANM'21 World Leading Meeting**

**October 20 - 23, 2021**

---

**EPS-007**

**Performance Of Different Myocardial Suppression Protocols For Assessing Inflammation**

B. Rodriguez-Alfonso, F. Dominguez-Rodriguez, R. Preto-Soñano, D. de Castro-Campos, S. Guzman-Ortiz, M. Mityasova-Casanovas; Hospital Universitario Puerta De Hierro, Majadahonda, SPAIN.

**EPS-008**

**Reliability of [111mTc-metabolotenobenzylguanidine cardiac SPECT assessment in postinfarction heart failure patients**

A. Teresinska, J. Wnuk, O. Wozniak, A. Maciag, E. K. Biernacka; National Institute of Cardiology, Warsaw, POLAND.

---

**EPS-009**

**Insulin loading for optimal cardiac Fluorine-18 fluorodeoxyglucose positron emission tomography: an easier and more efficient preparation**

Y. Chen; Quanzhou 1st hospital, Quanzhou, CHINA.

**EPS-010**

**The Clinical-Diagnostic Relevance of Visual Score 1 at [99mTc-Tc-2,3-dicarboxypropane-1,1-diphosphonate Scintigraphy ([99mTc-Tc-DPD] for Cardiac Amyloidosis**

L. Vetrone, R. Fracassaci, G. Angelucci, E. Fortunati, A. Giovannetti, R. Bonfiglioli, E. Tabacchi, S. Longhi, C. Gagliardi, E. Biagini, N. Galié, S. Fanti; Cardiovascular Research Institute, Tomsk National Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 2Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; 3Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; 4,5Medical Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 6Cardiovascular Research Institute, Tomsk National Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION.

**EPS-011**

**Coronary flow reserve in patients with preserved left ventricle ejection fraction and non-obstructive coronary artery disease**

A. Machulla, K. Kopus, A. Maltseva, K. Zavadovsky, E. Grakovskaya; Nuklearnaya Cardiological Scintigraphy Fund, Novosibirsk, RUSSIAN FEDERATION; 1, R. Bonfiglioli2, E. Tabacchi2, G. Argalia1, L. Vetrone1, N. Fracassaci, G. Angelucci, E. Fortunati, A. Giovannetti, R. Bonfiglioli, E. Tabacchi, S. Longhi, C. Gagliardi, E. Biagini, N. Galié, S. Fanti; Cardiovascular Research Institute, Tomsk National Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 1Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION; 2Medical Center “Avicenna”, Tomsk, RUSSIAN FEDERATION, 2Medical Center “Avicenna”, Tomsk, RUSSIAN FEDERATION, 3Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; 4Medical Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 5Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; 5Medical Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 6Cardiovascular Research Institute, Tomsk National Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION.

**EPS-012**

**Quantification of Cardiac 99mTc-bisphosphonates (DDP) uptake using SPECT-CT Images in Amyloidosis Transhyretin patients**

M. Solà, G. Masongs, A. Pujol, J. Deportos, M. N. Torres, M. H. Oliveres, S. Lafuente, V. Vallejo, M. Domínguez; Hospital Universitario Germans Trias i Pujol, Badalona, SPAIN.

**EPS-013**

**The value of CZT SPECT myocardial blood flow and reserve assessment in terms of identifying high-risk patients after surgical treatment of ischemic cardiomyopathy**

Y. Shipulin, A. Piyakhin, S. Andreiev, A. Machulla, M. Gulya, K. Zavadovsky, V. M. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

---

**OP-1090**

**Evaluation of C-11-methionine-PET/MRI in primary hyperparathyroidism**

N. Eberhardt1, J. P. Stenersen1, A. Wilkensbrand1, A. Müller-Remnitz1, C. Michalski1, P. Korff1, M. Beer1, C. Salbach1, T. Kull1, A. J. Beer1, 2Ulms University Medical Center, Department of Nuclear Medicine, Ulm, GERMANY; 3Surgical and Orthopaedic Practice Clinic S. Riedlingen, GERMANY; 4Ulms University Medical Centers. Department of General and Visceral Surgery, Ulm, GERMANY; 5Siemens Healthcare GmbH, Erlangen, GERMANY; 6Ulms University Medical Center, Department of Diagnostic and Interventional Radiology, Ulm, GERMANY.

---

**OP-1091**

**C11-Choline PET/CT usefulness in patients with primary hyperparathyroidism and negative or inconclusive 99mTc-MIBI scan**

A. Güler1,2, O. Cuenca-Vera3, I. Martínez-Rodriguez1, F. Gómez-de la Fuente1, M. De Arcocha-Torres1, A. Sánchez-Salmón1, J. Pinaqué1, P. Ferrer1, F. Debebeux4, H. Douard1, Y. Puchea1, T. Cauffhinal1, Q. Ceyrat5, L. Bordemare4; University Hospital of Bordeaux, Bordeaux, FRANCE.

**OP-1092**

**Influence of Music During Cardiac Stimulation for Myocardial Perfusion Imaging Studies**

A. Martínez-Amador1, S. Ruiz-Llana1, J. Jiménez-Bonilla1, J. Andrés-Pacheco1, R. Quince; Nuclear Medicine Service, Marqués de Valdecilla University Hospital, Molecular Imaging Group (IDIVAL), University of Cantabria, Santander, SPAIN.

**OP-1093**

**Type-HMID Quantification in Cardiac Amyloidosis: the Heart to Whole-Body Ratio**

A. Marques1, B. Rocha1, M. Cruz1, M. Pava1, S. Malhi1, P. Lopez1, J. Carvalho1, A. Albre1, C. Aguiar1, M. Mendes1, S. Pintado1; Centro Hospitalar de Lisboa Ocidental. Lisboa, PORTUGAL.

**OP-1094**

**Utility of Hybrid Imaging SPECT/CT VS Planar Imaging in ATR Cardiac Amyloidosis**

O. Bouriaggi1,2, N. Kapsoria1,2, J. Zigounas1,2, A. Patranitas1,2, M. Chakts1,2, A. Tsatsouhas1,2, S. Kokoumak1,2; University Hospital of Crete. Heraklion. GREECE; 1School of Medicine, University of Crete, Heraklion, GREECE.

**OP-1095**

**Transhyretin Cardiac Amyloidosis: The Utility of Cardiac Scintigraphy with 99mTc-HDP**

M. Tagliatori1,2, N. Paniagua Correa1,2, M. de la Rubia1,2, M. M. Camacho Nogueira1,2, M. M. Beregov1, A. K. Kondakov2, D. S. Kharina2, D. S. Kharina2, A. K. Kondakov2, D. S. Kharina2; 1Cardiology Research Institute, Tomsk National Research Center of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION; 2Cardiological Scintigraphy Fund, Novosibirsk, RUSSIAN FEDERATION.

**OP-1096**

**Global and Regional Coronary Flow Reserve assessed by routine perfusion SPECT improves the interpretation of the final report**

L. Philippe, C. Prunier-Asch1, Y. V. Yasgurski; Medecine Nucleaire Tourangeille, Chambby-les-Tours, FRANCE.
EPOCH is the only positive level 1 evidence, phase III RCT using SIRT to treat CLM that demonstrated statistically significant improvements in PFS and hepatic PFS in patients that had progressive disease after first-line chemotherapy.

**Progression Free Survival**

According to recist 1.1 by blinded independent central review
TheraSphere arm: 8.0 months (95% CI, 7.2, 9.2)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 31% risk reduction of overall progression or death compared to chemotherapy alone.

**Hepatic Progression-Free Survival**

According to RECIST 1.1 by blinded independent central review
TheraSphere arm: 9.1 months (95% CI, 7.8, 9.7)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 41% risk reduction of hepatic progression or death compared to chemotherapy alone.

---

**EPISODE 4**

EPOCH is the only positive level 1 evidence, phase III RCT using SIRT to treat CLM that demonstrated statistically significant improvements in PFS and hepatic PFS in patients that had progressive disease after first-line chemotherapy.

**Progression Free Survival**

According to recist 1.1 by blinded independent central review
TheraSphere arm: 8.0 months (95% CI, 7.2, 9.2)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 31% risk reduction of overall progression or death compared to chemotherapy alone.

**Hepatic Progression-Free Survival**

According to RECIST 1.1 by blinded independent central review
TheraSphere arm: 9.1 months (95% CI, 7.8, 9.7)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 41% risk reduction of hepatic progression or death compared to chemotherapy alone.

---

**EPISODE 5**

EPOCH is the only positive level 1 evidence, phase III RCT using SIRT to treat CLM that demonstrated statistically significant improvements in PFS and hepatic PFS in patients that had progressive disease after first-line chemotherapy.

**Progression Free Survival**

According to recist 1.1 by blinded independent central review
TheraSphere arm: 8.0 months (95% CI, 7.2, 9.2)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 31% risk reduction of overall progression or death compared to chemotherapy alone.

**Hepatic Progression-Free Survival**

According to RECIST 1.1 by blinded independent central review
TheraSphere arm: 9.1 months (95% CI, 7.8, 9.7)
Control arm: 7.2 months (95% CI, 7.1, 8.2)

Patients receiving TheraSphere with second-line chemotherapy had a 41% risk reduction of hepatic progression or death compared to chemotherapy alone.
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

SCIENTIFIC e-POSTERS

University “Aldo Moro” , Bari, ITALY.
G. Rubini; Parrilla2, D. Ramírez Ocaña2, M. Puentes Zarzuela2; R. Ruta, F. Iuele, A. G. Nappi, A. Gaudiano, A. R. Pisani, quantitative analysis in patients with suspicion of Prosthetic Valve And Intracardiac Devices

EPS-031
Role Of (18)F FDG PET/CT In Infective Endocarditis On Prosthetic Valve And Intracardiac Devices
N. Alvarez Mena; C. Ponce Herrera, A. Gutiérrez Cardo, S. Martin Aguilera, M. Nicolás Aguado, E. Espinosa Muñoz, V. Marín Ramírez, D. Ramírez Ocaña, M. Puentes Zarzuela, Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN, Hospital Regional Universitario de Málaga, Málaga, SPAIN.

EPS-032
Semiquantitative [(18)F] FDG PET/CT Analysis in infective Endocarditis On Prosthetic Valve And Intracardiac Devices
N. Alvarez Mena; 1C. Ponce Herrera, 2A. Gutiérrez Cardo, 3S. Martin Aguilera, 4M. Nicolás Aguado, 5E. Espinosa Muñoz, 2V. Marín Ramírez, 2D. Ramírez Ocaña, 2M. Puentes Zarzuela, 2Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN, 1Hospital Regional Universitario de Málaga, Málaga, SPAIN.

EPS-033
The effectiveness of the combination of extended fasting with dietary manipulation for suppressing physiologic myocardial 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for sarcoidosis
A. Georgakopoulou1, E. Mandel1, A. Papaojanou1, H. Galafas1, M. Metaxas1, L. Kólekas1, S. Papiris2, S. Chatzioannou1; 12nd Department of Radiology, General University Hospital “Attikon”, Medical School, National and Kapodistrian University, Athens, GREECE, 12Pulmonary Medicine Department, General University Hospital “Attikon”, Medical School, National and Kapodistrian University, Athens, GREECE, 13Aigina Medical School, Medical School, National and Kapodistrian University, Athens, GREECE, 14Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 15Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-034
Lung Segmentation and Measurements of Pulmonary Metabolic Activity with FDG-PET/CT Is Reproducible in Patients with COPD
A. Dogan1,2,3,4; 12Department of Medicine, 3Hospital South West Jutland, Ejsberg, DENMARK, 2Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK, 3Department of Clinical Engineering, Region of Southern Denmark, Ejsberg, DENMARK, 4Department of Medicine, Lillebaelt Hospital, Vejle, DENMARK, 5Stereo Diabetes Center, Odense, DENMARK, 6Department of Radiology and Nuclear Medicine, Hospital South West Jutland, Ejsberg, DENMARK

EPS-035
Staging of Alveolar Echinococcosis with PET/CT: Prediction of the Length of Benznidazole Therapy in Inoperable Patients
1Department of Nuclear Medicine, University Hospital Zurich / University of Zurich, Zurich, SWITZERLAND, 2Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, SWITZERLAND, Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, SWITZERLAND, 3Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, SWITZERLAND, 4Institute of Pathology, University of Zurich, Zurich, SWITZERLAND.

EPS-036
Added Diagnostic Value of Lung Perfusion Scintigraphy In Admitted COVID-19 Patients
M. Algarín; 1KFMC, Dhiarah, SAUDI ARABIA

EPS-037
Role of Perfusion Lung Scan in discharged patients post SARS-CoV2 pneumonia
M. I. De Rrines1, D. D’Arienzo1, G. Fiorentino2, A. Annunziato1, M. Flaiyr1, T. Valente1, G. Borelli1, M. Biulano1, G. Mazzaeroli1, M. Scarpato1; 1Nuclear Medicine Unit AO Ospedali dei Colli - Monaldi, Naples, ITALY, 2Respiratory Pathophysiology and Rehabilitation AO Ospedal dei Colli - Monaldi, Naples, ITALY.

EPS-038
Pulmonary Perfusion SPECT/CT Results in Thromboembolism Diagnosis in Patients at Post-COVID-19 Infection Phase
H. Nabati1, S. Demirtaş Şenlik2, M. Bas 2, B. Demirel1, U. Yılmaz, Dr. Abdurrahman Yurtseven Ankara Oncology Training and Research Hospital, Ankara, TURKEY.

EPS-039
Pulmonary Embolism Detection: Incremental values for Perfusion SPECT/CT in detection of PE in COVID-19 patients with deteriorating respiratory functions. Pilot Study
H. Elzeftawy, D. Omran, W. Wagga, A. ElZeftawy; King Faisal Specialist Hospital and Research Center, Jeddah, SAUDI ARABIA.

EPS-040
Diagnostic Contribution Of Lung Perfusion SPECT/CT Imaging During The COVID-19 Pandemic
N. Alvarez Mena; 1F. Sebastián Palacid, 2P. Turbay Eljach, 3C. García Fernández-Romero1, 2A. Riera-Mestre2, 2J. Mora-Lugan2, 1Hospital Universitari de Bellvitge, L’Hospitalet De Llobregat, SPAIN, 2Respiratory Pathophysiology and Rehabilitation, AO Ospedal dei Colli - Monaldi, Naples, ITALY.

EPS-041
Pulmonary Embolism in non-hospitalized COVID-19 infected patients without severe disease
O. Evbuomwan, G. Engelbrecht; University of The Free State, Bloemfontein, SOUTH AFRICA

EPS-042
Incremental values for Perfusion SPECT/CT in detection of PE in COVID-19 patients with deteriorating respiratory functions. Pilot Study
H. Elzeftawy, D. Omran, W. Wagga, A. ElZeftawy; King Faisal Specialist Hospital and Research Center, Jeddah, SAUDI ARABIA.

EPS-043
FDG PET-CT Imaging Of Immune Activation Post COVIDVaccination in Oncology Patients
S. AB, A. Husseim, M. Kula, W. Ibrahim; King Hamad University Hospital, ASGAY, BAHRAIN.

EPS-044
Our experience in the assessment of pulmonary embolism with lung perfusion SPECT/ CT in COVID-19 patients
M. Salcedo Pujantell, J. Deportes, M. Solá, V. Vallego, S. Lafuente-Campos, M. Olivares, M. Torres, G. Monagas; Hospital Universitario Germans Trias i Pujol, Badalona, SPAIN.

EPS-045
Ventilation/Perfusion Scintigraphy in the Assessment of Pulmonary Sequelae in COVID-19 Patients with Pneumonia and Pulmonary Embolism
C. Soldévea Lozaro1, J. Mora-Salvador1, M. Bajer-Ludzić1, A. Benitez-Segura2, G. Reyen-Joncs2, P. Navas2, S. Bonda-Brcić3, L. Fernández-Ramires1, A. Riera-Mestre2, A. Korte-Fuster2, J. Mora-Lugan2, M. Contes-Ramires1; 1Nuclear Medicine-PET (ID), Hospital Universitari de Bellvitge, L’Hospital de Llobregat, SPAIN, 2Innernal Medicine Department, Hospital Universitari de Bellvitge, L’Hospital De Llobregat, SPAIN.

EPS-046
Preliminary study of quantitative evaluation for lung glucose metabolism using [(18)F]FDG PET imaging in patients with pulmonary arterial hypertension related to congenital heart disease
X. Wang; 1L. Wang, 2W. Fang, 3C. Yan; 1Center of Structural Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 2Department of nuclear medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

**EPS-047**
The importance of precursor concentration for PET diagnostics with Ga-68-PSMA-11
N. Nikhady, Y. Zhao, A. Heim, U. Lützen, M. Zuhayra
Universitätsklinikum Schleswig-Holstein, Klinik für Nuklearmedizin, Molekulare Bildagnostik und Therapie, Kiel, GERMANY.

**EPS-048**
**Ga**-radiolabelling and pharmacological characterization of a kit-based formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) antagonist RM2 for convenient preparation of (**Ga**) Ga-RM2
C. Morgat,1 A. Chaste1, D. Virmont, S. Clavéron, M. Bernaët, M. Ziem, S. Chaiebbaj,1 E. Hendeb,1
1Nuclear Medicine Laboratory - University Hospital of Bordeaux, Bordeaux, FRANCE, 2University of Bordeaux, CNRS, FNCL, LMR S2IE, Bordeaux, FRANCE, 3Protéome Platforms, Univ Bordeaux, Bordeaux, FRANCE, 4Life Molecular Imaging, Berlin, GERMANY.

**EPS-049**
Securing Gallium-68 availability with liquid target production on mid-energy cyclotrons: Users’ experience and scaling up
C. Gameiro,1 F. Genovese2, S. Boschi3
1Università di Padova, Istituto di Chimica Molecolare di Padova, Padova, ITALY, 2Università degli Studi di Roma ‘La Sapienza’, Dipartimento di Chimica, Roma, ITALY, 3Università degli Studi di Padova, Dipartimento di Chimica, Padova, ITALY.

**EPS-050**
Production of Sm-153 with high specific activity for targeted radionuclide therapy
A. Gummesson,1 G. Schwenk,2 S. Knoller,2 S. Pataritz,2 M. Weitboeck, M. Kochs3, B. Krause2, C. Bergner2
1Department of Nuclear Medicine, Rostock University Medical Center, Rostock, GERMANY, 2CUP Laboratorium Dr. Freitag GmbH, Radeberg, GERMANY.

**EPS-051**
Optimization of the Radiolabelling of Silk Fibroin Nanoparticles with Tc-99m by a direct method
M. Asensio Ruiz1, A. Alonso Garcia1, J. Gena Anasati1,1 Luciana Pérez1, M. Martínez Martínez1,1
1Unidad de Radiodiagnóstico, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN, 2Instituto de Investigación Biomédica Arrixaca (IBAB), Arrixaca, Murcia, SPAIN, 3Departamento de Biotecnología, Genética y Mejora Vegetal, Instituto Murciano de Investigación y Desarrollo Agronómico y Alimentario, 40150-La Alberca, Murcia, SPAIN.

**EPS-052**
18F-PDMA-1007 Synthesis: a production upgrade that enabled a federal experience in Argentina
M. Agoli,1 G. Muzano,2 G. Casale,2 L. Sotano,3 J. Sandrolini,1 S. Filar,1 Centro de Medicina Nuclear Clínica Modelo, Paraná, ARGENTINA, 2Laboratorios Bacon, Buenos Aires, ARGENTINA.

**EPS-053**
Targeted alpha therapy with Actinium-225 radiotherapeutics: In-house preparation and quality control
R. Vatsa,1 S. Pandey, A. Chhabra, B. R. Mittal, J. Shukla, Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

**EPS-054**
Production of one or three patient doses (in one batch) of (**Lu**)Lu-PSMA-167 on a fully-automated synthesis module
A. Cancaya, M. Balzer, H. Anthauzer, W. Brenner, S. SpreckleyMeyers, Chandit Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Nuclear Medicine, Berlin, GERMANY.

**EPS-055**
Validation of an analytical method on HPLC for (**Lu**)Lu-PSMA-1
C. Brentot, A. Rey, L. Battet, S. Levesque, F. Cachin, M. Tempier, 1Pharmaceutical Department, Azienda USL of Modena and Research, Chandigarh, INDIA, 2Homi Bhabha Centre for Advanced Sciences, Indian Institute of Technology, Mumbai, INDIA.

**EPS-056**
EU vs US radiopharmaceutical manufacturing and dispensing modalities
C. Ignace1, F. Genovese2, S. Boschi3
1Università di Padova, Istituto di Chimica Molecolare di Padova, Padova, ITALY, 2Università degli Studi di Roma ‘La Sapienza’, Dipartimento di Chimica, Roma, ITALY, 3Università degli Studi di Padova, Dipartimento di Chimica, Padova, ITALY.

**EPS-057**
Time-dependent sterility testing to determine the viability of microorganisms and autosterilisation in radiopharmaceutical therapeutics
A. Gummesson,1 G. Schwenk,2 S. Knoller,2 S. Pataritz,2 M. Weitboeck, M. Kochs3, B. Krause2, C. Bergner2
1Department of Nuclear Medicine, Rostock University Medical Center, Rostock, GERMANY, 2CUP Laboratorium Dr. Freitag GmbH, Radeberg, GERMANY.

**EPS-058**
New radiopharmaceutical synthesis: Stability study of (**Lu**)Lu-PSMA-1
L. Battet, C. Brentot, A. Rey, S. Levesque, M. Tempier, Centre Jean Perrin, Clermont Ferrand, FRANCE.

**EPS-059**
Optimization of Radiolabelling of (**Ga**)Ga-Macroggregated Albumin
P. Bhadravat1, S. Mitthuri2, A. K. Jha3, P. Kamble4, K. Chitnis5, A. Nautiyal1, V. Rangamani1,1 Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

**EPS-060**
Production of W-188/Re-188 generator based on Al2O3
M. Karamivand, F. Johani, M. Davanpoosh, Pars Isotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

**EPS-061**
Comparison of the performance of four purification cartridges in the synthesis of 68Ga-PSMA-11
J. Stein,1 O. Cretiere,2 N. Verani,2 B. Demoré2,1 Nancy University Hospital, Pharmacy Department, Vandoeuvre-lès-Nancy, FRANCE, 2Lorraine Chimie Moléculaire de l’Université de Bourgogne, ICMUB, Dijon, FRANCE.

**EPS-062**
Quality Control of (**Ga**)Ga-PSMA-11 injectable solutions: preparation of a long-term stable PSMA-11 reference solution (3 μg/mL) for Chemical Purity determination
A. Iudicello1, F. Genovese2, S. Boschi3
1Università di Padova, Istituto di Chimica Molecolare di Padova, Padova, ITALY, 2Università degli Studi di Roma ‘La Sapienza’, Dipartimento di Chimica, Roma, ITALY, 3Università degli Studi di Padova, Dipartimento di Chimica, Padova, ITALY.

**EPS-063**
Development of (**At**)At and (**Re**)Re Radiochemicals for Pretargeted Radioimmunotherapy of Disseminated Cancer
C. Timperanza1, A. Jensen,2 E. Andeheim,2 S. Lindinger,2
1Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Cytotherm and PET Unit, KF-3882, Rigshospitalet, Copenhagen, DENMARK.

812

**EPS-064**
Synergy when treating ovarian cancer cell lines with Radium-224 and PARP inhibitors
M. Malenge, T. B. Bønsdorff, Oncocent AS, Oslo, NORWAY.

**EPS-065**
Theranostic Approach of CD38 and IL-1RAP Positive Haematological Malignancies Based on Radiolabelled Antibodies
J. Freney1, P. Belkue2,3 M. Moreau,2 C. Ross3, O. Casaravilas1, R. Ringenbach1,2 C. Ferrand3,2 B. Collin2,3
1Centre Georges Franchis Leclerc, Dijon, FRANCE, 2Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB, Dijon, FRANCE, 3Etablissement Français du Sang de Bourgogne Franche-Comté, Dijon, FRANCE.

**EPS-066**
Validation of an analytical method on HPLC for (**Lu**)Lu-PSMA-1
C. Brentot, A. Rey, L. Battet, S. Levesque, F. Cachin, M. Tempier, Centre-de-lutte contre le cancer Jean Perrin, Clermont Ferrand, FRANCE.
EPS-067
In Vitro and nanoSPECT/CT Imaging of Long-acting Radiolabeled PSMA Peptide in Animal Model of Prostate Cancer Bone Metastasis
Y. Huang, M. Chen, S. Chen, S. Lu, S. Li, L. Chen, M. Li, C. Chang, S. Fam
Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EPS-068
Assessing potential damage to the healthy vascular endothelium from targeted radiopharmaceutical therapeutics
R. Ramadan, L. Gennet, N. Doumi, A. Aertis, S. Bastuoir
Radiobiology Unit, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 2Department of Molecular Biotechnology, Ghent University, Ghent, BELGIUM

EPS-069
A local (para)sympathetic blockage to overcome PSMA ligand uptake in salivary glands
V. Nail, P. Garmet, A. Bouafagi, B. Louis, L. Balasse, S. Fernandez, G. Hache, D. Taïeb, B. Guillet
1Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale (CERIME), Marseille, FRANCE; 2Institute of Nuclear Energy Research, Taoyuan, TAIWAN; 3Cardiovasculaire et Nutrition (C2VN), Marseille, FRANCE.

EPS-070
Performance characterization of a multi pin-hole SPECT for preclinical imaging
L. Izagro, E. Pretor, M. Collante, M. Ecay, I. Peruvelas, J. M. Marti-Climent
1Medical Physics, Clínica Universidad de Navarra, Pamplona, SPAIN; 2Translational Molecular Imaging Unit, University of Navarra, IDiNA & Unidad de Radiodiagnosis, Clínica Universidad de Navarra, Pamplona, SPAIN.

EPS-071
Extensive in vitro and in vivo validation of SSTR2-mediated uptake and biodistribution of radiolabeled somatostatin analogues after treatment with HDAC inhibitor valproic acid
M. Klomp, L. J. Hofland, L. van den Brink, P. M. van Koetsveld, E. Dagan-Orug, L. W. de Kreij - de Brum, C. M. de Riddel, D. C. Stuurman, M. de Jong, S. U. Dalm
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-072
Validation of [(99mTc)]-2S,4R-4-Fluoroglutamine in Multiple Myeloma Mouse Models
S. Valtorta,1,2 M. Chui, D. Toscami,1 A. Sartori,1 A. Colav,1 A. Breit,1 G. Taurino,1 M. Gironi1, L. Ruffini1, F. Vaccandalo1,1,2,3, J. Zanardi2, M. Bellone1,2,3, R. M. Marasca1,2,3, G. Bussolati1,1,2,3, G. Guidoni1,1,2,3; 1Department of Medicine and Surgery and Tecnomed Foundation - University of Milano - Bicocca, Monza, ITALY; 2Department of Nuclear Medicine, San Raffaele Scientific Institute, IRCCS, Milan, ITALY; 3Department of Medicine and Surgery, University of Parma, Parma, ITALY; 4Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, IRCCS, Milan, ITALY; 5Università Vita-Salute San Raffaele, Milan, ITALY; 6Department of Medicine, ‘Nucleare” OsPEDAlatro Universitario di Parma’, Parma, ITALY; 7EFM-CNIR, Segrate, ITALY.

EPS-073
Preclinical investigation of a novel luteinizing hormone-releasing hormone antagonist for triple negative breast tumor-bearing model by SPECT/CT imaging
M. Weng, S. Lo, S. Wang, Y. Shih, M. Weng, C. Ho, S. Fam
Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EPS-074
Simultaneous Biodistribution Studies of (111)In-DTPA-HL and (111)In-DOTA-HL for Imaging of asialoglycoprotein receptor in Mice
H. Yu, C. Chen, C. Yang, K. Lin, C. Chien, C. Kuo, M. Wang; 1RIKEN Center for Biosystems Dynamic Research, Kobe, JAPAN; 2RIKEN Center for Molecular Imaging Science, Kobe, JAPAN; 3National Center for Genitrics and Gerontology, Nagoya, JAPAN.

EPS-075
EANM'21 WORLD LEADING MEETING
OCTOBER 20 - 23, 2021
WORLD LEADING MEETING  EANM'21
OCTOBER 20 - 23, 2021

EPS-076
Preclinical investigation of a novel luteinizing hormone-releasing hormone antagonist for triple negative breast tumor-bearing model by SPECT/CT imaging
M. Weng, S. Lo, S. Wang, Y. Shih, M. Weng, C. Ho, S. Fam
Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EPS-077
Radioactive and near-infrared fluorescence in vivo imaging of Non-Hodgkin Lymphoma using 99mTc/Cy7-Fab(Bevacizumab)
X. Caracho,1 C. Pereiro, C. Carreiras, M. Juncurena, D. Faria, M. Garcia,1 M. Fernandez,1 C. Buchpiguel,1 M. Cazenave,1 J. Abellanas,1 F. Vacondio,4 F. Zanardi4,1,2; 1Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, IRCCS, Milan, ITALY; 2Department of Medicine and Surgery, University of Parma, Parma, ITALY; 3Department of Nuclear Medicine, ‘Nucleare” OsPEDAlatro Universitario di Parma’, Parma, ITALY; 4Department of Food and Drug, University of Parma, Parma, ITALY.

EPS-078
Comparison Study of [(111)In]-DTPA-HL, [(111)Ga] Ga-NOTA-HL and [(111)FA]-NOTA-HL for Imaging of asialoglycoprotein receptor in Mice
H. Yu, C. Chen, C. Yang, K. Lin, C. Chien, C. Kuo, M. Wang; 1RIKEN Center for Biosystems Dynamic Research, Kobe, JAPAN; 2RIKEN Center for Molecular Imaging Science, Kobe, JAPAN; 3National Center for Genitrics and Gerontology, Nagoya, JAPAN.

EPS-079
Syntheses of the (111)In-labeled thymine-carbone conjugates for PET imaging-guided boron neutron capture therapy (BNCT)
Z. Zhang,1 M. Suzuki1,1; 1Riken Center for Biosystems Dynamic Research, Kobe, JAPAN; 2Riken Center for Molecular Imaging Science, Kobe, JAPAN; 3National Center for Genitrics and Gerontology, Nagoya, JAPAN.
EANM’21 — WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

SCIENTIFIC e-POSTERS
Cognitive Impairment: A Longitudinal Study
Hubalewska-Dydejczyk2;
Additional value of 2-[18 F]FDG PET/CT in detection of neurological syndromes having negative results of malignancy in patients with paraneoplastic syndrome.

EPS-085
Differential Diagnosis of Atypical Parkinsonian Disorders from Parkinson’s Disease using dual-phase F-18 FDG PET/CT
M. Cheon, S. Kim, S. Ha, J. Yoo; VHS Medical Center, Seoul, KOREA, REPUBLIC OF.

EPS-086
Regional Brain Amyloid Load Assessed by [11C]PIB PET/CT and Cognitive Performance in Patients with Mild Cognitive Impairment: A Longitudinal Study
J. Jiménez-Bonilla; M. de-Acosta-Torrejón; J. Martín-Navarro2; G. Cuenca; J. Martínez-Rodríguez; A. Sánchez-Salmón; N. Martínez-Amador; J. Gómez-De-la-Fuente; S. Ruiz-Llamas; A. Pausera; M. Gámez; S. López-García; C. Lagé; E. Rodríguez; P. Sánchez-Ibarri; R. Quirce; 1Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Vizcaya de las Nieves, Granada, SPAIN; 2School of Dentistry. Granada Biosalud Research Institute, Granada, SPAIN.

EPS-087
T. Latinen1; J. Miettinen2; N. Vartiainen2; H. Grohn1; T. M. Latinen1; 1University of Eastern Finland, Kuopio, FINLAND; 2Kuopio University Hospital, Kuopio, FINLAND.

EPS-088
Additional value of [18F]FDG PET/CT in detection of malignancy in patients with paraenepathological neurological syndromes having negative results of conventional radiological imaging
M. Opalska1; A. Sosor-Staszczuk1; P. Wężyk2; A. Skowak2; A. Hubala-Wysoka-Dziedzica2; 1Nuclear Medicine Unit. Endocrinology Department, University Hospital in Krakow, Krakow, POLAND; 2Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EPS-089
A meta-analysis of brain glucose hypo-metabolism in patients with disorders of consciousness
A. Sala1; B. Kaua2; A. Thibaut1; O. Gassiot1; S. Launey1; J. Amenn2; 1University of Liege, Liege, BELGIUM; 2Centre du Cerveau, University Hospital of Liege, Liege, BELGIUM.

EPS-090
Association of periodontitis with Intracerebral Beta-Amyloid Plaque Deposition measured by [18F]Florbetaben PET/CT
M. Rashki; E. Travín-Bohrer; T. Rudolph-Soleiro; M. Genez-Muñoz1; J. Gómez-Cortés; M. Gómez-Río; 1Department of Nuclear Medicine, University Hospital Virgen de las Nieves, Granada, SPAIN; 2School of Dentistry. Granada Biosalud Research Institute, Granada, SPAIN.

EPS-091
Perfusion-like images based on [18F]Florbetaben PET correlate well with brain metabolism in patients with inherited transthyretin-related amyloidosis
S. Reinen1; P. Aiken1; I. Conception1; J. P. Martin1; F. Olvera1; M. Silva1; N. Mateuf1; D. C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL; 2Philips Portugal S.A, Lisbon, PORTUGAL; 3Institute of Biophysics and Biomedical Engineering, Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL; 4Department of Neurosciences, CHULN, Hospital de Santa Maria, Lisbon, PORTUGAL; 5Instituto de Medicina Molecular, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, PORTUGAL.

EPS-092
The role of amyloid PET-CT with 18F-Flutemetamol in patients with mild cognitive impairment: Identification of the group at risk of developing Alzheimer’s Disease
L. Rodríguez-Bel; M. Martínez de Bourbon-Allanon; J. Campillo-Fuentes-Fumador; R. Reté-Ramírez; I. Rico-Pons1; P. Nustal; J. Vecchier-Conegra; G. Reyes-Llompart; J. Fernández-Barrosovoro; M. Cortés-Ramero; 1PET Unit. Department of Nuclear Medicine-IDI. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN; 2Department of Neurology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN; 3Neuropsychology Unit. Department of Neurology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN.

EPS-093
Texture Quantification Parameters for Alzheimer’s disease diagnosis measured by 11C-(R)-PK11195 PET images
M. Lapo Pais; L. Jorge1; R. Martins; N. Canasini2; C. Xavier2; A. Abou-Thabit1; J. Santana1; R. Bernardo2; 1,2, M. Castello-Branco1; 1Coimbra Institute for Biomolecular Imaging and Translational Research (CIBIT), University of Coimbra, Coimbra, PORTUGAL; 2Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, PORTUGAL; 3Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL; 4Department of Neurology, Coimbra University Hospital, Coimbra, PORTUGAL.

EPS-094
18F-FDOPA PET/CT diagnostic accuracy study in suspected brain tumors recurrence
D. Lisic Coscia; C. Silva, Dávila; C. Vigo Diaz; B. Fernández Llanas; M. Domínguez Grande; M. López Carballa; A. Llovera March, N. Martín-Fernández; F. González García; HUCA, Oviedo, SPAIN.

EPS-095
Technical improvements implemented in a PET dedicated to the brain (CaremiBrain) in its technical validation phase
R. Nespital Torres; A. Abadía-Ruiz; A. Delgado-Cano; M. Cabrera-Martín, G. González-Pavón2; C. Morera-Ballester2; M. Sanchís-Hernández2; J. Matías-Guiu3; J. Carreras-Delgado1; 1Department of Nuclear Medicine and Radiation Protection, University of Granada Biohealth Research Institute, Granada, SPAIN; 2School of Dentistry, University of Granada, Granada, SPAIN; 3Department of Neurosciences, CHULN, Hospital de Santa Maria, Lisbon, PORTUGAL; 2Philips Portuguesa S.A, Lisbon, PORTUGAL; 4Department of Oncology, University Hospital Centre Zagreb, Zagreb, CROATIA; 5Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, PORTUGAL; 6Mammal Genome Institute, Lisbon, PORTUGAL.

EPS-096
F-18-FET and F-18-choline PET/CT imaging in primary diagnosis of low-grade gliomas with impact on therapy
A. Golubic1; M. Hodak1; A. Misra-Kpan1; M. Zuc1; M. Bauc1; G. Mika1; J. Nemi1; D. Haic2; 1Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA; 2Nuclear Medicine Department, Faculty of Medicine and Dentistry, Pula1ary University Omiouc, Omiouc, CZECH REPUBLIC.

EPS-097
F-18 FDG thyroid incidental uptakes: can semiquantitative and volumetric parameters predict the final diagnosis?
F. Dondi1; A. Mazzoccoli; P. Bellini; A. Calabro1; M. Gregoretti1; D. Albanese1; R. Rinaldi1; M. Gazzetti1; E. Cenedez1; L. Comori1; R. Giubbi1; F. Bertagna1; 1Università degli Studi di Brescia, Brescia, ITALY; 2Speciali Civili di Brescia, Brescia, ITALY.

EPS-098
BRAFV600E mutational status in thyroid carcinoma patients - single center study
T. Makaziei1; N. Manescas1; S. Stepaniakos1; A. Jankulovska1; B. Stojkovska1; A. Oltomari1; R. Ioxanovic1; 1Institute of pathophysiology and nuclear medicine, Skopje, NORTH MACEDONIA; 2Institut of pathology, Skopje, NORTH MACEDONIA.

EPS-099
Postoperative basal serum thyroglobulin (TG) prior to radioiodine therapy as a predictive factor of recurrence in patients with differentiated thyroid cancer (DTC)
R. Núñez Muñoz1; Y. Carrero Ortega1; M. A. Atutxoa Sarrieta1; R. Valverde Jorge1; M. Nevaras llerena1; J. Genoli Subirats1; J. Santamaria Sandi1; M. Badola Molinuevo1; Oslakietas, Bilbao, SPAIN.

EPS-100
Low Radiiodine Dose in Postoperative Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid Carcinoma
O. Bourgoni1; N. Kapposntica1; A. Trumachov1; M. Shiha1; E. Papadaki1; S. Koukouraki1; 1University Hospital of Crete, Heraklion, GREECE; 2School of Medicine, University of Crete, Heraklion, GREECE.
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

EPS-102 The efficacy of radioactive iodine with cumulative activities over 600 mCi for the treatment of Differentiated Thyroid Carcinoma
A. Mazzeotti, D. Albano, F. D’Ambros, P. Beltrani, A. Calabrisi, M. Gregoriotti, F. Bertagna, R. Guibbiun; ASST Spedali Civili di Brescia, University of Brescia, Brescia, ITALY.

EPS-103 131I-SPECT/CT at the first radiiodine ablation and during follow-up in patients with differentiated thyroid carcinoma
S. Nuvoli, A. Mazonzini, G. Mela, M. Masina, M. L. Stazza, M. Randini, A. Spanu, G. Mededolu; University of Sassari, Sassari, ITALY.

EPS-104 Our Experience in the Use of Iodine-123 in the Diagnosis and Monitoring of Thyroid Cancer
M. Atalay, B. Gref, A. Hovakimian, B. Okdahian, Taliyan*; 1Ankara City Hospital, Ankara, TURKEY, 2University of Health Sciences, Ankara, TURKEY.

EPS-105 123I-FAPi PET/CT Accuracy In Patients With Recurrent Medullary Thyroid Carcinoma
U. Elbergaa, Z. Sayyarta, E. Shurib, S. Zakoura, Y. Caykla, Y. Celen, E. Akarsu; Gaziantep University, Gaziantep, TURKEY.

EPS-106 Knowing like the back of one’s hand the ***Tc-sestamibi Uptake Mechanism: Could a Simple Parathyroid Scan Be an Essential Tool for Studying BAT?
W. Jalloula, I. Rosalb, C. Archipa, A. Tatar, R. Tüeb, S. Chiperv, J. Gremoua*; 1University of Medicine and Pharmacy U.M.F “Grigore T. Popa”, Iasi, ROMANIA, 2Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EPS-107 Combinant lithium increases radioidine uptake and absorbed doses per volume-adjusted administered activity in Graves’ disease: A Comparison of conventional versus lithium augmented radioiodine therapy
S. Leali1,2,3,4, D. Polito2,3,4, S. Bortolillo1,2,3,4, G. Mola1,2,3,4, C. Spanu2,3,4, G. Sardella1,2,3,4, L. Iovene1,2,3,4, M. R. Aime1,2,3,4, G. Capanelli1,2,3,4, M. de Marchis1,2,3,4, M. Maimone1,2,3,4, L. Scopinaro1,2,3,4, C. Mingels1,2,3,4, J. Hünermund, K. P. Bohn, A. Rominger, A. Afshar-Noori; 1Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND, 2Department of Internal Medicine, University of Bern, Bern, SWITZERLAND, 3Department of Nuclear Medicine, University of Geneva, Geneva, SWITZERLAND, 4Department of Nuclear Medicine, Austin Health, Melbourne, AUSTRALIA.

EPS-108 Accuracy of Choline PET/CT vs Tc 99m Sestamibi SPECT/CT Parathyroid Imaging in Comparison to Histopathology in the Diagnosis of Parathyroid Adenoma
B. Teo; Philippine Heart Center, Quezon City, PHILIPPINES.

EPS-109 Kinetic analysis of 18F-FICETO in subjects with adenocortical pathologies and validation of simplified quantitative HCG method
L. O’Sullivan, M. Lubbenh, J. Slivin, A. Sundin, M. Gumė; F. Aigbirhio, M. Brown, A. Wall, T. Aisterm, S. Roslin, P. Hellman, G. Anton; 1Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, 2Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 3Department of Medicine, Wellcome Trust-IFIC Institute of Metabolic Science, University of Cambridge, Cambridge, UNITED KINGDOM, 4Department of Neuroimaging, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UNITED KINGDOM, 5Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UNITED KINGDOM, 6Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

EPS-110 Relation between Stratal to Pancreatic Dopaminergic Activity Ratio and Glycated Hemoglobin in Diabetic and Non-diabetic Patients
P. Kalmar; 1Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2Institute for Medical Informatics, Statistics and Documentation, Graz, AUSTRIA.

EPS-111 Concomitant lithium increases radioidine uptake and absorbed doses per volume-adjusted administered activity in Graves’ disease: A Comparison of conventional versus lithium augmented radioiodine therapy
F. Kresse1, A. Schafer-Schuler2, L. Rith1, F. Rosar1, H. Aladwan1, A. Schaefer-Schuler1, F. Kresse1, A. Schaefer-Schuler1, L. Rith1, H. Aladwan1, A. Schaefer-Schuler1, F. Kresse1, A. Schaefer-Schuler1, L. Rith1, H. Aladwan1; 1Department of Nuclear Medicine, Saarland University, Homburg, GERMANY, 2Department of Mathematics, University of Bologna, Bologna, ITALY.

EPS-112 Wednesday, October 20 - Saturday, October 23, 2021 on-demand post, release on Wednesday, October 20 at 00:00
EPS-113 e-Poster Presentation Session 8: Imaging in Recurrent Prostate Cancer
EPS-114 Predictive value of 68Ga-PSMA PET/CT in men with biochemical relapse after radical prostatectomy, undergoing salvage radiotherapy
F. Serani, H. Lazanaslar1, A. Farah1, C. Mallola, R. Men1, F. Medici1, G. Aluosi1, S. Fanti1; 1Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Department of Medical and Biomedical Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 3Radiation Oncology, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 4Radiation Oncology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, ITALY.

EPS-115 Role of 18F-fluorcholine PET/CT for guiding and monitoring reoperation in oligometastatic recurrent prostate cancer patients treated with stereotactic body radiotherapy
E. Noriega-Álvarez1, J. García Zoghbi1, M. Armo-Sará1, L. Calahorra Fernández1, P. V. Rios1, M. de Caba Ropil1, F. Leal Hernández1, M. V. Vilas Sánchez1, M. J. Donate Moreno1, A. M. García Cortégen1, A. M. Sonata Causey1; 1Urologist University Hospital of Ciudad Real, Albacete, SPAIN, 2Department of Mathematics, University of Castilla-La Mancha, Ciudad Real, SPAIN, 3Urológico University General Hospital of Ciudad Real, Ciudad Real, SPAIN, 4Radiology Therapy Oncologist, University Hospital of Ciudad Real, Ciudad Real, SPAIN, 5Urologist Virgen de la Luz Hospital, Cuenca, SPAIN, 6Urológico University General Hospital, Guadalajara, SPAIN, 7Radiation Therapy Oncologist, University General Hospital of Albacete, SPAIN, 8Urológico University Hospital of Ciudad Real, Albacete, SPAIN.

EPS-116 Utility of 18F-choline PET/CT images in real-time transrectal US-guided prostate biopsy

EPS-117 18F-fluciclovine PET/CT in recurrent prostate cancer: detection rate, image interpretation using PROMISE staging system and impact on clinical management
L. Filippi, A. Fontanori, P. Bagno, G. Spinelli, O. Bagno; 1Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, ITALY, 2Department of Radiotherapy, Santa Maria Goretti Hospital, Latina, ITALY, 3Oncology Unit, AUSL Latina (District 1) Sapienza University of Rome, Aprilia, ITALY.

EPS-118 Comparison of 18F-Fluciclovine and 18F-Fluorocholine PET/CT diagnostic performance in recurrent prostate cancer patients
C. Ferrari, A. G. Nappi, V. Lovelli, P. Mammucci, N. C. Merenda, G. Rubini; 1Section of Nuclear Medicine, DIM, University “NABA Mora”, Bari, ITALY.

EPS-119 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer patients with low prostate specific antigen (PSA) rates (<1.1 ng/mL). Searching for a suitable lower cut-off
P. Plaza López1, B. Domenech Basaro2, P. Piñeiro3, N. Romanes2, P. Risco2, O. Coroño1, M. Suarez-Piñera2, J. Torices-Caballero3; 1Hospital Quironsalud Barcelona, Barcelona, SPAIN, 2Hospital General Universitario de Albacete, Albacete, SPAIN, 3Hospital Quironsalud Barcelona, Barcelona, SPAIN.

EPS-120 Impact of 68Ga-PSMA PET-CT on radiotherapy planning in recurrent prostate cancer after radical prostatectomy
C. Varela-Pinto, A. Martíns, V. Sousa, T. Antunes, C. Lourenço; Hospital da Luz Lisboa, Lisbon, PORTUGAL.

EPS-121 Diagnostic accuracy of 18F-PSMA-1007 PET/CT in biochemical recurrent prostate cancer patients - a retrospective analysis
C. Mühlberg, J. Hunermond, K. P. Bohn, A. Römering, A. Alshar-Doerfler, J. L. Alberts; Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND.
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

SCIENTIFIC e-POSTERS

1, M. Daube-Witherspoon1, J. Scheuermann1, A. Young1, R. H. Lee
Section of Nuclear Medicine, DIM, University “Aldo Moro”,
CT compared to 18 F-fluciclovine PET/CT and 99m Tc-MDP
G. Gholami1, H. Dadgar3, A. Masoudifard1;
M. Cruz
Retrospective analysis of PET / CT with 18F-Choline for
I. Martínez-Rodríguez, O. Cuenca-Cancer
[11C]Choline PET/CT in the Follow-up of Prostate
EPS-125
A. G. Nappi, C. Ferrari, N. C. Merenda, G. Santo, C. V. Lavelli
biochemical recurrent prostate patients with
Diagnostic performance of 18F-Fluciclovine PET/CT in
A. Aghaei
induced pneumonia
EPS-123
1,2,3, M. A. Omrane1,2,3, S. Stadlbauer4,5, M. Roscher4,6, W.
hybrid molecule for preoperative PET/CT imaging and
First clinical application of a novel PSMA-11-derived
EPS-134
1Center for Advanced Medical Imaging (CAMI), St James’s
Comparing Q.Clear & OSEM algorithms in detecting
A. Galfano1, A. M. Bocciardi1, C. Rossetti1;
Longoni1, S. Tappero1, E. Gay1, M. Boccardo, C. Rossetti;
ASST Grande Ospedale Metropolitano Niguarda, Milan,
1 University of Milano-Bicocca, Milan, ITALY.

EPS-124
Diagnostic performance of 18F-Fluciclovine PET/CT in
L. Ballestar1, J. Garcia-Leiva2, M. Arribas1, J. Rodriguez1,
EPS-126
Retrospective analysis of PET / CT with 18F-Choline for
C. Tuschi1, A. Barba1, J. Rosas1, M. Rosas1, E. Pons1,
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

SCIENTIFIC e-POSTERS

1, M. Daube-Witherspoon1, J. Scheuermann1, A. Young1, R. H. Lee
Section of Nuclear Medicine, DIM, University “Aldo Moro”,
CT compared to 18 F-fluciclovine PET/CT and 99m Tc-MDP
G. Gholami1, H. Dadgar3, A. Masoudifard1;
M. Cruz
Retrospective analysis of PET / CT with 18F-Choline for
I. Martínez-Rodríguez, O. Cuenca-Cancer
[11C]Choline PET/CT in the Follow-up of Prostate
EPS-125
A. G. Nappi, C. Ferrari, N. C. Merenda, G. Santo, C. V. Lavelli
biochemical recurrent prostate patients with
Diagnostic performance of 18F-Fluciclovine PET/CT in
A. Aghaei
induced pneumonia
EPS-123
1,2,3, M. A. Omrane1,2,3, S. Stadlbauer4,5, M. Roscher4,6, W.
hybrid molecule for preoperative PET/CT imaging and
First clinical application of a novel PSMA-11-derived
EPS-134
1Center for Advanced Medical Imaging (CAMI), St James’s
Comparing Q.Clear & OSEM algorithms in detecting
A. Galfano1, A. M. Bocciardi1, C. Rossetti1;
Longoni1, S. Tappero1, E. Gay1, M. Boccardo, C. Rossetti;
ASST Grande Ospedale Metropolitano Niguarda, Milan,
1 University of Milano-Bicocca, Milan, ITALY.
EP5-141
“Ga-PSMA PET/CT in primary staging of prostate cancer (PC) patients: risk of metastatic disease”
M. Dyankova1, T. Stoever1, Z. Dancheva1, T. Vardanova1, S. Chausheva1, B. Chausheva1, A. Klisarova1; 1Medical University Varna “Prof. Dr. Paraskev Stoyanov”, Department of Nuclear Medicine, Varna, BULGARIA, 2St Marin University Hospital, Varna, BULGARIA.

EP5-142
Is there an ideal tracer for pre-surgical nodal staging primary PCa? Monocentric experience of 68Ga/PSMA and 18F/Fluciclovine performance in two high-risk populations
F. Mattana1, L. Biondi1, E. Balintzaft1, F. Costa1, A. Farolfi1, R. Mei1, C. Malizia1, M. Draghetta1, P. Castellucci1, R. Schiavina2, R. Bruno2, L. Zannon1, S. Fanelli1; 1IRCAS Azienda Ospedaliero-Universitaria di Bologna, Metropolitan Nuclear Medicine, Bologna, ITALY, 2IRCAS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, ITALY.

EP5-143
The impact of 68Ga-Ga-PSMA-11 PET/CT in primary staging of prostate cancer
F. Weitzer1, B. Pernthaler1, E. Plhak1, R. Riedl1, R. M. Aigner1; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Nuclear Medicine Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 3INAIL-DIMEILA, Università Cattolica del Sacro Cuore, Rome, ITALY, 4Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 5Hematology and Other Hematological Diseases.

EP5-144
Correlation of Intraoperative Malignant Lesions Using F18-Prostate Specific Membrane Antigen Positron Emission Tomography (F-18 PSMA1007 PET/CT) with Magnetic Resonance Imaging (MRI) and Transrectal Ultrasound (TRUS) Biopsy Results in Initial Staging of Prostate Cancer, Single Institution Experience
A. Sadeq1, W. Mohsh1, A. Emrani1, F. Marafi1, M. Ataee1; Jaber AAMIad center for Molecular Imaging, Shuwaikh Medical area, KUWAIT.

EP5-145
Gallium-68 ([68Ga] labeled prostate specific membrane antigen (PSMA)-11 PET/CT in primary nodal and distant staging of prostate cancer (PC) patients compared to conventional imaging modalities ( CT, MRI, bone scintigraphy): a retrospective single center study
M. Dyankova1, T. Stoever1, T. Vardanova1, S. Chausheva1, B. Chausheva1, A. Klisarova1; 1Medical University Varna “Prof. Dr. Paraskev Stoyanov”, Department of Nuclear Medicine, Varna, BULGARIA, 2St Marin University Hospital, Varna, BULGARIA.

EP5-146
The Role of PSMA PET/CT in Primary Staging of Prostate Cancer according PSMA-RADS scale and correlation with prognostic staging from AJCC 8th Edition
S. Medina-Ormelas1, P. Garcia-Hernandez, E. Gomez-Arugomosa, J. Vargas-Islamidas1; Instituto Nacional de Cancerologia, Mexico City, MEXICO.

EP5-147
“F-Florastamin PET/CT for the initial staging of patients with high-risk prostate cancer
W. H. Choi1, S. Boo1, Y. Choi1, H. Kim2, S. Lee2; 1Department of Nuclear Medicine, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF, 2Lymphoma and Other Hematological Diseases.

EP5-148
E. Triunbardi1, S. Amannuzzo1, A. Pelliccioni1, S. Hohaus4,5, E. Mosol, A. Giordano1; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Nuclear Medicine Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 3INAIL-DIMEILA, Università Cattolica del Sacro Cuore, Rome, ITALY, 4Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 5Hematology Unit, Department of Experimental and Clinical Biomedical Sciences, Firenze, ITALY.

EP5-149
18F-FDG PET/CT Volumetric and Radiomic Features predict Histological Types of Bulky Mediastinal Lymphoma
E. Abenavoli1, F. Lengnante1, B. Raciti1, F. Menghi2, S. Crisì3, I. Romano1, V. Mile1, R. Scaglìa1, V. Bern4; 1Section of Nuclear Medicine, Azienda Ospedaliera–Universitaria Careggi, Firenze, ITALY, 2Lymphoma unit, Hematology department, Careggi Hospital and University of Florence, Firenze, ITALY, 3Department of Radiology, Azienda Ospedaliera–Universitaria Careggi, Firenze, ITALY, 4Department of Radiology, Azienda Ospedaliera–Universitaria Careggi, L, Firenze, ITALY, 5Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY, 6Department of Experimental and Clinical Biomedical Sciences, Firenze, ITALY.

EP5-150
Predicting Time to Treatment in Follicular Lymphoma on Watchful Waiting using Baseline Metabolic Tumor Burden
D. Maccora1, L. Lecisotto1, R. Malisfonte1, F. DiAio1, S. Amannuzzo1, S. Hohaus1, V. Ruffini1; 1Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 3INAIL-DIMEILA, Università Cattolica del Sacro Cuore, Rome, ITALY, 4Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, 5Hematology Unit, Department of Experimental and Clinical Biomedical Sciences, Firenze, ITALY.

EP5-152
Can [F-18]FDG PET/CT early detect treatment-related cardiotoxicity in patients with lymphoma
F. Wei1, T. Yuan2, X. Chen, W. Wang; Peking university cancer hospital, BeiJing, CHINA.

EP5-153
Impact of [F-18]FDG PET / TC for Assessing Response to Chimeric Antigen Receptors T Cell Therapy (CAR-T Cells) in the Treatment of Refractory Non-Hodgkin Lymphoma
J. Andia Mantilla1, I. Gómez Fernández1, M. Baquero Oliveros1, A. Rodríguez Regí1, J. Ocaña Rincón1, C. Durán Barrera1, M. Kwon1, M. Bastos Orellana1, M. Toscano Sánchez1, J. Alonso Fanta2; Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP5-154
Utility of serial PET imaging by Peking criteria to prospectively predict prognosis in patients with diffuse large B-cell lymphoma
T. Yuan1, W. Wei1, X. Chen, X. Wang; Peking University Cancer Hospital & Institute, BeiJing, CHINA.

EP5-155
Quantification of whole-body ([F-18]FDG avid lymphoma lesions: advantages of semiautomated over manual segmentation
C. S. Constantino1, S. Leocadía1, F. Oliveira1, M. Silva1, C. Oliveira1, J. C. Castanheda1, A. Silva1, V. Reina2, M. Neves1, P. Lúcia1, J. Jodo1, D. C. Costa1; Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL.

EP5-156
Role of [F-18]FDG PET / TC in Predicting the Adverse Effects of Chimeric Antigen Receptors T Cell Therapy (CAR-T Cells) In The Treatment of Refractory Non-Hodgkin Lymphoma
I. Gómez Fernandez1, J. Andia Mantilla1, M. Baquero Oliveros1, A. Rodríguez Regí1, J. Andia Manjarrez1, M. Kwon1, M. Bastos Orellana1, M. Toscano Sánchez1, J. Alonso Fanta2; HSU Gregorio Marañón, Madrid, SPAIN.

EP5-157
Series interim “[F-18]FDG PET/CT stratify the prognosis of patients with Hodgkin lymphoma:based on Peking Criteria
M. Wei1, X. Chen1, T. Yuan2, X. Wang; Peking University Cancer Hospital, BeiJing, CHINA.
EANM'21 WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

EANM'21 WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

EAN-158
Evaluation of the volumetric parameters calculated with the 2-[18F]FDG PET/CT and the molecular characteristics in patients with diffuse large B cell lymphoma, not otherwise specified
S. Guzmán Ortiz1, J. Mucientes Rassia1, J. A. Vargas Nuñez1, J. L. Rodríguez Camillo1, A. Doctor de Luna1, M. B. Navarro Martí1, M. Mitjavila Casanovas1,2,3,4
1Puerta de Hierro University Hospital, Madrid, SPAIN, 2Autonomous University of Madrid, Madrid, SPAIN.

EAN-159
The role of 99mTc-FFDG PET/CT in Erdheim-Chester Disease
M. Pudas1, A. Palamaru-Nunuc1, K. López-Alabas1, X. Solansich-Moreno1, J. J. Rabies-Bals1, F. Llaneras-Tel1, J. E. Sánchez-Rodriguez1, L. Rodríguez-Ber1, S. Bondía-Bescos1, M. Cortés-Pudis1
1,2Hospital Universitario Vall d’Hebron, Barcelona, SPAIN, 3Department of Endocrinology, Jürgenellian University Medical College, Krakow, POLAND.

EAN-160
Assessment of PRRT Response from SUV-SPECT & PET, a-Poster Presentation Session 11: Neuroendocrine and Lymphoma
A. Cardozo Saavedra1, E. Gracia Antona1, J. Romera1; Rodríguez1, L. Rodríguez-Bel1, S. Bondía-Bescos1, M. Cortés-Pu1dis1
1Department of Nuclear Medicine - Würzburg University Hospital Universitärmedizin, Würzburg, GERMANY, 2Department of Hematology, Onco1logy and Radiotherapy, Heidelberg, GERMANY, 3University Hospital Heidelberg, Department of Hematology, Oncology and Radiotherapy, Heidelberg, GERMANY, 4Roswell Park Comprehensive Cancer Center, Buffalo, NY, UNITED STATES OF AMERICA.

EAN-161
Concordance between baseline 68Ga-DOTATOC PET/CT and first post-dose 177Lu-octreotate SPECT/CT (177Lu-OCT-DOTATE-SPECT/CT) images in patients with neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
A. Cardozo Saavedra1, M. Simó2, A. Páez-Sola1, M. Simó1, J. Capdevila2, S. Aguadé3,4,5
1Hospital Universitario Vall d’Hebron, Barcelona, SPAIN, 2Hospital Universitas Vasa, Helsingfors, Finland.

EAN-162
Assessment of PRRT Response from SUV-SPECT & PET, Personal Dosimeter and Biochemical Metrics
T. Alkahtani1,2, P. Y. Livieratos1, V. Lewington1, T. Alkahtani1
1,2Autonomous University of Madrid, Madrid, SPAIN.

EAN-163
Dynamic changes of SUVs in 68Ga-somatostatin analogue PET/CT response to PRRT as a predictive factor in patients with neuroendocrine tumors
M. Opalinski1, A. Sosa-Staszel1, A. Kami-Ruc1, A. Marzan1, K. Mozerski-Skalek1, A. Hulańska-Dydzylczyk1
1,2National Medical Unit, Endocrinology Department, University Hospital, Krakow, Kraków, POLAND, 3Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EAN-164
Evaluation of 177Lu-DOTATATE treatment in patients with metastatic or unresetable paragangliomas and pheochromocytomas
J. Carlon Sánchez1, S. G. Paolo Wohlwend1, P. Bello Arques1, J. C. Bernal Vargna1, A. Uthera Castro1, Hospital Universitario de Palencia, Palencia, SPAIN.

EAN-165
Role of Interim CT Scan in Patients with Neuroendocrine Tumors (NETs) Treated with 177Lu-octreotate (177LuLu): Love it or List it
S. Menendez-Sanchez1, A. Gancio-Bunza1, J. Hernando1, D. Vilarrovi-Rioscales1, A. Cardozo-Saavedra1, M. Simo2, J. Capdevila2, S. Aguadé3,4,5
1Hospital Universitario Vall d’Hebron, Barcelona, SPAIN, 2Hospital Universitas Vasa, Helsingfors, Finland.

EAN-166
Evaluation and improvements of small VOI method for kidney dosimetry in patients undergoing radioiodine targeted therapy with 131I-DOTATATE
1Department of Medical Radiation Sciences, Institute of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University Hospital, Gothenburg, SWEDEN, 2Department of Nuclear Medicine and Medical Imaging, Stockholm University Hospital, Stockholm, SWEDEN, 3Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, 4Department of Medical Radiation Sciences, Institute of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University Hospital, Gothenburg, SWEDEN, 5Department of Medical Radiation Sciences, Institute of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University Hospital, Gothenburg, SWEDEN.

EAN-167
Dynamic changes of SUVs in 68Ga-somatostatin analogue PET/CT response to PRRT as a predictive factor in patients with neuroendocrine tumors
M. Opalinski1, A. Sosa-Staszel1, A. Kami-Ruc1, A. Marzan1, K. Mozerski-Skalek1, A. Hulańska-Dydzylczyk1
1,2National Medical Unit, Endocrinology Department, University Hospital, Krakow, Kraków, POLAND, 3Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.

EAN-168
Simulation of selective ablative liver metastases in neuroendocrine tumor patients
V. Santoro-Fernandes1, B. Scho1, D. Huf1, T. Peck1, A. Dosiach1, S. Pettman1, R. Jenner1
1University of Wisconsin-Madison, Department of Medical Physics, Madison, WI, UNITED STATES OF AMERICA, 2University of Wisconsin-Madison, Department of Radiology, Madison, WI, UNITED STATES OF AMERICA, 3AQI Global, Inc., Madison, WI, UNITED STATES OF AMERICA, 4University of Wisconsin School of Medicine and Public Health, Department of Radiology, Section of Nuclear Medicine and Molecular Imaging, Madison, WI, UNITED STATES OF AMERICA, 5University of Wisconsin-Madison, Carbonne Cancer Center, Madison, WI, UNITED STATES OF AMERICA, 6University of Ljubljana, Institute of Physics, Ljubljana, SLOVENIA.

EAN-169
Toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumours
J. Bonilla Plaza1, A. Martínez Lara1, T. Navarro Martínez1, O. Alqawan1, J. Lopez-Villac1, P. Aspesi Hernandez1, M. Gutierrez Guzmán1, P. Paredes Rodriguez1, M. Orduña Diez2, Hospital Ramón y Cajal, Madrid, SPAIN.

EAN-170
Extended field imaging in F-18 FDG PET/CT in Multiple Myeloma; is it necessary?
Z. Kok1, P. P. Özcan1, A. Akdeniz2, Z. S. Sağlam2
1Akdeniz university faculty of medicine nuclear medicine department, Antalya, TURKEY, 2Akdeniz university faculty of medicine radiology department, Antalya, TURKEY.

EAN-171
Importance of non attenuation corrected 18F PET/CT images in multiple myeloma (MM) vertbroplasty treated patients to avoid false positive reported images
M. Agolli 1, S. Solari1, Centro de Medicina Nuclear Clinica Modella, Parana, ARGENTINA.

EAN-172
Image quality assessment of [68Ga] Gallium-CCK4-PET/CT in multiple myeloma and diffuse large B cell lymphoma
A. Lambertini1, P. Hartmann1, A. Haug2, A. K. Buck2
1Department of Nuclear Medicine – Würzburg University Hospital, Würzburg, GERMANY, 2Division of Nuclear Medicine – Medical University of Vienna, Vienna, AUSTRIA.

EAN-173
Correlation of histopathological and [18F]FDG-PET/CT data in patients with symptomatic multiple myeloma
M. Türk1, C. Sipirci2, S. Sauer1, J. Hillinger1, A. Dimitrakopoulou-Strauss1
1Ruprecht Karl University of Heidelberg, Heidelberg, GERMANY, 2German Cancer Research Center (DKFZ), CCLU Nuclear Medicine, Heidelberg, GERMANY, 3University Hospital Heidelberg, Department of Hematology, Oncology and Rheumatology, Heidelberg, GERMANY, 4Roswell Park Comprehensive Cancer Center, Buffalo, NY, UNITED STATES OF AMERICA.

EAN-174
Comparison of FDG PET/CT and MRI Imaging in the Evaluation of the Treatment Response in Patients with Head and Neck Cancer
M. Engin1, F. Aydil1, A. Arayci1, C. Dundar Caglayan1, E. Tezil2, K. Karsah1, A. Tat1, M. Genç Dözyar1
1Akdeniz university faculty of medicine nuclear medicine department, Antalya, TURKEY, 2Akdeniz university faculty of medicine radiology department, Antalya, TURKEY, 3Akdeniz university faculty of medicine medical oncology department, Antalya, TURKEY, 4Akdeniz university faculty of medicine radiation oncology department, Antalya, TURKEY.

EAN-175
Clinical Effectiveness of Sentinel Node Biopsy In Early Oral Cavity Carcinoma
Y. Herrera-Martínez1, A. De Bonilla-Damí1, V. Pachón-Garrido1, A. Álvarez1,2,3,4,5
1Hospital Universitario Virgen del Rocío, Seville, SPAIN, 2Hospital Universitario Universitario Virgen del Rocío, Seville, SPAIN.

EAN-176
The utility of multiparametric imaging with 18F-FDG PET and MRI in predicting survival outcome of patients with nasopharyngeal carcinoma
S. Chan1, C. Yeh1, T. Ng1, J. Chung1,2
1Huazlen Tsai Chi Hospital, Huazien, TAIWAN, 2Sinko Chang Gung Memorial Hospital, Taoyuan, TAIWAN.
EPS-178 Delayed complete metabolic response assessed with 18F-FDG-PET/CT in two time-points in patients with malignancies of the head and neck tumor after radiotherapy with or without systemic chemotherapy: three clinical cases

T. Yordanova, A. Kizhanova, T. Stoeva, S. Chauheva, M. Dyankova, Z. Dancheva, B. Chauxheva; Medical University Prof. Dr. P. Staynov, Department of nuclear medicine, Varna, BULGARIA.

EPS-179 Quantitative assessment of bone metastases in breast cancer patients

M. Mutuleanu, A. Lazar, I. Ionescu, M. Gheorghe; National Institute of Oncology “Prof.Dr.Alexandru Trestioreanu”, Bucharest, ROMANIA.

EPS-180 Metabolic Parameters By FDG PET-CT As Predictor Of Poor Prognosis In Breast Cancer Patients

S. Ali; I. Llahmadawzy, H. Fathy; 1National Cancer Institute, Cairo, EGYPT; 2National Cancer Institute, Cairo, EGYPT.

EPS-181 Incidental detection of breast cancer on [18F]fluorocholine PET/CT: a retrospective analysis

A. Androja; M. Hocevar1, S. Rep1, K. Kazdet1, L. Lezak1; 1Department of Nuclear Medicine, University medical centre Ljubljana, Ljubljana, SLOVENIA; 2Slovenian Oncological Surgery, Oncology institute Ljubljana, Ljubljana, SLOVENIA; 3Faculty of health sciences, Ljubljana, SLOVENIA.

EPS-182 Differences between supine and prone images in 18F-PET/CT in restaging breast cancer. Development of a soft matting device to acquire prone images with better resolution

M. Agolti; V. Čepek; 1Clinic of Nuclear Medicine, University Hospital, Erlangen, GERMANY; 2Department of Nuclear Medicine, Manisa, TURKEY; 3Celal Bayar University, Mersin University, Mersin, TURKEY.

EPS-183 Submandibular gland involvement, as an unusual and the only site of breast cancer metastasis, detected in FDG PET/CT study

A. Aghaei, M. Aghaei, A. Beigerman, S. Soyluoglu, B. Ozdemir; 1Department of Nuclear Medicine, Trakya University Department of Nuclear Medicine, Edirne, TURKEY; 2Trakya University, Department of Radiology, Edirne, TURKEY.

EPS-184 FDG Uptake in Breast Cancer and Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Association with Histopathological, Hormonal Status and Features

G. Alçın; T. Aksoy, T. F. Çermik; 1University of Health Sciences, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY.

EPS-185 18F-FDG PET/CT In The Characterization Of The Different Histological Subtypes Of Pulmonary Neuroendocrine Tumors And Its Prognostic Value

A. Periáñez Cepeda; P. García-Talavera San Miguel, I. Villanueva Curtis, J. Carrión Salazar, S. López-Puche, J. Badell-Martínez, C. Rosas Parada, B. Lucas Velázquez, F. Gómez-Camino; 1Department of Nuclear Medicine, University Hospital, Luján, BUENOS AIRES, Argentina; 2Depts. of Radiology and Internal Medicine, University Hospital, Luján, BUENOS AIRES, Argentina; 3Celal Bayar University, Mersin University, Mersin, TURKEY.

EPS-186 Dynamic whole-body [18F]-FDG PET/CT in patients with unclear lung tumors - evaluation of multiparametric dynamic imaging in a clinical setting

M. Weissinger; M. Ammannacher, H. Dietmann1, S. Gaitai1, L. Zender1, C. F. Rougier1; 1Department of Radiology, University Hospital Tübingen, Tübingen, GERMANY; 2Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY, 3Internal Medicine VII, University Hospital Tübingen, Tübingen, GERMANY.

EPS-187 Incidental Renal Mass on PET/CT in Lung Cancer Patients, Evaluation With Histopathological Radiological And Clinical Findings: Pearls, Pitfalls and False Positives

B. Özdemir; S. Seyluluğ1, U. Korakmaz1, B. Gunay1, B. Ural1; G. Oktay; 1Trakya University, Department of Nuclear Medicine, Edirne, TURKEY; 2Trakya University, Department of Radiology, Edirne, TURKEY.

EPS-188 Evaluation of Two Thoracic Dedicated Imaging Techniques for Lung CT Stabilisation Applied to PET/CT in Lung Nodule Assessment: High-Frequency Non-Invasive Ventilation (HF-NIV) and Breath-Hold (BH)

M. Jreige; E. Darogt, M. Happer, M. Nicro-Latonde, N. Schaefer, C. Bergelmann-Aubry, J. O. Piar; 1Lausanne University Hospital, Lausanne, SWITZERLAND.

EPS-189 Predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET / CT

F. Aras; A. Olmezoglu1, A. G. Kamas1, A. Kosut2, A. F. Ciftci2, A. Ay2, S. Cemel2, F. Sahin2; 1Celal Bayar University, School of Medicine, Department of Nuclear Medicine, Manisa, TURKEY; 2Celal Bayar University, School of Medicine, Radiation oncology, Manisa, TURKEY.

EPS-190 Renal metastasis of primary lung carcinoma is associated with death and progression predicted by F-18 FDG PET/CT

Z. Koc; P. P. Czarnecki, V. Engolak, Y. Karabulut; 1Mersin University, Mersin, TURKEY.

1712 Wednesday, October 20 - Saturday, October 23, 2021 on-demand prod, release on Wednesday, October 20 at 09:00

e-Poster Presentation Session 13: Image Acquisition / Reconstruction / Processing 1

EPS-191 Determination of Partial Volume Effect in Patient-Individual Kidney Phantoms for Tc-99m SPECT/CT

A. Grings; T. Kuwert, P. Ritt; 1Clinic of Nuclear Medicine, Erlangen, GERMANY.

EPS-192 Patient-Specific Phantoms for Tc-99m Brain Perfusion Imaging with SPECT/CT

A. Grings; M. Reynar1, A. H. Wijl1, T. Kuwert1, P. Ritt1; 1Clinic of Nuclear Medicine, University Hospital, Erlangen, GERMANY.

EPS-193 The potential of 18F-FDG PET/CT for monitoring disease progression of malignant PEComa

A. Martin1; A. Cappola1, A. Arena1, M. Danu1, G. Bald1, S. Sestri1; 1Hospital Santo Stefano, Nuclear Medicine Unit, Prato, ITALY; 2University of Florence, AOO Cavogio Nuclear Medicine Department, Florence, ITALY; 3Hospital Santo Stefano, Oncology Unit, Prato, ITALY.

EPS-194 Application of PET/CT Studies in Radiotherapy Using Deformation Algorithms


EPS-195 Dynamic PSMA PET/MRI imaging: initial results

M. Gammel, J. Raucher, M. Eber, W. A. Weber, S. G. Nekolla; TU München, München, GERMANY.

EPS-196 How refinements in the DROP-IN design improve surgical dexterity and surgical decision-making during radiosurgery

S. Azargoosh1, S. van Aperen1, E. J. StoI1, G. Rosendal1, S. Pulats1, S. i. van Leeuwen2, K. M. Houwing2, M. Boekemamp3, J. Verhaert, H. Del’Oglio4, J. I. van der Hage5, M. N. van Oosterom1, F. W. B. van Leeuwen1; 1Leiden University Medical Center, Leiden, NETHERLANDS; 2Department of Neurosurgery, University of Modena and Reggio Emilia, Via del Pizzoc, Modena, ITALY; 3InstrumentsS zaken ontwikkeling, Facilair bedrijf, Leiden University Medical Center, Leiden, NETHERLANDS; 4Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY; 5Department of Surgery, Leiden University Medical Center, Leiden, NETHERLANDS.

EPS-197 Dexterity and performance analysis in PET-navigated biopsies

I. Boekestijn, S. Azargoosh, L. Pronk, A. R. van Eerdt, M. N. van Oosterom, F. W. van Leeuwen, D. D. Rietbergen; Leiden University Medical Center, Leiden, NETHERLANDS.
EPS-199
Selective sentinel lymph node biopsy (SLNB) in infiltrating breast cancer and neoadjuvant therapy
S. Perez Quirós, L. Fuentes Moreno, A. Prieto Soriano, M. Ramirez Medina, G. Silvestre Egea, J. Cardona Arbanes, S. Gúzman Ortiz, V. Spinelli Rinté, M. Mitjavila Casanovas, Hospital Universitario Puerta de Hierro, Majadahonda, SPAIN.

EPS-200
3D digital reconstruction of anatomical models integrating PET/CT data for pre-operative planning in gynecologic oncology surgery: a preliminary study
L. Muraglia1, P. Castellucci2, B. Bortolani3, S. Lodi3, P. De Iaco4,1, M. Perrone1, L. Cercenelli3, E. Marcelli3, S. Fanti1;
1Università di Bologna, Bologna, ITALY, 2Metropolitan Nuclear Medicine, University Hospital, Aarhus N, DENMARK, 3Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, CANADA, 4Prostate Cancer Research and Development, University of Sydney-ANSTO NIF node, University of Sydney, Sydney, AUSTRALIA.

EPS-201
SEmi-Automated Analysis Of Amyloid-PET Images Allows To Shorten Acquisition Time With Accuracy Comparable To Standard Time
1European University Cyprus, Nicosia, CYPRUS, 2E.U.C. Research Center, Nicosia, CYPRUS, 3Fredrick Research Center, Nicosia, CYPRUS, 4Fredrick University, Nicosia, CYPRUS, 5Department of Medical Physics, State Health Services Organisation, Nicosia, CYPRUS, 6Department of Nuclear Medicine, Nicosia General Hospital, State Health Services Organisation, Nicosia, CYPRUS.

EPS-202
Optimization of cardiac atrial metabolism quantitative analysis with digital TOF-PET/CT
M. Hesse1, S. Marchandie2, B. Gerber1, R. Chambon1, V. Roelants1, Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

EPS-203
Motion Correction in 15O-water Cardiac PET
Y. Hsieh1, K. Brüser2, C. L. Wright1, B. Zhang1, P. Mianiawski3, M. V. Knopp4;
1The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EPS-204
Using prone position to reduce motion induced artefacts during SPECT myocardial perfusion imaging
I. Polycarpou1, G. Chatzou1, S. Panagis1, D. Kaziol2, I. G. Petrou3, T. Parpottas4,1;
1European University Cyprus, Nicosia, CYPRUS, 2E.U.C. Research Center, Nicosia, CYPRUS, 3Fredrick Research Center, Nicosia, CYPRUS, 4Fredrick University, Nicosia, CYPRUS, 5Department of Medical Physics, State Health Services Organisation, Nicosia, CYPRUS, 6Department of Nuclear Medicine, Nicosia General Hospital, State Health Services Organisation, Nicosia, CYPRUS.

EPS-205
The combination of a dedicated HD Readout Circuit and the TOFPE2 ASIC to Push the Timing Performance of PET Systems
V. Nadig1, S. Gandacker1, H. Rodarmelcher1, D. Schug2, B. Wessler1, V. Schulz3,1, B. Roth1,1;
1Department of Physics of Molecular Imaging Systems, Institute of Experimental Molecular Imaging, RWTH Aachen University, Aachen, GERMANY, 2Hyperion Hybrid Imaging Systems GmbH, Aachen, GERMANY, 3Aachen University Institute for Digital Medicine MEVIS, Aachen, GERMANY.

EPS-209
3D-printed Source Holder for Dose Calibrators Enables Quantification of the Geometrical Effect of Source Position in Activity Measurements
T. Miettinen1, S. Pelkonen1, L. Kavvada1, V. Rejonen1, E. Hepellänen2,1;
1Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, 2Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND.

EPS-210
EPS-208
On the Combination of a Dedicated HD Readout Circuit and the TOFPE2 ASIC to Push the Timing Performance of PET Systems

EPS-211
Evaluation of liver tumour size and activity using three-dimensional multi-modality imaging
A. Scott1,2, K. Mardon2, T. Hung3, W. Lakshantha4, M. V. Korn5,6,7;
1University of Queensland, Brisbane, AUSTRALIA, 2University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA, 3Philips Healthcare, Boston, MA, UNITED STATES OF AMERICA, 4Department of Nuclear Medicine, University of British Columbia, Vancouver, BC, CANADA, 5School of Medicine, University of Victoria, Vancouver, BC, CANADA, 6University of Sydney, Sydney, AUSTRALIA, 7University of Sydney-ANSTO NIF node, University of Sydney, Sydney, AUSTRALIA.

EPS-212
Dose Reduction Strategies for Optimizing [89ZR]Zr-Df-IAB2M2C PET Scans Using Virtual Reconstruction (VR) Techniques
R. Korn1, A. Abbott1, J. Sunderland1, I. Wilson1, W. Le1,1,2;
1ImaginAB, Inglewood, CA, UNITED STATES OF AMERICA, 2University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.

EPS-213
Assessing quantitative threshold with FES PET/CT imaging in metastatic breast cancer
L. Ferrer1, B. Mascherani1, T. Cäcker1, M. Lombrano1, S. Giraud2, A. Leduc-Pennec3, F. Kraebel-Bodéré3,4, C. Rousseau4,5,6,7;
1ICO René Gauducheau, St Herblain, FRANCE, 2CRCINA UMR 1232 INSERM, Nantes, FRANCE, 3University Hospital, Nantes, FRANCE, 4ICO Paul Papin, Angers, FRANCE, 5University Hospital, Brest, FRANCE, 6Nantes University, Nantes, FRANCE.

EPS-214
A new fully automated method for lung segmentation using low-dose CT
S. Urban1, E. Szabó2, Z. Mikó1, J. Cink1, Z. Besenyő1, L. Pávics1;
1Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, 2Institute of Informatics, University of Szeged, Szeged, HUNGARY.

EPS-215
R. Pedrego1,2, K. Cooper1, C. Rosier1, C. Goswamy1, A. Hart1, A. Rahm1, M. Usher2,1,2;
1BC Cancer Research Institute, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA, 3Genome Science Institute, Vancouver, BC, CANADA, 4Children’s Hospital, Vancouver, BC, CANADA, 5University of Victoria, Vancouver, BC, CANADA, 6BC Cancer, Vancouver, BC, CANADA.

EPS-216
Comparison of atlas-based and manual segmentation versus simple ROI placement for quantification of liver and spleen metabolism in FDG-PET/CT
T. Kotwal1, G. Kosaka1, A. Mahata1, S. B. Barrington1, P. Marsden1, B. M. Fischer1;
1King’s College London, London, UNITED KINGDOM.

EPS-217
Social Media for Scientific Research: a preliminary evaluation of the impact of Publication on Numbers of Citations of Medical Imaging Publications
A. Forcina Barreiro1, G. Convento2, S. Di Giorgio1, M. Grondelli1, B. Magazzù1, S. Tarchi1, M. Sollini1,2, N. Gozzi2, A. Chiti1,2;
1232 INSERM, Nantes, FRANCE, 2CRCINA UMR 1232 INSERM, Nantes, FRANCE.

EPS-218
Evaluation of Inter-user Variability and Time-savings for a Semi-automated Segmentation Method of Planar Gallbladder and Renal Exams
K. Krowiacek, T. J. Taylor, T. Martin1, S. McGurk1, S. Whittmash1, A. S. Nelson1;
1MM Software Inc, Cleveland, OH, UNITED STATES OF AMERICA, 2Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UNITED KINGDOM, 3Beth Israel Deaconess Medical Center, Boston, MA, UNITED STATES OF AMERICA.
EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

EANM’21  WORLD LEADING MEETING
OCTOBER 20 - 23, 2021

FINAL PROGRAMME
SCIENTIFIC e-POSTERS

Freitas1,2, S. Teixeira1,2, V. Vieira1,2, M. Machado1, C. Constantino1, F. Oliveira1, D. C. Costa1; 1Oxford University Hospitals, Oxford, UNITED KINGDOM, 2Royal

imaging deconvolution acquisitions for use in I-131 post-therapy planar

Key considerations when undertaking PSF, C. L. Wright, M. V. Knopp; 1EPS-222

MR scanner

Validation of PET data resampling methods to

Turku PET Centre, Turku University Hospital, Turku, FINLAND.

1904

Wednesday, October 20 - Saturday, October 23, 2021

on-demand pool, release on Wednesday, October 20 at 09:00

Technologists' e-Poster Presentation Session - Sharing Technologies' Experience

TEPS-01

Effective half-life, excretion and radiation exposure of 177 Lu PSMA

Y. Parlaê, D. Goksoy, G. Mutlu, K. Kavuncu, E. Sayit; C ek S Bayar University, Manisa, TURKEY.

TEPS-02

Reconstruction with 2 mm voxel size improves the detection of small parathyroid adenomas with [18F] fluorocholeline PET/CT

S. Rep; 1M. Hoesen2, P. Terer1, K. Zaletel2, A. Gudeman1, I. Lezak1; 1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of medicine, University of Ljubljana, Ljubljana, SLOVENIA.

TEPS-03

PET/CT reconstruction study using 2 mm voxel size for improved image quality

S. Rep; 1P. Terer1, J. Jensterle1, K. Zaletel1, I. Lezak1; 1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of medicine, University of Ljubljana, Ljubljana, SLOVENIA.

TEPS-04

Radiolabeling of a glucose derivative with technetium-99m for the diagnosis of brain cancer

E. de Juan, A. Buzancic, E. Ivetonic, R. Seder, I. Shekhovtsov, 1Tomsk State University, Tomsk, RUSSIAN FEDERATION, 2Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION.

TEPS-05

Results Of The Initial Examinations With MiBiTop 1 mg Freeze Dried Kit

S. Keresztes1, 1M. Madariaga1, G. Nagy1, S. Barna1, M. Antal1; 1Institute of Isotopes Co., Ltd., Budapest, HUNGARY, 2Soramed Ltd., Debrecen, HUNGARY.

TEPS-06

Fully-automated production of 68Ga-FAPi-46 in TRAÎSIS mini AIO and quality control with TLC and HPLC methods

R. Shukurov1, Z. Dadashov2, M. Valyev1, M. Balashov3, C. Isayev3, K. Ermanyaz2, F. Vail1, F. Nowrouzi3; 1Azerbaijan National Centre Of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, 2SOFIE, Turku University Hospital, Turku, FINLAND, 3Department of Nuclear Medicine, Baku, AZERBAIJAN.

TEPS-07

Technical validation of myocardial flow reserve measurement using a dynamic cadmium-zinc-telluride camera

T. Niimi, K. Uno1, S. Yoshida1; 1Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, 2Teikyo University, Tokyo, JAPAN.

TEPS-08

Evaluation of attenuation correction CT Parameters on PET Image Quality and Quantification

K. Binarz1, C. J. Wright1, M. V. Knopp; The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA.

TEPS-09

Technical influence of low counts on clinical images of brain perfusion SPECT

A. Sugura1, M. Ono2, T. Shibutani1, T. Asak1, Y. Kou1; 1Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, JAPAN, 2Department of Radiological Technology, Kanazawa Toyota General Hospital, Kanazawa, JAPAN.

TEPS-10

Investigation of optimal Reconstruction Conditions Using the Bayesian Penalized-Likelihood Algorithm in [(18F)]fluorocitrate PET Imaging for Brain Tumors

K. Tsuzura1, K. Watanabe1, M. Yohsen1, K. Memar1, K. Kamata1, K. Tanamoto1, N. Nishio1, K. Ishi1; 1QST Hospital, Chiba, JAPAN, 2Tokyo University, Tokyo, JAPAN, 3Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 4Fukushima Medical University, Fukushima, JAPAN, 5Institute for Quantum Medical Technology, Chiba, JAPAN.

TEPS-11

The Imaging Performance of 89Zr in TOF PET/CT system

Y. Parlaê, D. Goksoy, C. Serger, J. Medenics, G. Gumuser, O. Aras1, E. Sayit1; 1Department of Nuclear Medicine, Celal Bayar University, Manisa, TURKEY, 2Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir, TURKEY, 3Department of Radiology, Memorial Sloan Kettering Cancer, New York, NY, UNITED STATES OF AMERICA.

TEPS-12

Optimization of becquerel calibration factor for quantitative bone SPECT without attenuation and scatter correction in the lumbar spine: Head-to-head comparison with attenuation and scatter correction

K. H. Ishikawa1, M. Ono2, T. Shibutani1, T. Asak1, Y. Kou1; 1Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN, 2Department of Radiological Technology, Faculty of Medical Technology, Teikyo University, Ibaraki, JAPAN.

TEPS-13

Post COVID-19 vaccination reactive lymphadenopathy on 18F-FDG PET

A. Nasr, A. Alharni, L. Heyman; Saline University Hospital, Lund, SWEDEN.

TEPS-14

Hand-foot contamination monitoring in hospital radiopharmacy laboratory: 2020 follow-up data

K. Levenen1, C. Lehner1, M. Aulburg2, J. Lei1, J. Herken2; 1Department of Radiology and Nuclear Medicine, Social and healthcare joint authority of South Savo, Mikkel, FINLAND, 2Department of Medical Physics, South Savo Social and Health Care Authority, Mikkel, FINLAND.

TEPS-15

Factors that affect the accuracy of optical flow computed tomography

S. Iida, A. Nakamura1, K. Kikuchi2, K. Takano1; 1Department of Nuclear Medicine, Institute of National Radiological Sciences, Tokyo, JAPAN, 2Department of Nuclear Medicine, Cancer Institute, Tokyo, JAPAN.

TEPS-16

Influence of scintillation efficiency on the accuracy of optical flow computed tomography

S. Iida, A. Nakamura1, K. Kikuchi2, K. Takano1; 1Department of Nuclear Medicine, Institute of National Radiological Sciences, Tokyo, JAPAN, 2Department of Nuclear Medicine, Cancer Institute, Tokyo, JAPAN.
EPS-229
Prognostic value of radiomic parameters derived from initial PET/CT in head and neck cancers
C. Latappy, N. Antoniano, F. Tousser, A. Aliq, R. Pedrirot, O. Tankervyev, C. Cheze-Reslet

ChU de Poitiers, Department of Nuclear Medicine, Poitiers, FRANCE, INSERM UMR 1101, LATIM, BREST, FRANCE.

EPS-230
Prediction of CT radiomic features using PET radiomic features and vice versa
A. Jha1,2, S. Mishra1,2, U. B. Shenhane1,2, V. Jiauwar1, G. Mehta1,2, A. Nautiyal2,3, N. Purandare2,3, A. Dekker1, L. Wee1,2, Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS, Tata Memorial Hospital, Mumbai, INDIA, Homer Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EPS-231
Understandingomics data of lung cancer patients: Correlations between metabolomics and radiomics
L. Mesnati1, L. Decker1, R. Truyens2, G. Centurioni2, G. Correlations between metabolomics and radiomics
1Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS, Tata Memorial Hospital, Mumbai, INDIA, Homer Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EPS-232
Diagnostic value of baseline FDG PET/CT skeletal features in follicular lymphoma
J. Faudemer, L. Moulin, L. Vigna, J. Vaque, C. Lanot, C. de la Cau, CEMEA, Centre François Baclesse, Caen, FRANCE.

EPS-233
The Effect of Increasing the Number of Iterations on the Stability of PET Radiomic Features: A Phantom Study
E. Abhyuday, R. Smith1, L. Bartley2, C. Marshall, E. Spezi;
Cardiff University, Cardiff, UNITED KINGDOM, "Wales Research & Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM.

EPS-234
Phantom with Heterogenous Tumour Inserts to Explore the Impact of Varying Number of OSEM Subsets on PET Radiomic Features
E. Abhyuday, R. Smith1, L. Bartley2, C. Marshall, E. Spezi;
Cardiff University, Cardiff, UNITED KINGDOM, "Wales Research & Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM.

EPS-235
Feasibility and Optimization of Radiomic Settings for Differentiation of HC and AD using "18F-FDG and "18F-PET Scans
D. Peretti, G. Kolinger, E. Phelaner, F. Reiner, B. de Jong, P. De Donny1, R. Derckx, D. Villette Garcia1, R. Boelxand2;
1University Medical Center Groningen, Groningen, NETHERLANDS, 2University of Antwerp, Antwerp, BELGIUM, 3Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

EPS-236
Robustness of Radiomic Features against Reconstruction Settings in "18FJET and "18FJETE180 PET Imaging of Gliomas
A. J. Zoumen, A. Hodgson, F. Vettemann, J. Brosch-Lena, A. Gorsewich, G. Boning, P. Bartenstein, N. L. Albert, S. Ziegler, L. Karser, Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

EPS-237
18F-FDG PET radiomics predicts pathological data and survival of intrapathetic cholangiocarcinoma
F. Fiz, C. Mason, M. Solini, G. Costo, T. Dorfli, F. Inou, A. Chet, L. Vigna, G. Correlations between metabolomics and radiomics
1University Medical Center Groningen, Groningen, NETHERLANDS, 2Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

EPS-238
Effect of change of gross tumour volume on CT radiomic features
G. Mehta1,2, A. K. Jha1,2, S. Mishra1,2, V. Jiauwar1, G. Mehta1,2, A. Nautiyal2,3, N. Purandare2,3, A. Dekker1, L. Wee1,2, Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS, Tata Memorial Hospital, Mumbai, INDIA, Homer Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.

EPS-240
Artificial Intelligence Applications in SSTR Targeted PET/CT Images: Prediction of Response Assessment in GEP-NETs Undergoing PRRT with 311DOTATOC, R. Laudizzi1,2, A. Amenta, A. Saptaroi, A. Cornelis, A. Sterken, L. Croch, S. Baldan1, M. Bambasi, D. Anco, M. Ippolito1, M. Gaeta2, I. A. Burger1, F. Minutoli, S. Baldan1, Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, 2RUD-Medical Foundation, Palermo, ITALY, 3Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, SWITZERLAND, 4Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, ITALY, Nuclear Medicine Department, Cannizzaro Hospital, Catania, ITALY, 5Department of Nuclear Medicine, Humanitas Oncological Centre of Catania, Catania, ITALY, 6Section of Radiological Sciences, Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Messina, ITALY, 7Department of Nuclear Medicine, Kantonsspital Baden, Baden, SWITZERLAND.

EPS-241
Evaluation of Parametral Infiltration in Cervical Cancer by Radiomics Analysis of 18F-FDG PET
J. Zhu, F. Shang1, T. Wang1, X. Tang, H. Sun1, S. Liu1, "School of Life Science, Beijing Institute of Technology, Beijing, CHINA, Department of Radiology, Shenzhen Hospital of China Medical University, Shenyang, CHINA.

EPS-242
Non-invasive prognostic assessment of patients with NET liver metastases treated with PRRT: a "18Ga-DOMITATE PET-based radiomics evaluation
G. Centurioni, C. La Fougere, F. Fiz, Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tubingen, Tubingen, GERMANY.

EPS-243
Feasibility of 311DOTATOC treatment in patients with metastatic neuroendocrine tumours
J. Verhoeven, S. Fron, B. Descamps, C. Vanhore, J. Goethals, Ghent university, Ghent, BELGIUM.

EP-001
Pioglitazone sensitises human breast cancer cells to the TRAIL-induced cell death
Y. Zhao, M. Marx, M. Zuhayra, U. Lützen, Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Kiel, GERMANY.

EP-002
Evaluation of amino acid PET imaging in a head and neck cancer model
J. Verhoeven, S. Fron, B. Descamps, C. Vanhore, J. Goethals, Ghent university, Ghent, BELGIUM.

Preclinical Studies - Medical Preclinical - Preclinical Oncology

EPS-01
Evaluation of Parametral Infiltration in Cervical Cancer by Radiomics Analysis of 18F-FDG PET
J. Zhu, F. Shang1, T. Wang1, X. Tang, H. Sun1, S. Liu1, "School of Life Science, Beijing Institute of Technology, Beijing, CHINA, Department of Radiology, Shenzhen Hospital of China Medical University, Shenyang, CHINA.

EPS-02
Non-invasive prognostic assessment of patients with NET liver metastases treated with PRRT: a "18Ga-DOMITATE PET-based radiomics evaluation
G. Centurioni, C. La Fougere, F. Fiz, Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tubingen, Tubingen, GERMANY.

EP-001
Pioglitazone sensitises human breast cancer cells to the TRAIL-induced cell death
Y. Zhao, M. Marx, M. Zuhayra, U. Lützen, Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Kiel, GERMANY.
EP-003
Targeting CD-20 antigen expression in Melanoma with an Anti-CD-20 antibody
C. Perroni1, A. Carmacho1, M. Tavano1, M. Galera1, M. Cabrera1, M. Fernández2, J. Benech2, H. Cerecetto1, J. Gambini3, P. Cabral1
1Centro de Investigaciones Nucleares-Facultad de Ciencias-Universidad de la República, Montevideo, URUGUAY; 2Labortorio de Señalización Celular y Nanobiología, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, URUGUAY; 3Centro de Medicina Nuclear e Imagenología Moleculares, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.

EP-004
Evaluation of Radiotherapy associated with Temozolomide plus Metformin in a GBM immunocompetent microenvironment
D. Salvadori1, S. Valtonera1, G. Bertoli2, S. Todesc1, M. Iannone1, A. Coliva1, E. Tonnelli1, F. Zerboni1, S. Wito2, N. Di Muzio1, R. Moresco1
1Department of Medicine and Surgery and Tecnomedical Foundation, University of Milano—Bicocca, Monza, ITALY; 2Department of Radiation Oncology, San Raffaele Scientific Institute (CRCS), Milan, ITALY.

EP-005
Efficacy of 18F-fluorodeoxyglucose Positron Emission Tomography in Determining a Radiotherapy Effect
T. Otani1, S. Ishihara1, Y. Banaka1, K. Kubo1, H. Otaka1, K. Kondow2, H. Miyoshi1; 1Tobu University, Tokyo, JAPAN.

EP-006
Evaluation of treatment process in reducing retinoblastoma tumor size using iodine-125 plaque brachytherapy in animal model of rabbit
S. Moradi1, S. Shehban1, M. Mohkatin-Dazgir1, F. Ghassami2, F. Asadi-Armali1, M. Aygmond3; 1Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF; 2Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF; 3Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-007
18F-sodium fluoride-PET/MRI monitoring of chemotherapy response in breast cancer bone metastases: Proof of concept
M. Zia1, F. Lundstrom1, J. Mbiensson1, M. Lubbenink1, A. Sundin1; 1Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

EP-008
Utility of 18F-FDG PET-CT metrics predicting lymph node involvement in locally advanced breast cancer
Q. Pitalua Cortes1, O. Garcia Perez1, L. Torres Agredo1, N. Espada Aran1; 1Instituto Nacional de Cancerología, Mexico City, MEXICO, 2Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA.

EP-009
FGD PET/CT vs. PET/MRI with zero-echo time (ZTE): Comparing the capability of detection of lung metastasis and differentiating it from other lesions and the precision in fused images
J. Inukai1, M. Nagata1, Y. Zeng1, M. Tachibana2, K. Kubo1, T. Kunitomo1, M. Muzio2; 1Kobe University Graduate School of Medicine, Kobe, JAPAN, 2Kobe University Hospital, Kobe, JAPAN.

EP-010
Perfusion only SPECT CT only as a surrogate for VQ imaging in the COVID-19 era: a single centre experience
T. Hussain1, M. Vlahou1; 1Barts Health NHS Trust, London, UNITED KINGDOM.

EP-011
Prognostic and predictive value of radiomic parameters in 18F-FDG/PET/CT in non-small cell lung cancer patients treated with immunotherapy
F. Trouesset1, N. Antonioni1, A. Falvi Rusazzi1, C. Latapp2; 1CNAK, C. Chere-Le-Rest1; 2CHU de Poitiers, Poitiers, FRANCE, 2INSERM U1011, Brest, FRANCE.

EP-012
Serial change of functional volume of non-transplanted lung before and after unilateral lung transplantation
S. Nagamachi1, T. Shiraishi2, S. Miyahara2, R. Waseda2, K. Kubo1; 1Department of Thoracic Surgery, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN, 2Yokohama City, JAPAN.

EP-013
Correlation between bone scintigraphy and HE4 serum values with bone metabolism in lung cancer patients
J. Weissnersteiner1, E. Batbuskova1; 1Department of Nuclear Medicine, Hospital Poprad, Poprad, SLOVAKIA, 2Comenius University in Bratislava, Bratislava, SLOVAKIA.

EP-014
18F-FDG in suspected non-small cell lung carcinoma recurrence
P. García-Talavera San Miguel1, M. Mellado1, F. Gómez-Camino1, B. Lucas2, J. G. Wultermann1, C. Reheraerresa2, C. Roa1, M. E. Martin3, P. Tamayo4; 1Nuclear Medicine department, Hospital ClínicoUniversitario de Salamanca, Salamanca, SPAIN, 2Universidad de Salamanca, Salamanca, SPAIN.

EP-015
The Value of Future Remnant Liver Function Assessment in Pediatric Patients Before Extended Liver Resection
E. Kireeva1, K. Chaurasia1, A. Akhalsidze1, Y. Likar, D. Ryzhova, D. Yurchenko, A. Ayuzov, A. Lebedev, I. Ivanov, A. Eremeev, A. Khmelev; 1Krasnoyarsk Clinical Medical Academy, Krasnoyarsk, RUSSIAN FEDERATION.

EP-016
Significance of 68Ga-DOTA-NOC uptake in the pancreatic tail
D. Frega1, R. Souza1, M. Silvestre1, D. Fenem2, V. Vitorino, D. Bomm2, M. R. Carvalho1, P. Brandão1, P. Carvalho, P. Rato1, T. C. Fernandes1, L. Salgado1; 1Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PORTUGAL.
EP-017 Impact of Different Levels of Clear Reconstructions on [68Ga]DOTANOC PET/CT Image Quality in Overweight NEN Patients: Preliminary Results
G. Argalia1, E. Fortunati1, L. Zanoni1, S. Telo1, D. Calabò1, D. Calabò1, S. Cialdi1, D. Campara2, S. Fanì1, V. Ambrosini1, 2
1Nuclear Medicine, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY.

EP-018 Modified TCG: a new strong radiological marker to accurately predict early response to PRRT in GEP-NETs

EP-019 New "111In-pentetreotide
E. Cortes-Mancera1, J. Gonzalez-Diaz1, J. Soto Andonianagu1, G. Ferrer Florer1, B. Ocampo Garcia1
1Hospital Angeles del Pedregal, Mexico City, MEXICO.

EP-020 Radiomic Model Discriminating Low Grade Pancreatic Neuroendocrine Tumours Assessed by Biopsy of the Primary Lesion
Dündar Çağlayan1, A. Boz1, Ambrosini1,2; Istituto Nazionale Tumori Milano, Milan, ITALY.

EP-021 [68Ga]Ga-DOTANOC PET/CT in Neuroendocrine Tumours: Results of Data Collection in a Three-Years Electronic Archive
F. Fortunati1, G. Argalia2, L. Zanoni1, S. Telo1, D. Calabò1, D. Campara2, R. Casadei4, C. Ricci4, C. Mosconi6, S. Fanti1,2, V. Ambrosini1,3
1Nuclear Medicine, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY, 3Oncology, IRCCS, Azienda Ospedaliero- Universita di Bologna, Bologna, ITALY, 4DIMEC, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY.

EP-022 FDG PET/CT and Diffusion-Weighted MRI in Primary Staging of Rectal Cancer
A. Arçay1, Y. Aydar1, A. Kerever1, Z. G. Krapari1, M. N. Engin1, C. N. Durnu Ayçiçek1, A. Babar2, 1Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY, 2Department of Radiology, Antalya, TURKEY.

EP-023 Quantitative Parameters of 18F-FDG PET/CT as a biomarker of KRAS expression in Metastatic Colorectal Cancer
S. Mostafa1, S. Khaled1, A. Rayan1, A. Tawfik1, M. Makary1, N. M. Mostafa1, 1Assiut University, Clinical Oncology and Nuclear Medicine, Assiut, EGYPT, 2Medical Oncology Department, South Egypt Cancer Institute, Assiut, EGYPT.

EP-024 Evaluation of incidental gastrointestinal accumulations in 18F-FDG PET to differentiate malignant lesions from benign ones
D. Dezso1, K. Zalmbda1, Z. Ritter1, Z. Bán1, S. Sads1, E. Schmitt1, 1University of Pécs, Medical School, Department of Medical Imaging, Diagnostic, Division of Nuclear Medicine, Pécs, HUNGARY.

EP-025 Effect of cold intervention on 153ga-PSMA uptake of salivary glands
F. Gorton1, N. Ceyhan1, N. C. Gülalı1, 1Turkish Ministry of Health, Ankara City Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-026 Impact of the 18F-PSMA PET/CT in the evaluation of response to androgen deprivation therapy in prostate cancer, a single center experience
S. Medina Ornelas1, P. Garcia-Pérez1, M. Almazar-Avila1, N. Sobrevilla-Moreno1, M. Jiménez-Ríos1, Instituto Nacional de Carcinologia, Mexico City, MEXICO.

EP-027 Discrepancy between serum PSA and tumour burden in PSMA PET/CT: can we find an explanation?
L. Lemos1, P. Seara1, R. Silva1, A. Ferreira1, G. Costa1, 1Pedroso de Lima1,2, 1Centro Hospitalar e Universidade de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.

EP-028 The cause of high [18F]PSMA-1007 uptake in the urinary bladder in some of the [18F]PSMA-1007 patients: an explorative retrospective study
Y. Allach1, R. Pirée1, W. van Geemen1, M. Schilham1, P. E. Perk1, M. Gotthardt1, J. Nagyapáthó1, M. Janssen, 1Radboudumc, Nijmegen, NETHERLANDS.

EP-029 Radiopharmaceutical Biodynamics and the Factors Affecting Biodistribution in Ga68-PSMA PET/CT
A. Arçay Oztürk1, A. Boz1, M. Erkül1, G. Buur1, Y. Aydar1, Akdeniz University Hospital, Department of Nuclear Medicine, Antalya, TURKEY.

EP-030 Predictors of Ga68-PSMA-11 PET/CT tumour burden in castration resistant prostate cancer patients: a single centre experience
L. Calderoni1, A. Farolfi1, P. Castellucci1, F. Senani1, S. Telo1, S. Mattarone1, A. Meri1, E. Moarre1, S. Fanì1, 1Nuclear Medicine, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY.

EP-031 Response assessment to second-line systemic therapies in advanced prostate cancer using Ga-68 PSMA-11 PET/CT
L. Calderoni1, A. Farolfi1, P. Castellucci1, F. Senani1, S. Telo1, S. Mattarone1, A. Meri1, E. Moarre1, S. Fanì1, 1Nuclear Medicine, University of Bologna DIME, Bologna, ITALY, 2Nuclear Medicine University of Bologna IRCCS, Bologna, ITALY, 3Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITALY.

EP-032 Influence of 68Ga-PSMA-11 PET/CT on Clinical Management in Castration Resistant Prostate Cancer Patients: a Single Centre Experience
L. Vetrone1, S. Telo1, A. Giordanà1, A. Spagnoletti1, A. Farolfi1, L. Calderoni1, A. Meri1, P. Castellucci1, S. Fanì1, 1Nuclear Medicine, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 2Medical Oncology, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY, 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY, 4Medical Oncology, Azienda USL4, Instituto Nazionale dei Tumori, Milan, ITALY, 5Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universita di Bologna, Bologna, ITALY.
EP-034
Assessing correlation between 68Ga-PSMA-11 renal PET parameters and renal function tests
J. Schierz1, J. Sankay2, A. Alharbi3, A. Sankay3
1Municipal Hospital Dresden, Department of Radiology, Dresden, GERMANY; 2Kuwait University Faculty of Medicine, Department of Nuclear Medicine, Kuwait City, KUWAIT; 3Kuwait University, Faculty of Medicine, Department of Community Medicine and Behavioral Sciences, Kuwait City, KUWAIT; 4Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne, TURKEY.

EP-035
68Ga-PSMA-11 PET/CT for Bone Lesions in Early Castration Resistant Prostate Cancer Patients: a Single Centre Experience
L. Vetroni1, S. Toto1, A. Giordanò1, A. Spagnolella1, A. Faralli1, L. Calderoni1, S. Mattioni1, R. Mei1, P. Castelvecchi1, S. Fanì2,3
1Nuclear Medicine, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY; 2Medical Oncology Department I, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 3Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-036
Incidentalomas on PET-CT with 68Ga-PSMA
C. Varela Pinto, B. Martins, V. Sousa, I. Lorenzetti; Hospital da Luz Lisboa, Lisbon, PORTUGAL.

EP-037
True nmCRPC in high-risk patients on 18F-Choline PET/ MRI as compared with diagnostic imaging techniques accepted in international guidelines
J. Garcia1, A. Compte1, P. Bassa1, S. Mourelo1, S. Ortiz1, M. Soler1, E. Valls1, A. Blanch1, E. Riera1; CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-038
Impact of 68Ga-PSMA-11 PET/CT on Management of Biochemical Recurrence and High Risk Prostate Cancer Staging
K. De Man1, S. Pinot1, N. Van Lanen2, L. Deulre1, C. Fonteyne1, N. Lumen1, B. Van den Broeck1, K. Kersemans1, P. Ott1, V. Schellhart1; 1University Hospital Ghent, Ghent, BELGIUM; 2Laboratory of Radiopharmacy, Ghent, BELGIUM.

EP-09
Wednesday, October 20 - Saturday, October 23, 2021
e-Poster Area, release on Wednesday, October 20 at 09:00
Imaging Clinical Studies -> Oncological
Imaging Clinical Study -> Thyroid

EP-039
Possibly coexistence of Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC): data from two institute
K. Zaplatnikov1, V. Sukhov2
1MVZ Nuklearmedizin Mogeldorf, Nurnberg, GERMANY; 2Nikiforov Russian Center for Emergency and Radiation Medicine, St Petersburg, RUSSIAN FEDERATION.

EP-040
The use of FDG PET/CT in patients with recurrent differentiated thyroid cancer
O. Ekmençigil; University of Health Sciences, Selçuk Education and Research Hospital, Nuclear Medicine Dept., Istanbul, TURKEY.

EP-041
Health-related quality of life analysis in differentiated thyroid carcinoma patients: a Tunisian study
S. Mensi1, M. Ben Fredj1, M. Ben Rejeb2, T. Dardouri1, A. Ezzine1, K. Chaﬁ1; 1Departement of nuclear medecine, Sousse, TUNISIA; 2Department of Community Health and Epidemiology, Sousse, TUNISIA.

EP-10
Wednesday, October 20 - Saturday, October 23, 2021
e-Poster Area, release on Wednesday, October 20 at 09:00
Imaging Clinical Studies -> Oncological
Imaging Clinical Study -> Gynaecological

EP-042
Can Delayed Pelvic FDG PET/CT Scan Improve Lesion Detection and Differentiation?
K. Alanenėka, D. Vaitkienė, I. Kulokienė, S. Sediena, J. Smulienė; Lithuanian University of Health Sciences, Kaunas, LITHUANIA.
EP-043 Breast and Bilateral Axillary Lymph Nodes Metastases from Serous Ovarian Carcinoma and Treatment Response Demonstrated on 18F-FDG PET/CT
C. Sahin, S. Özgürer, T. Y. Erkil, N. Filizolu, S. Keşin, K. Nihalayeva, T. N. Kavsa, Z. C. Balaban, K. Oktüzoglu, F. Sem, T. Onen, H. T. Tarango, S. İnanır; Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY.

EP-044 Valuing 18-FDG PET/CT Efficiency in Examining Patients with Cervical Cancer
J. Stojanovic, I. Gezačić-Mitjević; Centre for Nuclear Medicine, Clinical Center of Serbia, Faculty of Medicine University of Belgrade, Belgrade, SERBIA.

EP-045 Prognostic Value of 18F-FDG PET/CT biomarkers in patients with diffuse large B-cell lymphoma treated with Chimeric Antigen Receptor T Cell Therapy, preliminary results
J. Cañadas Salazar, L. G. Olaz González, J. G. Vilanova Curto, F. Gómez-Camino López, P. García-Talavera San Miguel, A. C. Pérez Herreuela Cepeda, C. Reda Faranda, B. Lucas Velázquez, S. López Puche, J. A. Rodol Martinez, E. Martín Gómez, C. Montes Fuentes, L. Granado Alonso, M. E. Alonso Sansaquete, M. D. Caballero Barrigón, A. Martín García-Sanchez, P. Tamaya Alonso, S. Ozguven, T. Y. Erdil, N. Filizoglu, S. Kesim, K. C. Sahin, H. Turoglu, S. Inanır, M. Donegani, M. Bauckneht, S. Raffa, S. Chiola; University of Pécs Institute of Medical Imaging, Division of Nuclear Medicine, Pécs, HUNGARY; Semmelweis University Faculty of Medicine, Department of Biophysics and Radiation Biology, Budapest, HUNGARY; University of Pécs Institute of Bioanalytics, Pécs, HUNGARY; University of Pécs 1st Department of Internal Medicine, Pécs, HUNGARY.

EP-049 Association between Baseline Total Metabolic Tumor Volume, Interim Deauville 5-Point Scale and Progression Free Survival in Patients with Diffuse Large B-Cell Lymphoma
P. Kalmár, S. Haraz, E. Schott, T. Schwarz, P. Neumeister, C. Beham-Schmidt, C. Giterstein, R. M. Agren; Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA; Department of Internal Medicine, Division of Hematology, Graz, AUSTRIA; Institute of Pathology, Graz, AUSTRIA.

EP-050 The role of 18F-FDG PET/CT in evaluation of bone marrow involvement in patients with diffuse large B-cell lymphoma

EP-051 The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Survival in Paediatric Lymphoma: A Preliminary Review
J. Reed, M. Assingar, M. Vorster, M. Sathkeghe; University of Pretoria, Pretoria, SOUTH AFRICA; Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA; Department of Statistics, University of Pretoria, Pretoria, SOUTH AFRICA.

EP-052 Prognostic Value of 18F[F]FDG PET/CT at the End of Treatment in Follicular Lymphoma
C. Soldevila Lozano, M. Carreño Romero, E. Llanes-Tello, A. Palomar-Muñoz, S. Mencalad-Vilchez, E. González-Banaz; PET/CT Unit (IDO); Department of Nuclear Medicine, Hospital Universitat de Bellvitge, L’Hospitalet De Llobregat, SPAIN; Department of Hematology, ICO; Hospital Duran i Reynals-VALBEL, Hospital De Llobregat, SPAIN.

EP-053 Efficacy of 18F-FDG PET/CT in evaluation of Bone marrow involvement in patients with non Hodgkin Lymphoma and the influence of analytic parameters

EP-054 Role of [18F]FDG PET/CT in the evaluation of bone marrow at the initial staging of Non-Hodgkin Lymphoma patients

EP-055 The Role of 18F-FDG PET-CT in the Follow up of Tumor Response to Immunotherapy with Checkpoint Inhibitors in Patients with Advanced Melanoma
I. Kostadinova; Clinic of nuclear medicine, University Hospital Actiabdom City Clinic, Milaidost, Sofia, BULGARIA.

EP-056 The potential added value of SPECT/CT in the management of patients

EP-057 ROLL with Freehand-SPECT for assessment of surgical margins in breast cancer

EP-058 Long term follow-up of patients with Small Intestine Neuroendocrine Tumors submitted to Ex Vivo Beta-Radioguided Surgery with 90-YDOTATOC

1. Nuclear Medicine: Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY.
2. Medical Physics Department, IRCCS Azienda Ospedaliera Universitaria Bologna, Bologna, ITALY.
3. Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-061 Targeted Axillary Dissection by marking the positive lymph node with 99mTc-MAA and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. Initial experience


1. Nuclear Medicine-PET (IDI) department, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN.
2. Imaging Clinical Studies -> Other Oncological Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.
3. Diagnostic Imaging group, Technical Medical Centre, University of Twente, Enschede, NETHERLANDS.
4. Department of Urology and Division of Experimental Oncology, URI, University Research Institute, ICRIS San Raffaele Scientific Institute, Milan, ITALY.
5. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center. Leiden, NETHERLANDS.
6. University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY.

EP-062 Reduction of anxiety in patients undergoing lymphoscintigraphy for breast cancer without adequate information from the surgeon


Nuclear Medicine, Ancona, ITALY.

EP-063 Are magnetic nanoparticles combined with ICG 99mTc-nanocarrier suitable alternative for axillary staging in patients with locally advanced breast cancer (LABC)?

J. Escueña Niño, R. Valeriano Jange, M. Navares Hernandez, Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-064 Value of sentinel lymph node biopsy in vulvar cancer


Hospital Clinico Universitario, Valladolid, SPAIN.

EP-065 Sentinel lymph node in endometrial cancer and its impact on clinical practice


Hospital Universitario Cruces, Barakal, SPAIN.


Hospital Universitario De Prat, Valencia, SPAIN.

EP-067 Is the sentinel lymph node biopsy (SLNB) an adequate technique for axillary staging in patients with locally advanced breast cancer (LABC)?

J. Espeja Niño, R. Valeriano Jange, M. Navares Hernandez, Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-068 Non-Identification of Sentinel Lymph Nodes in Head and Neck Melanoma: Clinical Predictors and Outcome


UKC Sestre Milosrdnice, Zagreb, CROATIA.

EP-069 Re-injection of the tracer in cases of no sentinel node visualization in lymphoscintigraphy for breast cancer, increases the detection rate of sentinel nodes and therefore high number of unecessary axillary lymph node dissections can be avoided


1. Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.
2. Ox-surgery research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-070 Challenging visualization of sentinel lymph nodes in upper urinary tract urothelial carcinoma

W. Cytawa, W. Polom, P. Polom, M. Frankiewicz, E. Szurawka, P. Liss, M. Matuszewska,

Medical University of Gdansk, Gdansk, POLAND.

EP-071 Inguinal Lymph Node Relapse in Vulvar Carcinoma After Negative Sentinel Lymph Node Biopsy


Nuclear Medicine-PET (IDI) department, Bellvitge University Hospital-IDIBELL, L’Hospitalet De Llobregat, Barcelona, SPAIN.

EP-072 Detection of disseminated prostate cancer cells in sentinel lymph node by dielectrophoretic technology: proof-of-concept

C. Rousseau, E. Morenaris, D. Cochoneau, G. Aillet, T. Rousseau,

A. Morel-Thierry, D. Heymann.

1. Centro De Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Montevideo, URUGUAY.
2. Shanghai Jiao Tong University, Shanghai, CHINA.
3. University of Missouri, Columbia, Missouri, UNITED STATES OF AMERICA.
EP-078 Myocardial Perfusion SPECT Defects and Left Ventricular Ejection Fraction Accuracy
J. Lopo, R. Silva1, M. Caruth1, P. Lapa2, G. Costa1, J. Pedroso de Lima1,2;
1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Institute of Biomedical Sciences, University of Coimbra, Coimbra, PORTUGAL.

EP-079 Higher negative predictive value on seven years follow up of normal gated myocardial perfusion imaging in diabetic patients with HBA1c ≤7.3
N. Fatima1, M. Zaman1, S. Zaman2, A. Zaman2;
1University of Padua, Padua, ITALY, 2Department of Cardiovascular Sciences, Tomsk, RUSSIAN FEDERATION.

EP-080 Prevalence and Age-related Differences in the Occurrence and Severity of Adverse Effects to Vasodilators Used in Myocardial Perfusion Imaging
J. Momodu, A. Ayeni, K. Purbhoo, M. Vangu;
Department of Medicine, University of Witwatersrand, Parktown, SOUTH AFRICA.

EP-081 Incidence of Pathological Morphological Findings on Myocardial Perfusion SPECT/CT
Marmara University School of Medicine, Istanbul, TURKEY.

EP-082 Higher cardiac events with impaired exercise tolerance (METS <7) and lower ejection fraction <45% in patients with medium to large size fixed perfusion defects on gated myocardial perfusion scintigraphy with prior coronary revascularization
M. Zaman1, N. Fatimir, S. Zaman2, A. Zaman1;
1AKUH, Karachi, PAKISTAN, 2IDR Ruth Plau (CIMH), Karachi, PAKISTAN.

EP-083 Aspects of myocardial gated-SPECT in dextrocardia with situs inversus totalis
H. Haba1, A. Chidik1, D. Pizior1, L. Strimburu;
1Prof. Dr. Ion Chiricuta Institute of Oncology, Cluj-Napoca, ROMANIA, 2Povile Stancuciu Heart Institute, Cluj-Napoca, ROMANIA.

EP-084 The evaluation of myocardial perfusion of dynamic SPECT CZT in patients with non-obstructive coronary artery disease: comparison with blood lipid levels
A. Malteva, K. Kapasea, A. Machulsa, S. Belyazma, E. Grafakou, K. Zuzackovky;
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-085 Utility of 99m Tc-Diphosphonates scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis
Cardiac Uptake of 99m-Tc DPD as a Predictive Factor of Left Ventricular Wall Thickness in Patients with Transthyretin Cardiac Amyloidosis
University of Zaragoza, Zaragoza, SPAIN, 2General Internal Medicine Department. Hospital Universitari de Girona Dr. Josep Trueta, Girona, SPAIN, 3Medical Physics department, Bellvitge University-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, 4Hospital General de la Defensa de Zaragoza, Zaragoza, SPAIN, 5UCMMA, Zaragoza, SPAIN.

EP-086 Utility of 99mTc-HDMP scintigraphy detects transthyretin-related cardiac amyloidosis: a substitute for biopsy?
A. Cimino, E. Ruiz, L. Luongo, A. Mita;
Nuclear Medicine Unit, Lecco, ITALY.

EP-087 Myocardial uptake in patients with malignant prostate neoplasias Is there a relationship with transthyretin cardiac amyloidosis?
A. Roteta Unceta Barrenechea1, A. Andretis Guevara1, L. Tardín Canavazo1, Y. Saeek Delfilits2, T. Escalera Tempreda1, M. Delgado Castro1, P. Rozas Albor1, J. Meteva Piek1, P. Regina Martín1, M. Aihar Arrue1, A. Gracia Gutierrez1, E. Bueno Juanas1, I. Moreno Galazquez1, R. Pizeta Palacios1, S. Atenas Ayala1, C. Lahuentta Pueyo1, S. Menas-Guilherme2, E. Prats Rivero1, M. Hobo Oliveres1;
UCMMA - Clinica Hospital “Lazaro Blesa”, Zaragoza, SPAIN, 1UCMMA - Clinica Hospital “Lazaro Blesa”, Zaragoza, SPAIN, 2Clinic Hospital de la Deffensa de Zaragoza, Zaragoza, SPAIN, 3UCMMA, Zaragoza, SPAIN.

EP-091 99mTc-HDMP scintigraphy detects transthyretin-related cardiac amyloidosis: a substitute for biopsy?
A. Cimino, E. Ruiz, L. Luongo, A. Mita;
Nuclear Medicine Unit, Lecco, ITALY.

EP-092 Incidental findings of extra osseous Tc99m DPD uptake, in unselected patients undergoing bone scintigraphy
A. Daoumas, F. Spyrougou1, E. Pappastavrouas, G. Gazimoulas, E. Giammaroulis1, D. Boudaoud1, I. Iakovou1;
1Aristotle University, AHEPA hosp, Thessaloniki, GREECE, 2Ippokratis, NUC Med Centre, Thessaloniki, GREECE.

EP-093 Absolute in vivo SPECT-CT quantification of myocardial amyloid ATTR deposit in patients with a positive 99mTc-DPD scan
Hospital Clinico Universitario Valladolid, Valladolid, SPAIN.

EP-094 Differentiation ST-elevation from non-ST-elevation myocardial infarction on cardiac end-systolic Fluoro-18-fluorodeoxyglucose PET images using insulin intravenous preparation
Y. Chen, Quanzhou 1st hospital, Quanzhou, CHINA.
EP-095
Evaluation of single only sestamibi positive foci in patients with secondary hyperparathyroidism
A. Aktaş, Á. Gencoglu, G. Manyo, M. Haberal
Baskent University, Ankara, TURKEY.

EP-096
Thyrotropin value reached 20 days after levothyroxine withdrawal in Follow-up of Differentiated Thyroid Cancer
M. Torres Negreira, G. Siem, P. Dřábčan, G. dos Santos, J. Hernández, M. Mendoza, O. Alíasno,
Endocrinology and Metabolism Centre, Hospital de Clínicas, Montevideo, URUGUAY, 1Molecular Imaging Centre, Hospital de Clínicas, Montevideo, URUGUAY.

EP-097
Usefulness of Elastography in the Assessment of Cold Solid Thyroid Nodules
A. Štrok, M. Breznik, J. Bajuk, E. Pirnat, N. Bedernjak Bajuk, M. Kuhar, L. Dovjak,
1Endocrinology and Rare Tumours Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Forlì, ITALY, 2Faculty of Medical Sciences, University of Maribor, Maribor, SLOVENIA.

EP-098
[18F]-Fluorocholine PET/CT in primary hyperparathyroidism: Initial experience
J. Fernández Fernández, M. Muñoz de la Torre Casares, E. Ibañez, M. Lopez de la Torre Casares,
Virgen de las Nieves University Hospital, Granada, SPAIN, 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-099
Scintigraphic features of atypical parathyroid adenoma
Baskent University, Ankara, TURKEY, 1Basel University, Adana, TURKEY.

EP-100
The additional role of 18F-FDG PET/CT in the evaluation of suspected prosthetic valve infective endocarditis
C. Ferrari, R. Ruza, F. Jurk, A. Sciascio, C. Altini, A. Gaudiano, G. Rutini,
Section of Nuclear Medicine, DIM, University “Aldo Moro”, Bari, ITALY.

EP-101
Variations of myocardial uptake suppression and infective endocarditis detectability between a first conventional fasting-based FDG-PET and a second one scheduled on the next day after an Atkins diet
M. Germaini, C. Bourrier, F. Göhringer, C. Seitan-Suty, B. Leffew, V. Roch, L. Imbert, M. Claudin, E. Chevallier, P. Mane,
CHRU Nancy, Nancy, FRANCE.

EP-102
The role of 18F-FDG PET/CT in patients with IgG4 related disease. Our experience
1Endocrinology and Rare Tumours Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Forlì, ITALY, 2Faculty of Medical Sciences, University of Maribor, Maribor, SLOVENIA, 3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

EP-103
Adverse Prognostic Factors in Patients Refractory Pheochromocytoma and Paraganglioma After 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy
Kanazawa University Hospital, Kanazawa, JAPAN.

EP-104
177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: a joint analysis of phase II prospective clinical trials
“Oncoradiology and Rare Tumours Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Milano, ITALY, 1Nuclear Medicine and Radiometaabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Milano, ITALY, 2Unit of Biostatistic and clinical trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Milano, ITALY, 3Unit of Gastroenterology and Digestive Endoscopy, Forlì-Cesena Hospital, AUSL, Ramaglia, Forlì, ITALY, 4General and Oncology Surgery, Forlì, ITALY, 5Unit of Gastroenterology and Digestive Endoscopy, Forlì-Cesena Hospital, AUSL, Ramaglia, Forlì, ITALY, 6Azerbaijan National Centre of Oncology, Department of General Surgery, Baku, AZERBAIJAN, 7Nuclear Medicine Unit, Morgagni-Pierantoni Hospital, Forlì, ITALY.

EP-105
Associated with PRRT change of corrected SUVs max values in NET metastatic lesions assessed on [68Ga] Ga-DOTA-TATE PET/CT
1Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, University “Aldo Moro”, Bari, ITALY, 2Faculty of Medical Sciences, University of Maribor, Maribor, SLOVENIA, 3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL, 4International Atomic Energy Agency, Vienna, AUSTRIA, 5Azerbaijan National Centre of Oncology, Department of Uro-Oncology, Baku, AZERBAIJAN, 6Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.

EP-106
Body mass index and prior therapy lines conditioning response to [177Lu]Lu-DOTATATE therapy in neuroendocrine tumours
J. Fernández Fernández, M. Munros de Eguiluz, E. Tórroba Ibarrola, M. Lopez de la Torre Casares, E. González Flores, Vírgen de las Nieves University Hospital, Granada, SPAIN.

EP-20
Therapy Clinical Study -> Oncological Therapy Clinical Study -> Neuroendocrine Therapy

EP-23
Therapy Clinical Study -> Oncological Therapy Clinical Study -> Prostate Cancer Therapy

EP-22
Therapy Clinical Study -> Oncological Therapy Clinical Study -> Endocrinology Therapy

EP-09
Scintigraphic features of atypical parathyroid adenoma
Baskent University, Ankara, TURKEY, 1Basel University, Adana, TURKEY.

EP-09
18F-FDG PET/CT in primary hyperparathyroidism: Initial experience
J. Fernández Fernández, M. Muñoz de la Torre Casares, E. Ibañez, M. Lopez de la Torre Casares,
Virgen de las Nieves University Hospital, Granada, SPAIN, 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-09
[18F]-Fluorocholine PET/CT in primary hyperparathyroidism: Initial experience
J. Fernández Fernández, M. Muñoz de la Torre Casares, E. Ibañez, M. Lopez de la Torre Casares,
Virgen de las Nieves University Hospital, Granada, SPAIN, 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-09
18F-FDG PET/CT in primary hyperparathyroidism: Initial experience
J. Fernández Fernández, M. Muñoz de la Torre Casares, E. Ibañez, M. Lopez de la Torre Casares,
Virgen de las Nieves University Hospital, Granada, SPAIN, 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.
EP-24
Therapy Clinical Study -> Oncological Therapy Clinical Study -> Thyroid Therapy

EP-110
The Role of Early- and Late-Stimulated Thyroglobulin in Predicting Treatment Response One Year After RAIT in Low-Intermediate Risk DTC
A. Calabro1, D. Alibano, F. Donati, A. Mazzotti, P. Bollini, M. Gregoretti, F. Bertagna, R. Giubellini, ASST Spedali Civili di Brescia, University of Brescia, Brescia, ITALY.

EP-111
Postoperative outcome in patients with low-risk differentiated thyroid cancer treated without radioactive iodine ablation
P. Dong, L. Wang, L. Xiao, L. Yang, H. Huang, L. Li, West China Hospital of Sichuan University, Chengdu, CHINA.

EP-25
Therapy Clinical Study -> Oncological Therapy Clinical Study -> Other Oncological Treatments

EP-112
Feasibility and Therapeutic Potential of 177Lu-labeled monoclonal antibodies in the treatment of CD20-positive B-cell lymphoma: results of a phase 1 trial
H. Ahmadzadehfar, A. Jafari1, N. Jokar1, J. P. Marzouk1, J. M. Y. Tse1, Y. Yaghoobi1, H. E. Ahlman1, M. Alnuaimi, West China Hospital of Sichuan University, Chengdu, CHINA.

EP-26
Technical Studies -> Radiation Protection -> Radiation Exposure and Protection

EP-113
Establishment of National DRL for CT (PET) Hybrid Imaging Studies for Kuwait Population "The Second Phase National Dose Audit - 2020"
M. Masoomi, J. Al-Shammai, L. Al-Ra'add, H. Elahman1, J. Al-Shammai1, 1Medical Imaging Department, ADAN Hospital - MOH, Hadaya, KUWAIT, 2Department of Nuclear Medicine, Faculty of Medicine, Kuwait University, Jabiya, KUWAIT.

EP-114
Assessment of extremities and eye dose to staff involved in radiotherapy procedures in Kuwait
M. Alnuaimi, Kuwait Cancer Control Centre, Al-Sabah Medical Area - Shahrk, KUWAIT.

EP-115
Estimation of radiation exposure of workers in radiotherapy units in Kuwait using "RE" and "Lu"
J. Hudzieta, J. M. Fülöp2, J. Sabol3, A. Vondrák4, O. Kraft5, 1Asian Center for Nuclear Absorption (ACNA), Kuwait, 2ABRS, s.r.o., Samorin, SLOVAKIA, 3Faculty of Security Management PACR in Prague, Prague, CZECH REPUBLIC, 4Department of Physics, University of Oslo, Oslo, NORWAY.

EP-116
Relative Contributions to Patient Effective Dose in SPECT-CT Hybrid Imaging
J. Díez, J. Díez, A. Nicol, 1NHRI Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

EP-117
Evaluation of a custom-made software to calculate l-131 dose for ablation of small sizes of thyroid remnants from diagnostic l-123 SPECT/CT images
I. Lako1, J. Pera1, A. Hadykostantian1, P. Michael1, T. Leontiou5, T. Toffolli1, F. E. Toto1, E. Kyriacou5, M. Lyra4, T. Mirzaghad6, 1Aristotle University, Thessaloniki, GREECE, 2Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, CYPRUS, 3Department of Nuclear Medicine, Nicosia General Hospital, State Health Services Organization, Nicosia, CYPRUS, 4Frederick Research Center, Nicosia, CYPRUS, 5Department of Medical Physics, Bank of Cyprus Oncology Center, Nicosia, CYPRUS, 6Department of Medical Physics, German Oncology Center, Linsdorf, CYPRUS.

EP-118
Biodistribution and dosimetry after intraperitoneal injection of 188Re-refrigerated microparticles in rats
S. Westram, J. Forslet, C. H. Nienven, C. Stokke1, T. B. Bendriouch, 1Oncoinvent AS, Oslo, NORWAY, 2Minerva Imaging ApS, Copenhagen, DENMARK, 3Division of Radiology and Nuclear Medicine, University Hospital Oslo, Oslo, NORWAY, 4Department of Physics, University of Oslo, Oslo, NORWAY.

EP-119
Development of a digital three-dimensional rodent phantom for preclinical studies of radionuclide therapy
I. Miloichikova1, A. Bulatovskaya1, Y. Chernpenikova1, E. Gargon1, A. Gargon1, S. Stuchebrov1, M. Wegner1, 1TOMTOM Polytechnic University, Tomsk, RUSSIAN FEDERATION, 2TOMTOM Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION, 3University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, 4Hamburg University of Technology, Hamburg, GERMANY.

EP-120
Comparison of 3D dosimetry methods in hepatic radioembolisation with 90Y microspheres
N. Carrasco Vela1, N. Tejerda, P. Beker, R. Blazquez1, C. Olivas1, V. Gomez-Garner1, B. Lunari, D. Perez-Escuviar1, J. Torres-Espallardo1, 1Hospital Universitario Dr. Pérez, Valencia, SPAIN, 2Hospital Universitario y Politécnico La Fe, Valencia, SPAIN, 3Hospital Universitario Politécnico La Fe, Valencia, SPAIN, 4Hospital Universidade de Valenca, Valenca, SPAIN, 5Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, SPAIN.

EP-121
Determination of effective intra-renal half-life in radiogand therapy with 188Re-PSMA-617: Comparison of different approaches
C. Happe, L. Weber, W. T. Kranert, B. Blaichsch, D. Grön, N. Mader, A. Sabir, F. Grünwald, University Medical Center Frankfurt, Frankfurt, GERMANY.

EP-122
Dosimetry of Metastases in Treatments with 188Re-LU-DOTATE - Comparison Between two Calculation Software
T. Monserrat Fuertes1, N. Montenegro Iglesias1, Á. Álvarez Liéver1, D. Sán José Olmedo1, C. Arroyo Sánchez1, M. A. P. Monte2, P. Artigues Gàbria1, 1Hospital Universitario Central de Asturias, Oviedo, SPAIN, 2Hospital Universitario Cruces/Gurutzeta, Bilbao, SPAIN.

EP-123
A Monte Carlo Based Tool for Skin Dose Assessment in 188Re Treatment of Non-Melanoma Skin Cancer
S. V. Vigo1, F. Zagni, M. Nucetto1, L. Vottero1, A. Parini1, D. Mistraci1, F. Saouli1, P. Castelluccio1, S. Fant1, L. Stangani, Clinical Engineering Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 2Department of Oncological Medicine, University of Bologna, Bologna, ITALY, 3Department of Diagnostic and Speciality Medicine, University of Bologna, Bologna, ITALY, 4Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, 5Nuclear Medicine Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.
EP-29
Wednesday, October 20 - Saturday, October 23, 2021
Poster Area, release on Wednesday, October 20 at 09:00
Technical Studies - Radiopharmacy/ Radiochemistry - New Radiopharmaceuticals - SPECT

EP-124
Evaluation of new ⁶⁷Tc-labeled enrofloxacin derivatives as potential infection- or tumor-specific imaging agents
D. Papagiannopoulou1, G. Tanas1, L. Papadopoulou1, M. Kakarlik1, J. Ovakou1,
1 Aristotle University of Thessaloniki, School of Pharmacy, Thessaloniki, GREECE, 2 Aristotle University of Thessaloniki, Medical School, Thessaloniki, GREECE

EP-30
Wednesday, October 20 - Saturday, October 23, 2021
Poster Area, release on Wednesday, October 20 at 09:00
Technical Studies - Radiopharmacy/ Radiochemistry - New Radiopharmaceuticals - PET

EP-125
Synthesis of 68-Ga-NOTA-(Fab)-Traztuzumab, New PET Radiopharmaceutical for Imaging of Breast Cancer Expressing HER-2 Receptor
B. Shetye1, S. Mishra1, M. Pathan1, P. Monteny1,2, M. Kameswaram1, S. Shah2, S. Gupta3, V. Rangarajan1,2, 1 Dept of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, 2 Hombi Bhathna National Institute (HBNI), Deemed University, Mumbai, INDIA

EP-31
Wednesday, October 20 - Saturday, October 23, 2021
Poster Area, release on Wednesday, October 20 at 09:00
Technical Studies - Radiopharmacy/ Radiochemistry - Radiopharmaceutical Preparation and Quality Control

EP-127
In vitro stability assessment of in-house labeled ¹⁸⁸Ga Ga-EDTA
K. Chitin1, A. K. Iha1, S. Mithun1, A. Naoyuki1, P. Bhardwaj1, V. Rangarajan1,2
1 Tata Memorial Hospital, Mumbai, INDIA, 2 Hombi Bhathna National Institute (HBNI), Deemed University, Mumbai, INDIA

EP-128
Preparation and optimization of the radio-labeling method of ¹¹¹In-PSMA-INER-56
S. Chen1, S. Lot3, M. Li4, M. Chen4, W. Lai3, S. Li2
1 Institute of Nuclear Energy Research, Taoyuan, TAIWAN, 2 Institute of Nuclear Energy Research, Taoyuan, TAIWAN

EP-129
Preparation and preclinical studies of ⁶⁴ Cu-NOTA-EP-126 - PET
H. Yousefnia1, G. Aslani1, 1 Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, 2 Hombi Bhathna National Institute (HBNI), Deemed University, Mumbai, INDIA

EP-130
Comparative Study Before And During The SARS-CoV-2 Pandemic In Breast Cancer With SLNB After Neoadjuvant Chemotherapy
Hospital Clinico Universitario de Valladolid, Valladolid, SPAIN

EP-131
¹⁸⁸F-FDG brain PET in post-sARS-CoV-2 infection with neurological involvement/time-dependent severity of hypometabolism after the acute infection
A. Martin1,2, G. Calò1, L. Kiffa1, P. Plisnant1, P. Puthumbath1, S. Martelli1, D. Persand1, S. Sestini1, 1 Hospital Santo Stefano, Nuclear Medicine Unit, Prato, ITALY, 2 University of Florence, AUOC Careggi Nuclear Medicine Unit, Florence, ITALY, 3 University Vita Salka San Raffaele, Nuclear Medicine Unit Division of Neuroscience, Milan, ITALY, 4 Hospital Santo Stefano Neurology Unit, Prato, ITALY, 5 University of Genoa, Hospital San Martino, Genoa, ITALY

EP-132
Can FDG PET Predict Covid 19 Disease Severity and Discharge Time
F. Beytur1, S. Sager1, A. N. Aktas1, R. Karasu1, A. Nazari1, F. Aghazadeh1, S. Asir1, L. Uslu-Beyli2, H. B. Saymaz1, K. Sirenoglu1, 1 Cerrahpasa Faculty of Medicine, Nuclear Medicine Department, Istanbul, TURKEY, 2 Cerrahpasa Faculty of Medicine, Infectious Diseases Department, Istanbul, TURKEY

EP-133
Aspects of FDG-avid lymph nodes on FDG PET/CT following COVID-19 vaccines
P. Greco1, H. Truss1, A. M. Bertelme2, T. Kamouna1, C. Garcia1, 1 Nuclear Medicine Section, Diagnostic Imaging Department, Gustave Roussy, Villejuif, FRANCE, 2 Nuclear Medicine Laboratory, “Sp. Spinola” County Emergency Hospital, Iasi, ROMANIA

EP-134
Management of differentiated thyroid cancer through nuclear medicine facilities during COVID-19 emergency: the telemedicine challenge
M. Manganeli1, M. Klein1, C. Nappi1, E. Zampella1, V. Gaudieri1, M. Maurea1, M. Dri2, F. Valse2, E. Casazza2, M. De Lucio2, R. Bologna2, L. Piccioli1, M. Schiumberger1, A. Cuccia2
National Cancer Institute, School of Medicine, University Federico II, Naples, ITALY

EP-135
Nuclear medicine lung perfusion imaging after COVID-19: review of a patient cohort
B. Martins1, C. V. Pinta1, V. Sousa1, C. Coevers1, Hospital da Luz, Lisboa, PORTUGAL

EP-136
Molecular Imaging Findings Update on the NCI-NCTN Clinical Trial: Natural History of COVID-19 in Cancer Patients
M. Knopp1, C. Neider1, P. Bolton1, E. Huang1, B. Rini1, L. A. Kerd1, K. Shankar1
1 The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2 National Cancer Institute, Rockville, MD, UNITED STATES OF AMERICA, 3 National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA

EP-137
GSMPI can predict early cardiac dysfunction in elderly high-risk DTC patients after TSH suppression treatment
Y. Liu1, Zhengzhou University, Zhengzhou, CHINA

EP-138
J. Koutsikos1, P. Georgoulas1, S. Koulouri1, T. Lampakis1, I. Iakovou1, S. Tsirron1, D. Apostolopoulou1, T. Panachlis1, A. Fotopoulou1
1 Nuclear Medicine Department, 401 General Military Hospital, Athens, GREECE, 2 Nuclear Medicine Department, Henry Dunant Hospital Center, Athens, GREECE, 3 Nuclear Medicine Laboratory, University of Thessaly, University Hospital of Larissa, Larissa, GREECE, 4 Department of Nuclear Medicine, School of Medicine, University of Crete, Heraklion, Crete, GREECE, 5 Nuclear Medicine Department, Istaplos Medical Center, Athens, GREECE, 6 2nd Department of Nuclear Medicine, Aristi University, AHEPA Hospital, Thessaloniki, GREECE, 7 Nuclear Medicine Department, University Hospital of Ioannina, Ioannina, GREECE, 8 Department of Nuclear Medicine, University Hospital of Patras, Patras, GREECE, 9 Greek National Organization for the Provision of Health Services, Strategic Planning Division, Athens, GREECE

EP-139
Phase 1a intra-individual comparison trial of 10x ultrafast whole-body Na¹¹¹I digital PET/CT for assessing non-malignant and malignant osteoblastic lesions
C. Wright1, K. Brier1, Y. Huyet1, E. Folefac1, D. A. Diaz Pardo1, D. G. Staver1, M. V. Knopp1
1 The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2 Collaboration on Osteoblastic Lesions, Thessaly, GREECE, 3 National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, 4 National Cancer Institute, Rockville, MD, UNITED STATES OF AMERICA, 5 Van Andel Ingram Cancer Center, Nashville, TN, UNITED STATES OF AMERICA, 6 National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, 7 National Cancer Institute, Rockville, MD, UNITED STATES OF AMERICA

EP-140
Prognostic value of quantitative [18F]FDG-PET features in patients with metastatic soft tissue sarcoma
G. Kalisvaart1, W. Groetsch2, J. V. Bouve1, H. Geldermans1, J. A. van der Hage1, M. A. van der Sande1, J. L. Bloem1, L. de Greve1, C. Leiden, Leiden University Medical Center, NETHERLANDS
EP-148
Quantitative Assessment of Enthesitis Patients with Ankylosing Spondylitis
N. Dizdar1, M. Cagil2, A. Alioklu2, B. Dogur Cahit3, G. Kocak4, H. Genc5, M. Korkmaz6; 1Department of Nuclear Medicine, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, TURKEY; 2Department of Physical Medicine and Rehabilitation, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY; 3Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY.

EP-149
Clinical use of three-phase bone scintigraphy in identifying complications after knee replacement in patients with deforming osteoarthritis with COVID-19
P. Koral1, O. Shirshchina, M. Kostyuk2; 1Shalimov's National Institute of Surgery of Transplantation, Kiev, UKRAINE, 2Shalimov's National University of Health of Ukraine, Kiev, UKRAINE.

EP-150
Effectiveness of F-18 FDG PET/CT in initial Assessment of Necrotizing Otitis Externa (NOE) and Evaluation of Anti-Microbial Response
A. Hussien, A. M. Qala, O. Jabe, W. Ibrahim; King Hamad Hospital, Bahrain.>

EP-151
Relationship of F-18 FDG PET Imaging Findings with Bone Trauma Age
S. Orun1, U. Korkmaz, S. Soytlugah, G. Durmus Altun; 1Hospital Universitario Clínico San Cecilio, Granada, SPAIN.

EP-152
Evaluation of human anti-mouse antibodies prior to the administration of 99mTc-Bisellesomab
P. Guardia Jimena1, R. Amenaz Aguazua, M. Martinez de Valde Torres, D. Benito Ganta; Hospital Universitario San Cecilio, Granada, SPAIN.

EP-153
Influence of tocilizumab therapy on osteoarticular inflammatory activity assessed by 18F FDG PET/CT in patients with refractory polyarticular rheumatoid arthritis
I. Martinez-Rodriguez1, D. Prieto-Peria, A. Gutierrez-Gonzalez, M. De-Anguolas-Tames, C. Jimenez-Valcarce, J. Patel; 1Nuclear Medicine Service, Marques de Valdecilla University Hospital, Santander, SPAIN.

EP-154
Role of follow-up quantitative bone SPECT-CT in active condylar hyperplasia
D. Cáceres Silva, L. Mohamed Salem, T. E. Rodríguez Locarno, T. D. Cáceres Silva; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-155
Evolution of Renal Function in Living Kidney Donors
D. Cáceres Silva, L. Mohamed Salem, T. E. Rodríguez Locarno, T. D. Cáceres Silva; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-156
Detection of Thromboembolic Pulmonary Disease using Lung Perfusion SPECT/CT in the time of COVID-19: Outcome Analysis
T. H. Tan, R. Ismail; Sunway Medical Centre, Bandar Sunway, MALAYSIA.

EP-157
Comparison of GFR measurement with two-blood sample technique using 99mTc-DTPA vs. MDRD and CKD-EPI equations in potential kidney donors
J. Carvalho, A. B. Marques, F. Abreu, S. Pintão; Hospital de Santa Cruz - Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

EP-158
Recommending bone scan with 99mTc-MDP as the missing link but an effective method in the initial staging of patients with muscle invasive bladder carcinoma
A. Aghaei1, A. Masoudifar1, H. Ghaebari2, S. Shahrani3, K. Aryan4, S. Zakari5; 1Nuclear medicine research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 2Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 3Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 4Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 5Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-159
Quantitative Assessment of Lung Ventilation/Perfusion SPECT (V/Q scan): A Helping Tool in Pulmonary Embolism
S. Menéndez-Sánchez, A. Belmonte-Mendoza, A. Cardoso-Saavedra, M. Bonanet-Serrate1, S. Azaadavoud, F. Velaquez-Navia, F. Delpeñero-Claire, A. Aguado; Hospital Universitario Vall d’Hebron, Barcelona, SPAIN.

EP-160
Clinical values of DMSA SPECT in follow-up evaluation of renal injuries after conservative management
S. Cho1, Y. Yu, H. Xiong, J. K. Park, H. Song; Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF.

EP-161
Value of renal transplant scintigraphy: comparison with surgical occurrences and Doppler ultrasound resistive index
A. Marques, F. Abreu, J. Carvalho, S. Pintão; Centro Hospitalar de Lisboa Ocidental, Lisbon, PORTUGAL.

EP-162
Usefulness of 99mTc-MIBI SPECT/CT for the diagnosis of salivary gland tumors
A. Aghaei1, A. Masoudifar1, H. Ghaebari2, S. Shahrani3, K. Aryan4, S. Zakari5; 1Nuclear medicine research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 2Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 3Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 4Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 5Urology research center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-163
Prognostic value of diuretic MAG3 renogram in acute kidney injury
D. Cáceres Silva, T. E. Rodríguez Locarno, T. D. Cáceres Silva; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-164
Salivary Scintigraphy in the evaluation of xerostomia in patients treated with ImmunoModulated Radiotherapy for head and neck malignancy
P. U. N. Y. K. Roy, G. G. B. Smith, H. Mohan; Sri Sankara cancer research and Hospital center, Bangalore, INDIA.
EP-36
Wednesday, October 20 - Saturday, October 23, 2021
e-Poster Area, release on Wednesday, October 20 at 09:00

Technologist Digital ePoster

EP-171
The eye can see what the mind knows
A. Ghilardi, T. Pippi, G. Medolago, B. Onore

EP-172
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-173
Analytical method validation tests for the development of a new radiopharmaceutical drug: 151Lu-PSMA-1
M. Piquemal, A. Traldi, G. Medolago, B. Onore,

EP-174
Yttrium microspheres irradiated at the RT-T reactor for radioembolization of liver cancer

EP-175
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-176
Radiation safety in PET-CT preparation
T. Saita, S. Lohn, T. Rasta, J. Huszar, T. Bablar,
Tampere University of Applied Sciences, Tampere, FINLAND.

EP-177
Operational Organization of a Clinical and Translational Research Environment using Today’s Digital Technologies
L. Merrin, A. Appignani, M. M. Knappe, M. Tinkl, K. Biner, M. V. Knopp

EP-178
Contribution of Listening to Music in Reducing Anxiety in Bone Scintigraphy
M. Boa, E. Pereira, D. Branco, T. Guerreiro, L. Vieira

EP-179
The eye can see what the mind knows
A. Ghilardi, G. Medolago, B. Onore

EP-180
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-181
Analytical method validation tests for the development of a new radiopharmaceutical drug: 151Lu-PSMA-1
M. Piquemal, A. Traldi, G. Medolago, B. Onore,

EP-182
Yttrium microspheres irradiated at the RT-T reactor for radioembolization of liver cancer

EP-183
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-184
Radiation safety in PET-CT preparation
T. Saita, S. Lohn, T. Rasta, J. Huszar, T. Bablar,
Tampere University of Applied Sciences, Tampere, FINLAND.

EP-185
Operational Organization of a Clinical and Translational Research Environment using Today’s Digital Technologies
L. Merrin, A. Appignani, M. M. Knappe, M. Tinkl, K. Biner, M. V. Knopp

EP-186
Contribution of Listening to Music in Reducing Anxiety in Bone Scintigraphy
M. Boa, E. Pereira, D. Branco, T. Guerreiro, L. Vieira

EP-187
The eye can see what the mind knows
A. Ghilardi, G. Medolago, B. Onore

EP-188
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-189
Analytical method validation tests for the development of a new radiopharmaceutical drug: 151Lu-PSMA-1
M. Piquemal, A. Traldi, G. Medolago, B. Onore,

EP-190
Yttrium microspheres irradiated at the RT-T reactor for radioembolization of liver cancer

EP-191
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-192
Radiation safety in PET-CT preparation
T. Saita, S. Lohn, T. Rasta, J. Huszar, T. Bablar,
Tampere University of Applied Sciences, Tampere, FINLAND.

EP-193
Operational Organization of a Clinical and Translational Research Environment using Today’s Digital Technologies
L. Merrin, A. Appignani, M. M. Knappe, M. Tinkl, K. Biner, M. V. Knopp

EP-194
Contribution of Listening to Music in Reducing Anxiety in Bone Scintigraphy
M. Boa, E. Pereira, D. Branco, T. Guerreiro, L. Vieira

EP-195
The eye can see what the mind knows
A. Ghilardi, G. Medolago, B. Onore

EP-196
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-197
Analytical method validation tests for the development of a new radiopharmaceutical drug: 151Lu-PSMA-1
M. Piquemal, A. Traldi, G. Medolago, B. Onore,

EP-198
Yttrium microspheres irradiated at the RT-T reactor for radioembolization of liver cancer

EP-199
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-200
Radiation safety in PET-CT preparation
T. Saita, S. Lohn, T. Rasta, J. Huszar, T. Bablar,
Tampere University of Applied Sciences, Tampere, FINLAND.

EP-201
Operational Organization of a Clinical and Translational Research Environment using Today’s Digital Technologies
L. Merrin, A. Appignani, M. M. Knappe, M. Tinkl, K. Biner, M. V. Knopp

EP-202
Contribution of Listening to Music in Reducing Anxiety in Bone Scintigraphy
M. Boa, E. Pereira, D. Branco, T. Guerreiro, L. Vieira

EP-203
The eye can see what the mind knows
A. Ghilardi, G. Medolago, B. Onore

EP-204
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-205
Analytical method validation tests for the development of a new radiopharmaceutical drug: 151Lu-PSMA-1
M. Piquemal, A. Traldi, G. Medolago, B. Onore,

EP-206
Yttrium microspheres irradiated at the RT-T reactor for radioembolization of liver cancer

EP-207
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.

EP-208
Radiation safety in PET-CT preparation
T. Saita, S. Lohn, T. Rasta, J. Huszar, T. Bablar,
Tampere University of Applied Sciences, Tampere, FINLAND.

EP-209
Operational Organization of a Clinical and Translational Research Environment using Today’s Digital Technologies
L. Merrin, A. Appignani, M. M. Knappe, M. Tinkl, K. Biner, M. V. Knopp

EP-210
Contribution of Listening to Music in Reducing Anxiety in Bone Scintigraphy
M. Boa, E. Pereira, D. Branco, T. Guerreiro, L. Vieira

EP-211
The eye can see what the mind knows
A. Ghilardi, G. Medolago, B. Onore

EP-212
The usefulness of 99mTc-Pertechnetate scintigraphy and SPECT/CT in the workup of goiter
A. Tavellin, O. Cacucio, S. Rosiello, D. Gregolato,
Ospealde Mater Salutis, Legnago, ITALY.
**Wednesday, October 20, 2021 12:00 – 13:30, Channel 3**

**ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY**

Targeting PSMA in advanced prostate cancer: How will precision medicine evolve patient care?

---

**Wednesday, October 20, 2021 13:50 - 14:15, Channel 3**

**HERMES MEDICAL SOLUTIONS**

Innovations for personalized, fast and accurate dosimetry

**Welcoming words**

Tom Francke, CEO, Assoc. Prof., Hermes Medical Solutions, Stockholm, Sweden

**Impact of Dosimetry in Translational Research – Added Value for Probe Developments?**

Frederik L. Giesel, MD, Chairman of the Nuclear Medicine Department at the University Hospital Düsseldorf, Germany

**Latest Innovation in Dosimetry Software**

Helena McMeekin, MSc. Clinical Applications Scientist, Hermes Medical Solutions, UK

**Lu-177 PRRT Dosimetry in Clinical Practice**

Lydia Ram, Trainee Clinical Scientist, Queen Elizabeth Hospital, Birmingham, UK

Followed by a live Q&A with the speakers – 14:20 – 14:40 CEST

---

**Wednesday, October 20, 2021 16:15 - 17:45, Channel 3**

**ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY**

Advancing towards precision medicine with theranostics in oncology

**Welcome and introduction**

Shaunak Navalkissoor

**Moving towards precision medicine with RLT: Advances in imaging**

Vikas Prasad

**Moving towards precision medicine with RLT: Advances in blood biomarkers**

Andrea Frilling

**Moving towards precision medicine with RLT: Evolving theranostics in and beyond NETs**

Shaunak Navalkissoor

**How can we make the best use of all tools available for optimal patient outcomes?**

Panel discussion

**Summary and conclusion**

Shaunak Navalkissoor

---

**Wednesday, October 20, 2021 18:00 - 19:30, Channel 3**

**TELIX PHARMACEUTICALS**

The evolution of prostate cancer knowledge through PSMA

**Session introduction**

Dr. Laura Ravasi, Telix Pharmaceuticals

**Evolution of diagnostic imaging in prostate cancer: then and now**

Professor Louise Emmett, Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney, Australia

**The evolution in patient’s management through PSMA**

Associate Professor Jochen Christoph Walz, Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France

**The evolution in therapeutic options as PSMA is an actionable target**

Professor Dr. Ken Herrmann, Director of Clinic of Nuclear Medicine at University Hospital of Essen, Germany

**Closing remarks from Laura Ravasi**
<table>
<thead>
<tr>
<th># Thursday, October 21, 2021</th>
<th>09:00 - 09:45, Channel 3</th>
<th>GE HEALTHCARE</th>
</tr>
</thead>
</table>
| Digital Technology: Impacts on Cardiac Imaging | GE Healthcare | Easy Patient Management with New Cardiac CZT  
Prof. Tali Shrir, MD, Director of Nuclear Cardiology, Assuta Medical Center, Tel Aviv, Israel |
| Modern Diagnosis in Cardiac Diseases with PET/CT  
Prof. Juhani Knutti, MD, FESC, University of Turku and Turku University Hospital, Turku, Finland |  | Implementing Production of 13N-ammonia in an In-House PET Radiopharmacy  
Dr. Tom Christian Holm-Andersen, PhD, Chief Radiochemist / Head of Production Centre for Nuclear Medicine Haukeland University Hospital Bergen, Norway |
| Thursday, October 21, 2021  | 09:45 - 10:30, Channel 3 | GE HEALTHCARE |
| Overcoming the DLB Diagnosis Challenge: Perspectives for Neurologists and Nuclear Medicine Physicians | GE Healthcare | Prof. John O'Brien, Professor of Old Age Psychiatry, University of Cambridge  
Dr. George Petrides, Consultant Radionuclide Radiologist, Newcastle Upon Tyne Hospitals |
| Zulfiqar Haidar (host), Global Medical Lead Neurology, GE Healthcare |  | Thursday, October 21, 2021 10:45 - 12:15, Channel 3 |
| GE HEALTHCARE |
| How do Innovations Support Theranostics? | GE Healthcare | The Future of Precision Diagnostics – Immune PET  
Prof. Rod Hicks, University of Melbourne, Australia  
Dr. Simon Williams D.Phil, Department of Biomedical Imaging, Genentech Inc., USA |
| The place of SPECT in Theranostics  
Prof. Michael C. Kierski, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Germany |  | Prostate Cancer – the Role of PSMA PET  
Prof. Dr. Karolien Goffin, MD PhD, Nuclear Medicine & Molecular Imaging & PET-MR unit, University Hospital Leuven – KU Leuven, Belgium |
| How to Get your Clinic Ready for a Theranostics Approach?  
Prof. Andrei Iagaru, MD, Professor of Radiology – Nuclear Medicine and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, USA |  | Thursday, October 21, 2021 15:05 - 16:35, Channel 3 |
| TERUMO INTERVENTIONAL SYSTEMS |
| Establishing Individualised SIRT dosimetry with The Holmium Platform |  | Radiomics and Genomics – a match made in heaven?  
Prof. Dr. Alexander Haug, MD, PhD  
Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria |
| Quantification of myocardial 99mTc-HMDP uptake in patients with transthyretin-related cardiac amyloidosis: ready for clinical practice  
Prof. Alban Bailliez, MD, PhD and Nuclear Medicine Department-HUMA TEP, Faculty of Medicine, Lille, France |  | Starting with Holmium-166 SIRT in clinical practice  
Dr. A. Oliveira (São João Hospital, Portugal) |
| Integrated intelligence in molecular imaging: today and tomorrow  
Bruce Spottswoode, PhD  
Director, Clinical Applications Research, Siemens Healthineers Molecular Imaging, Knoxville, TN, USA |  | Individualized SIRT treatment planning & verification with the Holmium Platform: Practical aspects – PD  
Dr. B. Olschier (University Hospital Jena, Germany) |
| Carl von Gall, MD  
Product Manager Clinical Applications Oncology, Siemens Healthineers Molecular Imaging, Knoxville, TN, USA |  | Latest Holmium data & The Clinical Roadmap  
Prof. Dr. M. Lam (UMC Utrecht, Netherlands) |
| Future Innovations of Holmium-166 SIRT: Real time MR guided SIRT  
UMC, The Netherlands |  |  |
Thursday, October 21, 2021 16:50 – 18:20, Channel 3

**PEERVOICE**

Current and Emerging Radiopharmaceuticals for Prostate Cancer: Is There a Role for Both?

Welcome and Introduction
Neal Shore, MD, FACS (Myrtle Beach, South Carolina, USA)

Evolving Radiotherapeutic Landscape in Metastatic Prostate Cancer
Ken Hermann, MD, MBA (Essen, Germany)

The Patient Journey and the Place of Radiotherapies: Understanding How Patient Profiles Align With Clinical Evidence
Joe O’Sullivan, MD, FRCP, FRHRC, FRCP (Belfast, Northern Ireland)

Sequencing Radiotherapies in mPC: What Does the Data Tell Us?
Neal Shore, MD, FACS (Myrtle Beach, South Carolina, USA)

Cases in Practice: Identifying the Right Time for Radiopharmaceuticals in Men with mPC

"Ask the Faculty" and Take-Home Messages
Neal Shore, MD, FACS (Myrtle Beach, South Carolina, USA) and Ken Hermann, MD, MBA (Essen, Germany)

Friday, October 22, 2021 09:00 – 09:45, Channel 3

**GE HEALTHCARE**

Integrating PET Innovations into Practice

Clinical Translation of Digital PET/CT innovations
Dr. Martin W Hüellner, PD, Dr. med., Department of Nuclear Medicine University Hospital Zurich / University of Zurich, Switzerland

An Evaluation of the Effects of PET timing Resolution Versus NEC on Image Quality
Dr. Paul E. Kinahan PhD, Professor and Vice-Chair for Radiology Research, University of Washington, Seattle, USA

Friday, October 22, 2021 09:45 – 10:30, Channel 3

**GE HEALTHCARE**

Utility of Amyloid PET in the Diagnosis of Dementia

Prof. Renauld Lhomme, MD, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium

Prof. Bernard Hanseeuw MD PhD, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium

Gill Farrar PhD (Host), Global Medical Director, Neurology GE Healthcare

Friday, October 22, 2021 10:45 – 11:30, Channel 3

**SIRTEX HEALTHCARE**

Friday, October 22, 2021 15:05 – 16:35, Channel 3

**BOSTON SCIENTIFIC**

From HCC to Liver mCRC, accelerating treatment standards with Y-90 glass microspheres

What have we learnt from treating HCC?
Prof. Niklaus Schaefer, Medical Oncology & Nuclear Medicine, Lausanne University Hospital, Switzerland

EPOCH study design & result
Dr. Manuel Weber, Nuclear Medicine, Essen University Hospital, Germany

Dose response & dose toxicity relationship for Y-90 glass SIRT in CLM
Prof. Marin Lam, Nuclear Medicine, University Medical Centre Utrecht, Netherlands

Friday, October 22, 2021 16:50 – 18:20, Channel 3

**SPECTRUM DYNAMICS**

Innovations That Transform SPECT Imaging

CZT-based detector technology with unique scanner designs: clinical transformation of workflow; image quality and quantitation

Cardiology Imaging
- The significance of Emission Based Attenuation Correction in Myocardial Perfusion Imaging: an AI Application for routine implementation: TruCorr
- CZT SPECT Myocardial Blood flow role and relevance: clinical experience

SPECT/CT Imaging
- Localization and characterization: Role of the VERITON-CT SPECT/CT camera in the diagnosis of parathyroid adenomas
- Beyond Total-Body NM/CT Imaging: In vivo imaging with dynamic 3600CZT SPECT/CT; SUV quantitation impact in SPECT.
**EXHIBITORS & SPONSORS**

ABX-CRO advanced pharmaceutical services
Advanced Accelerator Applications, a Novartis company
Bayer AG
Blue Earth Diagnostics Ltd.
Borchardt Logistics GmbH
Boston Scientific
Bruker Biospin
Centre for Probe Development and Commercialization (CPDC)
Chelatec SAS
Comecer
Curium
Cyclomedica Europe Ltd.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eczacibasi-Monsol Nuclear Products Co.
GE Healthcare
Hermes Medical Solutions
IRE-ELIT
Isotopia Molecular Imaging Ltd.
ITM Isotopen Technologien München AG
JSC Isotope / Rusatom Healthcare
Jubilant DraxImage Inc, dba Jubilant Radiopharma
Medi-Radiopharma Ltd.
Mediso Medical Imaging Systems Ltd
MILabs B.V.
MIM Software
MR Solutions Ltd
NRG
OncoBeta GmbH
OncoSid Medical Ltd
Pars Isotope
PeerVoice
PMB-ALCEN
Point BioPharma
ROTOP Pharmaka GmbH
Poltatom
Siemens Healthcareers
Sirtex Medical Europe GmbH
Spectrum Dynamics Medical Ltd.
Sumitomo Heavy Industries Ltd
TelePharmaceuticals Ltd.
Teva Sinergie S.p.A.
Terumo Interventional Systems
Triskem International
United Imaging Healthcare Poland Spółka z o.o.
U.S. Department of Energy Isotope Program
Waters Corporation

**LIST OF SOCIETY BOOTHS**

AIMN - Italian Association of Nuclear Medicine
ANZSNM - Australian and New Zealand Society of Nuclear Medicine
AOFNMB - Asia Oceania Federation of Nuclear Medicine and Biology
ASNC - American Society of Nuclear Cardiology
BLNCC - Belgian Society of Nuclear Medicine
BNMS - British Nuclear Medicine Society
EAOR - European Association of Radiology
ESTRO - European Society for Radiotherapy and Oncology
HNNM&MI - Hellenic Society of Nuclear Medicine and Molecular Imaging
IAEA
JSNM - Japanese Society of Nuclear Medicine
KNSM - Korean Society of Nuclear Medicine
OGNMB - Austrian Society of Nuclear Medicine & Molecular Imaging
ONCIDIUM
SNMMI - Society of Nuclear Medicine and Molecular Imaging
TSNM - Turkish Society of Nuclear Medicine
UEMS/EBNM - European Union of Medical Specialists/Section and European Board of Nuclear Medicine
WFNMB - World Federation of Nuclear Medicine and Biology
Springer Nature
EARL
ESMRT
SASAI
ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
Blasewitzer Strasse 78-80
01307 Dresden, Germany
juliet.johnston@abx-cro.com
Welcome to ABX-CRO!
We are an international CRO with a strong focus on molecular imaging and internal radiotherapy clinical trials. In addition to conducting clinical trials, we provide specialised end-to-end services including consultancy for instance in pharmacokinetics and radiopharmacology and put our inhouse image core lab and data management department at the service of your demands. Find out how your project could benefit from our experience: Chat with us here or send a message to info@abx-cro.com. We’re looking forward to your ideas!

Advanced Accelerator Applications, a Novartis company
4, rue de la Tour de l’île,
1204 Genève, Switzerland
alim.latif_ext@novartis.com
At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radionuclide therapies and precision imaging radionuclides for oncology.

Advancing Nuclear Medicine by NRG
Westerduinweg 3
1755 LE Petten, Netherlands
https://www.advancingnuclearmedicine.com/en/field-lab

Advancing Nuclear Medicine by NRG
FIELD-LAB, an innovative joint R&D centre for nuclear medicine
NRG meets the need to accelerate the development of new nuclear therapies, usually hindered by high costs and the restricted availability of proper facilities and isotopes. FIELD-LAB has been created together with renowned Dutch Academic Medical Centres and dedicated industry partners, and was presented to the international nuclear medicine society early 2019. Now we take the next step by presenting the progress we have made on three innovative projects:
- Lu-177 n.c.a.: the isotope for targeted therapy
- Pt-195m: to increase effectivity of cisplatin chemotherapy
- Pb-212: promising alpha therapeutic isotope for targeted therapy
Each a hot-topic in the academic nuclear medicine world.
We expect various publication-ready topics by 2022. Physical construction of FIELD-LAB will start end of 2020 with supply of R&D testbatches expected by the beginning of 2023. The initiative is financially supported by the European Regional Development Fund (EU) and the Province of North Holland (NL).
Interested in becoming a FIELD-LAB partner? Please contact us via our website.
NRG - Nuclear. For life.

American Society of Nuclear Cardiology
9302 Lee Highway, Suite 1210
22031 Fairfax, United States of America
info@asnc.org
www.asnc.org
The American Society of Nuclear Cardiology (ASNC) is the international leader in education, advocacy, and quality in cardiovascular imaging, with 4,000 members worldwide. We provide our members with a variety of continuing medical education programs related to nuclear cardiology and cardiovascular computed tomography (CT). We promote accreditation and certification in nuclear cardiology. We establish standards and guidelines for training and practice. We serve as a representative in health policy and the principal advocacy voice for professionals in the field. Founded in 1993 by a group of nuclear cardiology specialists who sensed the need for a professional society dedicated solely to the needs of those who perform these procedures. ASNC’s membership is composed of cardiologists, radiologists, physicians, scientists, technologists, imaging specialists, and other professionals dedicated to the science and practice of nuclear cardiology.

QDOSE: The next step in MRT dosimetry:
Founded on more than 20 years of experience, we proudly present QDOSE as the flexible stand-alone software tool for safe, efficient and productive internal dosimetry. Providing a one-stop solution for multiple workflows, QDOSE is ready for your daily clinical routine use. Come over for a live demo session and explore how QDOSE can enhance your workflow.

At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radionuclide therapies and precision imaging radionuclides for oncology.

Physical construction of FIELD-LAB will start end of 2020 with supply of R&D testbatches expected by the beginning of 2023. The initiative is financially supported by the European Regional Development Fund (EU) and the Province of North Holland (NL).
Interested in becoming a FIELD-LAB partner? Please contact us via our website.
NRG - Nuclear. For life.
Associazione Italiana di Medicina Nucleare (AIMN)
Via Farini, 81
20159 Milano, Italy
segreteria@aimn.it
https://www.aimn.it

The official Italian Association of Nuclear Medicine and Molecular Imaging. It is composed by more than 900 members, mainly nuclear medicine physicians. The scope of the association is to widespread the knowledge of nuclear medicine field and to share all the information about the molecular imaging.

Australian and New Zealand Society of Nuclear Medicine
PO Box 6178
3133 Vermont South, Australia
secretariat@anzsnm.org.au
http://www.anzsnm.org.au

Founded in 1969, the ANZSNM is the major professional society for those practising Nuclear Medicine in Australia and New Zealand. Our focus is promoting excellence in Nuclear Medicine through education, research and a commitment to the highest professional standards. The Society uniquely includes Technologists, Physicists, Radiopharmacists, Physicians, Nurses, Chemists and others interested in the practice of Nuclear Medicine. It has close ties with other professional groups in Nuclear Medicine, most particularly, the Australasian Association of Nuclear Medicine Specialists (AANMS) which represents all practising medical doctors. Radiologists, Cardiologists, and Oncologists may also participate and be involved in this area of healthcare.

Belgian Society of Nuclear Medicine
Avenue Hippocrate 10
1200 Brussels, Belgium
office@belnuc.be
http://www.belnuc.be/

With currently over 300 members, the Belgian Society of Nuclear Medicine (better known as BELNUC) was founded in 1978 and is the prime scientific multidisciplinary organization welcoming all individuals active in nuclear medicine in Belgium, including physicians, physicists, engineers, radiopharmacists/chemists, technologists, scientists and students.

The focus of BELNUC is mainly on (i) organizing regular scientific meetings and seminars, in particular encouraging research and development by young individuals, (ii) promoting quality improvement, (iii) partnering with authorities and (iv) fostering relationships with the professional society of nuclear medicine with regards to daily practice, regulations, and reimbursement issues. You can keep up-to-date with all activities of BELNUC on www.belnuc.be, or by following our Facebook page www.facebook.com/BELNUC, or subscribing to our newsletter by contacting our office at office@belnuc.be.

Our next major international event will be the BELNUC ’22 Antwerp Symposium on 6-7-8th May 2022. The preliminary program is now available at www.belnuc22.be. See you in Antwerp!

Blue Earth Diagnostics Ltd
Magdalen Centre
1 Robert Robinson Avenue
OX4 4GA Oxford, United Kingdoms
accounts@blueearthdx.com
https://www.blueearthdiagnostics.com/

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company’s success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.
Borchardt Logistics GmbH
Fasanenweg 7c
65451 Kelsterbach, Germany
info@borchardt-logistics.de
http://www.borchardt-logistics.com
Ultra Sensitive Global Logistics, worldwide radioactive transports.

Boston Scientific
Rue René Caudron 2, Parc du Val St Quentin
78960 Vaisins-le-Bretonneux, France
info@bostonscientific.eu
http://www.bostonscientific.eu/

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.eu and connect on Twitter and Facebook.

British Nuclear Medicine Society
Sir Colin Campbell Building, Triumph Rd
NG7 2TU Nottingham, United Kingdom
contact@bnms.org.uk
http://www.bnms.org.uk

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS represents all craft groups in nuclear medicine and provides advice and guidelines for all those who practice nuclear medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK. It is also active internationally in supporting our colleagues in all aspects of nuclear medicine practice. Membership is open to those who have a substantial interest and involvement in the provision of nuclear medicine services in the UK and overseas. The official journal of the Society is Nuclear Medicine Communications. Officers of the Society: Dr John Buscombe, President, Mrs Jilly Croasdale, Honorary Treasurer, Dr Richard Graham, President Elect, Dr Stewart Redman, Honorary Secretary. At the BNMS booth, delegates can find: • Information on BNMS membership - discount to new members signing up at the meeting • Information about future meetings in the UK • BNMS Brochures and Publications • Answers to any other questions regarding the BNMS Pass by our stand for a chance to win free attendance at our Spring Meeting 2021 which will be held at the ICC Waterfront, Belfast in May 2021.

Bruker BioSpin GmbH
Rudolf-Plank-Str. 23
76275 Ettlingen, Germany
info@bruker.com

Bruker BioSpin - Innovation with Integrity

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application fields, such as oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Our range of techniques includes Magnetic Resonance Imaging (MRI), Nuclear Molecular Imaging with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), micro-CT (Micro Computed Tomography), and Magnetic Particle Imaging (MPI). By combining our novel PET, proven micro-CT and outstanding MRI technologies, we make translational multi-modal imaging more accessible to the research community and offer optimal solutions for laboratories. All while keeping in mind that software, animal handling and lab workflow is a key part of any laboratory.
Centre for Probe Development and Commercialization (CPDC)

1280 Main St W, Hamilton ON L8S 4L8, Kanada

cpdc@imagingprobes.ca

https://www.imagingprobes.ca/

At the Centre for Probe Development and Commercialization (CPDC), we discover, develop, and distribute radiopharmaceuticals. The CPDC was founded in 2008 as a non-for-profit Centre of Excellence for Commercialization and Research (CECR), specializing in radiopharmaceutical research and development. Since its inception, CPDC has gained expertise in GMP manufacturing of radiodiagnostics and radiotherapeutics and is now globally recognized as a leading GMP radiopharmaceutical manufacturing Contract Development and Manufacturing Organization (CDMO). CPDC uniquely offers the full range of scientific, technical, regulatory, logistics and business expertise combined with the full specialized infrastructure required to translate radiopharmaceuticals to the clinic and provide them to the commercial marketplace. With its superb experienced team and in collaboration with academic and pharma partners, CPDC has achieved several milestones including completion of over 30 radiopharmaceutical discovery, development, and manufacturing programs and translating over a dozen radiopharmaceuticals into clinical development, which currently support more than 25 clinical trials in 15 countries that span North America, Europe and Australia. CPDC succeeded in creating several companies in the radiopharmaceutical space, including Fusion Pharmaceuticals, and co-founded ARTIMS and CanProbe with leading experts in the field. Currently, CPDC is transitioning towards a for-profit state of the art CDMO dedicated to clinical and commercial manufacturing of radiotherapeutics that will transform patients’ lives by providing high quality drugs for the treatment of an array of diseases.

Chelatec

1 rue Aronnax
44800 Saint-Herblain, France

https://www.chelatec.com/

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalysis, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.

Our services cover/include:
- Bioconjugation
- Radioactive labeling
- Analytical controls (HPLC, TLC, LC-MS, GC-MS...)
- Stability studies (storage stability, plasma stability)
- In vitro assays (Binding affinity, IFR, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry).

COMECER

Via Maestri del Lavoro 90
48014 Castel Bolognese, Italy

marketing@comecer.com

https://www.comecer.com

Comecer, an AT5 company, is a developer and manufacturer of high-tech systems in the field of Aseptic Processing and Containment for Pharmaceutical Industries. It operates in the Radiopharmaceutical sector through the production of shielding systems and equipment for special applications, both for large industrial groups and for research institutions.

Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications.

Comecer products, such as shielded hot cells, synthesis and dispensing isolators, solid target systems and radiopharma injectors, are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide.

Curium

63, Avenue des Champs-Élysées
75008 Paris, France

genevieve.duhalgouet@curiumpharma.com

Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine.

The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve. An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

To learn more, visit curiumpharma.com
Cyclomedica Europe Ltd

- Unit A5 Calmount Business
- Dublin 12 Ballymount, Ireland
- info@cyclomedica.com
- http://www.cyclomedica.eu

Cyclomedica specialises in the diagnostic imaging field in lung health. It is known for the leading technology, the Technegas™ TechnegasPlus Generator.

Our vision, beyond PE drives our development from the diagnosis of pulmonary embolism, to embrace functional lung imaging through SPECT/CT to now emerge in the diagnostic contribution in clinical management of patients with airways diseases.

At Cyclomedica, our focus is to provide our customers with innovative Molecular Imaging solutions improving efficiency and effectiveness in patient care.

Our business is transforming and growing with the aim to explore new opportunities in order to deliver meaningful solutions and build our already strong service and product offering within the global market.

Eckert & Ziegler Medical

- Robert-Roessle-Straße 10
- 13125 Berlin, Germany
- http://www.medical.ezag.com

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group. With more than three decades of experience in the field, Medical represents our combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success.

We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing.

As a one-stop-shop for all your radiopharmaceutical needs our products include everything from hot cells to radiochemicals (e.g. Lu-177), radiopharmaceuticals (Ytriga, GalliaPharm®), radiosynthesis technology (Modular-Lab, KiLab) and radiochromatography equipment (e.g. AR-2000). Furthermore, we offer comprehensive solutions for LDR (IsoSeed®) and Ophthalmic Brachytherapy as well as X-ray therapy.

In addition the Eckert & Ziegler Group provides a wide range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications.

Eczacibasi-Monrol Nuclear Products Co.

- Rüzgarlıbahçe Mahallesi Kavak Sokak No.20
- 34805 Istanbul, Turkey
- monrol@monrol.com
- https://www.monrol.com

Eczacıbaşı-Monrol Nuclear Products Co. is a leading developer, manufacturing, and distributor of radiopharmaceutical products in the Balkans, Middle East, North Africa and also Central & Eastern Europe. Eczacıbaşı-Monrol also carries out its expertise all around the world with its EU-GMP grade produced high-quality radiopharmaceuticals and unique logistics infrastructure.

Eczacıbaşı-Monrol has 7 world-class production facilities, 4 in Turkey, 2 in Europe and 1 in Egypt employing modern and environmentally responsible production technologies. The company also operates 7 cyclotrons in our affiliates. Eczacıbaşı-Monrol services regional nuclear medicine needs through 300 employees and more than 20 distributors, delivering high-quality and customer-oriented service to nuclear medicine centers in Turkey and more than 50 countries around the world.

European Association of Cardiovascular Imaging (EACVI)

- European Heart House
- 06903 SOPHIA ANTIPOLIS Cedex, France
- eacvi@escardio.org
- https://www.escardio.org/EACVI

The European Association of Cardiovascular Imaging (EACVI), a branch of the European Society of Cardiology, is a not-for-profit organisation. Everything we do is to support our 14,000 members worldwide and all healthcare professionals - cardiologists, technologists, nurses, basic scientists and allied professionals – specialising in cardiovascular imaging so they can deliver the best possible evidence-based care to patients.

Our activities are driven by volunteers who are renowned experts from across all imaging techniques: echocardiography, cardiovascular magnetic resonance, nuclear cardiology and cardiac computed tomography.

Our Mission: to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
EIBIR (European Institute for Biomedical Imaging Research)

Am Gestade 1
1010 Vienna, Austria
office@eibir.org
www.eibir.org

The European Institute for Biomedical Imaging Research (EIBIR) is dedicated to the coordination of research projects and aims to support the development of biomedical imaging technologies and the dissemination of knowledge.

It is EIBIR’s mission to improve cooperation within the European biomedical imaging community, and foster interoperability through research networking activities and common initiatives, with the goal of improving the diagnosis, treatment, and prevention of diseases.

As a non-profit research organisation, EIBIR has helped scientists secure more than EUR 109 million in research funding.

EIBIR has developed an excellent track-record in consortium building, to project management, related services from proposal preparation, projects for 15 years offering professional research-related services from proposal preparation, consortium building, to project management, communication, and dissemination. Over the years, EIBIR has developed an excellent track-record in supporting international research consortia and has helped scientists secure more than EUR 109 million in research funding.

ESTRO (European Society for Radiotherapy and Oncology)

Rue Martin V 40,
1200 Brussels, Belgium
info@estro.org
https://www.estro.org/

About ESTRO

“Every cancer patient in Europe will have access to state of the art radiation therapy as part of a multidisciplinary approach where treatment is individualised for the specific patient’s cancer, taking account of the patient’s personal circumstances.”

- ESTRO Vision 2030 –

The European Society for Radiotherapy and Oncology (ESTRO) is a non-profit and scientific organisation that fosters the role of Radiation Oncology in the multimodality treatment of cancer. ESTRO promotes innovation, research and dissemination of science through its congresses, workshops, special meetings and peer-reviewed publications.

The Society also supports the professionals of Radiation Oncology in their educational development through a whole programme of teaching courses, online and onsite.

Do not miss on the virtual booth the presentations for ESTRO 2022, the next annual congress, the upcoming ICHNO-ECHNO 2022 conference and the Physics Workshop, the 2022 educational offer and our open access journals.

GE Healthcare

283, rue de la Miniere
78 533 BUC, France
Response@med.ge.com
https://www.gehealthcare.co.uk

GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform.

With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. Visit our website www.gehealthcare.co.uk (EMEA zone) for more information.

HSNM&MI (Hellenic Society for Nuclear Medicine and Molecular Imaging)

44-46 Ipokratous street
10680 Athens, Greece
info@nuclear-medicine.gr
https://nuclear-medicine.gr/

GE Healthcare

Founded in 1968, by the renowned Honoured Member of the Academy of Athens for Sciences and Philosophy, Professor of Medicine Vassilios Malamos, HSN&M&I is one of the oldest European societies in Nuclear Medicine.

HSNM&M&I aims:

- Scientific development of Nuclear Medicine and its biological applications.
- Contributing to research, study and optimization of Nuclear Medicine applications in Greece.
- Promoting Nuclear Medicine education in the context of continuing medical education
- Promoting cooperation of other disciplines in the field of Nuclear Medicine.
- Formulation, protection and compliance with radiation protection regulations, in accordance with the existing provisions, regarding handling, use and disposal of radioisotopes.
- Representation and cooperation of the Society’s representatives with the State, the European Union and international scientific bodies in general.

HSNM&M&I has a total of 328 members, including Nuclear Medicine physicians and residents, Nuclear physicists, Technologists, Radiobiologists and Radiopharmacists.

HSNM&M&I operates and acts as the main and only consultant for the Greek State, in any kind of issue including and interfering with Nuclear Medicine. Since the beginning, HSN&M&I has kept on collaborating worldwide with EANM, WFNM and IAEA. In addition, HSN&M&I has a leading role concerning the promotion of Nuclear Medicine in the Balkan region, by contributing to the organization of BCNM congresses.
Hermes Medical Solutions

Strandbergsgatan 16
112 51 Stockholm, Sweden

info@hermesmedical.com
https://www.hermesmedical.com/

At EANM 2021 Hermes Medical Solutions (HMS) is proud to show its latest products for visualisation, processing, remote and local reporting, management and storage of image data from multiple modalities within molecular imaging, nuclear medicine and radiology.

Visit us to find out you how you can:
- Accelerate your PET/CT, PET/MR, and SPECT/CT reporting with the latest intuitive, fast and powerful Affinity Viewer®
- Personalise the treatment of your patients with the most accurate and flexible CE-marked dosimetry software: HMS Dosimetry® Suite includes Voxel Dosimetry® with Monte-Carlo dose simulation and theranostic dose prediction, single timepoint dosimetry, pre- and post-intervention dosimetry for SIRT, and organ dosimetry using OLINDA/EXM®.
- Obtain superior quantification and image quality for any radionuclide and SPECT/CT camera with HMS’ latest SUV-SPECT® quantitative SPECT reconstruction, now with Bayesian noise suppression penalty factors, anatomical and VOI-based tools for Lung VQ SPECT and Lung Lobe Quantification using CT-derived anatomical information.

HMS’ leadership within molecular imaging and NM is built upon 45 years of continual innovation, strong customer service and sound clinical expertise. HMS provides the most comprehensive independent, vendor-neutral software suite for diagnosis and treatment planning, making precision personalised medicine a reality.

ICPO Foundation

Humboldtstraße 29
65189 Garching / Munich, Germany

info@icpo.foundation
www.icpo.foundation

We enable cancer patients worldwide to gain access to highly effective theranostic treatments in Precision Oncology.

International Atomic Energy Agency

Wagramer Strasse 5
1030 Vienna, Austria

info@iaea.org
https://www.iaea.org/

The International Atomic Energy Agency is the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field. It works for the safe, secure and peaceful uses of nuclear science and technology, contributing to international peace and security. The IAEA’s aim is to help build Member States’ capacities to support them in establishing high-quality health care worldwide. Since the IAEA began its work in human health over 50 years ago, the use of nuclear techniques in nuclear medicine and radiology has become one of the most widespread peaceful applications of atomic energy. The IAEA assists Member States with the coordination of research projects, expert guidance, equipment, the development of internationally harmonized guidelines, training and knowledge exchange.

IRE ELiT

Avenue de l’Espérance, 1
6220 Fleurus, Belgium
marketing@ire-elit.eu
http://www.ire.eu

IRE ELiT is a radiopharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy.

IRE ELiT places quality, reliability and services at the center of all its concerns to secure the supply and easy use of radiopharmaceuticals for its customers worldwide. IRE ELiT’s portfolio of customer-oriented solutions includes radiopharmaceuticals for diagnosis or treatment purposes, as well as equipment dedicated to their preparation.

Our main product is a Ge-68/Ga-68 generator, Galli Ad, a simple and innovative PET imaging solution used, mainly, for NET tumors and recurrent prostate cancers. Galli Ad is a fully integrated and closed system to get rapidly highly concentrated and very pure radiopharmaceuticals preparations minimizing loss of activity. Its innovative design, specific for cold kits reconstitution, limits the risk of misuse and contamination. This generator can be used manually or connected to a synthesis module.
Isotopia Molecular Imaging  
39 Alexander Yannai St.  
4927735 Petah Tikva, Israel  
info@isotopia.co.il  
https://isotopia.co.il/  
Lifesaving radio pharma solutions for theragnostic purposes. We understand that delivering the right treatment to the patient at the right time could be the tipping point in the patient’s care. That’s where our gold standard treatment and professional service make all the difference. We supply Lu-177 N.C.A and CA tailor-made to your requirements, and work with you closely to devise the optimal solution to support your growth. Isotopia around the globe Isotopia has enhanced its external distribution across North America by partnering with the Canadian CPDC to build a local manufacturing site, designed to:  
- Reduce complex logistics and customer costs.  
- Upscale production, shorten delivery time and reduce material loss.  
- Ensure timely and consistent delivery to all locations.  
- Respond to changing demand.  
We guarantee:  
- Availability – a weekly supply of Lu-177 N.C.A and CA all year round.  
- Minimum material loss – thanks to our unique V-shaped vial.  
- Maximum safety – while minimizing user exposure with a unique plexiglass insert.  
We are committed to meeting your acute need for round-the-clock availability and responsiveness to solve problems in real-time. At the moment of truth, we are there! Instant communication (even with a 10-hour time difference) and NO middle man.

ITM Isotopen Technologien München AG  
Walther von Dyck Strasse 4  
85748 Garching, Germany  
anjela.knoeppel@itm.ag  
https://itm-radiopharma.com  
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

Japanese Society of Nuclear Medicine  
NISSHIN Bldg. 3-1-17, Nishi-Azabu,  
Minato-ku, Tokyo 106-0031, JAPAN  
anm@jsnm.org  
http://jsnm.org/english/  
The Japanese Society of Nuclear Medicine was established in 1964 which currently has over 3,600 members. The JSNM has been working hard to promote the development of nuclear medicine through the collaboration with the SNMMI, EANM, AOFNMB (Asia and Oceania Federation of Nuclear Medicine and Biology), ARCCNM (Asian Regional Cooperative Council for Nuclear Medicine), World Federation of Nuclear Medicine and Biology (WFNMB) and individual societies of many countries.

JSC Isotope (ROSATOM)  
Pogodinskaya Str. 22  
119435 Moscow, Russia  
medical@isotop.ru  
Founded in 1958, Isotope JSC (part of Rusatom Healthcare JSC group) is a leading supplier of isotope products for nuclear medicine, focused on increasing availability of medical isotopes worldwide. Located in Moscow, Isotope JSC is responsible for the distribution and marketing of isotope products manufactured by the enterprises of ROSATOM State Corporation. We offer high-quality, cost-effective isotope-based products including radiopharmaceuticals and medicinal devices, as well as a wide range of raw materials (radioisotopes, stable isotopes). We supply over 20 critical medical isotopes to the international markets, among which are such core products as Mo-99, I-131, Lu-177, Ac-225, Ge-68/Ga-68 generators and others. Isotope JSC is a major supplier of medical isotopes to Latin America and Asia and one of the active members of European isotope market. Over 100 foreign companies in 50 countries across the world and around 600 Russian companies including healthcare institutions, manufacturing facilities, and scientific & research organizations are among partners of Isotope JSC.
We set a key target to contribute to the development of the modern nuclear medicine treatments and technologies to improve patients’ quality of life.
Jubilant Radiopharma

16751 TransCanada Hwy
HHH 4J4 Kirkland, Canada

donna.schork@jubil.com
http://www.jubilantradiopharma.com

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality, because they recognize the important role it plays in evaluating cardiac physiology and function. Whether you are looking to start a program or want to enhance your current practice; we are here to help you, every step of the way. Partnering with Cyclomedica in the EEA, they will provide expanded access to the next-generation PET products to enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.

Korean Society of Nuclear Medicine

Gumho Palace BD #1705, Jibong-ro 29, Jongro-gu
03121 Seoul, South Korea

knsn@ksnm.or.kr
https://ksnm.or.kr/

The Korean Society of Nuclear Medicine (KSNM) was established in 1961. The official bimonthly journal is ‘Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging)’ and publishes papers about nuclear medicine and related sciences. The KSNM hosts Annual Spring and Autumn Meetings with academic symposiums, scientific sessions, award ceremonies, and training courses. Currently, there are 130 institutions with nuclear medicine facilities in Korea. 395 board certified specialists and over 160 scientists dedicated to the field of nuclear medicine are members of the KSNM. The KSNM works closely with the government and industry to promote progress of nuclear medicine in Korea.

Clinical practice and research applying molecular imaging and radiopharmaceuticals will continue to flourish, and the KSNM is proud to lead the advancement of the field of nuclear medicine in Korea.

Medi-Radiopharma Ltd.

Szamos u. 10-12.
2030 Érd, Hungary

orders@mediradiopharma.hu
https://mediradiopharma.com/

Medi-Radiopharma Ltd. (MRP) has more than 25 years of experience in developing, manufacturing and supplying radiopharmaceutical products to customers around the globe. MRP specialises in the production and supply of generic in-vivo kits for Tc-99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products empower our customers with effective treatment and proven patient outcomes. MRP hold a diverse portfolio of proven products registered in 70 countries worldwide. We pride ourselves on our ability to deliver a steady supply of quality diagnostic and therapy solutions, with the highest standards of quality and safety assured at every stage. The company holds valid Manufacturer’s Authorisation, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesale Distributor, Good Laboratory Practice (GLP) Certificate, ISO certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals. MRP, together with its partner company, Radiopharmacy Laboratory Ltd., is also involved in the development of therapeutic radiopharmaceuticals. The company is open for requests and suggestions on new research and development projects in the field of nuclear medicine.

Mediso Medical Imaging Systems

Laborc str.3.
1037 Budapest, Hungary

https://mediso.com

Mediso works in the field of nuclear medicine since 1990 with a profile of development, manufacturing, selling and servicing molecular imaging multymodality devices. It offers complete solutions from hardware design to evaluation and quantification software for clinical patient care and preclinical research.

With its 30-years expertise, 1,300+ clinical cameras, Mediso is within the leaders in clinical patient care. Besides a unique triple modality clinical SPECT-CT-PET hybrid system, Mediso launched the new AnyScan® TRIO family which has a triple head SPECT detector design and dedicated multipinhole collimation technology.

Mediso has a leader position in the preclinical nuclear imaging market with 250+ commissioned preclinical cameras around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso launched the world’s first integrated PET/MR and SPECT/MR systems. Further on 3T and 7T cryogen-free magnets and PET insert have been added to the product line, resulting in the largest install base of integrated PET/MR systems. Products are sold directly or through a network of distributors with over 1500 imaging systems for clinical and preclinical imaging operating in 100+ countries around the globe.
MILabs

Duwboot 7a
3991 CD Houten, Netherlands
info@milabs.com
MILabs is a leading innovator in preclinical PET, SPECT, Optical, and X-ray CT imaging systems, available as stand-alone imaging devices or in any combination in a single integrated scalable platform. The scientific community recognizes all modalities for superior resolution and image quality. MILabs’ systems have received many international awards, and advanced preclinical imaging applications have been published by hundreds of satisfied users. By combining PET, SPECT, Optical, and CT on a single in-line platform, MILabs has introduced the first commercial system to exploit the many symbiotic strengths such as:
• Simultaneous Multi-isotope PET-PET and PET-SPECT imaging
• Sub-mm theranostic imaging including alpha- and beta-emitting radiotherapy isotopes
• Quantitative CT-guided Optical Tomography
This single-pass in-vivo imaging platform with synergistic multi-modal capabilities paves the way for rapid translation of precision medicine from bench to bedside.

MIM Software Inc.

25800 Science Park Dr #180
44122 Beachwood, United States of America
jmeisinger@mimsoftware.com
https://www.mimsoftware.com/
MIM Software Inc. provides a broad range of applications and solutions that support Radiology and Nuclear Medicine’s role in improving patient care. MIM Software’s Nuclear Medicine Solutions empowers both physicians and technologists to work harmoniously through the use of a common platform and set of tools for PET/CT, SPECT, and MRI.
MIM Encore® provides advanced visualization, image registration, segmentation, and analysis tools that are well-equipped to manage the latest advances in theranostics and other fields. MIM SurePlan™ MRT offers tools to support the feasibility of Molecular Radiotherapy Dosimetry within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and SPECTRA Quant® provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.
With MIM Software’s Contour ProtégéAI™ solution, clinicians can standardize and expedite the normal organ segmentation workflow. Contour ProtégéAI features next-generation segmentation that utilizes machine learning algorithms.

MR Solutions Ltd

Ashbourne House
The Guildway, Old Portsmouth Road
GU3 1LR Guildford, United Kingdom
exhibitions@mrsolutions.com
http://www.mrsolutions.com
MR SOLUTIONS GROUP develops and manufactures innovative MR, CT, PET and SPECT imaging solutions. All scanners are interchangeable between each other for multi-modality imaging.
The company is the worldwide leader in high-field cryogen-free MR and delivers systems up to 9.4T with a bore size up to 42 cm. This technology has exclusive features such as rotating the system to 90° and to change the field within few minutes. It doesn’t require pipes and heavy site building therefore the installation cost is extremely low.
PET/MR imaging is possible up to 9.4T simultaneously. PET and SPECT scanners are dissociable within a few minutes from the MR and pluggable onto the CT. It avoids duplicating the scanners for multi-modality imaging.

Oncidium foundation

Rue Emile Francqui 6 (boîte 5)
1435 Mont-Saint-Guibert, Belgium
tala@oncidium-life.org
https://www.oncidiumfoundation.org/
The Oncidium foundation is dedicated to supporting Radiotheranostics (RT) for cancer care in view of enhancing access, globally it strives to connect patients, practitioners, and experts in the Nuclear Medicine field by raising awareness and improving access to cancer treatments and clinical trials worldwide. It also searches and provides answers to the questions of who, what, when, where, why, and how regarding RT.
Together, let’s commit to enhance Access | Education | Hope.
Access – Make Radiotheranostics available, globally.
Education – Raise awareness to promote precision medicine and the benefits of RT for cancer therapy.
Hope – When other cures are not an option and support RT by financing specific therapy costs and their development worldwide.
OncoBeta GmbH
Schleißheimer Str. 91
85748 München, Germany
info@oncobeta.com
http://www.oncobeta.com

OncoBeta GmbH with its headquarters in Garching near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 OncoBeta® GmbH produces tungsten (wolfram)-188/rhenium-188 (188W/188Re) Generators for commercial use.

OncoSil Medical
Suite 503, Level 5
15 Blue Street
2060 North Sydney, NSW, Australia
cynthia.azucena@oncosil.com
http://oncosil.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microspheres in combination with chemotherapy.

OncoSil is our brachytherapy device. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

We believe in our technology and its ability to have a truly positive impact in Oncology.

Reference:

OGNMB - Austrian Society of Nuclear Medicine & Molecular Imaging
Schmidshofgasse 26, Top 5
1060 Vienna
info@ognmb.at
https://www.ognmb.at

The OGNMB represents the field of nuclear medicine and molecular imaging in Austria with more than 250 individual and supporting members. It welcomes researchers and employees of all fields involved, including radiochemists, medical physicists, technologists, radiopharmacists and of course trained nuclear medicine specialists as well as those in training.

The annual congress of the OGNMB is organized every two years in Bad Ischl (Austria). You are cordially invited to attend the next International Austrian Winter Symposium, taking place from Jan 19 - 22, 2022. Please check the website (https://congress.ognmb.at/) for further information.

PARS ISOTOPE
No.88, west 23 St. Azadegan Blvd.
South Sheikh Baharee
1439955416 Tehran, Iran
n.alai@parsisotope.com
http://www.parsisotope.com

Pars Isotope Co. is the leading producer and supplier of medical radioisotopes in the Middle East. With more than 50 products in the world of nuclear medicine, we supply different radiochemicals and solutions used in the treatment and diagnosis process. Based on our deep-seated knowledge and experience in radiopharmaceuticals production, we have succeeded to manufacture some unique radiopharmaceuticals and introduce different solutions to the international market. The most highly prized products in this range are PARSTEC (I) which is our TC-99m generator brand and PARS GalluGEN that is our Ge-68/Ga-68 generator.

To enhance the quality and quantity of medical products according to cGMP regulations Pars Isotope is involved in a project to implement new modern facilities for RRP, CKP, and PET in Iran. Additionally, we are focused on the following activities according to our profession and capabilities:
- Production of 12 diverse types of Tc-99m cold kits.
- Production of 5 different types of Tc-99m peptide kits.
- Production of different types of radiochemical generators used in PET & SPECT.
- Production of 22 various ready-to-use radiopharmaceuticals in diagnostics and therapeutics.
- Production of 7 different types of radiochemicals used in the production of radiopharmaceuticals.
- Development and optimization of advanced methodologies in the production of radiopharmaceuticals.
PeerVoice

1, rue Hildegard von Bingen
L-1282, Luxembourg

http://www.peervoice.com

PeerVoice understands that today’s healthcare professionals are expected to stay up to date with the latest medical information and to demonstrate continual improvements in patient care, but are often challenged to find the time. We facilitate excellence in clinical practice through live and online education designed to positively impact patient care. You can trust us to provide:

- Education designed to eliminate specific knowledge and/or practice gaps
- Objective discussion of the best-available evidence and treatment guidelines
- Practical clinical perspectives from internationally-renowned faculty
- An easy-to-use online educational platform that allows you to control how, when and where you learn

PMB-Alcen

Route des Michels CD56
Chemin de la Corneille
13790 Peynier, France

immagine@pmb-alcen.com
https://www.imigine.com

Located near Aix-en-Provence, in France, PMB is a 130-employee SME. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency...), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.

PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room, complete with an automated quality control device. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Quality control is then carried out through an automated process to test the synthesized molecule.

IMIGINE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process, by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging and theranostics. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, IMIGINE improves patient care.

POINT Biopharma Inc

4850 West 78th Street
46268 Indianapolis, Indiana,
United States of America

https://www.pointbiopharma.com/

POINT Biopharma Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), and manufacturing technology to revolutionize therapeutic drug development and radioligand commercialization.

ROTOP Pharmaka GmbH

Bautzner Landstraße 400
01328 Dresden, Germany

info@rotop-pharmaka.de
http://www.rotop-pharmaka.de

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With more than 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals, RDOTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

Our portfolio includes:
- RDOTOP Pharmaka | GMP production of Tc-99m cold kits
- RDOTOP Radiopharmacy | GMP production of radioactive radiopharmaceuticals
- RDOTOP Innovation Center | Full CRO Services, incl. API and kit development
Siemens Healthcare GmbH  
Henkestraße 127  
91052 Erlangen, Germany  
https://www.siemens-healthineers.com

At Siemens Healthineers, our purpose is to drive innovation to help humans live healthier and longer. Through our products, services and solutions we help physicians, medical staff, and healthcare providers prevent illnesses from occurring and to correctly diagnose and determine the right treatments for people who do become ill – resulting in fewer complications, shorter hospital stays, and faster patient recovery.

Our mission is to enable healthcare providers to increase value by expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. With our comprehensive portfolio – from in-vitro diagnostics and imaging to therapy and follow-up care – we address the complete care continuum for many of the world’s most threatening diseases.

Every hour, more than 240,000 patients are touched by technologies provided by Siemens Healthineers. We are at the center of clinical decision making with almost three-quarters of all critical clinical decisions influenced by our solutions. We are a leading medical technology company with over 120 years of experience and more than 65,000 highly dedicated employees around the globe who are innovating every day, truly shaping the future of healthcare.

Sirtex Medical Europe GmbH  
Joseph-Schumpeter-Allee 33  
53227 Bonn, Germany  
learn-emea@sirtex.com  
http://www.sirtex.com

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.

Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.

For further information please visit www.sirtex.com. Learn more about Sirtex in our interactive virtual booth https://www.sirtexvirtualbooth-emea.com

Society of Nuclear Medicine and Molecular Imaging (SNMMI)  
1850 Samuel Morse Dr.  
20190 Reston, United States of America  
memberinfo@snmmi.org  
www.snmmi.org

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 14,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

Spectrum Dynamics Medical  
rue de Lausanne 31  
1110 Morges, Switzerland  
info@spectrum-dynamics.com  
http://www.spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of SPECT imaging systems from analog to digital detection technology, enabling hospitals and clinicians to provide superior healthcare services with improved image quality, efficiency and quantitative clinical applications.


The D-SPECT employs digital detectors made of Cadmium Zinc Telluride (CZT), which along with ingenious hardware design, proprietary software and algorithms, enables imaging of cardiac patients at unprecedented speed, at a low radiation dose, and with superior image quality. The D-SPECT is the platform for advanced clinical applications such as Dual Isotope Imaging, Dynamic Imaging and Emission Map Attenuation Correction for Myocardial perfusion imaging.

In 2018, Spectrum Dynamics launched its digital SPECT-CT system VERITON-CT®, 80 cm bore, available in 16-slice or 64-slice configuration. VERITON-CT is the first 360° ring-shaped digital SPECT/CT enabling total body 3D imaging at high speed, low radiation dose, and with significant improvement in image quality. With 360-CT, routine planar clinical applications leap to 3D imaging, with significant benefits for patients and clinicians.
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Address</th>
<th>Website</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Springer Nature</td>
<td>Tiergartenstrasse 17, 69121 Heidelberg, Germany</td>
<td><a href="mailto:customerservice@springernature.com">customerservice@springernature.com</a></td>
<td>Springer Nature advances discovery by serving the whole research community. All the research we publish is robust and in the best possible format to be discovered, accessed, used, re-used and shared. Springer Nature is home to brands including Springer. Please visit springernature.com and @SpringerNature</td>
</tr>
<tr>
<td>Sumitomo Heavy Industries,Ltd.</td>
<td>ThinkPark Tower, 1-1 Osaki 2-chome, Shinagawa-ku 141-6025 Tokyo, Japan</td>
<td><a href="https://www.shi.co.jp/english/">https://www.shi.co.jp/english/</a></td>
<td>Sumitomo Heavy Industries, Ltd. (“SUMITOMO”) is one of the largest heavy machinery companies in Japan and manufactures various machinery and equipment, such as VLCC tanker, power boiler, plastic machinery, power transmission equipment and accelerator. In the field of accelerator, with long experiences, Sumitomo produces medical related equipment, i.e. proton therapy system and PET (“Positron Emission Tomography”) radio-tracer production system. Regarding PET radio-tracer production system, Sumitomo is the leading manufacture of cyclotrons as well as various synthesizers, hot cell and ancillary equipment with majority of market share in Asia. Sumitomo has an experience of delivering the PET cyclotron system over 30 years and delivered more than 200 PET systems in Asian countries, i.e. Japan, South Korea, China, Taiwan, Thailand, Malaysia, India, Philippines and Iraq.</td>
</tr>
<tr>
<td>Telix Pharmaceuticals</td>
<td>Rue de Hermée 255, 4040 Herstal, Belgium</td>
<td><a href="https://telixpharma.com/">https://telixpharma.com/</a></td>
<td>Telix was created to deliver on the promise of nuclear medicine. Nuclear medicine has historically suffered from a lack of commercial critical mass and commitment to late-stage product development. Molecules-targeted radiation (MTR) potentially offers better-informed treatment decisions and truly personalised therapy. Our product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer. We are an experienced team of drug developers, clinicians and executives, with a passion for radiation biology and oncology. Telix’s pipeline currently focuses on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio. In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anni.be. We are focused on the development and commercialisation of clinical-stage oncology programs. Telix Pharmaceuticals is focused on the development and commercialisation of several clinical-stage oncology assets in renal cancer, prostate cancer and brain cancer. We are also actively exploring indication expansion opportunities for our programs and platforms.</td>
</tr>
<tr>
<td>Tema Sinergie</td>
<td>Via Malpighi, 120, 48018 Faenza, Italy</td>
<td><a href="mailto:tema@temasinergie.com">tema@temasinergie.com</a></td>
<td>Professionalism, proactivity, passion and business intelligence are features that have distinguished us every day since 1965. Over 30 years of experience, together with continuous research, have allowed to develop a complete range of products and services that represent, both in Italy and worldwide, a fundamental landmark for all professionals dealing with ionizing radiations. From synthesis and dispensing hot cells, to dose drawing systems, radiopharmaceutical injectors, monitoring systems and much more, Tema Sinergie is the ideal partner for each and every application within the field of Nuclear Medicine.</td>
</tr>
</tbody>
</table>
Terumo Interventional Systems

Interleuvenlaan 40
3001 Leuven, Belgium

https://www.terumo-europe.com/en-EMEA

Terumo is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medicine professionals to ensure they have access to high quality tools for their patients. This partnership is based on Terumo’s comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patients needs.

QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.

QuiremSpheres™ are the first Holmium-166 microspheres on the market which brings a wide range of benefits from higher dose rate, to optimized imaging capabilities.

QuiremSpheres™ are also the first SIRT microspheres to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

Triskem International

3 rue des Champs Géons
35170 Bruz, France

contact@triskem.fr

https://www.triskem-international.com/

Triskem International develops, manufactures and commercializes selective resins for the separation and quality control of radionuclides for use in diagnosis and therapy such as Ga-67/8, Lu-177, Tb-161, Cu-61/47, Zr-89, Ga-68, alpha emitters, Ti-44/5, Sc-43/47 and many other radionuclides. Further to its range of resins Triskem also provides selective chromatography paper such as DGA Sheets (DGA,N & DGA,B) for quality control of radionuclides and generator effluents (Ra-223/Ac-225/Pb-212, Sr-90/Y-90, Ga-68, ...), and other separation supports for rapid purifications and QC.

Triskem’s resins are increasingly finding use in the production of radionuclides for radiotherapy and nuclear medicine, and are employed by leading radionuclide manufacturers worldwide.

Our R&D team is constantly working on the development of new resins and methods in order to help you with your separation needs.

If you have a special separation need, you are willing to participate in a R&D project or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us at contact@triskem.fr.

Turkish Society of Nuclear Medicine (TSNM)

Cinnah Caddesi Piyale Sok No: 10/12
0 6690 Ankara, Turkey

demesmelek@tsnm.org

http://www.tsnm.org

The society organizes several scientific activities each year, national congresses in spring and a symposium dedicated on a different topic of interest in winter season and regular educational events called “School of Nuclear Medicine” designed for residents and young physicians by the experts of the scientific task groups involved within TSNM. Currently TSNM has 875 members including physicians, physicists, pharmacists and technologists. The official journal of TSNM is “Molecular Imaging and Radionuclide Therapy, MIRT” (http://mirt.tsnmjournals.org). MIRT is published in English and indexed in PubMed, PubMed Central, EBSCO and some other scientific indexes and provides open access to its content. The society also publishes an electronic journal, “Nuclear Medicine Seminars” which is in Turkish dedicated to educational articles on specific topics by the invited editors in each issue.

UEMS

24 Ruc de l’Industrie
1040 Brussles, Belgium

uems@eann.org

https://uems.eann.org/

The European Union of Medical Specialists (UEMS) has existed for more than 50 years and is the political representative organisation for medical specialists in the European Union and associated countries. UEMS defined the basic principles in the field of training of European medical specialists to obtain a comparably high level of knowledge to allow free movement of specialists between member countries. Specialist Sections for each of the main disciplines practiced in the member states were created to coordinate and harmonise the specialist training and elaborate the criteria for the recognition of medical specialists. With successive enlargements of the European Union, the number of Specialist Sections gradually increased to 34. The UEMS created European “Boards”, working groups of the Specialist Sections, to guarantee optimal care by bringing the training of medical specialists to the highest possible level in the specialty concerned.
The U.S. DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research. The goals of the program are to:

- Produce and/or distribute radioactive and enriched stable isotopes that are in short supply, including valuable by-products and surplus materials, and perform related isotope services.
- Maintain the infrastructure required to produce and supply isotope products and to perform related services.
- Conduct R&D on new and improved isotope production and processing techniques that can make available new isotopes for research and applications.

The program also coordinates and supports isotope production at numerous universities, national laboratories, and commercial accelerator and reactor facilities throughout the nation to promote a reliable supply of domestic isotopes.

The National Isotope Development Center (NIDC) is funded by the DOE Isotope Program. It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories to maximize the outcomes for liver cancer patients.

United Imaging Healthcare Poland Sp. z o.o.

- U.S. Department of Energy Isotope Program

United Imaging Healthcare is dedicated to providing, developing and producing high-performance advanced medical imaging, radiotherapy equipment, and life science instruments, and offers intelligent digital solutions to customers worldwide. UIH was founded in 2011 and headquartered in Shanghai, with subsidiaries and R&D centers across China, the United States, United Arab Emirates, Australia, Poland, India and other parts of the world.

UIH has world-class talent including more than 140 scientists with global experience and more than 500 employees with rich R&D and management experience in the medical industry. 35% of our 5,800 employees are R&D personnel.

So far, 86 groundbreaking products have been launched, including a Total-Body PET/CT, HD TOF PET/MR, 3.0T MR and 640-Slice CT Scanner. All core technologies are developed in-house and have been globally or nationally recognized for world leading performance. Our products have been installed in 35 countries, including the U.S., Japan, Australia, New Zealand, Poland, India, UAE, Egypt, Morocco, South Africa, Argentina and Colombia.

With our mission “To Bring Equal Healthcare for All” and our vision “Leading World Healthcare Innovation,” we are committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

World Federation of Nuclear Medicine and Biology

- United Imaging Healthcare Poland Sp. z o.o.

Welcome to the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB 2022) Booth.

WFNMB 2022 is now less than a year away. We are preparing to make a great conference for everyone, regardless of the infection status of COVID-19. Let’s talk about the future of nuclear medicine and enjoy the Japanese “Omotenashi” in Kyoto and Kanazawa next September!
USEFUL CONTACTS

SCIENTIFIC PROGRAMME
EANM Executive Office
Ms. Susanne Koebe
Mr. Andreas Felsner (Congress Manager)
Schmalzhofgasse 26/5, 1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: s.koebe@eanm.org
Web: eanm21.eanm.org

INDUSTRY EXHIBITION
EANM Executive Office
Mr. Andreas Felsner (Congress Manager)
Mr. Alexander Berger
Ms. Olga Joachimsthal
Schmalzhofgasse 26/5, 1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: a.berger@eanm.org
Email: o.joachimsthal@eanm.org
Web: eanm21.eanm.org

REGISTRATION
EANM Executive Office
Ms. Petra Neubauer
Schmalzhofgasse 26/5, 1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: registration@eanm.org
Web: eanm21.eanm.org

OPENING HOURS
EANM Executive Office
October 20-23, 2021
08:00 to 18:00 CEST